[{"title":"Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China","googleId":"rgyxI7N8O5gJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420363833","googleCitationCount":771,"googleAuthor":"L Xie","doi":"10.1016/j.annonc.2020.03.296","elsevierAuthor":"Zhang L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-07-01","elsevierCoverDisplayDate":"July 2020","elsevierCitationCount":"449","altmetricAuthors":["L. Zhang","F. Zhu","L. Xie","C. Wang","J. Wang","R. Chen","P. Jia","H.Q. Guan","L. Peng","Y. Chen","P. Peng","P. Zhang","Q. Chu","Q. Shen","Y. Wang","S.Y. Xu","J.P. Zhao","M. Zhou"],"twitterCount":201,"altmetricId":78449276,"statusesArray":["1286354616154824705","1286354614900731905","1266034325012844545","1266033775575814145","1262779860042354689","1262779859102765058","1261096376357789704","1258193331416379394","1255687296227000320","1255369906016735232","1255245549038682113","1255183752449290243","1255155605972500480","1255154915934175233","1255148932071485446","1255143446513246215","1255142220769816585","1255141801993752578","1255140860666081282","1255139758570782720","1255139575678119938","1255139432090333189","1255138633897504768","1255138209261948937","1255126402095108097","1255126230287790085","1255125796131389441","1254364609940795393","1254320135155920899","1251497537992896513","1250867867420987392","1250867852539654144","1250505448215609345","1250504763529146370","1250422308243533825","1250422188219355143","1249559798951088129","1248932796057468930","1246911467313451008","1246908751698776064","1246897832986107907","1246896893973667840","1246287146362814465","1245290323821002753","1245128952240312330","1244981720346214400","1244977351278166016","1244852014460407808","1244750193377107968","1244750013638610944","1244706722045767680","1244638953287888898","1244557708298047488","1244542760683745282","1244509911024840704","1244410629005479936","1244394270926286854","1244393619680878597","1244339500601487370","1244306968501723141","1244302286303748096","1244287278928687106","1244272185650237442","1244252821383524356","1244243122596589573","1244241166956191744","1244231566424858624","1244230455299358721","1244228857114374146","1244206737718161408","1244203881044815873","1244200605813440512","1244079507742613504","1244078451759316993","1244055794187829249","1244038857877839877","1244027304306769920","1244025936338714625","1244016311673466881","1244015506501271552","1244013015990784000","1244005715062161408","1243982853995663360","1243954807360172032","1243947973618384896","1243935420183982080","1243935107301421057","1243928220736655362","1243926728004849666","1243923395999342592","1243919072691134471","1243913641830776832","1243902942949912576","1243902713546637312","1243902111479402496","1243896311537176582","1243894728636149760","1243887586449465344","1243884407649337344","1243882735267086336","1243871881272463361","1243864298935459843","1243864211102601219","1243860139607756800","1243859650295918593","1243859487695548416","1243855182561230848","1243850968674041856","1243838154555248642","1243836306553294850","1243835956148539392","1243835347265556480","1243834781026201601","1243831036028518401","1243829154979753984","1243822763426623490","1243811840355901441","1243805840987107329","1243791516952379392","1243781323447308288","1243776942060552196","1243753619486318592","1243753084179922944","1243750614292664325","1243748996927160320","1243748673999319040","1243745769284304899","1243743572014305280","1243712568612384768","1243706157170114560","1243693360470097921","1243692412624670720","1243692241023049729","1243691361947324416","1243670347179753474","1243670091310358529","1243668508124295170","1243664280672710664","1243663241047310339","1243662837534375937","1243660680579997696","1243658967986905093","1243651614617022464","1243651071794458626","1243650349677846528","1243646123253866496","1243644344718024711","1243643863190966274","1243642690098601988","1243642625976160259","1243642179391815680","1243641607716573188","1243637685861974021","1243632658858401793","1243626909835112449","1243625617905647617","1243625231224393740","1243622678449270784","1243619517118414848","1243617178324271111","1243614928696741888","1243614617391243266","1243604724005429253","1243604653369147395","1243599368273477635","1243588239266627585","1243585196563337218","1243584189523509254","1243582935292411912","1243581597443674113","1243580371570003968","1243580316675162117","1243580242893189124","1243579877598670850","1243578180432285703","1243572505203392512","1243571788174495745","1243571083258847233","1243570518101499904","1243570353324077059","1243569482754383875","1243568767361220614","1243567743590453248","1243566904494743552","1243565335778742273","1243563224726941698","1243562700174753792","1243562161252769799","1243557439468965891","1243555576652627977","1243543742684049408","1243538813479256067","1243537291475398659","1243535297427787777","1243535081655939073","1243533815781285888","1243532660728889344","1243530869471617025","1243530755382312960","1243528357117075457","1243528040493322241","1243527940434022400","1243525123623268355","1243524971504324609","1243524385790668800","1243515742949179393","1243514305330458626","1243511890405400577","1243511331774439428","1243511106741645313","1243511060793090048","1243510268971360256","1243503697201692672","1243503354996756480","1243501941633814528","1243501693930618880","1243501443065282561","1243501415789707264","1243501355588816897","1243500603587940353","1243500584918974464","1243499902925037573","1243499899481620481","1243499217672380416","1243498772111470592","1243495774341775361","1243494041725153280","1243492564117925895","1243492400053604354","1243492339580047362","1243491876793131008","1243489633033388037","1243487224651558915"]},{"title":"Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic","googleId":"jbBfhU99zq4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419309974","googleCitationCount":427,"googleAuthor":"M Yarchoan","doi":"10.1093/annonc/mdy495","elsevierAuthor":"Chan T.A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-01-01","elsevierCoverDisplayDate":"1 January 2019","elsevierCitationCount":"295","altmetricAuthors":["T.A. Chan","M. Yarchoan","E. Jaffee","C. Swanton","S.A. Quezada","A. Stenzinger","S. Peters"],"twitterCount":331,"altmetricId":50771120,"statusesArray":["1235521196017324034","1192544945757806592","1179741273823072258","1169483627102724097","1167035385953677312","1166695395810000898","1166323509909491712","1166261870623363072","1165895526803488768","1165843773051392000","1165622076608339968","1165590050631049216","1165571242029699072","1165549158721302529","1165547311524532224","1165541142408175616","1165527940278444032","1165524691240534016","1165518520563712002","1165486633396953088","1165482839867035649","1165482351876562944","1165453941728899072","1165453233235476485","1159473342312853505","1120877772774227968","1120667262145445888","1120091213783236616","1119995634784919552","1119709146717143040","1119344175516979201","1119341158654717952","1119234232549822464","1119224581984636928","1119220183984410624","1119182587891785729","1119154869045121024","1119137760558718977","1119134822151012352","1119125686730420225","1119062886981070848","1119042914636771328","1119024851841441792","1119010776415522816","1118993417235771393","1118969149093502976","1118962775299174407","1118960503580180480","1118957622567239680","1118954897783828484","1118951419934121984","1118925066257850368","1118901264748879873","1118856766962511873","1118832940300013568","1118813251242987520","1118789411456606214","1118786281528418310","1116363026142257154","1113294038176866305","1112693042975252480","1112518169074298886","1112507856719355910","1112066891529551872","1111987294418939904","1111904192564731904","1111882060065583104","1111844492489822209","1111796287291211782","1111759784712130561","1111746109616148487","1111733040605220865","1111726340095512576","1111719694585651200","1111164808097947649","1108695280617181185","1108640601287860224","1108635731650666496","1108600012701921280","1108599768413016065","1108487978433867776","1108487927158505472","1108480443563814913","1108480421984157698","1107975870600359936","1106678502944845825","1106648109738790914","1106237439864131589","1106227357575053313","1103483125877932032","1103301656157081600","1103288250494443520","1103273622200832001","1103245423664353286","1103191597280305153","1103163737802969088","1103136967963934720","1103055045132673024","1103050240997896199","1103044487419330560","1103006227984986112","1102988828644724737","1102967474146955265","1102967114254581765","1102964023992217600","1102955249818574849","1102954884020629504","1102952487747764225","1102950001028677632","1102947392725442560","1102947163485716480","1102946896560087040","1102507794039742465","1101673710627377152","1101148819222351873","1101000494636457984","1100783657235738624","1100772876360339456","1100606241557176321","1100532217032384512","1100525839291244546","1100516459086839808","1100510989391462400","1100508575531786242","1100417494278463489","1100401716753850369","1100382209700216833","1100380865237012480","1100372013997187072","1100358735795503106","1100335541197946880","1100334145757200384","1100327484569075713","1100326694169333760","1100326611428302848","1100321474953560064","1100320983980933120","1100318247067545600","1100314594331914240","1100313142159179777","1100308415426056192","1100298792253960192","1100294252196753408","1100288404099645440","1100283029497528320","1100278519073046530","1100274592785018880","1100261412310577157","1100227179919622148","1100181358280794112","1100170252158156803","1100158481645137925","1100153742761041920","1100151422870568960","1100150259517394944","1100148832455872514","1100143889514680321","1100137705424543744","1100133217208860673","1100130881983995906","1100129051770015745","1100124737877884928","1100123149050540033","1100118477719781377","1100113879311532034","1100112262034087937","1100108135619051521","1100101727578148864","1100094829617393676","1100090468199788545","1100084311552872448","1100078642737172482","1100073802589859843","1100072585558147072","1100068169496973313","1100061993518551042","1100060686665818112","1100058682509803525","1100058430016913414","1100058023500959744","1100057966068170754","1100056778266427392","1100048844170104832","1100047380953612288","1100045635208785920","1100044996890316800","1100044944784412679","1100040010848526336","1100039981135851521","1100039654550761473","1100039531368271873","1095007802307891202","1094715586549088257","1093492194286043136","1092567722901286913","1092378267716386816","1092074761537179648","1092003050292736000","1091750049892192257","1091693990955630593","1091600030203400192","1091408595936256002","1091406357096525825","1091381842903740426","1091377784457515010","1091365679113142274","1091310205516873729","1091239003414818816","1091140298141560832","1091027104391606273","1090980644069539842","1090956395095252993","1090948545966997505","1090927500845182976","1090911490591334400","1090908139787116549","1090876836454850560","1090869829458903041","1090867299333099520","1090864714341601281","1090863494948442112","1090845283867598854","1090841056562814976","1090704945500827650","1090674421013069824","1090662656078417922","1090651048400904192","1090645387919196162","1090633382336319488","1090628332964634624","1090626046821572608","1090625714481651712","1085772005780013058","1082864604840046592","1076185010762207232","1074436018563047424","1074411929316278272","1074402390156050432","1074397938959343616","1074391728130527232","1070516744345796608","1070321767070228480","1069850330777694208","1069760819867590656","1069733989370486789","1069579568103809024","1069567456543420417","1069553214771683328","1069545268524318720","1069512589661663233","1069504293705850881","1069495930351693825","1069491336041177089","1069477547224825856","1069472357578723328","1069452758510637057","1069443520044265473","1069421890350039040","1069396156327870465","1069389646860300288","1069365585811816448","1069355770075013120","1069304824079024129","1069304507165753344","1069285248695824384","1069281358260903937","1069280759486259203","1069271212738691073","1069269827183890433","1068940493227053056","1068824609099796480","1068670317394939904","1068663965704695810","1067384562316128256","1066758006480617472","1062908025751490560","1062678926101766144","1062295235093512193","1062042299398377472","1060850259440615426","1060219782677565441","1060204858786111488","1060167623814586372","1060139221296537600","1059955064259993600","1059936112670588928","1059919368023359488","1059915512891826177","1059912012925452288","1059905545682014208","1059900612522004480","1059892989542174720","1059892943430053890","1059889983836819457","1059884277675053062","1059880187612012545","1059860366904168448","1059856058439659520","1059848853480988673","1059842897942642690","1059839339306336256","1059831975752609793","1059827441349419010","1059820820674080774","1059817027035152385","1059815322981679105","1059808268875378688","1059803544704954368","1059802297830662148","1059800482888077313","1059796350718697472","1059792282189217794","1059782996482576384","1059781604220919809","1059781395512475649","1059777587935768576","1059775518130634753","1059774295617011712","1059773643985768449","1059773346232107009","1059772700758024192","1059771789004423170","1059768563635023873","1059768418994397184","1059766607088472065","1059765606310862849","1059764632217362439","1059761435079794688","1059745491041337345","1059744450518355968","1059738441309741056","1059738006184189952","1059737501663817728","1059734918593425408","1059732762272452609","1059728907786629120","1059727476274819072","1059714084982153221","1059713597776056320","1059712565209632773","1059710819477438464","1059708930023133184","1059708267914543104","1059700949458001920","1059700670461284352","1059698732059557888","1059694402506055681","1059692773056512006","1059690534627794945","1059682406397956097","1059681261453799424","1059680832342970369","1059680248336400384","1059675252194590720","1059671754652688384","1059671479221133312","1059659249696104448","1059653669946355719","1059629273256841216","1059615559808114688","1059606986218790913","1059601152692621313","1059596464740057093","1059587105079332865","1059586122911793152","1059585281802801158","1059585264417472512","1059580875719892992","1059579984464019456","1059577533832839171","1059574355401805825","1059570211450433541","1059570018403397633","1059568674200264704","1059567576915808262","1059566698402115584","1059564824722579460","1059564824055681025","1059564164237180935","1059564016341680128","1059563756617953280","1059562223578898434","1059560749314572289","1059559083806810113","1059553561921703936","1059551235945218049","1059551127505698816","1059550188069502976","1059549173714841600","1059549117943300097","1059548466639122433","1059545982067789824","1059543891869876225","1059541822530306049","1059541617521188865","1059540936848535552","1059540887536066560","1059539420448206848","1059539057678655490","1059538489493151744"]},{"title":"Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"9BFapTr-f0EJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31287-6/abstract","googleCitationCount":383,"googleAuthor":"F Cardoso","statusesArray":[]},{"title":"ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours …","googleId":"hWQqZLH2abIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311627","googleCitationCount":204,"googleAuthor":"N Colombo","doi":"10.1093/annonc/mdz062","elsevierAuthor":"Gupta N.","publicationName":"Oncotarget","elsevierCoverDate":"2021-01-05","elsevierCoverDisplayDate":"5 January 2021","elsevierCitationCount":"0","altmetricAuthors":["N. Colombo","C. Sessa","A. du Bois","J. Ledermann","W.G. McCluggage","I. McNeish","P. Morice","S. Pignata","I. Ray-Coquard","I. Vergote","T. Baert","I. Belaroussi","A. Dashora","S. Olbrecht","F. Planchamp","D. Querleu","T. Baert","S. Banerjee","I. Belaroussi","P. Blecharz","I. Bruchim","D. Cibula","N. Colombo","N. Concin","B. Davidson","A. Dashora","M. Devouassoux-Shisheboran","A. du Bois","A. Ferrero","R. Glasspool","A. González-Martin","V. Heinzelmann-Schwarz","F. Joly","J.W. Kim","F. Kridelka","J. Ledermann","D. Lorusso","S. Mahner","W.G. McCluggage","I. McNeish","M. Mikami","M.R. Mirza","P. Morice","S. Nicum","S. Olbrecht","D.M. O’Donnell","P. Pautier","F. Planchamp","S. Pignata","D. Querleu","I. Ray-Coquard","A. Rodolakis","J. Sehouli","F. Selcukbiricik","C. Sessa","N. Singh","D.S.P. Tan","D. Timmerman","G. Tognon","J. van der Velden","I. Vergote","P.O. Witteveen","A.G. Zeimet"],"twitterCount":18,"altmetricId":59826395,"statusesArray":["1327253781130698760","1278732166759952384","1127228137501126657","1126897973420601344","1126890873587941379","1126884984067952641","1126879681892851712","1126879569649242117","1125699278503141376","1125425629871116288","1124944102980714496","1124375257274560517","1124230910038007808","1124054354175102977","1124021329781510144","1124005589317758977","1123997929050710016","1123972715428315136"]},{"title":"Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001","googleId":"-rKOmtHlwLEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341931110X","googleCitationCount":214,"googleAuthor":"A Daud","doi":"10.1093/annonc/mdz011","elsevierAuthor":"Krakowski I.","publicationName":"Journal of the European Academy of Dermatology and Venereology","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"January 2021","elsevierCitationCount":"0","altmetricAuthors":["O. Hamid","C. Robert","A. Daud","F.S. Hodi","W.J. Hwu","R. Kefford","J.D. Wolchok","P. Hersey","R. Joseph","J.S. Weber","R. Dronca","T.C. Mitchell","A. Patnaik","H.M. Zarour","A.M. Joshua","Q. Zhao","E. Jensen","S. Ahsan","N. Ibrahim","A. Ribas"],"twitterCount":71,"altmetricId":54810010,"statusesArray":["1150216079693664256","1136807801047715840","1136598572605104129","1136295864882933760","1136285691611140097","1136285334109609984","1136200991731326976","1136199777828450304","1136182415922204673","1136172235482324992","1136166398898651142","1136152443161587712","1136055905135616000","1135984630442668033","1135948362157453312","1135933276013703169","1135925175860547585","1135923097242963968","1135922771937103872","1135922443732901888","1135921666494566400","1135920917345779713","1112568180889792512","1111627853802754049","1111342395713601538","1108631344253419520","1108457244729974784","1108449597934981121","1108449397644230656","1108289865643249664","1108118803068551170","1107250914090463232","1107188396546506752","1107108229811597312","1107084757685268483","1107043997242085376","1106775938027741184","1106604519784370176","1106599920205733888","1106480438766460929","1106473592290713602","1106462152582488064","1106436294031392768","1106427095616495617","1106386227136262144","1106367150674055168","1106314813163143170","1106263232837312512","1106258983919206401","1106255627968544768","1106218813815554048","1106205327933034496","1106196403695443969","1106173047940083712","1106148084822745088","1106117793114517504","1097819717430136832","1094023553748475905","1093945179235467264","1093944165090643969","1093941805488488448","1093939770638716934","1093449321364766720","1093201974433075205","1093192279097958400","1093113870347128832","1092874016761688066","1092845113867419648","1092507323702992896","1092494194579513349","1092492434007674886","1091982423590608896","1091845049602764801","1091768235744219136","1091722697032298496","1091722491352018950","1091692677207339009","1091680127430393857","1091640972314927104","1091638477668651009","1091621119898148864","1091604758350233600","1091521980082331648","1091363584846684160","1091356935465635841","1091349183926284288","1091348250970476545","1091342912871428096"]},{"title":"Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (n= 4532)","googleId":"6VRrWkF6U90J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420397970","googleCitationCount":208,"googleAuthor":"M Rugge","doi":"10.1016/j.annonc.2020.04.479","elsevierAuthor":"Montopoli M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-08-01","elsevierCoverDisplayDate":"August 2020","elsevierCitationCount":"122","altmetricAuthors":["M. Montopoli","S. Zumerle","R. Vettor","M. Rugge","M. Zorzi","C.V. Catapano","G.M. Carbone","A. Cavalli","F. Pagano","E. Ragazzi","T. Prayer-Galetti","A. Alimonti"],"twitterCount":108,"altmetricId":81534028,"statusesArray":["1359930493098094592","1354868886710198275","1338187171036008448","1338180075397767168","1336361036694360065","1332105835892199424","1322563065951342592","1322557584986046464","1303857607992463360","1303708868644663297","1303704211109093379","1303220944480108545","1303053036911296514","1299338025785126912","1296983234174054400","1296720901795438592","1296712770793029633","1296561488736292864","1296556359882878976","1282000082175291392","1281998539787132928","1281069747816161281","1281010902674944006","1280835443270057984","1280827991568809986","1280826997242056705","1280786180779290624","1280785466711818240","1280756295306485765","1280749376231501825","1280746478672084992","1280734692682215426","1280725854025179136","1280722930880528384","1280719676624912386","1280711352638734336","1280701589838106625","1280700604495495168","1280692556905566208","1280691481322442759","1280678668889657346","1280676846753820672","1280669864500367361","1280664066059571202","1280663807472340992","1280662770908893184","1280654495685451777","1280651619252817922","1280646388091510785","1277445805515829248","1275720328350707715","1272639198143668227","1271108905339367424","1268926222597337091","1268894058153476103","1268893718355968001","1265389962792484864","1265382878386573312","1265182970857562114","1265182573556371457","1265177164242128896","1264996882410921992","1264586032521060353","1264534981147312135","1263716256751984640","1263693536756731905","1263677188412497922","1263602879463673860","1263595711779663877","1262455185101684736","1261385305812275201","1260759858732826624","1260596360954482688","1260497178893733888","1260494220974002180","1260409868005015553","1260399381204873222","1260295974557290497","1259933352938868736","1259816678105456645","1259787091442974720","1259568498629582848","1259534261155233792","1259515564395057153","1259462777300803584","1259461599317897216","1259406844679860224","1259355664645787649","1259352773822464000","1259331727484432384","1259329606500392961","1259315421439832065","1259268272341635073","1259251065016463367","1259236971244933122","1259232773430222848","1259232660951629824","1259224309274378242","1259224043888222208","1259217848993538049","1259214006419697664","1259213439404294146","1259211110387003393","1259209717555105793","1259207796798697481","1259207380136603651","1259207344803778560","1259163136516554752","1259095931024216064","1258892807013642243","1258859316322488322","1258776141176987650","1258691987429040128","1258273431956738049"]},{"title":"Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations","googleId":"BsHjnbvXKucJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419360806","googleCitationCount":124,"googleAuthor":"S Ganatra","doi":"10.1016/j.annonc.2019.10.023","elsevierAuthor":"Curigliano G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-02-01","elsevierCoverDisplayDate":"February 2020","elsevierCitationCount":"63","altmetricAuthors":["G. Curigliano","D. Lenihan","M. Fradley","S. Ganatra","A. Barac","A. Blaes","J. Herrmann","C. Porter","A.R. Lyon","P. Lancellotti","A. Patel","J. DeCara","J. Mitchell","E. Harrison","J. Moslehi","R. Witteles","M.G. Calabro","R. Orecchia","E. de Azambuja","J.L. Zamorano","R. Krone","Z. Iakobishvili","J. Carver","S. Armenian","B. Ky","D. Cardinale","C.M. Cipolla","S. Dent","K. Jordan"],"twitterCount":89,"altmetricId":74160615,"statusesArray":["1286070814463291397","1285884061244895232","1264079755294519299","1264079676810473479","1228648315186745344","1223308529882357760","1222997414417596417","1222939719400595460","1222896089742708736","1222869320105123842","1222869265130360833","1222868209264742401","1222868118164443136","1222868080411512832","1220732303367864323","1220304271549325316","1219726883392315394","1219672874593636352","1219446391728066560","1219445070497243137","1219444578463469568","1219400021772316673","1219306439497474051","1219208249985196033","1219185815017799680","1219184445103771649","1219172205105483777","1219095957658374144","1219075114110681095","1219074869737844736","1219055530230140931","1218959434812137477","1218959343367921664","1218948154051244033","1218942174211059712","1218920420226797569","1218909155043487745","1218891664540033024","1218890685190897669","1218852326791950336","1218810582889062400","1218763383740215296","1218693969871286273","1218687648837046272","1218687488442519553","1218687448894656517","1218675753593778178","1218663173814980609","1218663090734206977","1218660455775965189","1218656758849249280","1218656675055443978","1218618528640774144","1218579766120501254","1218577053441720321","1218577030360510464","1218573698267074567","1218569007961460737","1218567801989976065","1218566482768076804","1218566452103581696","1218563472310644737","1218563252743036929","1218547052604526592","1218545811732226048","1218533729880236033","1218529179962105856","1218526604525260801","1218520206705860608","1218498951055364097","1218487982333841411","1218485036191821824","1218474692501295104","1218474614810185734","1218458804993560576","1218457844653142018","1218453679860109312","1218447303989702657","1218438958473994240","1218415931933761537","1218414743356088320","1218409978010177536","1218392206861590528","1218387066435842048","1218381236017590272","1218372950484606976","1218368871981289473","1218352744131629061","1218351130792615942","1218348587647754244","1218339901747486728","1218337364193501185","1218334220726231040","1218333592385925126","1218333443173556225","1218333390560284674","1218332344685408257","1218329793344823296","1218327410103476230","1218327174756950017"]},{"title":"Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study","googleId":"nuUZaLcYH6QJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310750","googleCitationCount":203,"googleAuthor":"","doi":"10.1093/annonc/mdy517","elsevierAuthor":"Adams S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-03-01","elsevierCoverDisplayDate":"1 March 2019","elsevierCitationCount":"151","altmetricAuthors":["S. Adams","P. Schmid","H.S. Rugo","E.P. Winer","D. Loirat","A. Awada","D.W. Cescon","H. Iwata","M. Campone","R. Nanda","R. Hui","G. Curigliano","D. Toppmeyer","J. O’Shaughnessy","S. Loi","S. Paluch-Shimon","A.R. Tan","D. Card","J. Zhao","V. Karantza","J. Cortés"],"twitterCount":5,"altmetricId":51802228,"statusesArray":["1155999791903465472","1071464600951013378","1070971039100928000","1069916710092836866","1067302771588808704"]},{"title":"Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast …","googleId":"wYsU2zHYLYsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419609786","googleCitationCount":151,"googleAuthor":"S Loibl","doi":"10.1093/annonc/mdz235","elsevierAuthor":"Burstein H.J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-10-01","elsevierCoverDisplayDate":"1 October 2019","elsevierCitationCount":"112","altmetricAuthors":["H.J. Burstein","G. Curigliano","S. Loibl","P. Dubsky","M. Gnant","P. Poortmans","M. Colleoni","C. Denkert","M. Piccart-Gebhart","M. Regan","H.-J. Senn","E.P. Winer","B. Thurlimann"],"twitterCount":196,"altmetricId":64491149,"statusesArray":["1204422075534004224","1204268744215801856","1201977119787671552","1200782368048631811","1197906238513844224","1197905626246123527","1197905350181081088","1195742327232323584","1192230040542547968","1178329135288127489","1176170957284626434","1176170576626368512","1173033444135358464","1172463961909944320","1171989194123677696","1171957076576260096","1171888610347560960","1171879106859937792","1171867355871358976","1171866571700146176","1171862511009878016","1171859862185238528","1171851424264839168","1171847826365661186","1171844223836000257","1171837456737587200","1171819783047634946","1171817584297218048","1171817321494712321","1171802683898060805","1171802084749889536","1170829705966161920","1169527467801022464","1169293267709628416","1169209239488860160","1169171264629563392","1167034986886615040","1166771536671510533","1166695880726077447","1165382866647289856","1164901654573043714","1163966973698428930","1163765519935254529","1163727713972232193","1163687027747037184","1162796258236469254","1162795630424657920","1161539507310800897","1160893405636907009","1160892685101744128","1160880743524065280","1160729269850529792","1160659635273195526","1160380737331302401","1160244522938511360","1160215308449255424","1160160808069926912","1160158961737326594","1160157710823936000","1160151565556207616","1159467016874536961","1159464109815062530","1159463799029686272","1159399247118139392","1159241978296582144","1159189199716794370","1159100638158041088","1159085345150922752","1159078053764452352","1159062601378254848","1159058054471720960","1159057122535063553","1159056843072839680","1158951120959692807","1158791558558310400","1158790385025654785","1158720078696853506","1158709702324342786","1158528929906548736","1158518299010973696","1158439755094331392","1158434346363248642","1158407795366125568","1158403506409226240","1158391452650606592","1158372147162746885","1158344201052012545","1158342073994678272","1158336191378481152","1158329893395951618","1158306962641227776","1158296327836590080","1158294331004002304","1158289288699797507","1158288001312665601","1158233305915023362","1158204685997826049","1158144756893061121","1158144560209571842","1158144456702513153","1158142714333941760","1158047304655355904","1158045024304730112","1158035396758036480","1158030168121909250","1158014465914417154","1158007430451613696","1158007151027204096","1158005059403186176","1157984921207672833","1157977201704341510","1157971338490986496","1157950225782333440","1157936667661144065","1157929157872906240","1157928753336635393","1157918231392161792","1157916284920750080","1157911988279943168","1157908227096530944","1157898509447774208","1157891180966875136","1157864097070944257","1157857025256296449","1157856993513811968","1157843241208897536","1157824606515978240","1157786631589568515","1157781064653426689","1157777851468435456","1157776947080040448","1157776142922899456","1157769657752809472","1157768867671941120","1157765678448939014","1157765661038456832","1157759109812424705","1157757763885379586","1157754931346116609","1157752574336016390","1157745709774454786","1157737079629123585","1157734632563064833","1157719893325824000","1157707442291183618","1157704436300562432","1157703155116912642","1157702957414146048","1157701732920713216","1157694823379456002","1157692287507476481","1157691559472762882","1157691025936310272","1157686707069837314","1157685164228501505","1157685044535791616","1157684959500521474","1157683352301817856","1157683060898508800","1157680551853264896","1157678512997724162","1157674474700967937","1157667181011689472","1157667076279959557","1157664021857939456","1157663854396084224","1157662193745350656","1157651985367273479","1157647251252101120","1157645989194412032","1157645876610981888","1157643298120622081","1157641032592498688","1157640859090857985","1157639901661335554","1157639620085129216","1157639547443916801","1157639113413222401","1157639018273804289","1157635715267608576","1157635331551895552","1157635201658499072","1157633141554720768","1157628530064318464","1157626323428421633","1157623635315744768","1157623247413895170","1157623127268048896","1157620073953148928","1157619923486535681","1157619005915635717","1157618382302302208","1157616609839779841","1157615736904462336","1157612753001074689","1157612241744781312","1157609671315927046","1157606928303951872","1157606505824292865","1157604133488087041"]},{"title":"CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced …","googleId":"9HCRc53DNvAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603893","googleCitationCount":174,"googleAuthor":"T Yau","doi":"10.1093/annonc/mdz394.029","elsevierAuthor":"Pinter M.","publicationName":"JAMA Oncology","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"January 2021","elsevierCitationCount":"3","altmetricAuthors":["T. Yau","J.W. Park","R.S. Finn","A.-L. Cheng","P. Mathurin","J. Edeline","M. Kudo","K.-H. Han","J.J. Harding","P. Merle","O. Rosmorduc","L. Wyrwicz","E. Schott","S.P. Choo","R.K. Kelley","D. Begic","G. Chen","J. Neely","J. Anderson","B. Sangro"],"twitterCount":6,"altmetricId":68417959,"statusesArray":["1276853893595402247","1276227058985832455","1275959702405484546","1275958919391830018","1275957913966637059","1275957768113930240","1275957199630630919","1275956822776492032"]},{"title":"Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry","googleId":"I8ZTgQgo1xcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312840","googleCitationCount":175,"googleAuthor":"J Mazieres","doi":"10.1093/annonc/mdz167","elsevierAuthor":"Mazieres J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-08-01","elsevierCoverDisplayDate":"1 August 2019","elsevierCitationCount":"131","altmetricAuthors":["J. Mazieres","A. Drilon","A. Lusque","L. Mhanna","A.B. Cortot","L. Mezquita","A.A. Thai","C. Mascaux","S. Couraud","R. Veillon","M. Van den Heuvel","J. Neal","N. Peled","M. Früh","T.L. Ng","V. Gounant","S. Popat","J. Diebold","J. Sabari","V.W. Zhu","S.I. Rothschild","P. Bironzo","A. Martinez-Marti","A. Curioni-Fontecedro","R. Rosell","M. Lattuca-Truc","M. Wiesweg","B. Besse","B. Solomon","F. Barlesi","R.D. Schouten","H. Wakelee","D.R. Camidge","G. Zalcman","S. Novello","S.I. Ou","J. Milia","O. Gautschi"],"twitterCount":74,"altmetricId":61025174,"statusesArray":["1174089870324768768","1173849938557657091","1173574002452779008","1173570031499694080","1172267101505146881","1171376468678496256","1171358205236195328","1171335367557111808","1171309068717297664","1171263958952448000","1171263799615246337","1171251746510921736","1171247295632822273","1171246875980312578","1171189006308167680","1140778640621228032","1140223677906268160","1136092518867709952","1135759277115793409","1134934876979912714","1134754755216052224","1134572324366299136","1134556794922123264","1134435093777395713","1134432914261848065","1134431961114656768","1134385652538253312","1134370442435813377","1134363858628423681","1134295663112523777","1134189797231255553","1134159160638169093","1134132278601420801","1134085546106662912","1134085400144818179","1134082546940166144","1134049748820877313","1134021105688039424","1134006127388221440","1134003296929308672","1133999583594471424","1133991604103069696","1133989325484548096","1133971086465544193","1133947506440716288","1133923969625497600","1133825097075232768","1133815122391126016","1133811567873744896","1133774250542809088","1133767495989510151","1133748412166184960","1133739794717184000","1133732094251864065","1133731631418761219","1133731317152194561","1133707320003878913","1133684156007895040","1133678850708316160","1133677292847190016","1133649460339384320","1133623568372248576","1133615666140012544","1133610625505071104","1133607231742795776","1133599685808218112","1133595039802843136","1133590963983724544","1133590553940119553","1133587405108387840","1133583244761456640","1133570629444231173","1133570506488274944","1133530845631770624","1133465736196874240","1133462501914566658","1133440760542617601","1133416975223447557","1133416686428794880","1133403295056388097","1133359725079400448","1133341178991206403","1133266924228489216","1133248228474916865","1133245202561470469","1133241577290240000","1133229006915088385","1133153875635056640","1133148070181523457","1133104841755119616","1133089190596554752","1133063600430563335","1131915690141769729"]},{"title":"Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report","googleId":"Sl5_4RzRQsIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)36387-0/pdf","googleCitationCount":221,"googleAuthor":"JM Michot","statusesArray":[]},{"title":"Novel patterns of response under immunotherapy","googleId":"GAMzWoEnEhoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341931083X","googleCitationCount":122,"googleAuthor":"Y Kanjanapan","doi":"10.1093/annonc/mdz003","elsevierAuthor":"Borcoman E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-03-01","elsevierCoverDisplayDate":"1 March 2019","elsevierCitationCount":"88","altmetricAuthors":["E. Borcoman","Y. Kanjanapan","S. Champiat","S. Kato","V. Servois","R. Kurzrock","S. Goel","P. Bedard","C. Le Tourneau"],"twitterCount":47,"altmetricId":54123198,"statusesArray":["1152387529548738568","1152060181175402501","1152043471714209792","1151965084975083520","1151963662191616010","1151959841486675968","1151901160309047297","1151900856196796416","1151794626413678593","1151789179547897857","1151743609152188416","1151735850666999808","1151731582744633344","1151724291651788802","1151599213236539393","1150618585406103557","1131532544908943360","1130830372667822080","1130790596124106752","1130790064076644352","1130719691205431296","1130718665920405504","1130649449380962304","1130598379829026817","1130563125550428162","1130487970157539329","1130480991146053632","1130331343773143042","1130208589879107584","1130208349549674497","1130048587369451520","1115144782140051456","1115141258169679872","1113019944436994048","1112948409516937216","1112750827909861377","1099038464996200449","1091029845180465152","1087929954858397696","1087813159660937216","1087785679948574721","1087593628233621505","1087589388274548736","1087586717018796032","1087573563245293569","1087519365799522305","1087490930477682688","1087447742534901760","1087347672510550016","1087341385815068672","1087329274728656900","1087328995366989826","1087309143935979521","1087299339649716224","1086559227630497793","1086557498419494912","1086511137829634048","1086418156426575877","1086363898775830529"]},{"title":"Correction to:“Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”","googleId":"XRWSwiszWlAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31151-2/abstract","googleCitationCount":156,"googleAuthor":"","statusesArray":[]},{"title":"IMbrave150: efficacy and safety results from a ph III study evaluating atezolizumab (atezo)+ bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for …","googleId":"Jm2AXK-pY6EJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419582072","googleCitationCount":132,"googleAuthor":"P Galle","doi":"10.1093/annonc/mdz446.002","elsevierAuthor":"Nault J.C.","publicationName":"Hepatology","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"January 2021","elsevierCitationCount":"4","altmetricAuthors":["A.-L. Cheng","S. Qin","M. Ikeda","P. Galle","M. Ducreux","A. Zhu","T.-Y. Kim","M. Kudo","V. Breder","P. Merle","A. Kaseb","D. Li","W. Verret","Z. Xu","S. Hernandez","J. Liu","C. Huang","S. Mulla","H.Y. Lim","R. Finn"],"twitterCount":0,"altmetricId":74984888,"statusesArray":[]},{"title":"A decade of clinical development of PARP inhibitors in perspective","googleId":"y6ldpFWClDAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419459851","googleCitationCount":112,"googleAuthor":"J Mateo","doi":"10.1093/annonc/mdz192","elsevierAuthor":"Mateo J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-09-01","elsevierCoverDisplayDate":"1 September 2019","elsevierCitationCount":"76","altmetricAuthors":["J. Mateo","C.J. Lord","V. Serra","A. Tutt","J. Balmaña","M. Castroviejo-Bermejo","C. Cruz","A. Oaknin","S.B. Kaye","J.S. de Bono"],"twitterCount":114,"altmetricId":62493598,"statusesArray":["1274413764549509127","1222922854863458305","1222647497866272769","1222600288684716032","1222486180240846849","1192485811415064577","1190707145211289600","1190240733359415299","1189877695129239556","1188109385882574848","1188092953887215622","1187699473646018561","1187636694541099008","1187252747655110656","1187171926029922305","1187148071693684736","1187084413009612805","1187044351513415682","1187034214316871683","1186989602839482368","1186980616765493248","1186979888118554624","1186977196457332736","1186975186161147905","1186972771722637312","1186968700542431233","1186966069325512706","1186965573911109637","1186929209417109504","1186918947716767744","1186918824983093250","1186892576248516608","1186890838321913856","1186890051889827840","1186829725207089153","1186767532155379712","1186688440412315650","1186601437226127361","1186599134205272065","1186597405975891968","1186569380210987009","1186565393189605376","1186565147512463360","1186562477238247424","1186562209247154176","1176171482826694656","1162798946152046592","1162798113385517057","1147002342249623552","1146696546102194176","1146646199493177344","1145698845227008000","1144474092692598784","1144380700025589761","1144359227596726277","1144312415439347712","1144243324611641345","1144203602367516672","1144197592915599361","1144192373058088960","1144188144042029061","1144184898686771202","1144160416819494912","1144159527396360192","1144143598146990080","1144138937537060864","1144135137061457920","1144132942236700672","1144131426033557504","1144119860072472576","1144027886384324608","1144026287087816704","1144014183585001473","1144006807251234816","1143989249022279685","1143977292764520453","1143976711786303488","1143973197714481152","1143925557358284800","1143915327996088320","1143915051146809345","1143912665556742144","1143897769616109568","1143890980275404801","1143890181134716929","1143885227128958977","1143881454964920320","1143875665588097024","1143875616367960064","1143871220892471296","1143870993611575299","1143869164676952065","1143868957503438848","1143867272429129728","1143865194151665664","1143861731237736449","1143856615889743878","1143856479738507265","1143407131338715136","1143023955189653504","1142983276212236289","1142703111468982273","1142542039726166016","1142499960212119553","1142422790370484225","1142422076042752000","1142407971068100608","1142406820847398912","1142405154253094912","1142371442585210880","1142334885144612866","1142269250029010945","1142239450149376000","1142238742624833536","1142219660017848320","1142206500955394049","1142197142049579008","1142192414490288129","1142163449084043264","1142154868397711360","1142116161703821312","1142114881874907142","1142110241649287170","1142085886697512960","1142078483461316609","1142072348591513602","1142069731421302784","1142067894441914368","1142067253564755968","1142065099164831745","1142063970502762496","1142063054819135490","1142062646973358085","1142035881441800197","1142024188045275136","1142021317128011779","1142013814096797696"]},{"title":"Collateral damage: the impact on outcomes from cancer surgery of the COVID-19 pandemic","googleId":"lz277TZzAp8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420398252","googleCitationCount":149,"googleAuthor":"A Sud","doi":"10.1016/j.annonc.2020.05.009","elsevierAuthor":"Sud A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-08-01","elsevierCoverDisplayDate":"August 2020","elsevierCitationCount":"77","altmetricAuthors":["A. Sud","M.E. Jones","J. Broggio","C. Loveday","B. Torr","A. Garrett","D.L. Nicol","S. Jhanji","S.A. Boyce","F. Gronthoud","P. Ward","J.M. Handy","N. Yousaf","J. Larkin","Y-E. Suh","S. Scott","P.D.P. Pharoah","C. Swanton","C. Abbosh","M. Williams","G. Lyratzopoulos","R. Houlston","C. Turnbull"],"twitterCount":267,"altmetricId":82375906,"statusesArray":["1349104211821277186","1330670296840491012","1308539426381979648","1306688334438129664","1306684098765664259","1301279221617049600","1300889317095608321","1300886696515506178","1300885812649762816","1300760015729389568","1293868665301950464","1287781178884403201","1283029019483676674","1282820813339734016","1282769286164086789","1268256115436945414","1265882653946978304","1265596506368770054","1265581378416115712","1265535478981410819","1265480326828232704","1265417478257213440","1265285445962924033","1265272599891886088","1265247099710562304","1265230151048142849","1264984200530276357","1264958017524596736","1264936018362413058","1264904555415863296","1264877128857894913","1264803072406159360","1264791284172152836","1264778080729604096","1264723046620966912","1264721860270358528","1264694523717988352","1264679344808562688","1264654432102465537","1264616529884254208","1264603822497968129","1264595990385848320","1264576589200789505","1264563271794692096","1264559186739896330","1264557426646429697","1264553767669764097","1264552216800759813","1264551529765314561","1264546776633270272","1264527979440410626","1264521947775410177","1264513772653289472","1264504794212900870","1264479412097032192","1264475710535712768","1264471976833282053","1264458098716131328","1264455883314077696","1264452113540640769","1264451894791069698","1264447156074582016","1264443074719166469","1264439648337620992","1264429553927290881","1264424251047763969","1264422337614688256","1264422254902943744","1264420850700128256","1264417936552464389","1264415359676923905","1264414724009189377","1264412760017952769","1264408352215490560","1264408029124050944","1264407489329737728","1264405379896786945","1264403362994323459","1264402839088107520","1264402745693335552","1264399865041358848","1264398908618412035","1264397531469021186","1264396858589433857","1264396285437571072","1264396095431544832","1264395893983371266","1264394944967577600","1264394482797199361","1264394168681578496","1264393035271593986","1264392057289875457","1264391051604885505","1264390803327156224","1264390321263333377","1264390022423285760","1264389931700346880","1264389564120080385","1264388801570496512","1264388444886794241","1264387642340319233","1264387140940636163","1264386929124151296","1264386788422017024","1264386375450853376","1264386194542125056","1264386135700025347","1264385913343205377","1264385704500645890","1264385595066814465","1264385560334012417","1264384895628881921","1264384621812252672","1264384574903119872","1264384526379180034","1264384502882762752","1264384204739088384","1264383923049635841","1264383890745176066","1264383802505388033","1264383718522671104","1264383616282435585","1264382862792458240","1264382742948728833","1264382604956090370","1264382542972624898","1264382447845814274","1264382294619553792","1264382291331018753","1264381797229645824","1264381776409092096","1264381664098213896","1264381547349671936","1264381120138874883","1264380856153620480","1264380802118402048","1264380625705930752","1264380376375611392","1264380373116555264","1264380364207697920","1264380254501642241","1264380178823811083","1264380094115729409","1264379961953181697","1264379764749598725","1264379671250194432","1264379648563122176","1264379515662471169","1264379448666673152","1264379353888108545","1264379348406005760","1264379336347529217","1264379270174068738","1264379146760642561","1264378945006383106","1264378837057654784","1264378766370893824","1264378604433158146","1264378603636248577","1264378557729472512","1264378557448536064","1264378555112263680","1264378551278632967","1264378439219511298","1264378408072609792","1264378355815776261","1264378330133991424","1264378237573976064","1264378180560924672","1264378097282895873","1264377990898683906","1264377793623851008","1264377762296586241","1264377725457965057","1264366928958615552","1264358250566352897","1264284393398505472","1264200959749763073","1264182447677333505","1264181673698213889","1264181529070239744","1264163553553952769","1264135367373938689","1263886777812692992","1263863127843766272","1263646913783640064","1263605837412446208","1263594330876305416","1263592382542442499","1263564069006716928","1263559778942492678","1263548077241020416","1263546996075323392","1263542851058745352","1263533196421070850","1263517010052493313","1263514278285451265","1263513002894123009","1263490259825942528","1263489376887222275","1263464162283454470","1263453185835966466","1263444769453334528","1263428044284465152","1263428020389515265","1263424465662349317","1263407965958279174","1263398150070558721","1263395477191569409","1263388234568077312","1263387665271074817","1263380993987293185","1263377699592114176","1263376668384772099","1263376317141135361","1263370856249659393","1263368838235721728","1263361536250335233","1263347025929744384","1263342400493273089","1263341635015806976","1263307229370990595","1263295349797642242","1263289873244532740","1263280484546732033","1263272448788590593","1263269825498935297","1263246511049256965","1263236417053954056","1263234357671518214","1263232109805735936","1263231753537441793","1263230335606755328","1263225038918111235","1263223646463590407","1263223434257072130","1263217061997789184","1263206541571887106","1263206529857191937","1263206352106684419","1263204207592603653","1263200322106855424","1263192028285976576","1263178811480461313","1263165283629510656","1263162302406307841","1263159566533120000","1263158976977534977","1263117795044327424","1263103680703684610","1263103484926103553","1263092512505430016","1263091863881486337","1263087796102639616","1263086378226782208","1263082788246310913","1263080658680926210","1263079517792407554","1263079404181356544","1263075743074041857","1263072944164569088","1263069847241609216","1263067415811948544","1263066838574956549","1263059928886980608","1263057686071070720","1263054724305006593","1263050526410883072","1263049223655829504","1263048684452929542","1263048437932703744","1263047127221055488","1263035887916658688","1263035108824621056","1263033270645788672","1263021475096866816","1263020953589755904","1263018348088090624","1263018034035339264","1263012856309702656","1263012571218673664","1263012070401945600","1263011927439147008","1263010375081037825","1263010054464249859","1263009824708665349"]},{"title":"Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York City","googleId":"pmM-tFJQxm4J","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/pmc7172785/","googleCitationCount":179,"googleAuthor":"","doi":"10.1016/j.annonc.2020.04.006","elsevierAuthor":"Miyashita H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-08-01","elsevierCoverDisplayDate":"August 2020","elsevierCitationCount":"106","altmetricAuthors":["H. Miyashita","T. Mikami","N. Chopra","T. Yamada","S. Chernyavsky","D. Rizk","C. Cruz"],"twitterCount":56,"altmetricId":80343232,"statusesArray":["1255311709243420673","1255245549038682113","1254411507166851072","1254238861649154054","1254193347897356288","1254178723135475712","1254161819226300417","1254160430219628544","1254117486074740737","1254078754525270022","1254064674821279744","1254056610886008832","1254054288533356544","1254033672103030785","1254006132877791233","1253977637074149376","1253947943511642113","1253946224862007296","1253884198936612864","1253803163158749186","1253779122758844416","1253778060064653315","1253775246911569923","1253772579267059713","1253767170703732736","1253766107976159235","1253756781429493760","1253719480934502401","1253709721791586304","1253709717370789889","1253707679962365952","1253697744654544898","1253696645201637377","1253696457355517953","1253695614501740545","1253695298205081603","1253688270095073281","1253687031898738688","1253680786685014020","1253675731374215168","1253672523511840770","1253672482202058760","1253671683396898816","1253671615914823682","1253670860369641473","1253632187792084993","1253629145994547200","1253605661910368258","1253596039585685505","1253592865252360194","1253581326726430720","1253572040004718592","1253570792291434496","1253570406692388865","1253391606721310726","1253373263209775109","1253364307271708673","1253334865954500610","1253048535429382144","1253021177360105505"]},{"title":"Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy","googleId":"6M7ygNDwgRwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312293","googleCitationCount":132,"googleAuthor":"M Silva","doi":"10.1093/annonc/mdz117","elsevierAuthor":"González Maldonado S.","publicationName":"International Journal of Cancer","elsevierCoverDate":"2021-03-01","elsevierCoverDisplayDate":"1 March 2021","elsevierCitationCount":"0","altmetricAuthors":["U. Pastorino","M. Silva","S. Sestini","F. Sabia","M. Boeri","A. Cantarutti","N. Sverzellati","G. Sozzi","G. Corrao","A. Marchianò"],"twitterCount":169,"altmetricId":58420812,"statusesArray":["1228660162082328576","1226268756780953600","1224733444078538752","1224727043419594753","1224682491950370817","1224677581875826688","1224676919087640577","1224676641290489856","1185210677331419136","1184842317569679362","1184760828710576128","1184757648224186369","1176171165460529152","1171897292091285505","1171895811648741376","1163598555346423808","1156920013564997632","1155118089605959681","1154601516197658624","1154340152644448256","1154055506199109632","1154047289507241984","1153967838681546753","1153808108252086275","1153777589296586752","1153777539900301312","1153776478670266369","1153764727094296577","1153754534281404417","1153752989833842694","1153752823756181504","1153749912812740609","1153738663924314112","1153699240146661376","1153688368615743488","1153687144214515712","1153682288296833024","1153680154285301760","1153671239254204422","1153670524830195712","1153670388355719168","1151558937860329472","1143167673532067840","1142799415360532482","1142792302303170560","1142681551613890561","1142449509575856128","1142436717854461953","1142420768166424577","1142419074552647681","1142410998315474945","1142391309803642881","1142243891640504320","1142207916583346176","1142149213108789248","1142135825116925952","1142127216387641346","1142127064167976969","1142124956291084290","1138224876068790272","1134744430223794176","1134555387968053248","1134489716688998400","1123111626318782464","1123000074362150912","1122967123981217792","1122960506841632768","1122941017358053377","1122865935596101632","1122859665807699968","1122842040008609793","1122828207076577281","1122825845104676864","1122805819127549952","1122805741222604801","1122803704640544768","1122803292822626305","1122803010898415617","1121362750599585795","1121359865136414720","1121156408907575301","1121032349112766464","1121027957630349313","1120924378093576193","1120756521715953664","1120727504258568194","1120719346651869185","1119322705009029120","1119319921454997504","1119255131541737472","1119250245714575361","1119212916966871042","1119175466907127808","1119123868239552513","1119119394750091264","1119119196745424896","1119117088369418243","1119116481805971456","1119115947002880001","1119115856858861569","1118244165706551297","1117916367137566720","1117787471499223050","1117746433153806338","1117717954118987777","1116575546559754241","1116457267379998721","1116456263469207552","1116273972415430656","1116266682450874368","1116084340012855296","1116081803524222977","1116060346018598913","1115920002820005888","1115690761113284609","1115679490502549505","1115567565609345024","1115468800109969408","1115425788390793216","1115334165791158274","1115310627361296391","1115303441729978373","1115295787834126340","1115279134312235008","1115241363782733825","1115238039071199238","1115235810025119745","1115235178547437569","1115173768689799168","1115145312212066305","1115139711524327425","1115133328120799232","1115128742626713601","1115126619851694080","1115121338648223751","1115058656154923008","1115054082505318400","1115050945002582017","1115032697334845440","1115010772197761025","1115004321282895873","1114999499284467712","1114990722195828736","1114989344123686918","1114974466348658688","1114968370150092800","1114931259237634048","1114930525612007425","1114926271480434689","1114923149752242178","1114907528217931778","1114890977448091660","1114879870797066240","1114879551715385344","1114877587489263616","1114830124166406144","1114816764246941696","1114816088251011072","1114799915757187073","1114791852136333312","1114782196852826113","1114715696716496896","1114707454263222273","1114676174058291201","1114660384722509824","1114659190369214464","1114644845946114049","1114626715870027776","1114625895250190338","1114621151764856832","1114590772479909888","1114589906037243904","1114587885389242368","1114536191234400258","1114530895149637639","1114529958448132098","1114524484160172033","1114524374017744897","1114513248462807041","1114505822804086784","1114505708228182018","1114498983072759809","1114477174910803968","1114462797277093888","1114456646896508928","1114443915447369728","1114431936708206592","1114412194093989890","1114380511864967168","1114370460530167808","1114335622930415621","1114318812436946944","1114310350478946305","1114291453969227777","1114284210498314240","1114283283867631617","1114282715757654018","1114272868416856065","1114272085063426048","1114270305420288000"]},{"title":"ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour …","googleId":"OhOda1_-_qUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312694","googleCitationCount":129,"googleAuthor":"C Luchini","doi":"10.1093/annonc/mdz116","elsevierAuthor":"Luchini C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-08-01","elsevierCoverDisplayDate":"1 August 2019","elsevierCitationCount":"76","altmetricAuthors":["C. Luchini","F. Bibeau","M.J.L. Ligtenberg","N. Singh","A. Nottegar","T. Bosse","R. Miller","N. Riaz","J.-Y. Douillard","F. Andre","A. Scarpa"],"twitterCount":140,"altmetricId":59973223,"statusesArray":["1358796656590823425","1358703282961539073","1358680358699425792","1270793617154568192","1211297026245353472","1211238906278092801","1211228519977684994","1211023242422554624","1211016921753247745","1211014164505923584","1191263732325703682","1168516925795835907","1168516762213728256","1157663854610079751","1151624226199101441","1129986873164587008","1129560667827179520","1129071494942928897","1129033466723618816","1129022319375073280","1128789611856125952","1128725673093337093","1128673115167449088","1128670077291716608","1128669936488984578","1128614197275680768","1128579666955132928","1128375711457325059","1128288236474904576","1128284531495264256","1128270754280349696","1128263143795433472","1128247494700179456","1128247326160539648","1128245745394618369","1128240074326454273","1127465195687817216","1127464250937679872","1126818853902848000","1126767367680217090","1126729983244754945","1126721720113434624","1126598724476706821","1126598590191869955","1126559958856884230","1126554633114193921","1126552645521551365","1126544088847847431","1126543817027534849","1126509820389912581","1126473458584571905","1126471883015241728","1126450305628037120","1126408444280541184","1126355771057373191","1126317387811307520","1126264696410079233","1126264215763701760","1126228054488096768","1126223139267076097","1126211284482052097","1126196115093762048","1126180380934123525","1126172028636213248","1126150032573521920","1126114171626696704","1126084306533662720","1126082423891034112","1126076392947339264","1126075911432962049","1126018113726812160","1125993240661045249","1125932227324465152","1125894534511177729","1125886066777579520","1125882639574028288","1125871763777310721","1125871095595323392","1125866422960381952","1125862366032420869","1125853151964422145","1125835833234223105","1125811267544014851","1125796864878686209","1125789084318932992","1125746693448843265","1125746149535535105","1125743717090983936","1125741612934496257","1125724857788796929","1125722653095018496","1125699458354831360","1125687924803231745","1125686676704116736","1125670929001078784","1125649468932657152","1125646702235537408","1125646392146432000","1125645057254674432","1125640607479869442","1125636528967962626","1125636495178719232","1125636287585705991","1125636123361988608","1125626632205524992","1125624743988682753","1125620877763149824","1125619968576512001","1125616649959366656","1125616284190822401","1125604144943960064","1125601941634060288","1125589443107332096","1125583697221173249","1125583445495824384","1125573475387756544","1125571017546637314","1125570172193005568","1125570131487227904","1125569562647441408","1125562755229081600","1125534825035829251","1125522824221863936","1125522711114067968","1125520139393404934","1125519502005895168","1125518120762904578","1125515529870090243","1125510611549351936","1125508913892225026","1125503272310194178","1125498940219117571","1125497916439789568","1125492498674143232","1125491959924183041","1125490935591256064","1125489523339689986","1125486099655270402","1125485939541803008","1125475840840667136","1125475385859350528","1125473144121094144","1125472748913004544","1125472511636983808","1125472225824530432","1125471956730548224","1125459359700594690","1125453182245666818","1125453182937681921","1125453076901527554","1125452161146605568","1125451459305312256","1125450935419801600","1125442315500294147","1125442146650271744","1125440423965732865","1125435819144167426","1125431257871949829","1125407917765791745","1125393281951698945","1125379359236395009","1125378125049806848","1125377442863046657","1125374728104026120","1125369013796790273","1125368608685789184","1125365523976351744","1125363678595956739","1125358587117654017","1125346659683188736","1125342566604509184","1125340658598907904","1125340048596131840","1125338358778081280"]},{"title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study","googleId":"HCWSEYGxVdoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312414","googleCitationCount":121,"googleAuthor":"","doi":"10.1093/annonc/mdz135","elsevierAuthor":"Dong A.","publicationName":"Journal of Gene Medicine","elsevierCoverDate":"2021-02-01","elsevierCoverDisplayDate":"February 2021","elsevierCitationCount":"0","altmetricAuthors":["U.A. Matulonis","R. Shapira-Frommer","A.D. Santin","A.S. Lisyanskaya","S. Pignata","I. Vergote","F. Raspagliesi","G.S. Sonke","M. Birrer","D.M. Provencher","J. Sehouli","N. Colombo","A. González-Martín","A. Oaknin","P.B. Ottevanger","V. Rudaitis","K. Katchar","H. Wu","S. Keefe","J. Ruman","J.A. Ledermann"],"twitterCount":12,"altmetricId":59967934,"statusesArray":["1222486808442748928","1153633747620761600","1126801932515987456","1126719739697385472","1126678688127438848","1126615431685595136","1126589041783255040","1126565075127607297","1126562484859465728","1125425968141733888","1125296091354869760","1124785153312559104","1124414085943021568"]},{"title":"Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer","googleId":"LrlT1bUzII8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312402","googleCitationCount":129,"googleAuthor":"AB Schrock","doi":"10.1093/annonc/mdz134","elsevierAuthor":"Zhou P.","publicationName":"Aging","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"January 2021","elsevierCitationCount":"0","altmetricAuthors":["A.B. Schrock","C. Ouyang","J. Sandhu","E. Sokol","D. Jin","J.S. Ross","V.A. Miller","D. Lim","I. Amanam","J. Chao","D. Catenacci","M. Cho","F. Braiteh","S.J. Klempner","S.M. Ali","M. Fakih"],"twitterCount":60,"altmetricId":59740488,"statusesArray":["1275742979152416768","1273127476982677509","1254802248665911297","1175119963797016582","1162669111299706882","1162647012149465088","1162470360991903745","1159467080447664129","1158386179034820609","1158104537682591745","1157948185781985280","1157569287323869184","1157402295891615744","1157316223417245696","1157306301174517760","1157260205635383296","1157243706514268160","1157237026141429760","1157228935714942976","1157212238811475969","1157211883683876864","1157189925109977088","1157189851911000064","1157172045261787136","1157163806256058368","1157142889555623938","1157076760162230272","1157053075774955520","1156998489836011521","1156996865960894465","1156992772613820417","1156984974517645319","1156970263596195841","1156958817642524673","1156957975698956288","1153079691546222593","1153066922285707266","1141687758148292608","1135418292787482624","1135284205234130948","1135266589778075648","1135266341290741760","1125907338563481600","1125836243307302912","1125811530057097217","1125392167646765063","1125008749805096961","1124744853240283137","1124685070487433216","1124650901132730369","1124598644261380096","1124573930528935936","1124549047556214784","1124417840352833536","1124369469265141765","1124362009053736967","1124359071082008577","1124346066009243648","1124305416308047872","1124255700992110593","1124251540414500864","1124251228417011712","1124206875162152960","1124090661257588738","1124083443342749696","1124043175415418890","1124021605829697538","1124021539458908162","1123856603076333572","1123823991209320450","1123822345184002048","1123804566561153030","1123667163745853441","1123647679718989824","1123588892148543488","1123587928851210241","1123522732094836736","1123339149279465477","1123320394360995841"]},{"title":"OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA …","googleId":"NaA7zsiFfF8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311111","googleCitationCount":141,"googleAuthor":"ME Robson","doi":"10.1093/annonc/mdz012","elsevierAuthor":"Gupta G.K.","publicationName":"Cancers","elsevierCoverDate":"2020-09-01","elsevierCoverDisplayDate":"September 2020","elsevierCitationCount":"5","altmetricAuthors":["M.E. Robson","N. Tung","P. Conte","S.-A. Im","E. Senkus","B. Xu","N. Masuda","S. Delaloge","W. Li","A. Armstrong","W. Wu","C. Goessl","S. Runswick","S.M. Domchek"],"twitterCount":34,"altmetricId":54335885,"statusesArray":["1169483997149376512","1137551751962288129","1092916471762747392","1091954419422380032","1091452761059643394","1091310923954847751","1091250656772419584","1091246133878255617","1091240967103889408","1091063592772820992","1090935886903107584","1090926492421214208","1090309206069133313","1089620989854535680","1089440016223399937","1088566893252960257","1088533696414666752","1088523547834748928","1088403084831789056","1088368346272215045","1088327621786529792","1088315902087565312","1088314241201754113","1088313069732798464","1088275133016477697","1088201504325095424","1088199707078348800","1088197285484417024","1088196674663731201","1088181931639037962","1088147343764058112","1088119193323606017","1088113634939727879","1088095434567045128"]},{"title":"Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study","googleId":"yIEhPn-jRE8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310762","googleCitationCount":161,"googleAuthor":"S Loi","doi":"10.1093/annonc/mdy518","elsevierAuthor":"Adams S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-03-01","elsevierCoverDisplayDate":"1 March 2019","elsevierCitationCount":"123","altmetricAuthors":["S. Adams","S. Loi","D. Toppmeyer","D.W. Cescon","M. De Laurentiis","R. Nanda","E.P. Winer","H. Mukai","K. Tamura","A. Armstrong","M.C. Liu","H. Iwata","L. Ryvo","P. Wimberger","H.S. Rugo","A.R. Tan","L. Jia","Y. Ding","V. Karantza","P. Schmid"],"twitterCount":42,"altmetricId":51780264,"statusesArray":["1155999791903465472","1071518348842844161","1071140358896214016","1070955914826526720","1070713073017724928","1070658128222543872","1070596550068441088","1070531337713582080","1070519437936214018","1070450899414327296","1070443832725135365","1070425271130566665","1070391357959757824","1070359810669977601","1070352698858504197","1070351197922623491","1070350493912829953","1070350458307235840","1070349823038185477","1068461018794401792","1068435478456741888","1068428370071957504","1068420583938027521","1067897644574539776","1067661931731927040","1067518529761497088","1067443602761150464","1067407741566758913","1067406812129964036","1067398080000114688","1067394427885428737","1067316384252727296","1067307984232030208","1067305526533517313","1067294447870795777","1067292667682402304","1067290757172736001","1067265015147835392","1067234355557224448","1067225293373538305","1067219600448749568","1067164663824220160","1067160786110476288","1067160643315343360","1067159720476139520","1067159502154153984","1067159209991593984","1067159098142195713"]},{"title":"Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers","googleId":"rxpHSpgEVSQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312025","googleCitationCount":107,"googleAuthor":"NJ Birkbak","doi":"10.1093/annonc/mdz108","elsevierAuthor":"Watson G.A.","publicationName":"British Journal of Clinical Pharmacology","elsevierCoverDate":"2020-09-01","elsevierCoverDisplayDate":"1 September 2020","elsevierCitationCount":"2","altmetricAuthors":["S. Trebeschi","S.G. Drago","N.J. Birkbak","I. Kurilova","A.M. Cǎlin","A. Delli Pizzi","F. Lalezari","D.M.J. Lambregts","M.W. Rohaan","C. Parmar","E.A. Rozeman","K.J. Hartemink","C. Swanton","J B A G Haanen","C.U. Blank","E.F. Smit","R.G.H. Beets-Tan","H.J.W.L Aerts"],"twitterCount":43,"altmetricId":57474773,"statusesArray":["1291998628043722752","1291703526817533953","1155118278106390532","1150149681437188098","1150040042934550529","1149693206201872384","1149692409195819009","1111765757917052930","1111652878299680770","1111650907249205251","1111649902998761474","1111627873897598982","1111443351063023617","1111411860580917248","1111377863112966145","1111352062401527808","1111340565118025735","1111337804062183424","1111282243329290242","1111262460848295936","1111250625046691841","1111223123213340674","1111167105309782016","1111166550369800193","1111153726977384449","1111147415292145665","1111139651610468353","1111113350828707843","1111028406332936192","1110975828660097024","1110950548596051969","1110949999859433472","1110932584245198848","1110916218041462784","1110903046094184448","1110415182205841409","1110415147628019712","1110413533353787392","1110314487532249090","1110313430060134400","1110309424399147008","1110096294662557697","1110092326712602624","1110091029980565504","1110086921919836161","1109840870315044864","1109840240922017794","1109292443592122368","1109292199462633472","1109062807176118272","1109062806467276803","1109032453371510784"]},{"title":"Managing COVID-19 in the oncology clinic and avoiding the distraction effect","googleId":"4cTsg-LBZ_oJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)36373-0/abstract","googleCitationCount":118,"googleAuthor":"M Bartoletti","statusesArray":[]},{"title":"Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"GWGDRocMmTUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)32563-1/abstract","googleCitationCount":88,"googleAuthor":"PA Ascierto","statusesArray":[]},{"title":"Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001","googleId":"AaDdn2x1JM8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312372","googleCitationCount":110,"googleAuthor":"GJ Riely","doi":"10.1093/annonc/mdz131","elsevierAuthor":"Chen J.A.","publicationName":"Current Treatment Options in Oncology","elsevierCoverDate":"2020-07-01","elsevierCoverDisplayDate":"1 July 2020","elsevierCitationCount":"0","altmetricAuthors":["A.T. Shaw","G.J. Riely","Y.-J. Bang","D.-W. Kim","D.R. Camidge","B.J. Solomon","M. Varella-Garcia","A.J. Iafrate","G.I. Shapiro","T. Usari","S.C. Wang","K.D. Wilner","J.W. Clark","S.-H.I. Ou"],"twitterCount":93,"altmetricId":58967868,"statusesArray":["1275455165940695047","1275168291372388361","1275158792171409409","1275155833668673547","1275152473880170498","1275151000890798080","1226267552369827840","1173051144047931392","1171291052910764032","1155572819545272320","1155118019691065344","1154513262941233158","1154447293963071488","1154421123444084743","1154407694876467203","1154394395916959745","1132108351125352449","1131976872257052672","1131961666399162368","1131954384693284864","1131855024055816192","1131811959215742976","1131803034743234560","1131793546871214080","1131791450381770752","1131768592565800961","1131671405760786433","1131659175061155840","1131646198782103552","1131646039859945473","1131645055700066304","1131643209199656960","1123268937423163392","1121673017870782464","1121458242641592321","1121312264722812928","1121260886147108865","1121239456441356296","1121158460538748934","1121124583879450624","1121101652969365504","1121092819882512390","1121083754729082883","1121047238665482242","1121040265295355904","1120932190777421824","1120880213032878081","1120841418606546945","1120780841200832513","1120741010349289473","1120704889422843906","1120700089616535559","1120685554440392710","1120671291336474625","1120650507046006784","1120592768986800133","1120571155314724865","1120570590438612992","1120553498872041473","1120546275039109120","1120530799525335041","1120494356090191873","1120489865022513157","1120485053463764994","1120479171124314112","1120460127679778816","1120456072941178881","1120448967316312064","1120448253584125952","1120375962179215360","1120125993904160768","1119934192169570309","1119679994442190850","1119346666354638849","1119259356158136321","1119255137132802048","1119225521471131652","1119224086734020608","1119213585098403840","1119212410760585216","1119210992536256514","1119210787170476033","1117791635016806400","1117775404947755008","1117760368506548224","1117643309604847616","1117440616626106368","1117438076706525184","1117396336788365312","1117387040050622465","1117349359224594432","1117201622776545282","1117200394856357888","1117196008562266112","1117187553529139201","1117181987163398144","1117179377169702918","1117158932127080448","1117150027019956224","1117129473277747201"]},{"title":"Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 …","googleId":"tw8SztNGAmoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419459887","googleCitationCount":81,"googleAuthor":"","doi":"10.1093/annonc/mdz197","elsevierAuthor":"Wang F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-09-01","elsevierCoverDisplayDate":"1 September 2019","elsevierCitationCount":"54","altmetricAuthors":["F. Wang","X.L. Wei","F.H. Wang","N. Xu","L. Shen","G.H. Dai","X.L. Yuan","Y. Chen","S.J. Yang","J.H. Shi","X.C. Hu","X.Y. Lin","Q.Y. Zhang","J.F. Feng","Y. Ba","Y.P. Liu","W. Li","Y.Q. Shu","Y. Jiang","Q. Li","J.W. Wang","H. Wu","H. Feng","S. Yao","R.H. Xu"],"twitterCount":34,"altmetricId":62672149,"statusesArray":["1188848605945384960","1185246919913639937","1185177492610600960","1185172326658301952","1185101866671235072","1185090919168647168","1185057313436196864","1184948432252866560","1184893680282419201","1184873376478846977","1184871017895755776","1184856530648211456","1184841715989004288","1184841682115682305","1184841642466922501","1164936750847971329","1162798829403549697","1162798449580003330","1146696583435735040","1146420564447207424","1145985509648285696","1145733016741920773","1145731385266540546","1143860506744115200","1143805698033238018","1143783623679606784","1143769973246124032","1143759585238560769","1143736569188245504","1143704322066329601","1143663414608355328","1143625823645253638","1143624250391220225","1143622524787466242","1143622393417621514","1143560741015867393","1143552218357850112","1143517740956733440","1143516979581661184","1143512134808039424","1143511696297717766"]},{"title":"European cancer mortality predictions for the year 2019 with focus on breast cancer","googleId":"JuabRO68Ai0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311561","googleCitationCount":103,"googleAuthor":"M Malvezzi","doi":"10.1093/annonc/mdz051","elsevierAuthor":"AlOmeir O.","publicationName":"Supportive Care in Cancer","elsevierCoverDate":"2020-11-01","elsevierCoverDisplayDate":"1 November 2020","elsevierCitationCount":"1","altmetricAuthors":["M. Malvezzi","G. Carioli","P. Bertuccio","P. Boffetta","F. Levi","C. La Vecchia","E. Negri"],"twitterCount":62,"altmetricId":57250371,"statusesArray":["1170382975000895490","1152187163540414466","1139534817182265344","1126788973899202560","1125548356711927808","1121460693344165891","1120709990036201473","1120452275196051465","1120420746159906816","1120390909965811712","1120384088198742017","1120377216494211079","1120371800758792193","1120364080043261952","1120351264913657856","1120347856185876480","1120342998225760256","1120331973321469952","1120329759748186112","1120327754359222272","1120327733245022210","1120327535097729024","1120326788826259456","1120326418162827264","1114184480355487744","1114173506403618816","1113144095826956290","1109918135988244481","1109796737944875010","1108497631490260992","1108483205370396674","1108454764059258880","1108379094310404097","1108378873916542976","1108336205769392134","1108304548299456513","1108294533178105861","1108279279811551232","1108272003583275008","1108271949116071936","1108138548207763456","1108119299795968000","1108116363674087424","1108073919297269762","1108056068821676032","1108047857108611073","1108034139658379265","1108030663586955265","1108029147157356544","1108028600459001861","1108026251434971137","1108022833878392832","1108020670397583360","1108018558473326592","1108010919294988288","1107998726604361728","1107996757143621633","1107993901380571136","1107985627419762693","1107976482259984385","1107968392131153921","1107966952495038464","1107964070542655489","1107963763783880705","1107963374250483712","1107963099867504640","1107962849056473088","1107961080062640129","1107960259157594116","1107960197480361984","1107934203486838784"]},{"title":"Development and validation of an individualized nomogram to identify occult peritoneal metastasis in patients with advanced gastric cancer","googleId":"fhrRhhCgghkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310816","googleCitationCount":105,"googleAuthor":"D Dong","doi":"10.1093/annonc/mdz001","elsevierAuthor":"Dong D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-03-01","elsevierCoverDisplayDate":"1 March 2019","elsevierCitationCount":"85","altmetricAuthors":["D. Dong","L. Tang","Z -Y Li","M -J Fang","J -B Gao","X -H Shan","X -J Ying","Y -S Sun","J. Fu","X -X Wang","L -M Li","Z -H Li","D -F Zhang","Y. Zhang","Z -M Li","F. Shan","Z -D Bu","J. Tian","J.-F. Ji"],"twitterCount":7,"altmetricId":55091298,"statusesArray":["1117039906218336256","1116702546309967872","1105160114653315078","1105145254309695488","1105064502209449984","1105051304483872780","1105030621296963585","1093962270382673920","1093524823785918464"]},{"title":"Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA","googleId":"o5vl8moVR8QJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420360580","googleCitationCount":98,"googleAuthor":"MC Liu","doi":"10.1016/j.annonc.2020.02.011","elsevierAuthor":"Liu M.C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-06-01","elsevierCoverDisplayDate":"June 2020","elsevierCitationCount":"59","altmetricAuthors":["M.C. Liu","G.R. Oxnard","E.A. Klein","C. Swanton","M.V. Seiden","Minetta C. Liu","Geoffrey R. Oxnard","Eric A. Klein","David Smith","Donald Richards","Timothy J. Yeatman","Allen L. Cohn","Rosanna Lapham","Jessica Clement","Alexander S. Parker","Mohan K. Tummala","Kristi McIntyre","Mikkael A. Sekeres","Alan H. Bryce","Robert Siegel","Xuezhong Wang","David P. Cosgrove","Nadeem R. Abu-Rustum","Jonathan Trent","David D. Thiel","Carlos Becerra","Manish Agrawal","Lawrence E. Garbo","Jeffrey K. Giguere","Ross M. Michels","Ronald P. Harris","Stephen L. Richey","Timothy A. McCarthy","David M. Waterhouse","Fergus J. Couch","Sharon T. Wilks","Amy K. Krie","Rama Balaraman","Alvaro Restrepo","Michael W. Meshad","Kimberly Rieger-Christ","Travis Sullivan","Christine M. Lee","Daniel R. Greenwald","William Oh","Che-Kai Tsao","Neil Fleshner","Hagen F. Kennecke","Maged F. Khalil","David R. Spigel","Atisha P. Manhas","Brian K. Ulrich","Philip A. Kovoor","Christopher Stokoe","Jay G. Courtright","Habte A. Yimer","Timothy G. Larson","Charles Swanton","Michael V. Seiden","Steven R. Cummings","Farnaz Absalan","Gregory Alexander","Brian Allen","Hamed Amini","Alexander M. Aravanis","Siddhartha Bagaria","Leila Bazargan","John F. Beausang","Jennifer Berman","Craig Betts","Alexander Blocker","Joerg Bredno","Robert Calef","Gordon Cann","Jeremy Carter","Christopher Chang","Hemanshi Chawla","Xiaoji Chen","Tom C. Chien","Daniel Civello","Konstantin Davydov","Vasiliki Demas","Mohini Desai","Zhao Dong","Saniya Fayzullina","Alexander P. Fields","Darya Filippova","Peter Freese","Eric T. Fung","Sante Gnerre","Samuel Gross","Meredith Halks-Miller","Megan P. Hall","Anne-Renee Hartman","Chenlu Hou","Earl Hubbell","Nathan Hunkapiller","Karthik Jagadeesh","Arash Jamshidi","Roger Jiang","Byoungsok Jung","TaeHyung Kim","Richard D. Klausner","Kathryn N. Kurtzman","Mark Lee","Wendy Lin","Jafi Lipson","Hai Liu","Qinwen Liu","Margarita Lopatin","Tara Maddala","M. Cyrus Maher","Collin Melton","Andrea Mich","Shivani Nautiyal","Jonathan Newman","Joshua Newman","Virgil Nicula","Cosmos Nicolaou","Ongjen Nikolic","Wenying Pan","Shilpen Patel","Sarah A. Prins","Richard Rava","Neda Ronaghi","Onur Sakarya","Ravi Vijaya Satya","Jan Schellenberger","Eric Scott","Amy J. Sehnert","Rita Shaknovich","Avinash Shanmugam","K.C. Shashidhar","Ling Shen","Archana Shenoy","Seyedmehdi Shojaee","Pranav Singh","Kristan K. Steffen","Susan Tang","Jonathan M. Toung","Anton Valouev","Oliver Venn","Richard T. Williams","Tony Wu","Hui H. Xu","Christopher Yakym","Xiao Yang","Jessica Yecies","Alexander S. Yip","Jack Youngren","Jeanne Yue","Jingyang Zhang","Lily Zhang","Lori (Quan) Zhang","Nan Zhang","Christina Curtis","Donald A. Berry"],"twitterCount":315,"altmetricId":78603989,"statusesArray":["1355430624295849985","1355234516831334401","1355173365321850886","1355150967180652545","1355109581932773384","1350338916189044738","1350115909147488259","1334872028004798464","1334818986589106176","1334539440493096969","1333775358638895104","1333548556226093059","1333422671330222086","1333354935287767040","1333232774212427777","1333170705907605505","1333150678206844935","1333136623874269185","1333131019504001035","1333130673587187715","1333126323527675905","1333117543817613312","1333117353111003139","1333116605983813637","1333093214799224835","1333085180861542401","1333082500973924352","1333082378282164228","1333081943907258368","1333001524700717056","1332978905205125122","1332856286019428359","1332795931562045441","1332753389504131073","1332740867237572608","1332735159595126786","1332726131586424834","1332713485340270597","1332708715699392513","1332701629624233985","1332700783339565058","1332696514523705346","1332696421997441028","1332695493072351232","1332685336716173312","1332684853196812295","1332671130293952519","1332665111014682624","1332644498480959495","1332644483431796736","1332638123587670016","1332628899851874305","1332628642174824449","1332622321052495883","1332618465224634369","1332618395783749632","1332615748993363970","1332614334116204544","1332604411147907072","1332600025491394560","1332599482471616513","1332599277709824001","1332599042078109698","1332598424819159040","1332598395568087040","1332597884148199426","1332596015325720582","1332590342768615424","1332586915661455362","1332574394036727813","1332574251430318080","1332573901310676993","1332573324237443072","1332560345152548864","1332491610798649346","1332473633567109120","1332473119576092678","1332461374920937474","1332454165365149696","1332445291157610497","1332440352834416641","1332439343122747394","1332421309066846208","1332398174636568583","1332397549257433093","1332392636515295232","1332391338688589831","1332389472995078146","1332382687944962049","1332379403280666628","1332378640747728897","1332358878575603717","1332351970338803712","1332343985273237504","1332342394155536386","1332341201979273217","1332336310489653248","1332335036662689799","1332334756676177926","1332333835938250756","1332333616601378821","1332333222953414656","1332315289204248576","1332311514854936579","1332303096798732294","1332296957805543425","1332295405275590657","1332294700557078529","1332289878294487040","1332286876238143490","1332285081885536257","1332284080881274880","1332283514587389954","1332282301556912128","1332281709740630017","1332276555024883720","1332269979409002496","1332254229617127424","1332247494747676672","1332241873210118145","1332241713633644546","1332241684571287553","1332241076556541953","1314237211718676482","1307919259826302977","1292719119041802242","1288532989245366273","1284480807671754752","1283095396953337857","1282118574530859008","1282106190705520640","1281837946534940673","1281682384035950593","1281622181357719554","1281581190512697344","1281517331806670849","1281478292617363456","1281468702853074945","1281455360591761409","1281342817693048832","1281341779774562309","1281282960050790400","1281255378383179783","1281245869061308416","1281239275313512450","1281237198533246976","1281212524227002369","1281206795239714816","1281194716671938561","1281167736832512000","1281156860171759616","1281139699541819392","1281135333057363968","1281129460385943552","1281123841796866053","1281088392726487040","1281077210368090112","1281075284482064384","1281073302090342400","1281072900313923584","1281072642980749313","1281062418156793857","1281053267082964992","1281049169034125312","1281038040870408194","1281037357177688064","1281026759815688192","1281020604762767369","1281019486691299328","1281009464376729602","1281006595158106112","1281000532467908608","1280997776919162881","1280995264539627525","1280993258148106240","1280986022248054798","1280985864320028675","1280985140643139585","1280983936697393152","1280982828621144064","1280977149634191360","1280977037214261254","1280973844426231809","1280970343876907010","1280969619780575232","1280969143500648461","1280968398780973057","1280967361819037702","1280965493361426432","1280964748738203648","1280959956762734594","1280954313507057667","1280953521597267968","1280953155665223681","1280942823617986560","1280942779909226497","1280941890960068611","1280940580210642946","1280937270426640387","1280936356999503872","1280935448030871552","1280935225883865100","1280933369740767233","1280933281140297730","1280931897074429955","1280930214034497537","1280930051651964929","1280927159310303232","1280926051015831555","1280925095159042050","1280924989810552832","1280923339318595584","1280920822811631616","1280919905831989249","1280916758258483201","1280914379500851203","1280914345996713984","1280911117074812933","1280911085537812481","1280910951328485378","1280909229210120192","1280904808170434560","1280902956343230465","1280902725778243585","1280902662926598150","1280900125456338944","1280898665742241795","1280898513396805634","1280894475984703489","1280893141604798465","1280891877521317888","1280890759697350656","1280890007851540481","1276449747818119169","1276419879210549248","1273251407148138497","1270528951270719490","1270506823859277836","1270480114787201025","1270472512913186816","1270468475526545410","1270363743621386243","1270282809429630990","1270251055771770881","1270201158074806272","1270169036396118019","1270162183171825666","1270151436593176576","1270115650250264577","1270111661832245249","1270059513752817664","1270049491320811525","1270024619651710977","1269990070356004864","1269979646705065985","1269978193349480455","1269976147326128128","1269975715711258624","1269961343756644354","1269947655926566913","1269945157375479808","1269943158202400769","1269941880881418240","1269941771200593920","1269941320296075265","1269938822290247680","1264618832360091650","1264513908661989382","1264508069565825024","1264327422788452352","1264324791764504578","1262766950050156548","1259877977837506560","1258564829582786561","1258563916709363714","1258489052761817088","1257938663926714369","1255951059698270209","1255935820688764929","1255882588276903938","1255713167688241152","1255713000046157824","1255606826101624832","1255601160141979649","1255446841946181633","1255445338166562817","1255427679794454529","1255419327467212801","1255415064061980680","1255410083007209474","1255406035818422275","1255385086247174145","1255384923835334656","1255379993628225542","1255373825266638848","1255369051301392384","1255291760198266883","1255267160521400321","1255261213048651776","1255257478352326657","1255251889500930048","1255235922842525697","1255233841444409347","1255220403137662978","1255219619985489925","1255219485453287429","1255218626371690504","1255206243955871746","1255203809803960321","1255203527917355009","1255200761438486528","1255200633352830978","1255200234310901766","1255199687059083269","1255199457072820225","1255199353507102720","1255198965903097862","1255198857845248000","1255198764974866434","1255198644732649472","1254517067270819844","1254509290334883841","1252424886871457792","1251517290698485761","1250580301673140225","1249690923400749058","1249578817716277250","1249552398315474944","1249546558908989440","1249544520334577664","1249508480286851073","1249135199251767296","1249135177139466243","1247798769082437637","1247712268772573185","1247617629294116868","1247587023214522371","1247448861196591104","1246899268838883328","1246895639566278656","1246117034007515138","1246097796857573377","1245978846798721024","1245795385051758593","1245669480887394304","1245668500972208128","1245633220592332800","1245304391466352641","1245294503822409730","1245257100718112768","1245221278513909761","1245207618009935874","1245194911663734786","1245116895793217536","1245078204349636608","1245024934335782914","1245018659057217536","1245007248696410113","1245006707383812101","1245005466326859780","1244991906850820096","1244988410365763585","1244975649720328193","1244951202925690880","1244946970998968320","1244939160248561665","1244935237747998720","1244931005712130049","1244923939199102977","1244922660011806723","1244914887731679235","1244910807907008514","1244903995015135232","1244903907198935045","1244903640533360640","1244900889988665351","1244900155914059776","1244899939454529536","1244899429775269888","1244897673007771649","1244896068208394240","1244894622943510528","1244893836532281344","1244892057526730753","1244891902362685441","1244891513814790145","1244890187605442560","1244887033547558912","1244882777595686913","1244851232830885888"]},{"title":"Vitamin D supplementation and total cancer incidence and mortality: a meta-analysis of randomized controlled trials","googleId":"p_bZDQKIRaAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311597","googleCitationCount":88,"googleAuthor":"DH Lee","doi":"10.1093/annonc/mdz059","elsevierAuthor":"Yeh W.Z.","publicationName":"British Journal of Pharmacology","elsevierCoverDate":"2020-09-01","elsevierCoverDisplayDate":"1 September 2020","elsevierCitationCount":"1","altmetricAuthors":["N. Keum","D.H. Lee","D.C. Greenwood","J.E. Manson","E. Giovannucci"],"twitterCount":46,"altmetricId":56012753,"statusesArray":["1360643935568281600","1350054638700019714","1344314233056493570","1185109483472740353","1180789631807361024","1148883919087001600","1148880700164231168","1113793293429694470","1113134439998078976","1113129245444902913","1113128194385874944","1113113138579288066","1111972783154778112","1111197364243611648","1110949348538568711","1110917588836642816","1110874530082361344","1110873911435116545","1110823168405585920","1110797129881186304","1110795671098089472","1110771539002167297","1110759794531545088","1110743152703365124","1110726449374351361","1110709148818309120","1110672438482927617","1110668321333088256","1110643022616805377","1110638156347555852","1110630559640899584","1110618713944977411","1110613488186073088","1110611576359452672","1110611364349968385","1110584290620989440","1110583890933096449","1110580565588303872","1107012861241499648","1107009199005974534","1100833414587056128","1100832385086689281","1100668610710773760","1100647928627150848","1100640675199098880","1100463980185825282","1100459688905371650","1100457879373574154","1100453935175880704","1100168061313839104","1100089772880654336","1100087395955834880","1099961388859117568","1099961162077220864"]},{"title":"Addition of docetaxel to hormonal therapy in low-and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the …","googleId":"aJ-Ko0Ibtj4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325527","googleCitationCount":78,"googleAuthor":"","doi":"10.1093/annonc/mdz396","elsevierAuthor":"Clarke N.W.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-03-01","elsevierCoverDisplayDate":"March 2020","elsevierCitationCount":"0","altmetricAuthors":["N.W. Clarke","A. Ali","F.C. Ingleby","A. Hoyle","C.L. Amos","G. Attard","C.D. Brawley","J. Calvert","S. Chowdhury","A. Cook","W. Cross","D.P. Dearnaley","H. Douis","D. Gilbert","S. Gillessen","R.J. Jones","R.E. Langley","A. MacNair","Z. Malik","M.D. Mason","D. Matheson","R. Millman","C.C. Parker","A.W.S. Ritchie","H. Rush","J.M. Russell","J. Brown","S. Beesley","A. Birtle","L. Capaldi","J. Gale","S. Gibbs","A. Lydon","A. Nikapota","A. Omlin","J.M. O'Sullivan","O. Parikh","A. Protheroe","S. Rudman","N.N. Srihari","M. Simms","J.S. Tanguay","S. Tolan","J. Wagstaff","J. Wallace","J. Wylie","A. Zarkar","M.R. Sydes","M.K.B. Parmar","N.D. James"],"twitterCount":179,"altmetricId":67326289,"statusesArray":["1301891449357848583","1301534845189984259","1301525725623848960","1301524980090441730","1301453364870422529","1301445568825180160","1301433539876003840","1222968921038512128","1222931938593259527","1222925343461445635","1222924327991021568","1214728781845467142","1214597060500082690","1214522437037101057","1214493680310083584","1213064037124231170","1179612907535032321","1179292683132690432","1179278951547572224","1179238143633047557","1179178593064296448","1179140202813693954","1179001536971718656","1178999854598688768","1178719918126174209","1178695031085027329","1178355341186277376","1178343417757290497","1178325806495490050","1178309478594285569","1178239679512096768","1178220679226888192","1178189233036636160","1178176362483466240","1178100218841194496","1178090042713149441","1178061219929964545","1178050158832914432","1178044936538730496","1178011866423087105","1177998772187680768","1177993980450967553","1177987142913388545","1177986648103149568","1177986246439772160","1177979486274490368","1177960097705799685","1177959244395614208","1177950831284543489","1177933931859075072","1177915838868811783","1177910806622674949","1177909646851497984","1177905933499977729","1177879545862639616","1177876365023956992","1177876170311757824","1177874753991917568","1177873920797663232","1177870781948334082","1177865761487908864","1177864713922850816","1177864411286892544","1177864411039420416","1177864404743753728","1177864309428252672","1177864178817802240","1177861116648665088","1177858618089246722","1177857611049381888","1177856945841029121","1177856230779318273","1177855543920254976","1177854544858042368","1177853886230650880","1177848262881099776","1177844344100777984","1177839609297932289","1177837298223849473","1177832258729893888","1177824670344732673","1177817775257116672","1177817183633788928","1177806427282382849","1177797992033718272","1177796882149588992","1177795934048178176","1177786616913563648","1177783091751833600","1177778516244480000","1177777580331737088","1177767890575122432","1177758098980839424","1177756153255727104","1177756105159712769","1177741869192826880","1177732651614011392","1177726414277218304","1177723169261719552","1177717309332439041","1177715138033401856","1177712839877959681","1177712565994082304","1177704039645089792","1177699825736933376","1177699012356521985","1177697567783604224","1177696476991905792","1177695668636442626","1177695611656654848","1177694252643635201","1177693231196364806","1177693094000693249","1177692246281527301","1177691225270423561","1177691012883517443","1177690279312277507","1177689194740768768","1177677344049422337","1177673299834413057","1177672878453645317","1177668267529273345","1177665912918310913","1177653834811936769","1177651984880603136","1177650061725097984","1177648881905086465","1177644203171631105","1177644068098203650","1177641687167963141","1177640383842414593","1177637127271661569","1177635437705338881","1177633691591270400","1177633630484602881","1177633171124432896","1177632985924931585","1177631748395536386","1177629350285500417","1177627925925056514","1177623732011065344","1177622590854066176","1177621932176543745","1177619196152307712","1177616848466128896","1177615601122103297","1177615543035158530","1177615379897704448","1177614367703126016","1177613344666112006","1177613300366008321","1177612856151248896","1177612717731000321","1177610824162127872","1177609651896094721","1177608921168715777","1177607103533350912","1177606607745761280","1177605987718422530","1177605725557686272","1177605379703881738","1177605255803985920","1177605035762606080","1177604782955077632","1177604625563885577","1177604393274769409","1177604303474659328","1177604066706432002","1177603955758682115","1177599761219670023","1177599331295088640","1177598760521781248","1177597870213488641","1177597121517772800","1177596254525759488","1177595937281253377","1177594004197842945","1177593841127493632","1177592808426729472","1177592030014234624","1177591921675403264","1177591738908598273","1177590942011928576","1177590356319395843","1177590235842187264","1177590182482206723","1177586525858684929","1177585270234828801","1177584236460556289","1177582905402347520","1177582358532411394","1177581488440664064","1177581110580191232","1177580784527585281","1177577794341089280","1177577073092759558","1177576026920144896","1177575837169790977","1177574574294257664","1177573397141819398"]},{"title":"Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer","googleId":"q2NPQJHIb-wJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312311","googleCitationCount":84,"googleAuthor":"MH Hong","doi":"10.1093/annonc/mdz123","elsevierAuthor":"Kas B.","publicationName":"JAMA Oncology","elsevierCoverDate":"2020-07-01","elsevierCoverDisplayDate":"July 2020","elsevierCitationCount":"13","altmetricAuthors":["C.G. Kim","K.H. Kim","K.-H. Pyo","C.-F. Xin","M.H. Hong","B.-C. Ahn","Y. Kim","S.J. Choi","H.I. Yoon","J.G. Lee","C.Y. Lee","S.Y. Park","S.-H. Park","B.C. Cho","H.S. Shim","E.-C. Shin","H.R. Kim"],"twitterCount":36,"altmetricId":58956835,"statusesArray":["1123342799364083714","1120530788129431552","1120126008282185729","1119737023936569344","1119669111569682432","1119636799448600576","1119514643821678592","1119490753875542018","1119484085427154944","1119414988098220037","1119367283468591104","1119276327377494017","1119274944897196032","1119272570635919361","1119259085428412416","1119256349345337344","1119246032787976193","1119246017537306625","1119238721331535873","1118292837223682048","1118156222421721088","1117910852089339904","1117897365564739585","1117880342243762176","1117880004577116161","1117628290666098688","1117490042660958211","1117413303108530178","1117413244996673543","1117396152024993792","1117388599266353153","1117388077939548160","1117265585488793601","1117203708729675776","1117055298579992582","1117055124243791874","1117054490178400256","1117031385930305536","1117029500007665664","1116991448858136577","1116987811276701696","1116984955786153985","1116982238783184896","1116980980290662401"]},{"title":"IMpower110: interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) …","googleId":"oiOwkryJ6fMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603595","googleCitationCount":78,"googleAuthor":"","doi":"10.1093/annonc/mdz293","elsevierAuthor":"Landre T.","publicationName":"Drugs and Aging","elsevierCoverDate":"2020-10-01","elsevierCoverDisplayDate":"1 October 2020","elsevierCitationCount":"0","altmetricAuthors":["D. Spigel","F. de Marinis","G. Giaccone","N. Reinmuth","A. Vergnenegre","C.H. Barrios","M. Morise","E. Felip","Z.G. Andric","S. Geater","M. Özgüroğlu","S. Mocci","M. McCleland","I. Enquist","K.M. Komatsubara","Y. Deng","H. Kuriki","X. Wen","J. Jassem","R.S. Herbst"],"twitterCount":1,"altmetricId":68179413,"statusesArray":["1260767800336871424"]},{"title":"Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed …","googleId":"m1ODQena_u8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310464","googleCitationCount":70,"googleAuthor":"S Lu","doi":"10.1093/annonc/mdy554","elsevierAuthor":"Wu Y.L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-02-01","elsevierCoverDisplayDate":"1 February 2019","elsevierCitationCount":"52","altmetricAuthors":["Y.-L. Wu","D. Planchard","S. Lu","H. Sun","N. Yamamoto","D.-W. Kim","D.S.W. Tan","J.C.-H. Yang","M. Azrif","T. Mitsudomi","K. Park","R.A. Soo","J.W.C. Chang","A. Alip","S. Peters","J.-Y. Douillard"],"twitterCount":2,"altmetricId":53798853,"statusesArray":["1222022481373888512","1162022921843253248","1083733948134498305"]},{"title":"Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression","googleId":"AJ6vBhtPHH8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419609841","googleCitationCount":63,"googleAuthor":"JF Gainor","doi":"10.1093/annonc/mdz288","elsevierAuthor":"Aguilar E.J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-10-01","elsevierCoverDisplayDate":"1 October 2019","elsevierCitationCount":"44","altmetricAuthors":["E.J. Aguilar","B. Ricciuti","J.F. Gainor","K.L. Kehl","S. Kravets","S. Dahlberg","M. Nishino","L.M. Sholl","A. Adeni","S. Subegdjo","S. Khosrowjerdi","R.M. Peterson","S. Digumarthy","C. Liu","J. Sauter","H. Rizvi","K.C. Arbour","B.W. Carter","J.V. Heymach","M. Altan","M.D. Hellmann","M.M. Awad"],"twitterCount":161,"altmetricId":65313926,"statusesArray":["1202867783282909185","1202809627722821632","1202178117101600768","1202172929896787971","1201995783870046208","1201960406203412480","1201756041974886400","1200773151577313280","1200464760858386432","1199748434472898561","1199561518964076544","1199512184327294977","1199456499942248448","1199456137701199877","1199447671552872448","1199431225557082115","1199402559364124672","1199395424148295681","1199392520922451968","1199387067412893697","1199382457163714560","1199382318168698881","1178410614923726848","1178382849491308544","1178345247136464897","1178326187745128448","1176931921319927809","1176930698533441536","1176922122582728704","1176907963157684230","1176874036489609217","1176864497706795009","1176815549944422402","1176614330521071616","1176608694462799873","1176606711064539136","1176585741733961729","1176576086496464896","1176559586964398082","1176524307742117890","1176522301182889984","1176519367703576579","1176515848434905088","1176512659308634113","1176511400065134592","1176170868986138624","1168966968902377472","1168964744348352515","1168518314550812674","1168242649331130368","1167101896609415168","1167054669962760193","1166961036714545152","1166960918590296064","1166859846697795585","1166858035664490496","1166809006628921350","1166808191369383936","1166774502803607552","1166768103201628160","1166757096605585415","1166729096425947137","1166725336546996225","1166725284575555586","1166718538251419648","1166713485176254464","1166707793036009472","1166706051741364226","1166699288010866688","1166683296572551169","1166672044114579456","1166669687519768576","1166668383930200065","1166667486487613441","1166666988329918464","1166381290167422977","1166297977960435712","1166255832889286656","1166042363917193216","1166022596527304704","1165991033504587776","1165989573094068224","1165966685326708737","1165954950716956672","1165942041681022977","1165918066586374144","1165879035517460481","1165858638185009153","1165856472007360512","1165849358518169601","1165787730615394304","1165766906978041856","1165744829894053888","1165720310446022656","1165670606878191617","1165663838819246080","1165651500325978112","1165634743456665601","1165625641590501377","1165606234973769730","1165598646668288000","1165597724399435776","1165596072011587584","1165595883997683712","1165570732602138624","1165545478290690048","1165499796154540032","1165454932666961921","1165433099041198081","1165399218778968064","1165397437428551681","1165376252988948481","1165348852012134401","1165309253835468800","1165303773734064129","1165301481601454080","1165285727401402368","1165285556034707456","1165278720808165376","1165271792791052289","1165268913728282624","1165265979309547525","1165257476264091648","1165256622710624257","1165252243731316736","1165243500562014213","1165239502580801536","1165234146383450113","1165201618431807488","1165182728276283392","1165180255516200960","1165176588880744449","1165171836637863938","1165162511781519360","1165160015864320000","1165150378725400576","1165148838593585153","1165146275404308480","1165145659856437248","1165130005988487168","1165124353475928064","1165014304372002816","1164986880447963138","1164978020064661506","1164968533333331968","1164910400934051841","1164901281225412608","1164890020362293249","1164881443404812288","1164878011696656384","1164873974825803777","1164871102562045952","1164865332558929920","1164851799871885313","1164842512021778434","1164838455852974080","1164814847369867264","1164807649554075659","1164793833948794880","1164785129228607488","1164784604219240448","1164784251671154688","1164779178018799616","1164768240255455232","1164765184268783616","1164762931503853568","1164761911004561408","1164760953814077441","1164760126286229504","1164748865301442562","1164746377349533696","1164723628518174722","1164708724734251008","1164699464096997376","1164695201992126465","1164685252712914946","1164677490910126080","1164677185225089026","1164674668571140100","1164674558177103872","1164673999789445120","1164673845103661056","1164666037859733510","1164662723218759681","1164659318815383553","1164658928766148614","1164658150772887553","1164655509405913090","1164655223836749826","1164651874248810496","1164651755864502272","1164651552805548032","1164651206645616640"]},{"title":"ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research","googleId":"TfDayX7T_hMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419459929","googleCitationCount":84,"googleAuthor":"C Marchiò","doi":"10.1093/annonc/mdz204","elsevierAuthor":"Marchiò C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-09-01","elsevierCoverDisplayDate":"1 September 2019","elsevierCitationCount":"67","altmetricAuthors":["C. Marchiò","M. Scaltriti","M. Ladanyi","A.J. Iafrate","F. Bibeau","M. Dietel","J.F. Hechtman","T. Troiani","F. López-Rios","J.-Y. Douillard","F. Andrè","J.S. Reis-Filho"],"twitterCount":92,"altmetricId":63080177,"statusesArray":["1212386554544570369","1204067718057644033","1198939112788709376","1198819356727230469","1185845804243783682","1176453064259244032","1176306238767763457","1176202574191632385","1176170975072858112","1176168555332562944","1176166315066896385","1176146694813212676","1176068178864148482","1159467150698041344","1159418799642296321","1158993588962897920","1158331950777716736","1156987335554359296","1156977831555096576","1156976688342929413","1156934894225780736","1156923953807597568","1156851813284503557","1156814509857824768","1156804138715484160","1156713522467880966","1156636233734529025","1156604794716532737","1156596334650155010","1156572887752552450","1156557179622576129","1156555201538666496","1156543820156297217","1156516849372270592","1156511099229003776","1156509330931376128","1156509145987735552","1156507994722635776","1156507871363969025","1156507380760399872","1153585322346733568","1149370707681394688","1149238222758789120","1149234370252857344","1148179846067085318","1148116417373528065","1147675590461255680","1147590539879075840","1147357812714065920","1147176799857569793","1147101431553560576","1147060267878146048","1147027255278919680","1147008277944950784","1146895817401413632","1146886071311065088","1146869054428405761","1146862577030447106","1146856817584168960","1146854922949922816","1146853152681074688","1146814462676148225","1146809479469699072","1146795041870012417","1146786291406839809","1146781447111528452","1146762374411513861","1146757997374377985","1146735858965536769","1146707706922881024","1146702549858365440","1146695620448661505","1146695056855883777","1146694605494247424","1146677359921258496","1146675549131157504","1146674912368762880","1146666789948010498","1146665072938405889","1146658241419628544","1146658130857811970","1146656275163426816","1146655004322873344","1146649606631153664","1146638915840950274","1146638235440832513","1146635681428455424","1146620979826720773","1146575070103343104","1146573318490918912","1146570256963514368","1146565909693136897","1146562291305013248","1146529023566241794","1146528743772610560","1146526008096542727","1146523228313128960","1146522198204702721","1146515518154780672","1146514727855484928"]},{"title":"Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or …","googleId":"MtuPwyffdCMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310361","googleCitationCount":70,"googleAuthor":"","doi":"10.1093/annonc/mdy540","elsevierAuthor":"Boku N.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-02-01","elsevierCoverDisplayDate":"1 February 2019","elsevierCitationCount":"55","altmetricAuthors":["N. Boku","M.-H. Ryu","K. Kato","H.C. Chung","K. Minashi","K.-W. Lee","H. Cho","W.K. Kang","Y. Komatsu","M. Tsuda","K. Yamaguchi","H. Hara","S. Fumita","M. Azuma","L.-T. Chen","Y.-K. Kang"],"twitterCount":21,"altmetricId":53767604,"statusesArray":["1133112218709630977","1133104929932025856","1133084639852158977","1133084250574675968","1130469373167132672","1102216734247927809","1101934253959458817","1101933807496761345","1101831869929271297","1088991935325528064","1088857266772738049","1088720602532331521","1088507541968093185","1088506869142953985","1088506243877126144","1088502011610378240","1088499296260026370","1088468319781507072","1088465333038526464","1088457799485386752","1088454985245847552","1088451382561013761"]},{"title":"PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous …","googleId":"WgptB7ZVt1wJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603996","googleCitationCount":70,"googleAuthor":"J Mateo","doi":"10.1093/annonc/mdz394.039","elsevierCitationCount":0,"altmetricAuthors":["M. Hussain","J. Mateo","K. Fizazi","F. Saad","N.D. Shore","S. Sandhu","K.N. Chi","O. Sartor","N. Agarwal","D. Olmos","A. Thiery-Vuillemin","P. Twardowski","N. Mehra","C. Goessl","J. Kang","J. Burgents","W. Wu","A. Kohlmann","C.A. Adelman","J. de Bono"],"twitterCount":0,"altmetricId":68179451,"statusesArray":[]},{"title":"How liquid biopsies can change clinical practice in oncology","googleId":"TtpBLXHkp8cJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419609725","googleCitationCount":55,"googleAuthor":"G Siravegna","doi":"10.1093/annonc/mdz227","elsevierAuthor":"Siravegna G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-10-01","elsevierCoverDisplayDate":"1 October 2019","elsevierCitationCount":"40","altmetricAuthors":["G. Siravegna","B. Mussolin","T. Venesio","S. Marsoni","J. Seoane","C. Dive","N. Papadopoulos","S. Kopetz","R.B. Corcoran","L.L. Siu","A. Bardelli"],"twitterCount":57,"altmetricId":64515702,"statusesArray":["1233815064139964416","1233747255208927232","1226834989792288770","1226650447827656704","1226597394193829894","1226505015252127747","1226503046919852032","1226497540457193472","1226494584655618049","1226280025776967681","1226223667824209926","1226216912134246400","1194122282282536961","1194117379417993216","1163407108685160448","1163022500437118976","1163004188684689409","1162994767980113920","1161800852421709825","1160743988158222336","1160729127638523905","1160727683317272577","1158842254703808512","1158723910466252805","1158463995361267712","1158407333887860737","1158389789176950786","1158353093102358528","1158329359775612928","1158163214238175233","1158161848283406342","1158159698425610240","1158133624308416513","1158126010690408448","1158060949645025291","1158043949883244546","1158043528473088000","1158041106241613824","1158034826517209088","1158022607704248323","1157995632403132416","1157993514015318016","1157982626608799745","1157982250962771968","1157975815365283841","1157969207545479168","1157955383702372355","1157954248476262400","1157917138646196224","1157916482321494016","1157916455461097472","1157912035570659333","1157904348464254976","1157858263699902464","1157853846267408384","1157787827041554433","1157787072008077315","1157771856939819008","1157768524955365377","1157767423082340353","1157762262230323203","1157722388982849536","1157700747464716288","1157692670770388993"]},{"title":"Correction to:“Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”","googleId":"_3pKC04ni6sJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31152-4/abstract","googleCitationCount":72,"googleAuthor":"A Vogel","statusesArray":[]},{"title":"A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer …","googleId":"f__GGZDtafkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312785","googleCitationCount":102,"googleAuthor":"S Loibl","doi":"10.1093/annonc/mdz158","elsevierAuthor":"Loibl S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-08-01","elsevierCoverDisplayDate":"1 August 2019","elsevierCitationCount":"73","altmetricAuthors":["S. Loibl","M. Untch","N. Burchardi","J. Huober","B.V. Sinn","J.-U. Blohmer","E.-M. Grischke","J. Furlanetto","H. Tesch","C. Hanusch","K. Engels","M. Rezai","C. Jackisch","W.D. Schmitt","G. von Minckwitz","J. Thomalla","S. Kümmel","B. Rautenberg","P.A. Fasching","K. Weber","K. Rhiem","C. Denkert","A. Schneeweiss"],"twitterCount":47,"altmetricId":60557668,"statusesArray":["1166695812862304256","1163314373676474368","1162795801388691457","1162795148104863744","1161505507754070016","1161453021424967680","1161331657284227072","1161293443944996866","1161288753064943619","1161287918566223872","1161254802577416199","1161143640686678016","1161127783168401408","1161122378807558144","1161080419279941634","1161052565221642240","1161039722006773760","1161022665488027649","1160978516890046466","1160949972168167424","1160943310195908608","1160943017336770560","1160910321990754305","1160906967042445313","1160906220565401600","1160900383125807104","1160899967373811712","1160898605647106048","1160898184442458114","1160880401000357889","1160874602861662208","1160865704985473024","1160865014745653248","1132724215310897153","1132132693817225216","1131994257051594752","1131970428488970240","1131963312546017280","1131910953027739648","1131872024773763073","1131871461524746240","1130460181844746240","1129727639151960067","1129446240624582657","1129431876777725952","1129378799693586434","1129365189785260033","1129289877286211584","1129264860318064640","1129260520211660800","1129259443240230912","1129247734765170688","1129243187887955968","1129228883700736001","1129131367206412295"]},{"title":"ClarIDHy: a global, phase III, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an …","googleId":"jfU-RHVtjGkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341960387X","googleCitationCount":68,"googleAuthor":"","doi":"10.1093/annonc/mdz394.027","elsevierAuthor":"Vienot A.","publicationName":"Clinics and Research in Hepatology and Gastroenterology","elsevierCoverDate":"2020-11-01","elsevierCoverDisplayDate":"November 2020","elsevierCitationCount":"0","altmetricAuthors":["G.K. Abou-Alfa","T. Macarulla Mercade","M. Javle","R.K. Kelley","S. Lubner","J. Adeva","J.M. Cleary","D.V. Catenacci","M.J. Borad","J.A. Bridgewater","W.P. Harris","A.G. Murphy","D.-Y. Oh","J. Whisenant","B. Wu","L. Jiang","C. Gliser","S.S. Pandya","J.W. Valle","A.X. Zhu"],"twitterCount":0,"altmetricId":69142278,"statusesArray":[]},{"title":"Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of> 2 …","googleId":"ubmiQDXRcIgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312104","googleCitationCount":81,"googleAuthor":"Y Fradet","doi":"10.1093/annonc/mdz127","elsevierAuthor":"Lebossé F.","publicationName":"Bulletin du Cancer","elsevierCoverDate":"2020-10-01","elsevierCoverDisplayDate":"October 2020","elsevierCitationCount":"0","altmetricAuthors":["Y. Fradet","J. Bellmunt","D.J. Vaughn","J.L. Lee","L. Fong","N.J. Vogelzang","M.A. Climent","D.P. Petrylak","T.K. Choueiri","A. Necchi","W. Gerritsen","H. Gurney","D.I. Quinn","S. Culine","C.N. Sternberg","K. Nam","T.L. Frenkl","R.F. Perini","R. de Wit","D.F. Bajorin"],"twitterCount":43,"altmetricId":59897015,"statusesArray":["1148280377884250115","1148258061808783362","1148243546958454784","1146272281066397697","1145739784553238530","1145614792721195008","1144114802039676928","1144108381818576896","1143961191292837888","1131528859126575105","1131476091816820736","1131290193196212227","1131265614188830727","1131099124361826305","1131097988288241664","1131074218320453637","1131069763013226502","1131051975284580352","1131050281855176704","1131048296699580416","1129626706988421120","1129317248081059841","1129146713657270272","1129140147868569600","1129113790509920257","1129092933846818817","1129006050559057921","1126865802181906433","1126736051576291333","1126545928608014338","1126416397662289920","1126409073291931648","1126372787231371264","1126259162315358208","1126224253240655872","1126170268995661826","1126129604136189953","1126118759578517505","1126116595355590656","1126112044841783296","1126102201611505664","1126074386623102976","1126068257423802369","1126065008671109120","1126064197924732929","1125712257000906752","1125397558245888000","1124568109753556992"]},{"title":"Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"keaXfXE_JPQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)36394-8/pdf","googleCitationCount":44,"googleAuthor":"M Falconi","statusesArray":[]},{"title":"EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer","googleId":"sHKJXYmEJUUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312724","googleCitationCount":66,"googleAuthor":"HA Yu","doi":"10.1093/annonc/mdz141","elsevierAuthor":"Hastings K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-08-01","elsevierCoverDisplayDate":"1 August 2019","elsevierCitationCount":"53","altmetricAuthors":["K. Hastings","H.A. Yu","W. Wei","F. Sanchez-Vega","M. DeVeaux","J. Choi","H. Rizvi","A. Lisberg","A. Truini","C.A. Lydon","Z. Liu","B.S. Henick","A. Wurtz","G. Cai","A.J. Plodkowski","N.M. Long","D.F. Halpenny","J. Killam","I. Oliva","N. Schultz","G.J. Riely","M.E. Arcila","M. Ladanyi","D. Zelterman","R.S. Herbst","S.B. Goldberg","M.M. Awad","E.B. Garon","S. Gettinger","M.D. Hellmann","K. Politi"],"twitterCount":138,"altmetricId":60461303,"statusesArray":["1289232692991598592","1222859758782308352","1216165690056593408","1196399261342035969","1195071563298508800","1187876215652265989","1187791381260980224","1187706268372344835","1187704874433036288","1187704640642715650","1187702341383925760","1187700485341503490","1187700437924884481","1185943553408671745","1184064902446698496","1183980772832829440","1183969888211292161","1181567262727139328","1181542228516311040","1176982182767845377","1176214215851421697","1176180224523997184","1176131637647568903","1176125251756933121","1175960266665844736","1175787734960660480","1175757760694276096","1175755286495268865","1175748609129811968","1175728424490545152","1175699805777092608","1175697733476388864","1175682399314894848","1175672898067075073","1175666392479105025","1175643016809213952","1175611280255643651","1175586881062481922","1175547716920840192","1175533861167456256","1175531027365842950","1175516250446938112","1175509380927774720","1175505366609776640","1175503909865119744","1175485299515957250","1175467683342684162","1175465511351738369","1175458222259486720","1175455094764187653","1175440642882883585","1175435994683904005","1175430806086541314","1175426484715974657","1175414724424589317","1175413930941763586","1175409487345344512","1175397762474467328","1175396827241336832","1175392605577703424","1175375910977134592","1175351486051758080","1175347017998045184","1175329571471855616","1175323445044875264","1175321102651969536","1175319630036033536","1175284133888765952","1175274254130208768","1175268901749501953","1175266846469054464","1175259029343547392","1175253560088563713","1175243240762535936","1175242947975159809","1175237955784282112","1175191387509145600","1175180470306234369","1175175326852374529","1175170753140072448","1175163575385542656","1175161423758004224","1175157487747653632","1175157264170258432","1175156710106963968","1175156221910892545","1175152516637417472","1175148100836646912","1175129066921500678","1175109785148149761","1175098174186246144","1175082781073989633","1175072469759094785","1175068094160658432","1175058830759202816","1175057843390537730","1147181511428530177","1147178057297305601","1146334149864644609","1146002502464225285","1145979650952372224","1145883428556017664","1145868312712294400","1145815317303767041","1145761259981135872","1145559758834950144","1145523794511048704","1145273451042824192","1145230210612092928","1145229568053338113","1145226647160774656","1145024527514185729","1145014245978824705","1144966422017335302","1144963377955053568","1144880923206459393","1144880823998603264","1144874839926333440","1144870350422859777","1144844577121193984","1144837938577956864","1144837764392742914","1144825897381502977","1144803335507070976","1144787361017974784","1144783366526525440","1144780257075093505","1144776635863822336","1144770054170578944","1144752818416508928","1144752357030465536","1144734693121810433","1144732181769666560","1144732046180270081","1144720886307655682","1144720613447258114","1144720446149025792","1144720120872390656","1144665787409555456","1144646918729019392","1144593702020636674","1144586990676934657","1144575271095246848","1144566504811139073","1144532189763137537","1144514064284028928","1144491895759839233","1144464311139483651","1144454368315367424","1144433316533276672","1144425294322757632","1144417466858266624","1144411132678955008","1144410965192003584","1144409638063861761","1144409607428857856","1144372013076766720","1144340830150430720","1144327377897558017","1144273857915867138","1144267500349284354","1144253051345223680","1143179072731844611","1143177514212352007","1143168160524316674","1139078994454810625","1134755503802916864","1134370535226454016","1134026304867655680","1133986614206717953","1133886780053307392","1133851144839749634","1133848150869925889","1133839626731491329","1133733557329944577","1133711885772238848","1133692196132085760","1133651160332754944","1133635565902094336","1133630361290858496","1133599451837325312","1131517306323054592","1131492512655450112","1131434822621192192","1131246172528664577","1131207528803688448","1130743503309463552","1130435597200441345","1129415365677572096","1129411033590902784","1129379038462730240","1129299138544324608","1128515856051392512"]},{"title":"Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"bcTa42E45d4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)32555-2/abstract","googleCitationCount":84,"googleAuthor":"S Filetti","statusesArray":[]},{"title":"COVID-19 in patients with lung cancer","googleId":"lHxSTdF7C0QJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375342039894X","googleCitationCount":56,"googleAuthor":"","doi":"10.1016/j.annonc.2020.06.007","elsevierAuthor":"Luo J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-10-01","elsevierCoverDisplayDate":"October 2020","elsevierCitationCount":"27","altmetricAuthors":["J. Luo","H. Rizvi","I.R. Preeshagul","J.V. Egger","D. Hoyos","C. Bandlamudi","C.G. McCarthy","C.J. Falcon","A.J. Schoenfeld","K.C. Arbour","J.E. Chaft","R.M. Daly","A. Drilon","J. Eng","A. Iqbal","W.V. Lai","B.T. Li","P. Lito","A. Namakydoust","K. Ng","M. Offin","P.K. Paik","G.J. Riely","C.M. Rudin","H.A. Yu","M.G. Zauderer","M.T.A. Donoghue","M. Łuksza","B.D. Greenbaum","M.G. Kris","M.D. Hellmann"],"twitterCount":23,"altmetricId":84239322,"statusesArray":["1313875539468328964","1313698873643339778","1313669012027584513","1313668509055045634","1313655655908204545","1313633128339181569","1313628545705537538","1313622891079053314","1291533165283213312","1291532383049547776","1291531905473503232","1291531853501997057","1291531643367436290","1291531361077981184","1291531218060603392","1291531133042204672","1285452504982081537","1285341876317327360","1285339133389541379","1285260853420462082","1285237837047062529","1285234077713432576","1285233167855611905","1274439451117150208","1273645766075191297","1273580333640953856","1273574464303837185","1273571912095076354"]},{"title":"Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors","googleId":"SrujySyAX1QJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310440","googleCitationCount":72,"googleAuthor":"N Steeghs","doi":"10.1093/annonc/mdy551","elsevierAuthor":"Heinhuis K.M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-02-01","elsevierCoverDisplayDate":"1 February 2019","elsevierCitationCount":"50","altmetricAuthors":["K.M. Heinhuis","W. Ros","M. Kok","N. Steeghs","J.H. Beijnen","J.H.M. Schellens"],"twitterCount":44,"altmetricId":53511211,"statusesArray":["1120612844343578625","1120611150469718016","1120609582693408771","1118372421382410240","1118267961188462594","1118264621318725633","1118235988453670912","1118187380698226690","1113970144076750853","1113607383417143296","1113607379537391616","1113607270628122624","1113573026489094144","1113496762151518219","1113486477697126400","1113426020621799424","1113325284558888962","1113324986700369925","1113318572175052801","1113318367694397440","1113293291997540352","1113291181025243136","1113282870527713280","1113246908875661313","1113226299273830401","1113184069750280193","1113183280600363009","1113170708962643970","1113151587734704128","1113146607539642368","1113127400424923137","1113117434163138561","1113090020959838208","1113076905979400194","1113076135041040384","1113075164047040512","1113072960364056577","1113071746964312064","1113070891611684864","1113067478882541571","1113067171528073218","1113066903864401920","1113063566544781312","1102460315202187264","1102116770796785664","1100093113153044484","1081599977615286272"]},{"title":"Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO–ESMO initiative endorsed by …","googleId":"fCfp8uuhvtQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310038","googleCitationCount":58,"googleAuthor":"G Pentheroudakis","doi":"10.1093/annonc/mdy502","elsevierAuthor":"Muro K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-01-01","elsevierCoverDisplayDate":"1 January 2019","elsevierCitationCount":"50","altmetricAuthors":["K. Muro","E. Van Cutsem","Y. Narita","G. Pentheroudakis","E. Baba","J. Li","M -H Ryu","W I Wan Zamaniah","W -P Yong","K -H Yeh","K. Kato","Z. Lu","B.C. Cho","I.M. Nor","M. Ng","L -T Chen","T.E. Nakajima","K. Shitara","H. Kawakami","T. Tsushima","T. Yoshino","F. Lordick","E. Martinelli","E.C. Smyth","D. Arnold","H. Minami","J. Tabernero","J -Y Douillard"],"twitterCount":15,"altmetricId":51601359,"statusesArray":["1133853101620891648","1133733105657892864","1133693673445609472","1133689563388547073","1133688058879127552","1133662254346526720","1133659281973104640","1133356486510415872","1068936291461541889","1068594243315224576","1068467177366335489","1067544589026832384","1066992009427202048","1066733746467102725","1066733011742466048","1065943239046381568"]},{"title":"TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer","googleId":"XH4YP-gxFQIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420359469","googleCitationCount":49,"googleAuthor":"GR Oxnard","doi":"10.1016/j.annonc.2020.01.013","elsevierAuthor":"Oxnard G.R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-04-01","elsevierCoverDisplayDate":"April 2020","elsevierCitationCount":"35","altmetricAuthors":["G.R. Oxnard","J.C.-H. Yang","H. Yu","S.-W. Kim","H. Saka","L. Horn","K. Goto","Y. Ohe","H. Mann","K.S. Thress","M.M. Frigault","K. Vishwanathan","D. Ghiorghiu","S.S. Ramalingam","M.-J. Ahn"],"twitterCount":26,"altmetricId":75322003,"statusesArray":["1237332907775098884","1237187082604261376","1237152290995396612","1237078172547420163","1237063884617351169","1236923741634015232","1236914661200736256","1236283312588689408","1236239677973241856","1235972619448520704","1235942509672427521","1235851769743175680","1235823454252724224","1235820031767744517","1235813169236303873","1235807855199969282","1235796754785763329","1235724878218747905","1235707276582768640","1235678945644875776","1235623481322147840","1235612649087545345","1235601510693658629","1235567761922891778","1235549946499096576","1235549942258810880","1235546298067140608","1225786341423636481","1225758391492104192","1225752148195074051","1225752115353702406"]},{"title":"The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor?","googleId":"4roaPHV5OkEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419609671","googleCitationCount":41,"googleAuthor":"A Elkrief","doi":"10.1093/annonc/mdz206","elsevierAuthor":"Elkrief A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-10-01","elsevierCoverDisplayDate":"1 October 2019","elsevierCitationCount":"33","altmetricAuthors":["A. Elkrief","L. Derosa","G. Kroemer","L. Zitvogel","B. Routy"],"twitterCount":56,"altmetricId":63076276,"statusesArray":["1222474567949541379","1204795559070056448","1204770706749304832","1204594931559522304","1204069243957977089","1201811914617217025","1201181481512718336","1200783214496931840","1200781781919813632","1200779367451942912","1200771962295005184","1195062259262902272","1173516131300102144","1173324347341180930","1155166418935209984","1153619133424160769","1153546909023444992","1153522120493867008","1153485289664344065","1153401051875295232","1153399238644117504","1153382295606321153","1153376256324452358","1153375494982819847","1153371379909025792","1151212974071308288","1148771019869474816","1148770530100744192","1148478674959626240","1148374115402698752","1148364545083289601","1148361200314413056","1148356894953824256","1148355274966818823","1148352937892175878","1148221836498481153","1148221182996410369","1148109360209567744","1148088470310703104","1147965589815566336","1147963358567645186","1147903719599513601","1147899847963549696","1147844616194068481","1147789105448853504","1147767940374302720","1147765868862087168","1147657025632866304","1147624046370021376","1147620402509672448","1146794215357255680","1146775326124597252","1146758874332053506","1146720343400177664","1146513574615027714","1146485374690189312","1146482399309631488","1146423454972776456","1146419847883943937","1146382064759037953","1146368964500611072"]},{"title":"Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): final overall survival analysis","googleId":"iPUKuO-jOJIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604369","googleCitationCount":58,"googleAuthor":"","doi":"10.1093/annonc/mdz394.076","elsevierAuthor":"Vavala T.","publicationName":"Journal of Clinical Pathology","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"2021","elsevierCitationCount":"0","altmetricAuthors":["S.S. Ramalingam","J.E. Gray","Y. Ohe","B.C. Cho","J. Vansteenkiste","C. Zhou","T. Reungwetwattana","Y. Cheng","B. Chewaskulyong","R. Shah","K.H. Lee","P. Cheema","M. Tiseo","T. John","M.C. Lin","F. Imamura","R. Hodge","Y. Rukazenkov","J.-C. Soria","D. Planchard"],"twitterCount":1,"altmetricId":67608254,"statusesArray":["1179670138439835649"]},{"title":"Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up✰","googleId":"6sxlIn7jgPMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)35465-1/abstract","googleCitationCount":32,"googleAuthor":"L Arcaini","statusesArray":[]},{"title":"OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer","googleId":"_9FpTDPFRjsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310294","googleCitationCount":68,"googleAuthor":"EA Blair","doi":"10.1093/annonc/mdy522","elsevierAuthor":"Göttgens E.L.","publicationName":"Radiotherapy and Oncology","elsevierCoverDate":"2020-08-01","elsevierCoverDisplayDate":"August 2020","elsevierCitationCount":"1","altmetricAuthors":["T.Y. Seiwert","C.C. Foster","E.A. Blair","T.G. Karrison","N. Agrawal","J.M. Melotek","L. Portugal","R.J. Brisson","A. Dekker","S. Kochanny","Z. Gooi","M.W. Lingen","V.M. Villaflor","D.T. Ginat","D.J. Haraf","E.E. Vokes"],"twitterCount":14,"altmetricId":52180542,"statusesArray":["1235527114767527936","1179405295145103361","1163151403197566978","1163136537883660289","1163125408382029825","1084854966685188096","1072138188133724161","1070680104785858565","1070679253606383616","1070520527947816961","1070020971262705665","1070015345728077827","1070013620405366784","1069990376688271360","1069980267933261824"]},{"title":"Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge","googleId":"Y_RnIY7LBNMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310245","googleCitationCount":57,"googleAuthor":"JM Loree","doi":"10.1093/annonc/mdy509","elsevierAuthor":"Parseghian C.M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-02-01","elsevierCoverDisplayDate":"1 February 2019","elsevierCitationCount":"41","altmetricAuthors":["C.M. Parseghian","J.M. Loree","V.K. Morris","X. Liu","K.K. Clifton","S. Napolitano","J.T. Henry","A.A. Pereira","E. Vilar","B. Johnson","B. Kee","K. Raghav","A. Dasari","J. Wu","N. Garg","V.M. Raymond","K.C. Banks","A.A. Talasaz","R.B. Lanman","J.H. Strickler","D.S. Hong","R.B. Corcoran","M.J. Overman","S. Kopetz"],"twitterCount":11,"altmetricId":51654035,"statusesArray":["1146827100390752256","1146702591553953792","1146655727366430723","1146544399612076032","1146509067608891392","1146466722184142849","1124284395387404288","1068081648305082368","1067816504203329537","1066372439599403013","1066368127301283840"]},{"title":"Association of tumour mutational burden with outcomes in patients with select advanced solid tumours treated with pembrolizumab in KEYNOTE-158","googleId":"SFv0W1jJUaIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594042","googleCitationCount":51,"googleAuthor":"MG Fakih","doi":"10.1093/annonc/mdz253.018","elsevierCitationCount":0,"altmetricAuthors":["A. Marabelle","M.G. Fakih","J. Lopez","M. Shah","R. Shapira-Frommer","K. Nakagawa","H.C. Chung","H.L. Kindler","J.A. Lopez-Martin","W. Miller","A. Italiano","S. Kao","S.A. Piha-Paul","J.-P. Delord","R.R. McWilliams","D. Aurora-Garg","M. Chen","F. Jin","K. Norwood","Y.-J. Bang"],"twitterCount":0,"altmetricId":86405391,"statusesArray":[]},{"title":"HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib","googleId":"6srZZ6G8ZiAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310774","googleCitationCount":56,"googleAuthor":"","doi":"10.1093/annonc/mdy542","elsevierAuthor":"Wang Y.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-03-01","elsevierCoverDisplayDate":"1 March 2019","elsevierCitationCount":"49","altmetricAuthors":["Y. Wang","T. Jiang","Z. Qin","J. Jiang","Q. Wang","S. Yang","C. Rivard","G. Gao","T.L. Ng","M.M. Tu","H. Yu","H. Ji","C. Zhou","S. Ren","J. Zhang","P. Bunn","R.C. Doebele","D.R. Camidge","F.R. Hirsch"],"twitterCount":31,"altmetricId":53596185,"statusesArray":["1242786567464214528","1091149684737855488","1091101143097319424","1091088645879156736","1091086174406565888","1091042439496904706","1091033373932425218","1091032506634256384","1090924986188091392","1090909084289781760","1090848517214691328","1090826909494038528","1090750195048968192","1090661356842508288","1084972461874180096","1084902608014258177","1084583279297208320","1083166805055528960","1083151746552217600","1083150396900679680","1083116626923401216","1083106569557028864","1083091129497718784","1083061631603654656","1083038029823070208","1083036708046848001","1083035578172530688","1083029172723818497","1083018552892772354","1083013223526219776","1083007871250546688","1083006896976678915","1082999937762131968","1082703471579746305","1082664820627902465","1082638256813080576"]},{"title":"Severe immune-related adverse events are common with sequential PD-(L) 1 blockade and osimertinib","googleId":"k4fb_JXeXpgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311652","googleCitationCount":69,"googleAuthor":"AJ Schoenfeld","doi":"10.1093/annonc/mdz077","elsevierAuthor":"Zhai X.","publicationName":"Cancer Biology and Medicine","elsevierCoverDate":"2020-08-01","elsevierCoverDisplayDate":"1 August 2020","elsevierCitationCount":"0","altmetricAuthors":["A.J. Schoenfeld","K.C. Arbour","H. Rizvi","A.N. Iqbal","S.M. Gadgeel","J. Girshman","M.G. Kris","G.J. Riely","H.A. Yu","M.D. Hellmann"],"twitterCount":54,"altmetricId":56948983,"statusesArray":["1327733504881414144","1306689719594610688","1306453127311228935","1306359802038226944","1306304216538001408","1306302983324360705","1306302606235570181","1174363305395113984","1174338923348320256","1173907373112492033","1140414595124908033","1129740523563098119","1129723447527895040","1129721267576197120","1129720810791415808","1124557265686671361","1109982319157358593","1109332322539704320","1108154615642685440","1107377104822239232","1107241461328818182","1107010361335693315","1106874074096156673","1106616586201227264","1106367505809833984","1106367050543435777","1106365064305668111","1106364764131901441","1106363486324568069","1106358860015697921","1106351054617235456","1106170644507578368","1106168217012133888","1106104583833743360","1106056921016995841","1106053586654396416","1106045910889295872","1106041570195922945","1106033526766354433","1106033497188126725","1106020846936690688","1106019602490777600","1105980421672714242","1105978447606616065","1105968228638097410","1105934327026761729","1105934121610723328","1105917421662228480","1105906605286137856","1105903432450355200","1105898938790494210","1105892821179850752","1105839544744665088","1105830258555654145","1105813314523881472","1105809672664174592","1105805392079142912","1105796184831070209","1105793422567206912","1105774074645569538","1105774053934039041","1105772740651483137"]},{"title":"Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort …","googleId":"gbNFMnT5byAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420360324","googleCitationCount":46,"googleAuthor":"","doi":"10.1016/j.annonc.2020.01.072","elsevierAuthor":"Schmid P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-05-01","elsevierCoverDisplayDate":"May 2020","elsevierCitationCount":"28","altmetricAuthors":["P. Schmid","R. Salgado","Y.H. Park","E. Muñoz-Couselo","S.B. Kim","J. Sohn","S.-A. Im","T. Foukakis","S. Kuemmel","R. Dent","L. Yin","A. Wang","K. Tryfonidis","V. Karantza","J. Cortés","S. Loi"],"twitterCount":38,"altmetricId":76197297,"statusesArray":["1250386962453860352","1233330477433524225","1230716434969350144","1230419488593473538","1230418755353751552","1229967827333001216","1229824241790570507","1229743993954717696","1229732037587873792","1229662970449408002","1229625306455035904","1229580449263104000","1229500859534450689","1229479214035931139","1229459111055679489","1229451678988062721","1229444713331163141","1229444395046514688","1229430931485843456","1229429757915197441","1229429716018290688","1229414807327182849","1229414391260622848","1229386481464172544","1229372137934381056","1229371160850239489","1229366986091761664","1229366000958787585","1229363192305942528","1229343224973660160","1229329279676272640","1229327967182053377","1229325616580845568","1229324857210556416","1229324793318690816","1229324225145659392","1229322774033731584","1229319767472902144","1229319672211705856","1229319629979471874"]},{"title":"Prevalence and mutational determinants of high tumor mutation burden in breast cancer","googleId":"dEErZ208wSoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419406984","googleCitationCount":37,"googleAuthor":"R Barroso-Sousa","doi":"10.1016/j.annonc.2019.11.010","elsevierAuthor":"Barroso-Sousa R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-03-01","elsevierCoverDisplayDate":"March 2020","elsevierCitationCount":"28","altmetricAuthors":["R. Barroso-Sousa","E. Jain","O. Cohen","D. Kim","J. Buendia-Buendia","E. Winer","N. Lin","S.M. Tolaney","N. Wagle"],"twitterCount":39,"altmetricId":73852022,"statusesArray":["1272170067627618305","1254893994913550338","1254862318850027524","1254547759522213888","1254541144626728960","1254458282518949888","1254444011370287104","1254435585579601920","1254410743639945219","1254386998078590976","1229415478424166401","1225836082702553089","1225331981556293632","1225320768977895424","1225300466621394944","1225274709387902977","1225240012607938560","1225227685124804608","1216977849082662912","1216951105139113984","1216641776003485696","1216641740494557184","1216105162504392704","1216057246209146880","1216034790492770305","1215998221098659841","1215993900780998657","1215993035521175553","1215988360709275649","1215885380274270208","1215883549989113856","1215882591422730241","1215877962161184769","1215813108498870272","1215787812600942593","1215782529506119681","1215782506819203073","1215774507065073666","1215764769392586753","1215764111172276224","1215764079496908800","1215759884743999491","1215758115607478272","1215755456066543617","1215750054289559552","1215744588146597888","1215730105638641666","1215728838576984064","1215723288694931456","1215706428427657219","1215704516236075010","1215698452522455041","1215689576418856960"]},{"title":"Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 …","googleId":"2auh0-fIwtYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419595217","googleCitationCount":43,"googleAuthor":"H Gogas","doi":"10.1093/annonc/mdz255","elsevierAuthor":"Kitano S.","publicationName":"Cancer Chemotherapy and Pharmacology","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"January 2021","elsevierCitationCount":"0","altmetricAuthors":["J.S. Weber","M. Del Vecchio","M. Mandala","H. Gogas","A.M. Arance","S. Dalle","C.L. Cowey","M. Schenker","J.J. Grob","V. Chiarion-Sileni","I. Marquez-Rodas","M.O. Butler","M. Maio","M.R. Middleton","T. Tang","A. Saci","V. De Pril","M. Lobo","J.M.G. Larkin","P.A. Ascierto"],"twitterCount":0,"altmetricId":68179434,"statusesArray":[]},{"title":"Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma","googleId":"zevF3PiDyUsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341931227X","googleCitationCount":54,"googleAuthor":"YJL Jansen","doi":"10.1093/annonc/mdz110","elsevierAuthor":"Fedorova L.V.","publicationName":"Annals of Hematology","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"2021","elsevierCitationCount":"0","altmetricAuthors":["Y.J.L. Jansen","E.A. Rozeman","R. Mason","S.M. Goldinger","M.H. Geukes Foppen","L. Hoejberg","H. Schmidt","J.V. van Thienen","J.B.A.G. Haanen","L. Tiainen","I.M. Svane","S. Mäkelä","T. Seremet","A. Arance","R. Dummer","L. Bastholt","M. Nyakas","O. Straume","A.M. Menzies","G.V. Long","V. Atkinson","C.U. Blank","B. Neyns"],"twitterCount":86,"altmetricId":58001485,"statusesArray":["1179057808903413760","1172021366268289030","1153787162032103424","1135672513348943872","1135670780522586119","1135668724097277952","1135665652109336581","1121093115388022784","1120903860753707008","1120798704598831105","1120783424288018432","1120744743296589829","1120125403136438272","1117027547634642944","1115667200369553408","1115470780832387072","1114968365855068160","1114711971729944576","1114512930878439428","1114449985343557632","1114322936796782592","1114197715913728000","1114197107487989762","1114146195402784768","1114133056099618816","1114120943616647168","1114113985236877312","1114106684337684480","1114101060098981890","1114097520572022784","1114087245630320640","1114085796158398464","1114084871679426561","1114083250639519744","1114046145976774656","1114038824785580032","1113925283290030080","1113735351422595072","1113631121953017857","1113569782740045824","1113410855796768768","1113410130580836352","1113350254395625472","1113350010144481280","1113347926581968896","1113347884500619264","1113264881229131781","1113235727763091456","1113132082904137728","1113100781727563777","1113083057257426944","1113081918105350145","1113079683715743744","1113077762946936833","1113071579209007104","1113071399290142720","1113058748677873664","1113015479638114304","1113014763674632192","1112995427438088194","1112980247308197893","1112958800015888384","1112941027101499393","1112919983607214080","1112916120703549440","1112915899177205760","1112915516090474501","1112910287668215809","1112903320341893120","1112899110540066821","1112885357266288640","1112881203135180800","1112860772118388736","1112838539518111744","1112825612463497221","1112805785065701379","1112801747968327680","1112750632149139462","1112738473251876864","1112732306006069254","1112675141224484870","1112668915853914113","1112650861770129408","1112624861468393472","1112598006388400128","1112576517970776064","1112545647343927298","1112520632959414272","1112507243445043200","1112189406268391424","1112189278920949760","1112014127017320449","1111901981180747776","1111581450174939137","1111512899523092481","1111504437015662592"]},{"title":"Randomised efficacy and safety results for atezolizumab (Atezo)+ bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular …","googleId":"vDaSB3-vMv0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341960390X","googleCitationCount":47,"googleAuthor":"","doi":"10.1093/annonc/mdz394.030","elsevierAuthor":"Pinter M.","publicationName":"JAMA Oncology","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"January 2021","elsevierCitationCount":"3","altmetricAuthors":["M. Lee","B.-Y. Ryoo","C.-H. Hsu","K. Numata","S. Stein","W. Verret","S. Hack","J. Spahn","B. Liu","H. Abdullah","R. He","K.-H. Lee"],"twitterCount":0,"altmetricId":83417949,"statusesArray":[]},{"title":"Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study","googleId":"y851gSX83Z0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341931035X","googleCitationCount":56,"googleAuthor":"","doi":"10.1093/annonc/mdy539","elsevierAuthor":"Hong D.S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-02-01","elsevierCoverDisplayDate":"1 February 2019","elsevierCitationCount":"40","altmetricAuthors":["D.S. Hong","T.M. Bauer","J.J. Lee","A. Dowlati","M.S. Brose","A.F. Farago","M. Taylor","A.T. Shaw","S. Montez","F. Meric-Bernstam","S. Smith","B.B. Tuch","K. Ebata","S. Cruickshank","M.C. Cox","H.A. Burris","R.C. Doebele"],"twitterCount":95,"altmetricId":53889240,"statusesArray":["1102612038306709504","1101680517190246402","1101678788851707910","1101223836643659779","1101100532897329153","1101083551435505666","1101072238021935104","1101027880820244480","1100881667328217090","1100874040128921600","1100871837993426944","1100857466898825216","1100851473712365569","1100813689639317506","1100811535130087424","1100810156634505216","1100807102661099523","1100802578798075904","1100784866877153282","1100773567409545217","1096929713086517248","1096824859961765888","1095125116558684161","1095056209101709314","1095041281393377290","1095027571060760576","1094933816387518465","1094918657942175745","1094873733381029888","1094793163976273921","1092438866202644482","1091622261591818240","1091546567864020993","1091463905061289984","1091454301849845761","1091413983893041154","1091326006349230080","1091322691276148736","1091292483450036225","1091292451036377088","1091239216745533440","1091238432624574464","1090998121000095746","1090929975199449090","1090895814380175360","1090834528225165312","1090741030092242944","1090737536165662721","1090733229567406080","1090732125257633797","1090691089021972481","1090682460696915969","1090667769887105025","1090665426533658624","1090633181101993985","1090627945486417920","1090610174530863104","1090593694846275584","1090528209165275136","1090525908606296064","1090522995335020544","1090441968264597504","1090429649837064198","1090416023323508738","1090389988158726144","1090374050776576000","1090373125018210305","1090362260009160704","1090360562784092161","1090357201577795584","1090344961302818816","1090323475930275841","1090313685447462913","1090309626875334664","1090304056923435008","1090291298173562881","1090276957722419200","1090269421304635393","1086420143092174849","1086414513727885313","1086375477906939904","1086345469410926592","1086331618283773954","1086296755405291520","1086284304790048768","1086279198828687360","1086277789290917888","1085770736617181184","1085766693656252416","1085191916868628482","1085088666559696896","1085056948456714240","1085045334575738882","1085013430233382912","1084981329182113792","1084940197865897989","1084901292114206720","1084892715433766912","1084885146577317889","1084869689656922113"]},{"title":"Aspirin and the risk of colorectal and other digestive tract cancers: an updated meta-analysis through 2019","googleId":"n-YQWNTmXLoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420360737","googleCitationCount":37,"googleAuthor":"C Bosetti","doi":"10.1016/j.annonc.2020.02.012","elsevierAuthor":"Bosetti C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-05-01","elsevierCoverDisplayDate":"May 2020","elsevierCitationCount":"19","altmetricAuthors":["C. Bosetti","C. Santucci","S. Gallus","M. Martinetti","C. La Vecchia"],"twitterCount":19,"altmetricId":79872817,"statusesArray":["1304244324826263554","1261314425560203264","1257515933423239170","1257514326404915201","1253695955238436864","1252915788681375745","1252833916660019200","1252669309031026688","1252644717679927296","1252642705009594368","1252642489690755072","1252634315222999040","1252599408853569539","1252591067842531329","1252576388764200962","1252571062182666240","1252568983653539841","1252507536235696128","1251190869425782784"]},{"title":"Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant …","googleId":"vLCJ9MCArbMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325515","googleCitationCount":50,"googleAuthor":"G Bataillon","doi":"10.1093/annonc/mdz395","elsevierAuthor":"Park J.H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-12-01","elsevierCoverDisplayDate":"1 December 2019","elsevierCitationCount":"32","altmetricAuthors":["J H Park","S F Jonas","G Bataillon","C Criscitiello","R Salgado","S Loi","G Viale","H J Lee","M V Dieci","S -B Kim","A Vincent-Salomon","G Curigliano","F André","S Michiels"],"twitterCount":46,"altmetricId":67482561,"statusesArray":["1216408577168019456","1196450165705641984","1183228665368383488","1180113139200708608","1179890466642374657","1179612765335556096","1179461026959577088","1179345207407583232","1179232378184765441","1179166504476131328","1179133989241704449","1179132949289148416","1178947756196536320","1178938241275383808","1178922429147750400","1178910570965286912","1178905119703719937","1178900121062449153","1178880527496933376","1178878741205966848","1178877805729370113","1178877295706157056","1178873281153253376","1178801764298035200","1178798310561390600","1178786870064566272","1178776061204525056","1178775831809871873","1178774881208606720","1178758259622256640","1178748880189607936","1178732320297295873","1178731536662839300","1178719076794949633","1178718382243405827","1178715416128045056","1178714759715282945","1178714049686704134","1178706120396795904","1178702692396478464","1178701792177209345","1178701181729685505","1178686245133836288","1178684467738742784","1178679682121768960","1178679405595549697","1178678442700808192","1178678410484289538","1178676842523430912","1178675906275155968","1178673519770656769","1178671411663118338","1178669634058358786","1178668797416411137","1178668335652839424"]},{"title":"Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in …","googleId":"lSKLqWIqryIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311147","googleCitationCount":62,"googleAuthor":"WT Barry","doi":"10.1093/annonc/mdz018","elsevierAuthor":"Neves K.B.","publicationName":"Clinical Science","elsevierCoverDate":"2020-09-01","elsevierCoverDisplayDate":"September 2020","elsevierCitationCount":"1","altmetricAuthors":["J.F. Liu","W.T. Barry","M. Birrer","J.-M. Lee","R.J. Buckanovich","G.F. Fleming","B.J. Rimel","M.K. Buss","S.R. Nattam","J. Hurteau","W. Luo","J. Curtis","C. Whalen","E.C. Kohn","S.P. Ivy","U.A. Matulonis"],"twitterCount":25,"altmetricId":55112927,"statusesArray":["1131735315868110849","1131673358330933251","1131629071769620480","1131604733938917376","1131578186784026625","1131504506771054593","1131495260385943552","1131495070337835008","1131492465557561345","1130440632613462017","1129222889046183936","1129107203653292034","1097479695237410818","1096390996563238914","1096390531549196288","1096376565678702593","1096294050142015489","1096263269281644544","1096160343150264320","1096152471695552513","1096093216695148544","1096092579723177984","1096059675299192838","1096031303034654720","1095681130559225856","1095256620928507904","1093614355726372865"]},{"title":"Hereditary gastrointestinal cancers: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"hqTJ9bBmyZUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)60977-4/abstract","googleCitationCount":40,"googleAuthor":"F Carneiro","statusesArray":[]},{"title":"Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting","googleId":"7RVfRil2YBcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419609737","googleCitationCount":37,"googleAuthor":"","doi":"10.1093/annonc/mdz228","elsevierAuthor":"Amant F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-10-01","elsevierCoverDisplayDate":"1 October 2019","elsevierCitationCount":"23","altmetricAuthors":["F. Amant","P. Berveiller","I.A. Boere","E. Cardonick","R. Fruscio","M. Fumagalli","M.J. Halaska","A. Hasenburg","A.L.V. Johansson","M. Lambertini","C.A.R. Lok","C. Maggen","P. Morice","F. Peccatori","P. Poortmans","K. Van Calsteren","T. Vandenbroucke","M. van Gerwen","M. van den Heuvel-Eibrink","F. Zagouri","I. Zapardiel"],"twitterCount":31,"altmetricId":65306759,"statusesArray":["1311278282726232066","1311270584760721410","1311253626438918145","1311250356832055301","1200784679168806913","1190490280408993792","1176170698521239553","1173979804003119104","1173574222272057344","1173459426696663041","1173446499008765952","1173425631272431618","1173410316442636288","1173409211096518656","1173249311947161602","1173223410425421824","1173221309775527938","1173220870023712768","1170151604739346433","1169755524549828608","1169716676193075201","1169709935954993155","1169652844821188608","1169602750465769472","1169597244867305472","1169596319511412738","1167858332943601665","1167570208250314752","1167476053725466624","1167448768280764417","1167444641735675909","1167412336765931520","1167393609840242689","1167392087823867905","1167391764094705665","1164807742470512641","1164710845441404928","1164603154136260608","1164575328775344128","1164575266204782594"]},{"title":"FIGHT-202: A phase II study of pemigatinib in patients (pts) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA)","googleId":"tzJq6OAr2FIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603911","googleCitationCount":45,"googleAuthor":"A Hollebecque","doi":"10.1093/annonc/mdz394.031","elsevierAuthor":"Vienot A.","publicationName":"Clinics and Research in Hepatology and Gastroenterology","elsevierCoverDate":"2020-11-01","elsevierCoverDisplayDate":"November 2020","elsevierCitationCount":"0","altmetricAuthors":["A. Vogel","V. Sahai","A. Hollebecque","G. Vaccaro","D. Melisi","R. Al-Rajabi","A.S. Paulson","M.J. Borad","D. Gallinson","A.G. Murphy","D.-Y. Oh","E. Dotan","D.V. Catenacci","E. Van Cutsem","C.F. Lihou","H. Zhen","L. Féliz","G.K. Abou-Alfa"],"twitterCount":0,"altmetricId":79022186,"statusesArray":[]},{"title":"Lower detection rates of SARS-COV2 antibodies in cancer patients versus health care workers after symptomatic COVID-19","googleId":"DPJ-rk9FW2YJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/PMC7252166","googleCitationCount":48,"googleAuthor":"","doi":"10.1016/j.annonc.2020.04.475","elsevierAuthor":"Solodky M.L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-08-01","elsevierCoverDisplayDate":"August 2020","elsevierCitationCount":"27","altmetricAuthors":["M.L. Solodky","C. Galvez","B. Russias","P. Detourbet","V. N’Guyen-Bonin","A.-L. Herr","P. Zrounba","J.-Y. Blay"],"twitterCount":61,"altmetricId":80990045,"statusesArray":["1262711459815067648","1261348488119549954","1261345381369012230","1261343372037554177","1261199178383966209","1260155345911021570","1259041223668633600","1258793339660500994","1258671980456353797","1258670042650161155","1258661592457248769","1258563562273943554","1258559418414833677","1258558624017891330","1258558500306776064","1258558405796597767","1258285173180968960","1258083760014270464","1258072248214224896","1258050103971110914","1258040934429855747","1258017967280775169","1257998431538352129","1257957434963918848","1257914383277137920","1257890692405354497","1257832470197809153","1257791314860670982","1257790203068133380","1257785367392063488","1257781674861039619","1257458620725428228","1257250330854785024","1257235427477663744","1257214620516958213","1256928322061316096","1256840168117620737","1256813895995580416","1256623394876989441","1256582972783898625","1256547757952827395","1256547352804024325","1256527504967426048","1256525329641943040","1256525040079773698","1256515283377885184","1256441208848728064","1256432945604091904","1256379782016708610","1256340103447736323","1256318880693260288","1256317598087745542","1256317144188375040","1256315492740083712","1256312165067132928","1256277931627814913","1256275679953530882","1256270887361417216","1256242598987137024","1256239760349298691","1256235591013933057","1256235454967545858","1256234168821915653","1256218904709550089","1256180214910062592","1256165661505708032","1256165133585440768"]},{"title":"Identifying patients with NTRK fusion cancer","googleId":"_zVnDmJ_F8wJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419551183","googleCitationCount":46,"googleAuthor":"JF Hechtman","doi":"10.1093/annonc/mdz384","elsevierAuthor":"Solomon J.P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-11-01","elsevierCoverDisplayDate":"1 November 2019","elsevierCitationCount":"34","altmetricAuthors":["J.P. Solomon","R. Benayed","J.F. Hechtman","M. Ladanyi"],"twitterCount":3,"altmetricId":70762978,"statusesArray":["1197420454824296448","1196942363106480129","1196745953316761600"]},{"title":"TRK inhibitors in TRK fusion-positive cancers","googleId":"pbNES49JFCwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419551146","googleCitationCount":51,"googleAuthor":"A Drilon","doi":"10.1093/annonc/mdz282","elsevierAuthor":"Drilon A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-11-01","elsevierCoverDisplayDate":"1 November 2019","elsevierCitationCount":"40","altmetricAuthors":["A. Drilon"],"twitterCount":2,"altmetricId":70781567,"statusesArray":["1196947966549880832","1196842332244471808"]},{"title":"Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) …","googleId":"jkx2c8Pi3gsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312906","googleCitationCount":47,"googleAuthor":"T Sato","doi":"10.1093/annonc/mdz176","elsevierAuthor":"Khoja L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-08-01","elsevierCoverDisplayDate":"1 August 2019","elsevierCitationCount":"25","altmetricAuthors":["L. Khoja","E.G. Atenafu","S. Suciu","S. Leyvraz","T. Sato","E. Marshall","U. Keilholz","L. Zimmer","S.P. Patel","S. Piperno-Neumann","J. Piulats","T.T. Kivelä","C. Pfoehler","S. Bhatia","P. Huppert","L.B.J. Van Iersel","I.J.M. De Vries","N. Penel","T. Vogl","T. Cheng","G. Fiorentini","F. Mouriaux","A. Tarhini","P.M. Patel","R. Carvajal","A.M. Joshua"],"twitterCount":9,"altmetricId":61478505,"statusesArray":["1277421862151237632","1173348669191385088","1144107489006194688","1143991534725074944","1143988148776517632","1143827212820504576","1143815759971225600","1143814129175683072","1143812119596425217","1136497879487590400","1135717046900133888","1135715557997572096"]},{"title":"Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for …","googleId":"Djtj1qIVatgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419309858","googleCitationCount":50,"googleAuthor":"YP Chen","doi":"10.1093/annonc/mdy470","elsevierAuthor":"Chen Y.P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-01-01","elsevierCoverDisplayDate":"1 January 2019","elsevierCitationCount":"32","altmetricAuthors":["Y.-P. Chen","Y.-Q. Wang","J.-W. Lv","Y.-Q. Li","M.L.K. Chua","Q.-T. Le","N. Lee","A. Dimitrios Colevas","T. Seiwert","D.N. Hayes","N. Riaz","J.B. Vermorken","B. O’Sullivan","Q.-M. He","X.-J. Yang","L.-L. Tang","Y.-P. Mao","Y. Sun","N. Liu","J. Ma"],"twitterCount":16,"altmetricId":50993919,"statusesArray":["1106968873138642946","1088265842096107521","1063174961563611136","1063112648437444608","1063106854811848704","1062632021229486081","1062349630820691968","1062284263402471425","1061827533379821568","1061617447533506561","1061489581978079232","1061318290147028992","1061251995774926849","1061224322684121088","1061055354614702086","1060866761946525698","1060561729086783488"]},{"title":"Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal …","googleId":"oF-X3zRFY_wJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603674","googleCitationCount":48,"googleAuthor":"S Chia","doi":"10.1093/annonc/mdz394.007","elsevierCitationCount":0,"altmetricAuthors":["D.J. Slamon","P. Neven","S. Chia","P.A. Fasching","M. De Laurentiis","S.-A. Im","K. Petrakova","G.V. Bianchi","F.J. Esteva","M. Martin","A. Nusch","G.S. Sonke","L. De la Cruz-Merino","J.T. Beck","X. Pivot","M. Sondhi","Y. Wang","A. Chakravartty","K. Rodriguez-Lorenc","G. Jerusalem"],"twitterCount":0,"altmetricId":68179380,"statusesArray":[]},{"title":"Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and …","googleId":"nT3V-MJosoEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325539","googleCitationCount":33,"googleAuthor":"U Dafni","doi":"10.1093/annonc/mdz398","elsevierAuthor":"Dafni U.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-12-01","elsevierCoverDisplayDate":"1 December 2019","elsevierCitationCount":"23","altmetricAuthors":["U Dafni","O Michielin","S Martin Lluesma","Z Tsourti","V Polydoropoulou","D Karlis","M J Besser","J Haanen","I -M Svane","P S Ohashi","U S Kammula","A Orcurto","S Zimmermann","L Trueb","C A Klebanoff","M T Lotze","L E Kandalaft","G Coukos"],"twitterCount":11,"altmetricId":67509333,"statusesArray":["1224400787268341762","1223011466732822528","1222888923975880704","1222800084745773056","1222787113634205697","1222781779171405825","1222781758317481985","1222780923353206784","1180128380152406016","1180125324144717824","1178901545146097664","1178897903408078850"]},{"title":"Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after …","googleId":"4AdrvcxzRfAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310427","googleCitationCount":45,"googleAuthor":"SJ Luen","doi":"10.1093/annonc/mdy547","elsevierAuthor":"Luen S.J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-02-01","elsevierCoverDisplayDate":"1 February 2019","elsevierCitationCount":"33","altmetricAuthors":["S.J. Luen","R. Salgado","M.V. Dieci","A. Vingiani","G. Curigliano","R.E. Gould","C. Castaneda","T. D’Alfonso","J. Sanchez","E. Cheng","E. Andreopoulou","M. Castillo","S. Adams","S. Demaria","W.F. Symmans","S. Michiels","S. Loi"],"twitterCount":27,"altmetricId":53258877,"statusesArray":["1196013989626568706","1086091437278523393","1081909965378514945","1081754419102928897","1081389467670216704","1079752685476208642","1079747555745906688","1079536777843625985","1079362482282659840","1079298173284294656","1079136082145562626","1079090494511165441","1079058869010292736","1079036738046251008","1079031719553044480","1079021631127896065","1079019535120896000","1079014799722401794","1079013396006064133","1079006458426011648","1079001425529720832","1079001335872274433","1078974268917116934","1078973150086348800","1078959755115278336","1078949391661191168","1078948205923045376","1078946660724756480"]},{"title":"Timing of radiotherapy (RT) after radical prostatectomy (RP): first results from the RADICALS RT randomised controlled trial (RCT)","googleId":"_gO3PTzClp8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604023","googleCitationCount":43,"googleAuthor":"HG Kynaston","doi":"10.1093/annonc/mdz394.042","elsevierAuthor":"Kokorovic A.","publicationName":"Canadian Urological Association Journal","elsevierCoverDate":"2020-04-28","elsevierCoverDisplayDate":"April 2020","elsevierCitationCount":"3","altmetricAuthors":["C. Parker","N.W. Clarke","A. Cook","H.G. Kynaston","P. Meidahl Petersen","W. Cross","R. Persad","C. Catton","J. Logue","H. Payne","F. Saad","K. Brasso","H. Lindberg","A. Zarkar","R. Raman","M.A. Roder","C. Heath","W.R. Parulekar","M.K.B. Parmar","M.R. Sydes"],"twitterCount":3,"altmetricId":68179449,"statusesArray":["1200050339946401793","1200049781965545472","1200047233904840707"]},{"title":"KEYNOTE-522: Phase III study of pembrolizumab (pembro)+ chemotherapy (chemo) vs placebo (pbo)+ chemo as neoadjuvant treatment, followed by pembro …","googleId":"wESk3ByKIIwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603637","googleCitationCount":43,"googleAuthor":"R Dent","doi":"10.1093/annonc/mdz394.003","elsevierAuthor":"Navani V.","publicationName":"British Journal of Clinical Pharmacology","elsevierCoverDate":"2020-09-01","elsevierCoverDisplayDate":"1 September 2020","elsevierCitationCount":"1","altmetricAuthors":["P. Schmid","J. Cortés","R. Dent","L. Pusztai","H.L. McArthur","S. Kuemmel","J. Bergh","C. Denkert","Y.H. Park","R. Hui","N. Harbeck","M. Takahashi","T. Foukakis","P.A. Fasching","F. Cardoso","L. Jia","V. Karantza","J. Zhao","G. Aktan","J. O’Shaughnessy"],"twitterCount":0,"altmetricId":68179388,"statusesArray":[]},{"title":"Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer","googleId":"YgTrH2tOFsIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420326016","googleCitationCount":45,"googleAuthor":"F Saad","doi":"10.1093/annonc/mdz397","elsevierAuthor":"Small E.J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-11-01","elsevierCoverDisplayDate":"November 2019","elsevierCitationCount":"33","altmetricAuthors":["E.J. Small","F. Saad","S. Chowdhury","S. Oudard","B.A. Hadaschik","J.N. Graff","D. Olmos","P.N. Mainwaring","J.Y. Lee","H. Uemura","P. De Porre","A.A. Smith","K. Zhang","A. Lopez-Gitlitz","M.R. Smith"],"twitterCount":37,"altmetricId":67409635,"statusesArray":["1230985304665919489","1230983771165511681","1222931643419123712","1222925608960872451","1214169762542030848","1213012692124012544","1212580943371747328","1211786764265934853","1211469161605545984","1211288288595566596","1211197586067116032","1211190363051958274","1210634375148253184","1210567508207570944","1210560289604849665","1210529663711358976","1182794894537945088","1182360280078135296","1182353781616513027","1182351965772275712","1182348854982840326","1178793076028055564","1178396596309880832","1178356618796384257","1178355205106065409","1178352092827783174","1178336917974376448","1178245441357524992","1178185851160993792","1178099630975963137","1178073265144811520","1178014472616710144","1177999577955237888","1177993643098963968","1177975733693681665","1177973227949309953","1177971360510959616","1177965936525099014","1177961950229274626","1177961891819327488","1177961757517778944","1177961020679176192"]},{"title":"Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma","googleId":"ITC6lEts3YAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341931004X","googleCitationCount":44,"googleAuthor":"","doi":"10.1093/annonc/mdy507","elsevierAuthor":"Oliva M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-01-01","elsevierCoverDisplayDate":"1 January 2019","elsevierCitationCount":"36","altmetricAuthors":["M. Oliva","A. Spreafico","M. Taberna","L. Alemany","B. Coburn","R. Mesia","L.L. Siu"],"twitterCount":60,"altmetricId":51530719,"statusesArray":["1235521769336758272","1235520543169769472","1130522983657820160","1130522931082256385","1091826876513951744","1091694302902800385","1091464383996276736","1091353124747595776","1091112694948732928","1091077415240171520","1090992570728108032","1090991788763037696","1090988409911472128","1090988113214636036","1089783765247893504","1089782242350649345","1089772868731318273","1089772166726455296","1089295611315216384","1089252193264377862","1088135699851812865","1087244302022074370","1087126374903676930","1087078831821934592","1085961086636052485","1085919139355602945","1085892273202704384","1085870531226681345","1085854542238007296","1085851908663926784","1085846544866172929","1085841302225186816","1085775970978746368","1085752781141508097","1085722771768918017","1085677495674900481","1085666134811136000","1085665123069497344","1085663314120769537","1085657688590016515","1085648420377747456","1085632656392495104","1085626194832306177","1085625839486754816","1085608317706272770","1085604579155296257","1085589715435311111","1085589564893343744","1085566596612083714","1085557263815897088","1085495149260623872","1085476602723663874","1085475249737461763","1085470263062552576","1085467550861938688","1085465166114746368","1085464820072116224","1085464065412091904","1085462898988568577","1085461678634893312","1066372407290720259","1066368427462467585","1065532766220103680","1065502925512937472","1065492220147568640","1065468019688841217"]},{"title":"Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium","googleId":"X7U2Z5pwlL0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311275","googleCitationCount":48,"googleAuthor":"R Alden","doi":"10.1093/annonc/mdz046","elsevierAuthor":"Siravegna G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-10-01","elsevierCoverDisplayDate":"1 October 2019","elsevierCitationCount":"40","altmetricAuthors":["B.T. Li","F. Janku","B. Jung","C. Hou","K. Madwani","R. Alden","P. Razavi","J.S. Reis-Filho","R. Shen","J.M. Isbell","A.W. Blocker","N. Eattock","S. Gnerre","R.V. Satya","H. Xu","C. Zhao","M.P. Hall","Y. Hu","A.J. Sehnert","D. Brown","M. Ladanyi","C.M. Rudin","N. Hunkapiller","N. Feeney","G.B. Mills","C.P. Paweletz","P.A. Janne","D.B. Solit","G.J. Riely","A. Aravanis","G.R. Oxnard"],"twitterCount":74,"altmetricId":57315344,"statusesArray":["1252553800423899137","1155856024764583936","1129769751671169025","1129625658131402753","1129448497042853888","1129443526461329409","1129443219090149379","1129436044343021572","1129432463585947648","1129432383147728898","1129427133644845056","1129417022121623553","1129414904186920960","1129414789698949121","1115314784268845057","1115312637846478848","1115300672386113537","1115288801998458881","1115273343182286849","1112053878936219648","1111584954469765122","1111557967822929920","1111371884371668992","1111299723204403201","1111278263551315968","1111275591330865154","1111275464327397376","1111214816645902336","1111167099211272197","1111002028275318790","1110838723376234496","1110728493283848192","1110709030236930048","1110684851030634496","1110673754504478720","1110631116871028736","1110627091924557826","1110605935830016003","1110599033725308929","1110593113708470273","1110592085483237376","1110580911165329409","1110576956804755456","1110574992637480960","1110574803952566274","1110571540297457664","1110570240730116096","1110560543952326656","1110547187879030784","1110538544093777920","1110537527784624129","1110525741626769408","1110524773707206662","1110317461126238209","1110139892674297857","1110069546558386176","1109985334043922433","1109887800529375233","1109874404975087618","1109856787996528643","1109853758492762113","1109851779288756224","1109847837095936000","1109845656921931777","1109845648856268800","1109843868240003074","1109840130293010433","1109839805712605189","1109219464321613824","1109096198303043584","1109088338009620481","1108963785643945984","1108796745046286336","1108789879817883648","1108712496909766658","1108702429250371584","1108469522867064838","1108468803816644609","1108468206971338758","1108410710990774272","1108405089918582784","1108365654778892288","1108346992898592768","1108343946034466817","1108339926049808384","1108306209579388928","1108306084756930566","1108266400160845824","1108245743880396800","1108161364294430720"]},{"title":"ESO–ESMO 4th International consensus guidelines for breast cancer in young women (BCY4)","googleId":"5OA652yhaLwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420363638","googleCitationCount":34,"googleAuthor":"F Cardoso","doi":"10.1016/j.annonc.2020.03.284","elsevierAuthor":"Paluch-Shimon S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-06-01","elsevierCoverDisplayDate":"June 2020","elsevierCitationCount":"27","altmetricAuthors":["S. Paluch-Shimon","F. Cardoso","A.H. Partridge","O. Abulkhair","H.A. Azim","G. Bianchi-Micheli","M.-J. Cardoso","G. Curigliano","K.A. Gelmon","N. Harbeck","J. Merschdorf","P. Poortmans","G. Pruneri","E. Senkus","T. Spanic","V. Stearns","Y. Wengström","F. Peccatori","O. Pagani"],"twitterCount":10,"altmetricId":77933557,"statusesArray":["1286071626899918848","1286066059754184704","1285990985885863936","1285920435004211201","1285918790488858624","1285918738487926784","1285915246771699714","1285883164804747264","1270935938428858368","1261247302196326401","1242029960031657985","1240971442717691904"]},{"title":"Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"EacC5X8DeNoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39932-4/abstract","googleCitationCount":29,"googleAuthor":"","statusesArray":[]},{"title":"Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer","googleId":"XSoIvimC20kJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419459917","googleCitationCount":38,"googleAuthor":"B Lee","doi":"10.1093/annonc/mdz200","elsevierAuthor":"Lee B.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-09-01","elsevierCoverDisplayDate":"1 September 2019","elsevierCitationCount":"27","altmetricAuthors":["B. Lee","L. Lipton","J. Cohen","J. Tie","A.A. Javed","L. Li","D. Goldstein","M. Burge","P. Cooray","A. Nagrial","N.C. Tebbutt","B. Thomson","M. Nikfarjam","M. Harris","A. Haydon","B. Lawrence","D.W.M. Tai","K. Simons","A.M. Lennon","C.L. Wolfgang","C. Tomasetti","N. Papadopoulos","K.W. Kinzler","B. Vogelstein","P. Gibbs"],"twitterCount":8,"altmetricId":62844326,"statusesArray":["1151792261266411520","1145532103448129536","1145480066735828992","1145238870692417536","1145209561734950912","1145136396182667265","1145135847471292416","1144723708717805568"]},{"title":"Association between tissue TMB (tTMB) and clinical outcomes with pembrolizumab monotherapy (pembro) in PD-L1-positive advanced NSCLC in the …","googleId":"bTEH5zyfKmEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604370","googleCitationCount":37,"googleAuthor":"RS Herbst","doi":"10.1093/annonc/mdz394.077","elsevierAuthor":"Chakraborty A.","publicationName":"Biochemical Society Transactions","elsevierCoverDate":"2020-12-01","elsevierCoverDisplayDate":"December 2020","elsevierCitationCount":"0","altmetricAuthors":["R.S. Herbst","G. Lopes","D.M. Kowalski","M. Nishio","Y.-L. Wu","G. de Castro Junior","P. Baas","D.-W. Kim","M.A. Gubens","R. Cristescu","D. Aurora-Garg","A. Albright","M. Ayers","A. Loboda","J. Lunceford","J. Kobie","G.M. Lubiniecki","M.C. Pietanza","B. Piperdi","T.S.K. Mok"],"twitterCount":0,"altmetricId":69820636,"statusesArray":[]},{"title":"Long-course preoperative chemoradiation versus 5× 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results …","googleId":"-ztpBsjY5VQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312967","googleCitationCount":48,"googleAuthor":"W Michalski","doi":"10.1093/annonc/mdz186","elsevierAuthor":"Ciseł B.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-08-01","elsevierCoverDisplayDate":"1 August 2019","elsevierCitationCount":"30","altmetricAuthors":["B. Ciseł","L. Pietrzak","W. Michalski","L. Wyrwicz","A. Rutkowski","E. Kosakowska","A. Cencelewicz","M. Spałek","W. Polkowski","M. Jankiewicz","R. Styliński","M. Bębenek","B. Kapturkiewicz","A. Maciejczyk","J. Sadowski","J. Zygulska","W. Zegarski","M. Jankowski","M. Las-Jankowska","Z. Toczko","U. Żelazowska-Omiotek","L. Kępka","J. Socha","E. Wasilewska-Tesluk","W. Markiewicz","J. Kładny","A. Majewski","W. Kapuściński","R. Suwiński","K. Bujko"],"twitterCount":33,"altmetricId":62567962,"statusesArray":["1270662138395193344","1241032328224202753","1241023997120143361","1241023422479679489","1239876766706987008","1239671041087193088","1239631747584643080","1239612240182923264","1239598274023231488","1239495663202832384","1239478890936107008","1239477349676089346","1239472144607776768","1239454412847730688","1239453302326206464","1239453068695134209","1239231960343613444","1239230545332068352","1239230283590676480","1239230126828765189","1239227962194567169","1238913228912185344","1143624270330900480","1143623892692611072","1143623378160381952","1143492530178285569","1143142275741970432","1143002230376689664","1142898493494878208","1142852153826000896","1142850974970761216","1142801994878521346","1142793722117201921","1142789644049928192","1142786576029822978","1142785141065969665","1142781184704995332","1142743728638967809","1142725652476518401","1142652754915135494","1142574768434102273","1142573208970899458"]},{"title":"Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma","googleId":"3bdR8-4wfLMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375342039308X","googleCitationCount":37,"googleAuthor":"TK Choueiri","doi":"10.1016/j.annonc.2020.04.010","elsevierAuthor":"Choueiri T.K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-08-01","elsevierCoverDisplayDate":"August 2020","elsevierCitationCount":"25","altmetricAuthors":["T.K. Choueiri","R.J. Motzer","B.I. Rini","J. Haanen","M.T. Campbell","B. Venugopal","C. Kollmannsberger","G. Gravis-Mescam","M. Uemura","J.L. Lee","M.-O. Grimm","H. Gurney","M. Schmidinger","J. Larkin","M.B. Atkins","S.K. Pal","J. Wang","M. Mariani","S. Krishnaswami","P. Cislo","A. Chudnovsky","C. Fowst","B. Huang","A. di Pietro","L. Albiges"],"twitterCount":74,"altmetricId":80611142,"statusesArray":["1281134939954647043","1258685810498469888","1256511145663496192","1255921868869156865","1254893033339924486","1254807828906246146","1254702558423199745","1254694422140399616","1254692253538418688","1254680471214206976","1254671663372931073","1254638801454084096","1254607750023335937","1254572306157973505","1254560355252162560","1254542956129738753","1254531069174398976","1254530942598885377","1254508231424118784","1254504749732372481","1254502127294009344","1254492975272525828","1254487515764932608","1254485381594013696","1254477607837499392","1254476971775492100","1254474165937209344","1254473841000230916","1254465096237096960","1254464492290953222","1254462460519763975","1254462038174097409","1254459225268461568","1254444757868261376","1254437212537552896","1254436156265160705","1254435769478901760","1254434346972348416","1254432747243724802","1254423842677821447","1254423558744428545","1254418267592065026","1254418113040273408","1254415907721342978","1254415489742393345","1254413104097738752","1254403469131354112","1254399029129207808","1254397756791312384","1254396728578650112","1254391451468922887","1254389201736536064","1254383173347278849","1254377731480936449","1254376184038612992","1254373622560354304","1254373570676916225","1254372105648508931","1254370638350827523","1254368077703254017","1254366202685788162","1254363768257236993","1254363434671583235","1254361509054099456","1254354421397565440","1254348721682370560","1254339558218633221","1254337864290181122","1254329362494763010","1254328259988336640","1254321099996901376","1254321096343662593","1254320416304357376","1254316781264687104","1254315033393324032","1254314797065175040","1254314775024218112","1254314457582444544","1254313726980886528","1254306717778706432","1254305648885587973","1254303535338008576","1254299045025271808","1254298508712083457","1254298369654169600"]},{"title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group","googleId":"95DDbU11eX0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420399713","googleCitationCount":32,"googleAuthor":"J Remon","doi":"10.1016/j.annonc.2020.07.014","elsevierAuthor":"Mosele F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-11-01","elsevierCoverDisplayDate":"November 2020","elsevierCitationCount":"7","altmetricAuthors":["F. Mosele","J. Remon","J. Mateo","C.B. Westphalen","F. Barlesi","M.P. Lolkema","N. Normanno","A. Scarpa","M. Robson","F. Meric-Bernstam","N. Wagle","A. Stenzinger","J. Bonastre","A. Bayle","S. Michiels","I. Bièche","E. Rouleau","S. Jezdic","J-Y. Douillard","J.S. Reis-Filho","R. Dienstmann","F. André"],"twitterCount":45,"altmetricId":88850694,"statusesArray":["1358344478210277390","1317603289018605575","1316566875434778625","1316200454141997058","1316174436492402688","1316066147641458692","1316050061311213570","1313750520947851264","1309286946615644160","1307192465686966272","1306876620616224776","1306771260207247361","1306715001240068096","1306700788585189376","1306500475949404160","1306394999089704960","1306352962869043201","1306326581133160449","1306300074985771008","1306292868638744578","1306290517102206978","1302930752385044481","1301518056796106755","1300586601412689925","1300395036450881539","1299285889525272576","1299174529319620609","1299028458731962369","1298958236582846464","1298549461992513536","1298353247141408771","1298311859527798784","1298302232237047811","1298288783406768128","1298288740733878272","1298288317700636672","1298284780077953024","1298276534709620736","1298273683333554178","1298266176271691778","1298262571682693120","1298261975059722248","1298261933485748235","1298261691675770880","1298260659373666305","1298260428628226055","1298247690795376643"]},{"title":"Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial","googleId":"zr4CoiyuQnAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310403","googleCitationCount":40,"googleAuthor":"RS Herbst","doi":"10.1093/annonc/mdy545","elsevierAuthor":"Herbst R.S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-02-01","elsevierCoverDisplayDate":"1 February 2019","elsevierCitationCount":"35","altmetricAuthors":["R.S. Herbst","P. Baas","J.L. Perez-Gracia","E. Felip","D.-W. Kim","J.-Y. Han","J.R. Molina","J.-H. Kim","C. Dubos Arvis","M.-J. Ahn","M. Majem","M.J. Fidler","V. Surmont","G. de Castro","M. Garrido","Y. Shentu","K. Emancipator","A. Samkari","E.H. Jensen","G.M. Lubiniecki","E.B. Garon"],"twitterCount":25,"altmetricId":54090333,"statusesArray":["1089261594775818241","1088529330689507338","1088423699336912897","1087995723319259137","1087961154364891141","1087831526702747648","1087826949827743744","1087824308389330946","1087816660017442817","1087701926039470080","1087666988615417856","1087644271061004293","1087643036136493056","1087628967207727105","1087264325658701824","1086979049103085568","1086903980255522818","1086848402778779648","1086847254776987648","1086766695086141442","1086719281902030849","1086668023702929409","1086636645699469312","1086485527828811776","1086308961018675205","1086171771445878785","1086169788559310848"]},{"title":"Surgery in reference centers improves survival of sarcoma patients: a nationwide study","googleId":"iWz5eFiC5KIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312323","googleCitationCount":45,"googleAuthor":"JY Blay","doi":"10.1093/annonc/mdz124","elsevierAuthor":"Mesko N.W.","publicationName":"Surgical Oncology Clinics of North America","elsevierCoverDate":"2020-10-01","elsevierCoverDisplayDate":"October 2020","elsevierCitationCount":"0","altmetricAuthors":["J.-Y. Blay","C. Honoré","E. Stoeckle","P. Meeus","M. Jafari","F. Gouin","P. Anract","G. Ferron","A. Rochwerger","M. Ropars","S. Carrere","F. Marchal","F. Sirveaux","A. Di Marco","L.R. Le Nail","J. Guiramand","G. Vaz","J.-C. Machiavello","O. Marco","S. Causeret","P. Gimbergues","F. Fiorenza","L. Chaigneau","F. Guillemin","J.-M. Guilloit","F. Dujardin","J.-P. Spano","J.-C. Ruzic","A. Michot","P. Soibinet","E. Bompas","C. Chevreau","F. Duffaud","M. Rios","C. Perrin","N. Firmin","F. Bertucci","C. Le Pechoux","F. Le Loarer","O. Collard","M. Karanian-Philippe","M. Brahmi","A. Dufresne","A. Dupré","F. Ducimetière","A. Giraud","D. Pérol","M. Toulmonde","I. Ray-Coquard","A. Italiano","A. Le Cesne","N. Penel","S. Bonvalot"],"twitterCount":41,"altmetricId":60216044,"statusesArray":["1155118202281779201","1152565537186230272","1152475145589538816","1152327770644602886","1152311376456667139","1152293233499738112","1151671717347188737","1151432334589288449","1151395684526034944","1151218757022494720","1151187170625019906","1151175849758117890","1151153227888566273","1140993795523325952","1140956404951502848","1140915670973997058","1140865178529075200","1140859678659887105","1140846336465678341","1140788804485296129","1140715239966728192","1140692992556240896","1140624357389156354","1140616839908798469","1140602942367686656","1140596320689721347","1140591173800644612","1140537733095546880","1140533182539993088","1140512559667326977","1140364056878039041","1140346235305566211","1140337970005860353","1140318366906777600","1140304471349714944","1140279893223251969","1140278160912785409","1140128270781964288","1140016039637454848","1139664233262649345","1139656568725749761","1128201608586768384","1128198773929385984","1128198440301879297","1126805507262623744","1126799460657504256"]},{"title":"Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): post-hoc …","googleId":"0jR1BCf407QJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603698","googleCitationCount":46,"googleAuthor":"S Loi","doi":"10.1093/annonc/mdz394.009","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas …","googleId":"scNCVpsFdAAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325904","googleCitationCount":31,"googleAuthor":"V Makker","doi":"10.1093/annonc/mdz291","elsevierAuthor":"Jhaveri K.L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-11-01","elsevierCoverDisplayDate":"November 2019","elsevierCitationCount":"27","altmetricAuthors":["K.L. Jhaveri","X.V. Wang","V. Makker","S.-W. Luoh","E.P. Mitchell","J.A. Zwiebel","E. Sharon","R.J. Gray","S. Li","L.M. McShane","L.V. Rubinstein","D. Patton","P.M. Williams","S.R. Hamilton","B.A. Conley","C.L. Arteaga","L.N. Harris","P.J. O’Dwyer","A.P. Chen","K.T. Flaherty"],"twitterCount":16,"altmetricId":65889838,"statusesArray":["1222477133722767360","1171295381721944064","1169897951491047425","1169895533944528898","1169605503141335041","1169589251673120768","1169562247238230016","1169555578370195456","1169552333732073472","1169549591320113152","1169546965098459136","1169482207909613569","1169370328117723136","1169342675167956992","1169331598564700161","1169331452305170436","1169312362781925378","1169298394545672193","1169236730232397824"]},{"title":"Testing for COVID-19 in lung cancer patients","googleId":"rGnGMrUMu8AJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39293-0/pdf","googleCitationCount":39,"googleAuthor":"S Peters","statusesArray":[]},{"title":"A multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural …","googleId":"haiUYizilZ8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604515","googleCitationCount":37,"googleAuthor":"","doi":"10.1093/annonc/mdz394.091","elsevierCitationCount":0,"altmetricAuthors":["S. Popat","A. Curioni-Fontecedro","V. Polydoropoulou","R. Shah","M. O’Brien","A. Pope","P. Fisher","J. Spicer","A. Roy","D. Gilligan","O. Gautschi","E. Nadal","W.-D. Janthur","R. López Castro","R. García Campelo","H. Roschitzki-Voser","B. Ruepp","S. Rusakiewicz","S. Peters","R.A. Stahel"],"twitterCount":1,"altmetricId":67608243,"statusesArray":["1179669982780805120"]},{"title":"Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: Tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and …","googleId":"odR8Vk1w7u8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604382","googleCitationCount":34,"googleAuthor":"","doi":"10.1093/annonc/mdz394.078","elsevierCitationCount":0,"altmetricAuthors":["L. Paz-Ares","C.J. Langer","S. Novello","B. Halmos","Y. Cheng","S.M. Gadgeel","R. Hui","S. Sugawara","H. Borghaei","R. Cristescu","D. Aurora-Garg","A. Albright","A. Loboda","J. Kobie","J. Lunceford","M. Ayers","G.M. Lubiniecki","M.C. Pietanza","B. Piperdi","M.C. Garassino"],"twitterCount":0,"altmetricId":69820639,"statusesArray":[]},{"title":"Cerebrospinal fluid cell-free tumour DNA as a liquid biopsy for primary brain tumours and central nervous system metastases","googleId":"HuF1PmDnk7EJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310397","googleCitationCount":37,"googleAuthor":"A Bardelli","doi":"10.1093/annonc/mdy544","elsevierAuthor":"Seoane J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-02-01","elsevierCoverDisplayDate":"1 February 2019","elsevierCitationCount":"24","altmetricAuthors":["J. Seoane","L. De Mattos-Arruda","E. Le Rhun","A. Bardelli","M. Weller"],"twitterCount":23,"altmetricId":53009558,"statusesArray":["1235720927662370817","1235562843228868609","1117670117859631104","1117650156692889600","1103190952930357248","1102966910570975233","1087051320228487169","1086719375820890112","1086551364463935488","1086534853607198720","1086455674945581056","1086346093460443136","1086310207477686272","1086266842950205440","1086195940313255936","1086185726868377600","1086175854424539138","1086171900403945472","1086151757040898050","1086106816663162882","1086058348783517696","1086014057906405376","1085649636889522176","1076812924595961856","1076234679706181636"]},{"title":"Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus","googleId":"gkwEA2X7cC0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420399488","googleCitationCount":37,"googleAuthor":"S Banerjee","doi":"10.1016/j.annonc.2020.07.010","elsevierAuthor":"Curigliano G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-10-01","elsevierCoverDisplayDate":"October 2020","elsevierCitationCount":"20","altmetricAuthors":["G. Curigliano","S. Banerjee","A. Cervantes","M.C. Garassino","P. Garrido","N. Girard","J. Haanen","K. Jordan","F. Lordick","J.P. Machiels","O. Michielin","S. Peters","J. Tabernero","J.Y. Douillard","G. Pentheroudakis","A. Addeo","L. Albiges","P.A. Ascierto","S. Banerjee","F. Barlesi","C. Caldas","F. Cardoso","A. Cervantes","I.F. Chaberny","N.I. Cherny","T.K. Choueiri","M.L.K. Chua","C. Criscitiello","G. Curigliano","E. de Azambuja","D. De Ruysscher","E. de Vries","R. Dent","J.Y. Douillard","D. D’Ugo","R. Dziadziuszko","C. Faivre-Finn","E. Felip","M. Garassino","P. Garrido","N. Girard","R. Glynne-Jones","V. Golfinopoulos","J. Haanen","E. Hamilton","P.A. Jänne","K. Jordan","R. Kanesvaran","S.B. Kim","U.G. Liebert","F. Lordick","J.P. Machiels","O. Michielin","T.S.K. Mok","G. Morgan","R. Obermannova","K. Park","A. Passaro","G. Pentheroudakis","S. Peters","M. Reck","R. Salazar Soler","F. Scotté","S. Senan","C. Sessa","E. Smyth","R. Soo","J.C. Soria","J. Spicer","F. Strasser","J. Tabernero","D.S.W. Tan","D. Trapani","E. Van Cutsem","H. van Halteren","P.E. van Schil","G. Veronesi","J. Yang"],"twitterCount":7,"altmetricId":87054624,"statusesArray":["1319247124320653313","1319227467660394499","1319173228087136257","1319153459518726145","1318981754070368258","1318971626441027589","1297842227566305281"]},{"title":"Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment …","googleId":"WAIpjOgnfGAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419459954","googleCitationCount":47,"googleAuthor":"J Taieb","doi":"10.1093/annonc/mdz208","elsevierAuthor":"Taieb J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-09-01","elsevierCoverDisplayDate":"1 September 2019","elsevierCitationCount":"29","altmetricAuthors":["J. Taieb","Q. Shi","L. Pederson","S. Alberts","N. Wolmark","E. Van Cutsem","A. de Gramont","R. Kerr","A. Grothey","S. Lonardi","T. Yoshino","G. Yothers","F.A. Sinicrope","A. Zaanan","T. André"],"twitterCount":34,"altmetricId":63076326,"statusesArray":["1204482026839171072","1191095731676954624","1189439121023995906","1189006450900852741","1188936818609283073","1188920004231815171","1188890052648153093","1188881188011806720","1188870273824673792","1188869001574666242","1188858859953250304","1188852860584452097","1188848435883118597","1188842478167822339","1188841798032117761","1188833601808408576","1188831367074762752","1188829425015459841","1188817958648201217","1150078579176173569","1149999673131884544","1149993215665348609","1149990104980697088","1149951673739218946","1149939916819894272","1149896398156029953","1149726754224820225","1149709948642832385","1149673765774581760","1148180186967531522","1147087459462844416","1147064431299452933","1147036132665888773","1147032776102883328","1147027062793940992","1147022514289303553","1146493565993934849","1146473110201352193","1146471651086704640","1146461897279062017","1146407682770968576","1146397151951564800","1146393558586462208","1146391243926188034","1146381997687918592","1146369102065393664"]},{"title":"Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after …","googleId":"46IxcFkiSocJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30259-5/abstract","googleCitationCount":47,"googleAuthor":"TK Owonikoko","statusesArray":[]},{"title":"Adjuvant or salvage radiotherapy for the treatment of localised prostate cancer? A prospectively planned aggregate data meta-analysis","googleId":"hQu2ROH9aHQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604011","googleCitationCount":34,"googleAuthor":"","doi":"10.1093/annonc/mdz394.041","elsevierAuthor":"Kokorovic A.","publicationName":"Canadian Urological Association Journal","elsevierCoverDate":"2020-04-28","elsevierCoverDisplayDate":"April 2020","elsevierCitationCount":"3","altmetricAuthors":["C.L. Vale","M. Brihoum","S. Chabaud","A. Cook","D. Fisher","S. Forcat","C. Fraser-Browne","A. Herschtal","A. Kneebone","S. Nénan","C. Parker","M.K.B. Parmar","M. Pearse","P. Richaud","E. Rogozińska","P. Sargos","M.R. Sydes","J.F. Tierney"],"twitterCount":3,"altmetricId":68179447,"statusesArray":["1200753682284982278","1200081224011833344","1200047310262210563"]},{"title":"Optimizing panel-based tumor mutational burden (TMB) measurement","googleId":"S1HxzZuQ0lgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419459930","googleCitationCount":47,"googleAuthor":"J Budczies","doi":"10.1093/annonc/mdz205","elsevierAuthor":"Budczies J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-09-01","elsevierCoverDisplayDate":"1 September 2019","elsevierCitationCount":"32","altmetricAuthors":["J. Budczies","M. Allgäuer","K. Litchfield","E. Rempel","P. Christopoulos","D. Kazdal","V. Endris","M. Thomas","S. Fröhling","S. Peters","C. Swanton","P. Schirmacher","A. Stenzinger"],"twitterCount":33,"altmetricId":63079759,"statusesArray":["1268558390394933248","1222532053834428417","1222505305528885248","1199560201441030144","1189917423966666752","1156805894375641088","1156805371417300997","1156704776513564672","1156607504962510850","1156572696928555009","1156549085257596929","1156549033487470592","1156544257144033280","1156505448075452416","1156504810788667392","1150846885776592896","1150789408725098498","1150695944532320256","1150611812334940167","1147525386982559745","1146933160422150144","1146897251056398336","1146853706769543169","1146727143688364032","1146725861682376704","1146655620562608128","1146651915046047749","1146604143198507008","1146544373427003399","1146497156427198465","1146494283677147140","1146473887015821312","1146472297710010368","1146471227864694784","1146452225042132993","1146430534916235264","1146407579117133826","1146404373607714816","1146397068560351232","1146393574130499584","1146392174403182592"]},{"title":"Phase III study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastatic gBRCA-associated breast cancer","googleId":"eziLk_KxKjYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603686","googleCitationCount":37,"googleAuthor":"H Wildiers","doi":"10.1093/annonc/mdz394.008","elsevierCitationCount":0,"altmetricAuthors":["V.C. Diéras","H.S. Han","B. Kaufman","H. Wildiers","M. Friedlander","J.-P. Ayoub","S.L. Puhalla","I. Bondarenko","M. Campone","E.H. Jakobsen","M. Jalving","C. Oprean","M. Palácová","Y.H. Park","Y. Shparyk","E. Yañez","M. Dudley","C.K. Ratajczak","D. Maag","B.K. Arun"],"twitterCount":0,"altmetricId":68179385,"statusesArray":[]},{"title":"IMvigor130: Efficacy and safety from a phase III study of atezolizumab (atezo) as monotherapy or combined with platinum-based chemotherapy (PBC) vs …","googleId":"s2ZbG56JeBoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604072","googleCitationCount":35,"googleAuthor":"ID Davis","doi":"10.1093/annonc/mdz394.047","elsevierAuthor":"Fender H.E.","publicationName":"Best Practice Onkologie","elsevierCoverDate":"2020-09-01","elsevierCoverDisplayDate":"1 September 2020","elsevierCitationCount":"0","altmetricAuthors":["E. Grande","M. Galsky","J.A. Arranz Arija","M. De Santis","I.D. Davis","U.F.F. De Giorgi","M. Mencinger","E. Kikuchi","X. Garcia del Muro","M. Gumus","M. Özgüroğlu","A. Rezazadeh Kalebasty","S.H. Park","B.Y. Alekseev","F.A.B. Schutz","J.-R. Li","A. Mecke","S. Mariathasan","A. Thastrom","A. Bamias"],"twitterCount":2,"altmetricId":68179454,"statusesArray":["1188481556861476864","1188177503849984000"]},{"title":"Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: current evidence and future challenges","googleId":"m-l39GxGlyoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354675","googleCitationCount":24,"googleAuthor":"HM Kuerer","doi":"10.1016/j.annonc.2019.10.012","elsevierAuthor":"Heil J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"January 2020","elsevierCitationCount":"16","altmetricAuthors":["J. Heil","H.M. Kuerer","A. Pfob","G. Rauch","H.P. Sinn","M. Golatta","G.J. Liefers","M.J. Vrancken Peeters"],"twitterCount":2,"altmetricId":80938390,"statusesArray":["1357978960769019905","1258411292412518401"]},{"title":"Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial","googleId":"DsYea6thfiUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311676","googleCitationCount":42,"googleAuthor":"","doi":"10.1093/annonc/mdz080","elsevierAuthor":"Hofman V.","publicationName":"Lung Cancer","elsevierCoverDate":"2020-07-01","elsevierCoverDisplayDate":"July 2020","elsevierCitationCount":"1","altmetricAuthors":["O. Trédan","Q. Wang","D. Pissaloux","P. Cassier","A. de la Fouchardière","J. Fayette","F. Desseigne","I. Ray-Coquard","C. de la Fouchardière","D. Frappaz","P.-E. Heudel","A. Bonneville-Levard","A. Fléchon","M. Sarabi","P. Guibert","T. Bachelot","M. Pérol","B. You","N. Bonnin","O. Collard","C. Leyronnas","V. Attignon","C. Baudet","E. Sohier","J.-P. Villemin","A. Viari","S. Boyault","S. Lantuejoul","S. Paindavoine","I. Treillleux","C. Rodriguez","V. Agrapart","V. Corset","G. Garin","S. Chabaud","D. Pérol","J.-Y. Blay"],"twitterCount":44,"altmetricId":57207578,"statusesArray":["1154554609244917760","1154541766617391104","1138159682508533761","1112622213390315520","1112461196983238658","1112373867962613762","1112370348798828544","1112326586492162048","1112311417108119552","1112310950407929856","1112296334806183936","1112167183914885120","1112054087967797249","1111936799461515266","1111931798223835136","1111918309321179142","1111908800871698432","1111907259246882816","1111843706187845632","1111744781284196359","1111744228697231361","1111708260170719232","1111703003088719872","1111340777555353600","1111218304960679936","1110996682131542016","1110958376773656579","1110954749535363072","1110787809135247360","1110739847722004485","1110734951266336768","1110715618666246144","1110656205729529862","1110653127202615297","1110645376183349248","1110631542420918273","1110587018445312000","1110498828107595778","1110461382611345408","1110457669909995521","1110098725215588352","1109817537754222593","1109488519964250114","1109471012532469761","1107975716564623360","1107154061764235264","1106133509981143042"]},{"title":"Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a …","googleId":"Dtv_9UGKk2AJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311184","googleCitationCount":42,"googleAuthor":"O Chinot","doi":"10.1093/annonc/mdz032","elsevierAuthor":"Yang H.","publicationName":"Journal of Cellular Physiology","elsevierCoverDate":"2020-12-01","elsevierCoverDisplayDate":"1 December 2020","elsevierCitationCount":"0","altmetricAuthors":["H. Ghesquieres","M. Chevrier","M. Laadhari","O. Chinot","S. Choquet","C. Moluçon-Chabrot","P. Beauchesne","R. Gressin","F. Morschhauser","A. Schmitt","E. Gyan","K. Hoang-Xuan","E. Nicolas-Virelizier","N. Cassoux","V. Touitou","M. Le Garff-Tavernier","A. Savignoni","I. Turbiez","V. Soumelis","C. Houillier","C. Soussain"],"twitterCount":48,"altmetricId":54771429,"statusesArray":["1228149060554625024","1224388987235831810","1224187419701981185","1224168198771224576","1224142417114423296","1224070794084569089","1224067620862861313","1224057293030842368","1224054977263538178","1223829032019488768","1223803766786400256","1222964460853383171","1222657408671059970","1222648566906224640","1222489204090920960","1222477126252650496","1148432918026575874","1148368351560904705","1148115138140090368","1148023646176366592","1140336344364986368","1096771481567182848","1096189697431429121","1095895214676471808","1095752683988938752","1095593145130209280","1094690161026387968","1092854148784099330","1092288919146778624","1092242170495545344","1092159855983542275","1092148016583188480","1092017497077891072","1091995792485822465","1091978018166394880","1091925067649273857","1091916060692017152","1091849154048024576","1091795511802298371","1091774514529210369","1091770598655750144","1091770497174568960","1091769916246642688","1091767789789024257","1091762268344336384","1091742793905647617","1091740959346487297","1091737855678992384","1091734890234740736","1091734021518835713","1091731724441145347","1091726131118657536","1091723343001280513","1091708745883766784","1091700371548852224","1091694625776156678","1091693657462374400","1091083951459000321","1091026036467343360","1090954735870332928","1090949082531749888","1090929536685039616"]},{"title":"Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE …","googleId":"PfhwiaB7TbAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420364152","googleCitationCount":31,"googleAuthor":"T André","doi":"10.1016/j.annonc.2020.03.310","elsevierAuthor":"Pagès F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-09-01","elsevierCoverDisplayDate":"September 2020","elsevierCitationCount":"0","altmetricAuthors":["F. Pagès","T. André","J. Taieb","D. Vernerey","J. Henriques","C. Borg","F. Marliot","R. Ben Jannet","C. Louvet","L. Mineur","J. Bennouna","J. Desrame","R. Faroux","A. Kirilovsky","A. Duval","P. Laurent-Puig","M. Svrcek","F. Hermitte","A. Catteau","J. Galon","J.-F. Emile"],"twitterCount":11,"altmetricId":79937886,"statusesArray":["1303474653348810753","1300814076294172672","1300702331990945793","1300465646535352321","1300438190201933824","1300436457170046977","1274777774008471553","1268664974408376322","1266311305067184128","1265583535282425857","1265576809216774151","1250883797979066368"]},{"title":"Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas","googleId":"n1EqoQcwYrQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375342036018X","googleCitationCount":25,"googleAuthor":"AJ Schoenfeld","doi":"10.1016/j.annonc.2020.01.065","elsevierAuthor":"Schoenfeld A.J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-05-01","elsevierCoverDisplayDate":"May 2020","elsevierCitationCount":"14","altmetricAuthors":["A.J. Schoenfeld","H. Rizvi","C. Bandlamudi","J.L. Sauter","W.D. Travis","N. Rekhtman","A.J. Plodkowski","R. Perez-Johnston","P. Sawan","A. Beras","J.V. Egger","M. Ladanyi","K.C. Arbour","C.M. Rudin","G.J. Riely","B.S. Taylor","M.T.A. Donoghue","M.D. Hellmann"],"twitterCount":74,"altmetricId":75709463,"statusesArray":["1271836733890613248","1271233020842979328","1270603192284459009","1270531389251891203","1270397147683287041","1270393721255628800","1270381669133037569","1270308431476465664","1270251183861620737","1270127828005031936","1270127018466611200","1270086659590193153","1270083027016781825","1270082757809627142","1270075877997662210","1270036499833270273","1270029985764474880","1270024027982233600","1270023938744160258","1270015340995661827","1270006034334179328","1270005191887241216","1269988430265692160","1269975590926520327","1269939030122250240","1269932736749416450","1269931970513035267","1269930302052409346","1269924027990183936","1269892291746988037","1269860801583689732","1269836620871671819","1269828285988507648","1269828019927035909","1269823991172259846","1240307938474037249","1229414994732777472","1227666688163958784","1227500123019599873","1227368493290573825","1227329071203438594","1227305881848762370","1227291469951700992","1227262525730906116","1227247695393361922","1227243789007245313","1227231535411220480","1227220140779089920","1227141947137122304","1227133850775511040","1227133537821704192","1227133494683414530","1227126020441956354","1227104510411264001","1227097089965985797","1227077521268600832","1227065624842522624","1227060453307637760","1227003145605275648","1226990451179192320","1226987902036566018","1226986549490933760","1226979283521933314","1226971181607157761","1226970924567666689","1226943675214725121","1226930334899560448","1226923373583896577","1226922242589720577","1226915363339849728","1226897311910985729","1226873893702553600","1226873647731793921","1226853620206985219","1226852992994988032","1226846908318126081","1226843522369753088","1226837455665541120","1226825118271320065","1226823956910542849","1226823389597306884","1226820432214528000","1226817514094510080","1226817211949633536","1226817195583377408","1226816310769864704"]},{"title":"Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc …","googleId":"KcAJOZ_YqfwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420359275","googleCitationCount":32,"googleAuthor":"","doi":"10.1016/j.annonc.2020.01.006","elsevierAuthor":"Chalabi M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-04-01","elsevierCoverDisplayDate":"April 2020","elsevierCitationCount":"23","altmetricAuthors":["M. Chalabi","A. Cardona","D.R. Nagarkar","A. Dhawahir Scala","D.R. Gandara","A. Rittmeyer","M.L. Albert","T. Powles","M. Kok","F.G. Herrera"],"twitterCount":20,"altmetricId":74454706,"statusesArray":["1309485593559068679","1307242670398423041","1265515789614022661","1248245065291411457","1248242520930181120","1240629421909979143","1240592149999165440","1234524030583087109","1232148471471276032","1231975876792684544","1231933480176476161","1231930581354565634","1231927952310337536","1231926888253329408","1225640138652315648","1225505615268777995","1225502670754107393","1225383285477560320","1225364410446860289","1225344217758593025","1220797665740558339","1220752748473409536"]},{"title":"Crizotinib in c-MET-or ROS1-positive NSCLC: results of the AcSé phase II trial","googleId":"sqRXiDd8Py0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325606","googleCitationCount":42,"googleAuthor":"J Mazières","doi":"10.1093/annonc/mdz407","elsevierAuthor":"Moro-Sibilot D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-12-01","elsevierCoverDisplayDate":"1 December 2019","elsevierCitationCount":"30","altmetricAuthors":["D. Moro-Sibilot","N. Cozic","M. Pérol","J. Mazières","J. Otto","P.J. Souquet","R. Bahleda","M. Wislez","G. Zalcman","S.D. Guibert","F. Barlési","B. Mennecier","I. Monnet","R. Sabatier","S. Bota","C. Dubos","V. Verriele","V. Haddad","G. Ferretti","A. Cortot","F. De Fraipont","M. Jimenez","N. Hoog-Labouret","G. Vassal"],"twitterCount":33,"altmetricId":67695583,"statusesArray":["1222489206880120833","1191526642444853248","1184613952946237440","1184561009752707078","1183640526798708737","1183356478368964608","1183316008007811072","1183288063449092096","1182942911727591425","1182904229280833542","1182858874384199680","1182826640012767233","1182764479718789121","1182763045040414723","1182760752937082881","1182536871907397633","1182224625394208769","1182209455125127169","1182171261188923392","1182170887908405248","1182096916626264065","1182005948237385729","1182001139585150976","1182000600277348352","1181975733301727232","1181975334499078145","1181975201732530177","1181974296702271488","1181943444257857536","1181916829318410240","1181913830181474304","1181911021885284352","1181908921151148034","1181310640796909573","1181290220723036160","1181089536799133696","1181041405906415616","1180955586978091008","1180926787980804096","1180922711977140225","1180915898770698240","1180891039328018432","1180891005320646656","1180883849863147520","1180881985922723840","1180881930713088000","1180851733767053314","1180838093034840064","1180791582792007680","1180780726729543680","1180779207238062080","1180190875697254405"]},{"title":"KEYNOTE-119: Phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (mTNBC)","googleId":"9VGjLlghH7wJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603704","googleCitationCount":33,"googleAuthor":"","doi":"10.1093/annonc/mdz394.010","elsevierCitationCount":0,"altmetricAuthors":["J. Cortés","O. Lipatov","S.-A. Im","A. Gonçalves","K.S. Lee","P. Schmid","K. Tamura","L. Testa","I. Witzel","S. Ohtani","S. Zambelli","N. Harbeck","F. André","R. Dent","X. Zhou","V. Karantza","J.A. Mejia","E.P. Winer"],"twitterCount":0,"altmetricId":68179391,"statusesArray":[]},{"title":"Targeting the PI3-kinase pathway in triple-negative breast cancer","googleId":"yltm_eoRTw4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312396","googleCitationCount":41,"googleAuthor":"","doi":"10.1093/annonc/mdz133","elsevierAuthor":"Xu M.","publicationName":"Aging","elsevierCoverDate":"2021-01-15","elsevierCoverDisplayDate":"15 January 2021","elsevierCitationCount":"0","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Preliminary results from the TRITON2 study of rucaparib in patients (pts) with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate …","googleId":"IQkfwHD4KNsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419590627","googleCitationCount":32,"googleAuthor":"D Campbell","doi":"10.1093/annonc/mdz248.003","elsevierAuthor":"Marhold M.","publicationName":"Memo - Magazine of European Medical Oncology","elsevierCoverDate":"2020-12-01","elsevierCoverDisplayDate":"December 2020","elsevierCitationCount":"1","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma","googleId":"McdKD_h4194J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419590329","googleCitationCount":42,"googleAuthor":"YY Janjigian","doi":"10.1093/annonc/mdz247.143","elsevierCitationCount":0,"altmetricAuthors":["Y.Y. Janjigian","S. Maron","J.F. Chou","A.R. Gabler","M.Z. Simmons","P. Momtaz","M. Shcherba","G.Y. Ku","E. Won","F. Sanchez-Vega","H. Gerdes","D.P. Kelsen","D.H. Ilson","D. Solit","N. Schultz","P.M. Shah","M. Capanu","J.F. Hechtman","M. Lamendola-Essel"],"twitterCount":0,"altmetricId":68179431,"statusesArray":[]},{"title":"Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian …","googleId":"g34MC1v7YkUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604138","googleCitationCount":33,"googleAuthor":"IL Ray-Coquard","doi":"10.1093/annonc/mdz394.053","elsevierCitationCount":0,"altmetricAuthors":["I.L. Ray-Coquard","P. Pautier","S. Pignata","D. Pérol","A. González-Martín","P. Sevelda","K. Fujiwara","I.B. Vergote","N. Colombo","J. Mäenpää","F. Selle","J. Sehouli","D. Lorusso","E M Guerra Alia","C. Lefeuvre-Plesse","U. Canzler","A. Lortholary","F. Marmé","E. Pujade-Lauraine","P. Harter"],"twitterCount":0,"altmetricId":68179382,"statusesArray":[]},{"title":"Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of …","googleId":"VEewJf0Hu6kJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312827","googleCitationCount":33,"googleAuthor":"","doi":"10.1093/annonc/mdz163","elsevierAuthor":"Gomez-Roca C.A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-08-01","elsevierCoverDisplayDate":"1 August 2019","elsevierCitationCount":"27","altmetricAuthors":["C.A. Gomez-Roca","A. Italiano","C. Le Tourneau","P.A. Cassier","M. Toulmonde","S.P. D’Angelo","M. Campone","K.L. Weber","D. Loirat","M.A. Cannarile","A.-M. Jegg","C. Ries","R. Christen","G. Meneses-Lorente","W. Jacob","I. Klaman","C.-H. Ooi","C. Watson","K. Wonde","B. Reis","F. Michielin","D. Rüttinger","J.-P. Delord","J.-Y. Blay"],"twitterCount":1,"altmetricId":60889699,"statusesArray":["1131427533067563009"]},{"title":"European cancer mortality predictions for the year 2020 with a focus on prostate cancer","googleId":"XzTgOemXGA4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420360567","googleCitationCount":23,"googleAuthor":"P Bertuccio","doi":"10.1016/j.annonc.2020.02.009","elsevierAuthor":"Carioli G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-05-01","elsevierCoverDisplayDate":"May 2020","elsevierCitationCount":"13","altmetricAuthors":["G. Carioli","P. Bertuccio","P. Boffetta","F. Levi","C. La Vecchia","E. Negri","M. Malvezzi"],"twitterCount":1,"altmetricId":80131560,"statusesArray":["1254025370468311041"]},{"title":"Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy","googleId":"0OFd8l-6wQQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375342036364X","googleCitationCount":21,"googleAuthor":"AM Menzies","doi":"10.1016/j.annonc.2020.03.285","elsevierAuthor":"Haanen J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-06-01","elsevierCoverDisplayDate":"June 2020","elsevierCitationCount":"15","altmetricAuthors":["J. Haanen","M.S. Ernstoff","Y. Wang","A.M. Menzies","I. Puzanov","P. Grivas","J. Larkin","S. Peters","J.A. Thompson","M. Obeid"],"twitterCount":44,"altmetricId":77933863,"statusesArray":["1279306898148397056","1278918520705822720","1278767929597837312","1269999486484582400","1264511869202595841","1264281836596932615","1264242626833899522","1264180062397640710","1264178530243547138","1264139780587225089","1264125578107551746","1264112726151962625","1264111092516761600","1264109548836716544","1264109341344489478","1264108330148126725","1264098758092099584","1264089344857518080","1264087913618423808","1264085503608938496","1264084393011838976","1264082454626926595","1264078602792034306","1264047258322042880","1264045672392806411","1263980897604419587","1263941596283916288","1263916829526970370","1263906504396156932","1263896367589662722","1263895195583680512","1263883246376488960","1263846075351343105","1263841115217833984","1263839119106625537","1263827365106462720","1263804987638980609","1263789364728877057","1263763232675835904","1263761863533363201","1263759938993586176","1263754189525696512","1263753519984771073","1262331622369759232","1241752456612151297","1241563386292436995","1241563257980063744","1240972416672768000"]},{"title":"A phase Ib trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): updated results","googleId":"7mOFh48MmssJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419589633","googleCitationCount":35,"googleAuthor":"J Llovet","doi":"10.1093/annonc/mdz247.073","elsevierAuthor":"Pinter M.","publicationName":"JAMA Oncology","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"January 2021","elsevierCitationCount":"3","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen—To Offer More …","googleId":"zmzE8yWnucEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325898","googleCitationCount":25,"googleAuthor":"JMS Bartlett","doi":"10.1093/annonc/mdz289","elsevierAuthor":"Bartlett J.M.S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-11-01","elsevierCoverDisplayDate":"November 2019","elsevierCitationCount":"18","altmetricAuthors":["J.M.S. Bartlett","D.C. Sgroi","K. Treuner","Y. Zhang","I. Ahmed","T. Piper","R. Salunga","E.F. Brachtel","S.J. Pirrie","C.A. Schnabel","D.W. Rea"],"twitterCount":15,"altmetricId":65601327,"statusesArray":["1174310893712281600","1173196661146996737","1173190324186992640","1173181598197604357","1173109800734871552","1173087123479683075","1173066315902476289","1173037432373207045","1171758618879901696","1171368807929196545","1169887291902320640","1169662330877206529","1169647567082262532","1169641338314383362","1167003406076141570"]},{"title":"CTONG 1509: Phase III study of bevacizumab with or without erlotinib in untreated Chinese patients with advanced EGFR-mutated NSCLC","googleId":"9vGOynXF3HQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419596880","googleCitationCount":32,"googleAuthor":"","doi":"10.1093/annonc/mdz260.002","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Efficacy of PI3K inhibitors in advanced breast cancer","googleId":"fpx7lM_LjGEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375342034374X","googleCitationCount":35,"googleAuthor":"F Andre","doi":"10.1093/annonc/mdz381","elsevierAuthor":"Duggan M.R.","publicationName":"Aging","elsevierCoverDate":"2021-01-15","elsevierCoverDisplayDate":"15 January 2021","elsevierCitationCount":"0","altmetricAuthors":["B. Verret","J. Cortes","T. Bachelot","F. Andre","M. Arnedos"],"twitterCount":6,"altmetricId":73183780,"statusesArray":["1217778386757615616","1217475292312240133","1217389391728934914","1209249288024416261","1209224566096191500","1209221056608768002"]},{"title":"Context matters—consensus molecular subtypes of colorectal cancer as biomarkers for clinical trials","googleId":"YxGnAiwPREoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311317","googleCitationCount":34,"googleAuthor":"E Fontana","doi":"10.1093/annonc/mdz052","elsevierAuthor":"Xie Y.H.","publicationName":"Signal Transduction and Targeted Therapy","elsevierCoverDate":"2020-12-01","elsevierCoverDisplayDate":"1 December 2020","elsevierCitationCount":"46","altmetricAuthors":["E. Fontana","K. Eason","A. Cervantes","R. Salazar","A. Sadanandam"],"twitterCount":5,"altmetricId":56081343,"statusesArray":["1252550409471709185","1127174321481363456","1126870350346821633","1100491677125525504","1100472823422898183"]},{"title":"How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer","googleId":"5-2L4DxJ1PAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312037","googleCitationCount":32,"googleAuthor":"S Peters","doi":"10.1093/annonc/mdz109","elsevierAuthor":"Reinmuth N.","publicationName":"Onkologe","elsevierCoverDate":"2021-02-01","elsevierCoverDisplayDate":"February 2021","elsevierCitationCount":"0","altmetricAuthors":["S. Peters","M. Reck","E.F. Smit","T. Mok","M.D. Hellmann"],"twitterCount":152,"altmetricId":57830669,"statusesArray":["1291712204622802944","1291678172824637440","1215870769802203137","1213017185301364736","1213013164926918656","1205252851372609538","1205243053499441152","1205212473646731264","1205196801780924417","1205161676288528386","1205149904240168961","1205096214141767680","1205094284988440576","1205091329438470146","1205091298073440256","1205081031180726272","1205057112742793222","1205049344245850112","1205046846688759809","1167035385953677312","1166695395810000898","1166323509909491712","1166261870623363072","1165985691328663553","1165895526803488768","1165843773051392000","1165654031965933568","1165621937424478208","1165590050631049216","1165571242029699072","1165549158721302529","1165547311524532224","1165541142408175616","1165527940278444032","1165524691240534016","1165518520563712002","1165486633396953088","1165482839867035649","1165482351876562944","1165453941728899072","1165453233235476485","1149965519761661952","1149923610120859649","1149824994819661824","1149557525970214912","1149259507945660416","1149194291757162497","1149192634054971392","1149178294211940352","1148912574160932865","1148905996577849344","1148904659588931584","1148827215733374976","1148809993920978944","1148790812647526400","1148781204482736128","1148745219237715974","1148736557580353536","1148736341754220547","1148731142423531521","1148717211999076352","1148700482950619137","1148696401292881920","1148696131997712385","1148696066906316801","1148694399234334720","1148660834853367811","1148656160154763265","1148637740273156096","1148630903528099840","1148624472447959040","1148624003231363073","1148622548491526146","1148609461923115008","1148577124351172608","1148576861494153216","1148576307149602816","1147525467324465154","1146507817093931009","1146414507834499072","1146293215710064640","1146171827976323072","1146152645096366082","1146150616424755200","1146147612938162176","1146145258255933440","1146144412399017985","1146143740089831425","1146050374928875520","1128392556381974529","1120381649487716352","1115296009016500226","1115248457537740802","1113040989302767618","1112844578267123712","1112808112241737729","1112047048193437698","1112041555035111424","1112025464535552001","1112022766599970817","1112022306241552385","1112018157273796608","1111931948509945856","1111928794594582528","1111928267219456001","1111923096540323842","1111917662030970880","1111916337549451264","1111866647592267777","1111773820543733760","1111696310866972673","1111669928090894336","1111625962427420672","1111605402536431616","1111574435465781248","1111555860755566592","1111553062697492482","1111552670374912000","1111530547648581632","1111515774517215232","1111515753369554944","1111515296127422467","1111484297972772864","1111412205017194497","1111401312149630978","1111384044237803521","1111371110929457152","1111347238968676354","1111339138781978625","1111318732863873025","1111314006797701120","1111305506314870784","1111301923372597248","1111294206578970624","1111281010639962113","1111257449057710080","1111240288251588608","1111213384685350912","1111201873246281728","1111180835619852289","1111167512400539648","1111159478538457089","1111152982790422528","1111150170740150273","1111138772874346496","1111136736665653248","1111085766069899264","1111078228783968259","1111077903553478656","1111076025138597889","1111074507756834816","1111067430783049728","1111061475689283585","1111057860148916224","1111048934863052800","1111045177114800128","1111037724721451008","1111034979721588736","1111031889140350976","1111023395553116160","1111021240893014019","1111008283438002182","1111004070121230337","1110997445926891528","1110997418655522817","1110989683272622080","1110967451846692865","1110966019399536641","1110965944921272321","1110953998213877761","1110948524663828480","1110946185643245569","1110938162451353600","1110928994193412096","1110926038320730112","1110924066989502470","1110911209279152128","1110897653213208576","1110895903567601664","1110895533579796480","1110886558599655425","1110878124449755136","1110875473653825536","1110867477083230208","1110867168575393793","1110855283159515136","1110854995983978502","1110854977503838208","1110853839446396929","1110852679004098560","1110852299411222528","1110849568848183296","1110849075342204928","1110846670047203329","1110845211209535489","1110841958346510336","1110839530846932994","1110836771565252609","1110834999572475905","1110834519417020417"]},{"title":"Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants","googleId":"iRLLQHPhEfIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312049","googleCitationCount":31,"googleAuthor":"C Ay","doi":"10.1093/annonc/mdz111","elsevierAuthor":"Sorigue M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-07-01","elsevierCoverDisplayDate":"1 July 2019","elsevierCitationCount":"0","altmetricAuthors":["C. Ay","J. Beyer-Westendorf","I. Pabinger"],"twitterCount":171,"altmetricId":58171838,"statusesArray":["1188038193330958336","1170091127367753728","1161216170575433728","1160736449303580673","1160601860455182336","1155094182006075393","1153375334215143424","1152365181059645440","1152337867735293952","1152076646536495104","1151815921075412992","1151701703470850049","1151691119509610497","1151673935114752001","1151669596816105472","1151594306140090368","1151557871919927298","1151521280484618241","1151513373529583617","1151494837163778048","1151483811730845698","1151471814746484736","1151470458451234816","1151456278566191105","1151448952610467840","1151443442435858432","1151399286313246720","1151390535116083201","1151375260853272576","1151361916725583873","1151347551980986368","1151286293621555200","1151270614474379264","1151250327724838912","1151248935610195969","1151248289448304642","1151229383669166081","1151224329339842560","1151216564236165121","1151192727947816967","1151174908472373248","1151121088836984834","1151120241570832385","1151115440481067009","1151112320829075456","1151105789014282245","1151089786041466880","1151087118015315968","1151081874267283456","1151078933900746752","1151078048441221120","1151075748557611008","1151056892891979776","1151055517789433856","1151051004881846272","1151047824341180417","1151043895175856129","1151039532634116102","1151035158193233920","1151034493777715201","1151030825934176257","1151021243942023168","1151016174324506624","1151015907872903174","1150991875102388224","1150971222634717184","1150960309185732608","1150953071100485633","1150951432973148160","1150946129787400192","1150935060218093578","1150928680421646340","1150921960588795904","1150918356490498049","1150898963148500992","1150898665692770304","1150896180705951744","1150885150122741762","1150883463354028032","1150882339322585090","1150870862918295553","1150870319953010689","1150869687061876736","1150865326294360066","1150864559072145408","1150858812154363906","1150855647019315202","1150851715589165058","1150851189346635777","1150850709400764417","1150849960793006080","1150844785827155968","1150843935868293120","1150840722012213248","1150840605347442695","1150835460849197058","1150831249751236608","1150830574266920961","1150829967774760962","1150821915969368065","1150821830388674560","1150820146883284993","1150819811833843717","1150817948401053696","1150815124254593024","1150811984994004992","1150810098631106560","1150808170949820429","1150806913191424000","1150806212189085698","1150802322907443200","1150802194926624768","1150800472284028929","1150799303356682240","1150798846227877888","1150798572700520448","1150796982618873856","1150794726376988673","1150786774328860673","1150784345654857728","1150782870862073856","1150780720488411138","1150780375695810561","1150779702346473472","1150778741259476992","1150778422442020865","1150778183500926977","1150777707216723969","1150777462026133504","1150775656709533696","1150773317479124992","1150733209111617537","1150723347875074048","1150646935352725504","1150633417190662145","1150630614967734272","1150628477521006592","1150619873401286657","1150608979862654976","1150587684785721344","1150566173861244929","1150561754470080512","1150552580621254662","1150551256588541959","1150550857009836037","1150549048249716742","1150509349363752960","1150215903667052546","1150105435355136000","1150023422191296512","1150004691922759681","1149868769386356736","1149824560117833734","1149824509983113217","1149817035960061952","1149806066420649986","1149786038082199552","1149713155934887937","1149712510989283328","1149687266354323457","1149685402544091145","1149607282583302146","1149606669518639104","1149567849645502465","1149560732792438784","1149559235702714369","1149491074940858368","1149485040276893703","1149419635575590912","1149417070888652800","1149411732001054720","1149381779587063809","1149379263470145537","1149372263919230976","1149353032485867521","1149348799929815040","1149348181441822720","1149318308497362945","1149298732036321280","1149297551616745473","1149253512712327169","1149249890259746817","1149249482829119488","1131081323962146816","1129324428628844544","1113547844332457985","1113442142226198528","1113399482232713217","1112442059326193665","1112397333243801600","1112392042712322048","1112377014739238914","1112299837322653696"]},{"title":"JSCO—ESMO—ASCO—JSMO—TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with …","googleId":"TpO_JrFmmc8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420363869","googleCitationCount":16,"googleAuthor":"G Pentheroudakis","doi":"10.1016/j.annonc.2020.03.299","elsevierAuthor":"Yoshino T.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-07-01","elsevierCoverDisplayDate":"July 2020","elsevierCitationCount":"12","altmetricAuthors":["T. Yoshino","G. Pentheroudakis","S. Mishima","M.J. Overman","K.-H. Yeh","E. Baba","Y. Naito","F. Calvo","A. Saxena","L.-T. Chen","M. Takeda","A. Cervantes","H. Taniguchi","K. Yoshida","Y. Kodera","Y. Kitagawa","J. Tabernero","H. Burris","J.-Y. Douillard"],"twitterCount":35,"altmetricId":79258841,"statusesArray":["1290985679103488001","1290255697427324928","1290253990584705024","1290250678217015297","1290250081162076167","1268329146972766209","1267914279145156608","1254814516531118081","1253673625145704449","1250218540663222272","1250055621837303809","1249985574351626240","1249956825472081921","1249845022930792448","1249837529861365761","1249821194427043840","1249759557670313990","1249738148449382400","1249733830732324868","1249731658791575552","1249731513500999680","1249730442099675139","1249728435657871361","1249715439506161664","1249712722784260098","1249711945323810822","1249678898872430593","1249673460655120384","1249669742153150465","1249655058217738240","1249653426994192384","1249651493357203457","1249649897399152647","1249648354205880320","1249642217037352962","1248942749493145601","1248808453239431169","1248552320595451905","1247463244014456832"]},{"title":"Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized …","googleId":"vdJ68Hd32cgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419360788","googleCitationCount":22,"googleAuthor":"AS Mansfield","doi":"10.1016/j.annonc.2019.10.021","elsevierAuthor":"Mansfield A.S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-02-01","elsevierCoverDisplayDate":"February 2020","elsevierCitationCount":"13","altmetricAuthors":["A.S. Mansfield","A. Każarnowicz","N. Karaseva","A. Sánchez","R. De Boer","Z. Andric","M. Reck","S. Atagi","J.-S. Lee","M. Garassino","S.V. Liu","L. Horn","X. Wen","C. Quach","W. Yu","F. Kabbinavar","S. Lam","S. Morris","R. Califano"],"twitterCount":39,"altmetricId":74168411,"statusesArray":["1235946060943691782","1224377976801939457","1224356839816679425","1224356778147827719","1224291176733388801","1224271767008632832","1224271324538908672","1220053835219177472","1219360440007958530","1219344395138285568","1219339957778644992","1219316778016354304","1219184428997578754","1219001634031882241","1218976434942697472","1218964619106058240","1218924428018491403","1218919448570028033","1218846117108092928","1218823011270385664","1218768480314576896","1218749334122127361","1218744670165094400","1218687822355296256","1218684180525207553","1218682512299515904","1218679298305024006","1218648040610975744","1218619380717834241","1218619246474907651","1218589949190012928","1218573944875126784","1218572963827605504","1218548783929348097","1218534275630469121","1218510424431386624","1218495811878780928","1218489229090705408","1218480176813703169","1218466680806039552","1218461849722720256","1218458992957186050","1218431229235793920","1218392397056552960","1218382876338638850","1218343043587362817","1218309716570451969"]},{"title":"Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?","googleId":"IKVOgxvMniQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419459875","googleCitationCount":46,"googleAuthor":"S Heeke","doi":"10.1093/annonc/mdz196","elsevierAuthor":"Hofman P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-09-01","elsevierCoverDisplayDate":"1 September 2019","elsevierCitationCount":"34","altmetricAuthors":["P. Hofman","S. Heeke","C. Alix-Panabières","K. Pantel"],"twitterCount":36,"altmetricId":62584131,"statusesArray":["1268486914853593089","1268485153652985856","1199052837117943809","1196489944895754245","1196347636640555008","1196279907564838914","1196213404358381568","1196188531749728256","1180417721844076544","1149709870515593217","1149661826759585792","1146957880353935361","1146901602697121794","1146825295531393024","1146791449134096384","1146770496857497600","1146731930798493696","1146702676245303296","1145683979632177152","1145643349900255232","1145373042996121605","1145273671663181824","1145251836250611715","1144886766526222336","1144857908972347393","1144752147256532992","1144586657561268226","1144572849925033985","1144548615022493696","1144521545521479680","1144516310468091904","1144487931681263616","1144486190411730946","1144476362247307264","1143269384967917568","1143248790964637696","1143193099994304512","1143188756587057155","1142908173075927040","1142890964429656064","1142872593826889729","1142754188599840768"]},{"title":"A meta-analysis of the accuracy of a neuroendocrine tumor mRNA genomic biomarker (NETest) in blood","googleId":"XJ0zydUFezMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419390842","googleCitationCount":19,"googleAuthor":"A Califano","doi":"10.1016/j.annonc.2019.11.003","elsevierAuthor":"Öberg K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-02-01","elsevierCoverDisplayDate":"February 2020","elsevierCitationCount":"8","altmetricAuthors":["K. Öberg","A. Califano","J.R. Strosberg","S. Ma","U. Pape","L. Bodei","G. Kaltsas","C. Toumpanakis","J.R. Goldenring","A. Frilling","S. Paulson"],"twitterCount":7,"altmetricId":74274383,"statusesArray":["1306986296330518528","1306968168947224576","1306816236613963776","1306755160799145990","1306710101059940352","1306707132620963841","1227277608783618049","1219959530320121857","1219266567915085825"]},{"title":"A randomized phase II/III study to assess the efficacy of trametinib in patients with recurrent or progressive low-grade serous ovarian or peritoneal cancer","googleId":"ftZkpvQEy4gJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604187","googleCitationCount":30,"googleAuthor":"W Brady","doi":"10.1093/annonc/mdz394.058","elsevierAuthor":"De Thaye E.","publicationName":"Scientific Reports","elsevierCoverDate":"2020-12-01","elsevierCoverDisplayDate":"1 December 2020","elsevierCitationCount":"1","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase …","googleId":"ldY6Wor-mcsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325576","googleCitationCount":37,"googleAuthor":"J Mizusawa","doi":"10.1093/annonc/mdz402","elsevierAuthor":"Morizane C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-12-01","elsevierCoverDisplayDate":"1 December 2019","elsevierCitationCount":"24","altmetricAuthors":["C. Morizane","T. Okusaka","J. Mizusawa","H. Katayama","M. Ueno","M. Ikeda","M. Ozaka","N. Okano","K. Sugimori","A. Fukutomi","H. Hara","N. Mizuno","H. Yanagimoto","K. Wada","K. Tobimatsu","K. Yane","S. Nakamori","H. Yamaguchi","A. Asagi","S. Yukisawa","Y. Kojima","K. Kawabe","Y. Kawamoto","R. Sugimoto","T. Iwai","K. Nakamura","H. Miyakawa","T. Yamashita","A. Hosokawa","T. Ioka","N. Kato","K. Shioji","K. Shimizu","T. Nakagohri","K. Kamata","H. Ishii","J. Furuse"],"twitterCount":15,"altmetricId":67509306,"statusesArray":["1274533176975560704","1273743553538097154","1216408643345768450","1182899367893712905","1182636907001335810","1180327725204004864","1180166975340847104","1180083484192198656","1180076806902140929","1180065508827287552","1180063209002127361","1180057392018575360","1180056313268592640","1180056205248598017","1180055961253240832","1178897789767561216"]},{"title":"Atypical lung feature on chest CT in a lung adenocarcinoma cancer patient infected with COVID-19","googleId":"Wxh0euKHR5oJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)36080-4/pdf","googleCitationCount":32,"googleAuthor":"","statusesArray":[]},{"title":"Phase I study of AMG 510, a novel molecule targeting KRAS G12C mutant solid tumours","googleId":"Tgqxylw0bP4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586689","googleCitationCount":33,"googleAuthor":"MG Fakih","doi":"10.1093/annonc/mdz244.008","elsevierAuthor":"Kattan W.E.","publicationName":"Biochemical Journal","elsevierCoverDate":"2020-08-01","elsevierCoverDisplayDate":"August 2020","elsevierCitationCount":"1","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines","googleId":"Dhb1MBgBk1cJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42448-2/abstract","googleCitationCount":16,"googleAuthor":"M Lambertini","statusesArray":[]},{"title":"A phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with …","googleId":"XTj-dKLPALQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603601","googleCitationCount":30,"googleAuthor":"","doi":"10.1093/annonc/mdz394","elsevierAuthor":"Demartino P.C.","publicationName":"JAMA Internal Medicine","elsevierCoverDate":"2021-02-01","elsevierCoverDisplayDate":"February 2021","elsevierCitationCount":"0","altmetricAuthors":["K. Fizazi","A. Maillard","N. Penel","G. Baciarello","D. Allouache","G. Daugaard","A. Van de Wouw","G. Soler","E. Vauleon","L. Chaigneau","R. Janssen","F. Losa Gaspa","R. Morales Barrera","C. Balana","D. Tosi","B. Chauffert","C.A. Schnabel","G. Martineau","S. Culine","I. Borget"],"twitterCount":1,"altmetricId":67579395,"statusesArray":["1179410536875864064"]},{"title":"Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors","googleId":"c5uc3zECzYoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312281","googleCitationCount":35,"googleAuthor":"MD Hellmann","doi":"10.1093/annonc/mdz113","elsevierAuthor":"Hirano H.","publicationName":"Japanese Journal of Clinical Oncology","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"1 January 2021","elsevierCitationCount":"0","altmetricAuthors":["M.D. Hellmann","T.-W. Kim","C.B. Lee","B.-C. Goh","W.H. Miller","D.-Y. Oh","R. Jamal","C.-E. Chee","L.Q.M. Chow","J.F. Gainor","J. Desai","B.J. Solomon","M. Das Thakur","B. Pitcher","P. Foster","G. Hernandez","M.J. Wongchenko","E. Cha","Y.-J. Bang","L.L. Siu","J. Bendell"],"twitterCount":9,"altmetricId":58342287,"statusesArray":["1120125250807767040","1115681707217145856","1113370454700564480","1113354827814326274","1113267356065705985","1113063430544515073","1113048067501182978","1111828409280135174","1111828158003597312"]},{"title":"Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish …","googleId":"7v36ISbrmggJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311081","googleCitationCount":30,"googleAuthor":"R Garcia-Sanz","doi":"10.1093/annonc/mdz009","elsevierAuthor":"von Tresckow B.","publicationName":"Hematologic Malignancies","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"0","altmetricAuthors":["R. Garcia-Sanz","A. Sureda","F. de la Cruz","M. Canales","A.P. Gonzalez","J.L. Pinana","A. Rodriguez","A. Gutierrez","E. Domingo-Domenech","B. Sanchez-Gonzalez","G. Rodriguez","J. Lopez","M. Moreno","M.J. Rodriguez-Salazar","S. Jimenez-Cabrera","M.D. Caballero","C. Martinez"],"twitterCount":65,"altmetricId":54123189,"statusesArray":["1252668332718936071","1225719591776784389","1224580277399359488","1223251367189536770","1223147753720700928","1223142654810230784","1222995756484911104","1222964627216175104","1222911363833647105","1222888172381777922","1222836705314639872","1222823091358834688","1222797210544410630","1222796674306859008","1222796652504854528","1222793220825980928","1222791236941119488","1222649187168288768","1222648142279192576","1222606418135715840","1222489202115383296","1140683047915937792","1140638357313077250","1140586868448419842","1140546033631617024","1140545883706187776","1140445844774117377","1140368162627698688","1140366916957167616","1140352257189437440","1140352041451163654","1140339720108564480","1140334553799823360","1097533972563804161","1094956281041993728","1089554846854901760","1089472536277143553","1088802403867115520","1088502758011998208","1088499719872032769","1088487598148923392","1088485329772793856","1087447426120728576","1087395807756722177","1087348787700469761","1087297528989650944","1087297140886589440","1087221851665899521","1087143294260305920","1087075478580666370","1087020164099522567","1086978315490127878","1086975876342927360","1086950862289813504","1086932110835941376","1086901725435478016","1086899623577440256","1086897428207468544","1086896387806191616","1086895793926295552","1086837866326564865","1086830618833494016","1086801643075719168","1086801588499464194","1086778496913944576","1086763481934770178","1086749256805945344","1086741585809821697","1086716149973307392","1086713959296700417","1086711678979489793","1086688795846733824","1086679362756321281","1086675372027117570","1086637129562800128","1086636883441041409","1086613728219590657","1086612914604335104","1086601300022910976","1086579452912562177","1086363847571767297"]},{"title":"Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"vHGSYVVrN1kJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)36079-8/fulltext","googleCitationCount":14,"googleAuthor":"Y Ofran","statusesArray":[]},{"title":"Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II …","googleId":"Xi6pgvJcNVAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419609816","googleCitationCount":24,"googleAuthor":"","doi":"10.1093/annonc/mdz278","elsevierAuthor":"Weiss J.M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-10-01","elsevierCoverDisplayDate":"1 October 2019","elsevierCitationCount":"17","altmetricAuthors":["J.M. Weiss","T. Csoszi","M. Maglakelidze","R.J. Hoyer","J.T. Beck","M. Domine Gomez","A. Lowczak","R. Aljumaily","C.M. Rocha Lima","R.V. Boccia","W. Hanna","P. Nikolinakos","V.K. Chiu","T.K. Owonikoko","S.R. Schuster","M.A. Hussein","D.A. Richards","P. Sawrycki","I. Bulat","J.T. Hamm","L.L. Hart","S. Adler","J.M. Antal","A.Y. Lai","J.A. Sorrentino","Z. Yang","R.K. Malik","S.R. Morris","P.J. Roberts","K.H. Dragnev"],"twitterCount":85,"altmetricId":65832399,"statusesArray":["1198313685984391174","1198250505190985729","1197860355202076676","1197116556687351812","1197115392608497665","1178349149399519233","1177240873966305281","1174204664293838848","1171769623240294402","1171361383751045122","1171289889276669953","1169904047660265474","1169609808368066560","1169599420373118979","1169481809681367041","1169464543191261186","1169442579026522113","1169441442076483585","1169365597999624192","1169348457171226624","1169340579303571457","1169327901440913410","1169317728596963328","1169308494471860229","1169284725258588160","1169281927653687296","1169267380322652162","1169222575643344896","1169218869547810816","1169210181210652673","1169141645390094336","1169131857067290627","1169131514577260544","1169125546212626432","1169121847276969984","1169116665306591232","1169115266418139136","1169111880402649089","1169109396640731136","1169106870352527360","1169106747660746757","1169106488859779076","1169101455682428928","1169066417532100609","1169056067566915586","1169053654462160897","1169049995724541952","1169042686189477888","1169040714975653889","1169038100267331584","1169033014636097538","1169030196990750720","1169029513960931328","1169028990633500673","1169024823567237122","1169018936186363913","1169004807371329536","1168997690765656064","1168995458972291073","1168992156251578369","1168984094627291136","1168983890494656512","1168963924739416064","1168930125834018816","1168922656323899392","1168914127550668800","1168883755940900866","1168883699691261955","1168874394720116736","1168872437100044288","1168871134001061888","1168865551076118528","1168864796416139264","1168855808232382464","1168849750894006272","1168848813416538112","1168848544545091585","1168848465889304578","1168840488310464512","1168839788906070017","1168838537443184640","1168837474044579840","1168835606190809088","1168834307256967169","1168832644731170816","1168829298574319617","1168823557692039168","1168823520765153281","1168821914971885568","1168818813149818881"]},{"title":"A segregated-team model to maintain cancer care during the COVID-19 outbreak at an academic center in Singapore.","googleId":"_odR_iob2lcJ","googleLink":"https://europepmc.org/article/pmc/pmc7174823","googleCitationCount":34,"googleAuthor":"","statusesArray":[]},{"title":"Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions","googleId":"G2AOastoQf8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419621721","googleCitationCount":33,"googleAuthor":"","doi":"10.1093/annonc/mdz338.077","elsevierCitationCount":0,"altmetricAuthors":["Pasi A. Jänne","Joel W. Neal","D.R. Camidge","Alexander Spira","Zofia Piotrowska","Leora Horn","Daniel B. Costa","Anne Tsao","Jyoti Patel","Shirish Gadgeel","Lyudmila Bazhenova","Viola W Zhu","Howard West","Sylvie Vincent","Jian Zhu","Shuanglian Li","Gregory J. Riely"],"twitterCount":0,"altmetricId":68314288,"statusesArray":[]},{"title":"Man against machine reloaded: performance of a market-approved convolutional neural network in classifying a broad spectrum of skin lesions in comparison …","googleId":"-kDojCbHCYcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354687","googleCitationCount":24,"googleAuthor":"W Stolz","doi":"10.1016/j.annonc.2019.10.013","elsevierAuthor":"Haenssle H.A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"January 2020","elsevierCitationCount":"20","altmetricAuthors":["H.A. Haenssle","C. Fink","F. Toberer","J. Winkler","W. Stolz","T. Deinlein","R. Hofmann-Wellenhof","A. Lallas","S. Emmert","T. Buhl","M. Zutt","A. Blum","M.S. Abassi","L. Thomas","I. Tromme","P. Tschandl","A. Enk","A. Rosenberger","Christina Alt","Marie Bachelerie","Sonali Bajaj","Alise Balcere","Sophie Baricault","Clément Barthaux","Yvonne Beckenbauer","Ines Bertlich","Andreas Blum","Marie-France Bouthenet","Sophie Brassat","Philipp Marcel Buck","Kristina Buder-Bakhaya","Maria-Letizia Cappelletti","Cécile Chabbert","Julie De Labarthe","Eveline DeCoster","Teresa Deinlein","Michèle Dobler","Daphnée Dumon","Steffen Emmert","Julie Gachon-Buffet","Mikhail Gusarov","Franziska Hartmann","Julia Hartmann","Anke Herrmann","Isabelle Hoorens","Eva Hulstaert","Raimonds Karls","Andreea Kolonte","Christian Kromer","Aimilios Lallas","Céline Le Blanc Vasseux","Annabelle Levy-Roy","Pawel Majenka","Marine Marc","Veronique Martin Bourret","Nadège Michelet-Brunacci","Christina Mitteldorf","Jean Paroissien","Camille Picard","Diana Plise","Valérie Reymann","Fabrice Ribeaudeau","Pauline Richez","Hélène Roche Plaine","Deborah Salik","Elke Sattler","Sarah Schäfer","Roland Schneiderbauer","Thierry Secchi","Karen Talour","Lukas Trennheuser","Alexander Wald","Priscila Wölbing","Pascale Zukervar"],"twitterCount":4,"altmetricId":73785439,"statusesArray":["1218948951333883905","1218913559767396352","1217833803332431873","1215227747162738688"]},{"title":"Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the …","googleId":"wu2l1553meYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31045-2/abstract","googleCitationCount":39,"googleAuthor":"S Peters","statusesArray":[]},{"title":"Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA","googleId":"RVX2Q5TKAzEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341931155X","googleCitationCount":28,"googleAuthor":"S Sandhu","doi":"10.1093/annonc/mdz048","elsevierAuthor":"Keller L.","publicationName":"British Journal of Cancer","elsevierCoverDate":"2021-01-19","elsevierCoverDisplayDate":"19 January 2021","elsevierCitationCount":"2","altmetricAuthors":["L. Tan","S. Sandhu","R.J. Lee","J. Li","J. Callahan","S. Ftouni","N. Dhomen","P. Middlehurst","A. Wallace","J. Raleigh","A. Hatzimihalis","M.A. Henderson","M. Shackleton","A. Haydon","V. Mar","D.E. Gyorki","D. Oudit","M.A. Dawson","R.J. Hicks","P. Lorigan","G.A. McArthur","R. Marais","S.Q. Wong","S.-J. Dawson"],"twitterCount":19,"altmetricId":56633253,"statusesArray":["1271786411943882752","1166729982321811462","1138648651234971650","1108731408430837761","1106392584207777792","1106392460249333760","1105680797271416838","1105372944547700737","1105372844735770624","1105069630832476160","1104238912996868096","1104020154495582209","1104012761833586688","1103988980721307653","1103986486452600833","1103962728308199427","1103956678767202304","1103953522712891393","1103951869905457152","1103906695963525121","1103648760909848577","1103572068879269888"]},{"title":"BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with …","googleId":"bF6-xN0csoQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311718","googleCitationCount":27,"googleAuthor":"","doi":"10.1093/annonc/mdz086","elsevierAuthor":"Malik N.","publicationName":"Biochemical Journal","elsevierCoverDate":"2019-10-30","elsevierCoverDisplayDate":"30 October 2019","elsevierCitationCount":"2","altmetricAuthors":["N.C. Turner","E. Alarcón","A.C. Armstrong","M. Philco","Y.A. López Chuken","M.-P. Sablin","K. Tamura","A. Gómez Villanueva","J.A. Pérez-Fidalgo","S.Y.A. Cheung","C. Corcoran","M. Cullberg","B.R. Davies","E.C. de Bruin","A. Foxley","J.P.O. Lindemann","R. Maudsley","M. Moschetta","E. Outhwaite","M. Pass","P. Rugman","G. Schiavon","M. Oliveira"],"twitterCount":13,"altmetricId":56944981,"statusesArray":["1180601021912928257","1111773186901700608","1111616216513294338","1111615871351291904","1106177744843489283","1106155911851241472","1106086864954580992","1105894319947464706","1105886146511269889","1105845272834273280","1105796443779010560","1105771525968293888","1105764541642752000","1105749994756362240"]},{"title":"Pre-specified interim analysis of GALAHAD: a phase II study of niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and …","googleId":"QaKgNGYqg6AJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604035","googleCitationCount":30,"googleAuthor":"MR Smith","doi":"10.1093/annonc/mdz394.043","elsevierCitationCount":0,"altmetricAuthors":["M.R. Smith","S.K. Sandhu","W.K. Kelly","H.I. Scher","E. Efstathiou","P.N. Lara","E.Y. Yu","D.J. George","K.N. Chi","F. Saad","J. Summa","J.M. Freedman","G.E. Mason","E. Zhu","D. Ricci","J.S. Simon","S. Cheng","K. Fizazi"],"twitterCount":0,"altmetricId":76694492,"statusesArray":[]},{"title":"Biological background of the genomic variations of cf-DNA in healthy individuals","googleId":"Vl0F2c7sxd4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310737","googleCitationCount":30,"googleAuthor":"","doi":"10.1093/annonc/mdy513","elsevierAuthor":"Liu J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-03-01","elsevierCoverDisplayDate":"1 March 2019","elsevierCitationCount":"20","altmetricAuthors":["J. Liu","X. Chen","J. Wang","S. Zhou","C.L. Wang","M.Z. Ye","X.Y. Wang","Y. Song","Y.Q. Wang","L.T. Zhang","R.H. Wu","H.M. Yang","S.D. Zhu","M.Z. Zhou","X.C. Zhang","H.M. Zhu","Z.Y. Qian"],"twitterCount":77,"altmetricId":51614606,"statusesArray":["1243193846785335296","1242784052152684544","1068848258754199552","1068246897217818624","1068235593774235655","1068209827594158080","1068155133941428225","1068139573484707842","1068134988082802688","1067698916928442369","1067390336937291777","1067250177424138242","1067211992858050561","1067196820378591232","1067088889548988419","1067078890861092864","1067004373010653185","1067004334758658048","1066991656665341953","1066860141784424448","1066833844857434114","1066806665784279040","1066801822772469760","1066797371894444034","1066794692858269698","1066794592014618625","1066789118645075975","1066779563508867073","1066775943224659968","1066767735978369024","1066766872106934273","1066766677638025219","1066760175107825664","1066744856205291520","1066743249430241280","1066692950120378370","1066618165235306496","1066594132229931008","1066587007919505408","1066585702652100608","1066472442208690177","1066422701441601536","1066411433729105922","1066361914442375169","1066352177197797376","1066339093691465728","1066336057527013376","1066335331589517312","1066316802412679173","1066308686639976450","1066305449828454405","1066219062110244864","1066204432424214530","1066190899905011712","1066189232648130560","1066176325415620608","1066174958684893185","1066174921267535873","1066160924967542784","1066155211314655232","1066147526422790146","1066140610283925504","1066125217850904576","1066123007196884995","1066115052833513472","1066113100892450816","1066110704305008640","1066108916398989312","1066107961121128453","1066102513433223168","1066101873294364673","1066078055351894016","1066064783974297601","1066062848059744256","1066062141235519488","1066061967603851265","1066052912588165126","1066048352591233025","1066048042544103424","1066047208691093504","1066043651917262849","1066042561024978944","1066042055292477445","1066039194882056192"]},{"title":"Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in …","googleId":"Y27Ab4e_nEEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341960983X","googleCitationCount":22,"googleAuthor":"G Villacampa","doi":"10.1093/annonc/mdz287","elsevierAuthor":"Dienstmann R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-10-01","elsevierCoverDisplayDate":"1 October 2019","elsevierCitationCount":"16","altmetricAuthors":["R. Dienstmann","G. Villacampa","A. Sveen","M.J. Mason","D. Niedzwiecki","A. Nesbakken","V. Moreno","R.S. Warren","R.A. Lothe","J. Guinney"],"twitterCount":55,"altmetricId":65563712,"statusesArray":["1222710153180377088","1202901739525083141","1202482070058090496","1202030644890685443","1202003983801503744","1201982669820768256","1201935833550458880","1201920942114529282","1201885966287421441","1201882064737505281","1201876022943199232","1201858899042865152","1201834891522060289","1201803490202464256","1201785871256768512","1201753867182051328","1201736257853898752","1201678046086017024","1201631917260431360","1201631759525240832","1201574286714134531","1201553865084194817","1201549084613599232","1201540153304604672","1201536311787573254","1201534389747933185","1201532872479391744","1201531428711870464","1201530933666467840","1201530238460682241","1201515267957805056","1201514715018678273","1201514259685019648","1201508130494005253","1201505941096673287","1201505487726022656","1201497014929780736","1201496653770788864","1176170768620634112","1171833418583162881","1168247461305098240","1168077295313215488","1168073080209436672","1167509700969209863","1167178725542301696","1167177706439630849","1167153884583907329","1167120256000843776","1167090735600066560","1167055083328233473","1167054557802897409","1167047750061613056","1167033306896113664","1167025599409508352","1167015191072186368","1167008036134641664","1166961076707176448","1166948680454332416","1166947837688647680","1166922127662034949","1166864349862027264","1166781602220904448","1166779982120701954","1166779263858675712","1166777390669926402","1166761717696647168","1166752021250236423","1166749765318713344","1166749188668809216","1166732472777752577","1166732345228943360","1166730860642492416"]},{"title":"Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast …","googleId":"qxb0mfJK-zsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311615","googleCitationCount":33,"googleAuthor":"","doi":"10.1093/annonc/mdz061","elsevierAuthor":"Poggio F.","publicationName":"JCO Oncology Practice","elsevierCoverDate":"2020-11-01","elsevierCoverDisplayDate":"November 2020","elsevierCitationCount":"9","altmetricAuthors":["T. Bachelot","E. Ciruelos","A. Schneeweiss","F. Puglisi","T. Peretz-Yablonski","I. Bondarenko","S. Paluch-Shimon","A. Wardley","J.-L. Merot","Y. du Toit","V. Easton","N. Lindegger","D. Miles","Kamel Bouzid","Mario Campone","Bruno Coudert","Zbigniew Nowecki","Hassan Errihani","Florence Dalenc","Ana Ferreira","Max Mano","Francesco Ricci","Haralabos Kalofonos","Claudia Andreetta","Filippo Montemurro","Sophie Barrett","Qingyuan Zhang","Dimitris Mavroudis","Juan Matus","Carlos Beato","Xichun Hu","Rabab Gaafar","Hamdy Abdel Azeem","Christophe Perrin","Johannes Ettl","Istvan Lang","Sunil Verma","Huiping Li","Etienne Brain","Oliver Hoffmann","Anna Cariello","Carlo Tondini","Taher Altwegeiri","Niklas Loman","Michael Lux","Antonio Frassoldati","Zeba Aziz","Fernando Salas","Joanna Streb","Andrzej Wronski","Salomón Menjón Beltrán","Irfan Cicin","Peter Schmid","Robert Laing","Zhongsheng Tong","Katalin Boer","Balazs Juhasz","Luca Gianni","Giuseppe Curigliano","Alejandro Juarez","Snezana Susnjar","Erika Matos","Ruchan Uslu","Hans Wildiers","Marcelo Cruz","Hugues Bourgeois","Raquel von Schumann","Salomón Stemmer","Flavia Morales Vásquez","Adriana Dominguez","Marek Wojtukiewicz","Jasna Trifunovic","Jose Juan Illarramendi","Laura Garcia","Yann Izarzugaza Peron","Maria Jose Echarri","Natliia Voitko","Duncan Wheatley","Simon Waters","Richard De Boer","Guy Jerusalem","Véronique Cocquyt","Carlos Barrios","Lawrence Panasci","Johanna Mattson","Minna Tanner","Michel Gozy","Georgios Vasilopoulos","Janos Revesz","Luciano Latini","Cesare Gridelli","Jesus Lazaro","Antonio Gonzalez","Agusti Barnadas Molins","Eduardo Martinez","Jesús Alarcón","Ana Arance","Leif Klint","Oleksiy Kovalyov","Richard Baird","Belinda Yeo","Nicole McCarthy","Richard Greil","Shusen Wang","Xavier Artignan","Paule Augereau","Ingolf Juhasz-Boess","Roger Ngan","Hadassah Goldberg","Francesco Di Costanzo","Francesco Ferraù","Eduardas Aleknavicius","Kamran Rashid","Luís Costa","Jose Angel Garcia","Luis Ruiz de la Cruz","Rafael López López","Olga Del Val","Ozgur Ozyilkan","Fathi Azribi","Mark Verrill","Nicholas Turner","Jane Beith","Andreas Petzer","Jurandyr Andrade","Vanessa Bernstein","Daniel Rayson","Ibtessam Saad Eldin","Mihaëla Achille","Volkmar Mueller","Alessandra Gennari","Stefano Cascinu","Marwan Ghosn","Nagi El-Saghir","Joan Van den Bosch","Rianne Oosterkamp","Monika Kukulska","Ignacio Pelaez","Carolina Hernandez","Maria del Mar Gordon","Elsa Dalmau","Jose Luis Alonso","Sercan Aksoy","Hasan Senol Coskun","Yaroslav Shparyk","Mohini Varughese","Udaiveer Panwar","Lisa Barraclough","Nicola Levitt","Jonathan Hicks","Anna Rigg","Mark Allen","Cecila Castillo","Luis Enrique Fein","Robin Stuart-Harris","Christian Singer","Herbert Stoeger","Sasha Smiljanic","Jifeng Feng","Miguel Cedeño","Jean Francois Berdah","Hubert Orfeuvre","Anthony Goncalves","Eva-Maria Grischke","Eike Simon","Steffen Wagner","Anna Efremidou","Konstantinos Papazisis","Ella Evron","Moshe Inbar","Noa Ben Baruch","David Geffen","Natalya Karminsky","Enzo Maria Ruggeri","Cavanna Luigi","Donatella Grasso","Elona Juozaityte","Jeronimo Rafael Rodriguez Cid","Henk Roerdink","Neelum Siddiqi","José Luís Passos Coelho","Elisa Garcia Garre","Andres Garcia","Noelia Martínez Jañez","Maria Helena Lopez Ceballos","Mireia Mele","María García","Alberto Arcediano","Karen McAdam","Timothy Perren","Jonathan Hicks","Wendy Taylor","Alison Humphreys","Raul Vera","Luis Alberto Kaen","Günther Steger","Johannes Andel","Jacques de Grève","Manon Huizing","Roberto Hegg","Anil Joy","Sandeep Sehdev","Riina Kütner","Johanna Ruohola","Nadine Dohollou","Jessica Grosjean","Philippe Laplaige","Rémy Largillier","Philippe Martin","Virginie Pottier","Jerome Alexandre","Bernd Christensen","Dirk-Michael Zahm","Fariba Khandan","Hans-Joachim Lueck","Georgios Fountzilas","Georgeta Fried","Alice Giacobino","Andrea Bonetti","Yanin Chavarri Guerra","Laurens Van Warmerdam","Annette Van der Velden","Suzan Vrijaldenhoven","Felix de Jongh","Milagros Cavero","Raquel Andres Conejero","Adolfo Murias","Salvador Saura","Amparo Oltra","Andres Redondo","Nuria Ribelles","Kilian Bachmeier","Johnathan Joffe","Prabir Chakraborti","Mark Beresford","Mohammad Butt","Christopher Poole","Gassan Yordi","Natasha Woodward","Gilberto Amorim","Nadia Califaretti","Susan Fox","Andre Robidoux","NanLi Li","Nenxiao Li","Jun Jiang","Tannia Soria","Peeter Padrik","Outi Saarni","Dominique Genet","Stéphanie Catala","Hugues Barletta","Luis Teixeira","Thomas Facchini","Tobias Hesse","Thorsten Kühn","Angelika Ober","Roland Repp","Willibald Schroeder","Dimitrios Pectasides","Gyorgy Bodoky","Zsuzsanna Kahan","Irina Jiveliouk","Ora Rosengarten","Oscar Alabiso","Mario Perez","Yes Van de Wouw","Jolanta Smok-Kalwat","Margarida Damasceno","Gabriela Sousa","Omalkhair Abulkhair","Antonio Antón Torres","Maria Purificación Martinez","Jesús Garcia Mata","Marta Santisteban Jesús Florián Jerico","Antonio Llombart","Rosa Sanchez","Juan Carlos Torrego","Clara Olier Garate","Cesar Rodriguez","Rosa Llorente","Diego Soto de Prado","Javier Cortés","Cristina Llorca","Antonio Galán","Gemma Viñas Villaro","Ulrik Narbe","Helena Granstam Bjömeklett","Sarah Westwell","Jackie Newby","Mariam Jafri","Robinson Rodríguez","Isabel Alonso"],"twitterCount":14,"altmetricId":55963846,"statusesArray":["1222779999104663552","1147990633266733056","1104544561915813890","1104079597535195136","1104072645753126913","1104012869220397056","1104007610422968320","1103620377756995584","1099952151382712320","1099670085323710464","1099604704185720832","1099604355248906240","1099452135828275200","1099446189811032064","1099428902223503360","1099428856744816640"]},{"title":"Methods for measuring financial toxicity after cancer diagnosis and treatment: a systematic review and its implications","googleId":"8-5nGcFfh-IJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341931244X","googleCitationCount":32,"googleAuthor":"B Surmann","doi":"10.1093/annonc/mdz140","elsevierAuthor":"Ushkalova E.A.","publicationName":"Farmakoekonomika","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"0","altmetricAuthors":["J. Witte","K. Mehlis","B. Surmann","R. Lingnau","O. Damm","W. Greiner","E.C. Winkler"],"twitterCount":52,"altmetricId":59825560,"statusesArray":["1359519240730996739","1307776826920628227","1307546413488898048","1307511338751504384","1307456782252544004","1168873477933346816","1168873426192359424","1166695934715138054","1161956929348014082","1161953952650452992","1159466915720568833","1159422847975976961","1159213472372023296","1159103199372042240","1159063287759159296","1159056586469466118","1159047983759056897","1159039011723370499","1159011516794003456","1159010617044475904","1159008803318190080","1158997894227267584","1158993386113765376","1158966614328561665","1158951688780185601","1158815472760033284","1158777966156845056","1158754961813118976","1158752505624330240","1158735492541644800","1158734863261810689","1158728813821353986","1157060252296261632","1156215797594906624","1154639016727212033","1154288072244322304","1154266764794109952","1154266504008994818","1154265709217759232","1154190136634150913","1154186496527753216","1154059224776790016","1154006651315392512","1153991804292947968","1153991278553718784","1153990828387426305","1153989352093093888","1153975679060447233","1153973127942213632","1153970718092288000","1153961272456749057","1153934746159742976","1153872941232168960","1153841938858041344","1153768077265428482","1153730076057333761","1153720411034673153","1153714702184153088","1153711860522389507","1153711722651275264","1132538548136161281","1132537709459890177","1123969669612937216","1123967467745882119"]},{"title":"Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations","googleId":"ugBFpA5s_MgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341936079X","googleCitationCount":23,"googleAuthor":"J Mazieres","doi":"10.1016/j.annonc.2019.10.022","elsevierAuthor":"Mazieres J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-02-01","elsevierCoverDisplayDate":"February 2020","elsevierCitationCount":"18","altmetricAuthors":["J. Mazieres","C. Cropet","L. Montané","F. Barlesi","P.J. Souquet","X. Quantin","C. Dubos-Arvis","J. Otto","L. Favier","V. Avrillon","J. Cadranel","D. Moro-Sibilot","I. Monnet","V. Westeel","J. Le Treut","E. Brain","J. Trédaniel","M. Jaffro","S. Collot","G.R. Ferretti","C. Tiffon","C. Mahier-Ait Oukhatar","J.Y. Blay"],"twitterCount":49,"altmetricId":73927271,"statusesArray":["1312763773271277568","1233104660547940353","1231228347277041665","1230839743639904256","1227027677728661515","1226081000993636352","1226076480154800134","1225761285872156673","1225678842586525696","1225671576755924993","1225595133195767808","1225589425331027969","1225548765345538048","1225526051549392916","1225519210236915721","1225495320655691779","1225480406352396290","1225410213743714305","1225398048903368704","1225396216839712768","1225382807989608451","1225377505068158976","1225362830989447168","1225359913804877827","1225358491717640192","1224065937969729541","1221454479251427334","1220978873678123009","1220688528608153600","1220097971402039297","1219928657810132992","1219736687183650816","1219707748348317696","1219707719298551808","1219647416040771584","1219620960376172544","1219592506331095041","1219586018036240384","1219579485588283393","1219544783074492416","1219525004850802688","1219522580094365698","1219520596515676160","1219519943818891264","1219509564401471488","1219506929803976705","1219404464135774208","1219380614157230080","1219367290644373505","1219364511746007040","1219358213092585473","1219351422375997441","1219346520740376581","1219329749656440838","1219328141338075136","1219322597705494534","1219322263394230273"]},{"title":"Trastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC): initial results from the MOUNTAINEER trial","googleId":"vuVmkjkJ76AJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419587488","googleCitationCount":28,"googleAuthor":"A Cercek","doi":"10.1093/annonc/mdz246.005","elsevierAuthor":"Sartore-Bianchi A.","publicationName":"JAMA Oncology","elsevierCoverDate":"2020-06-01","elsevierCoverDisplayDate":"June 2020","elsevierCitationCount":"4","altmetricAuthors":["J.H. Strickler","T. Zemla","F.-S. Ou","A. Cercek","C. Wu","F.A. Sanchez","J. Hubbard","B. Jaszewski","L. Bandel","B. Schweitzer","D. Niedzwiecki","N. Kemeny","P.M. Boland","K. Ng","T. Bekaii-Saab"],"twitterCount":0,"altmetricId":68179407,"statusesArray":[]},{"title":"Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial","googleId":"WNw8KdGG1d8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311950","googleCitationCount":26,"googleAuthor":"I Garcia-Murillas","doi":"10.1093/annonc/mdz085","elsevierAuthor":"Hrebien S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-06-01","elsevierCoverDisplayDate":"1 June 2019","elsevierCitationCount":"20","altmetricAuthors":["S. Hrebien","V. Citi","I. Garcia-Murillas","R. Cutts","K. Fenwick","I. Kozarewa","R. McEwen","J. Ratnayake","R. Maudsley","T.H. Carr","E.C. de Bruin","G. Schiavon","M. Oliveira","N. Turner"],"twitterCount":44,"altmetricId":56944915,"statusesArray":["1291684027573796864","1174715202115424256","1169186382310465537","1160372147790856192","1160372098507743232","1160310262496260096","1123487374489595904","1123448385279856642","1123324578351210503","1123193120210993152","1123183883875278850","1123179960649142272","1123176211788775424","1123175341655306240","1123168783227543552","1123156865133744129","1123152899113144321","1123127773088739329","1123098031153401856","1123082865317687297","1123078331077988352","1123035522321080320","1123009511168643073","1123006600741101568","1122999973707169792","1122971658799677440","1122951703735820289","1122911551474864141","1122886476738519041","1122849299447123968","1122831324421722112","1122831188467617792","1122827236967477248","1122772533810319360","1112067463280279552","1106477031125147649","1106320890084638720","1106096196135911424","1106083862554259456","1106067963587760131","1106038883370913792","1105934323038015489","1105917502146646016","1105916655895486465","1105916585410285571","1105842473715277824","1105838487964737537","1105819057725403136","1105796081403789314","1105770575761293314","1105764758211493888","1105749392869470209"]},{"title":"Registrational results of LOXO-292 in patients with RET-altered thyroid cancers","googleId":"0-t99iZiuDYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604539","googleCitationCount":26,"googleAuthor":"A Drilon","doi":"10.1093/annonc/mdz394.093","elsevierAuthor":"Dadu R.","publicationName":"Endocrine-Related Cancer","elsevierCoverDate":"2020-08-01","elsevierCoverDisplayDate":"August 2020","elsevierCitationCount":"0","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Adverse event profile for immunotherapy agents compared with chemotherapy in solid organ tumors: a systematic review and meta-analysis of randomized …","googleId":"8FF-j098uYEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354638","googleCitationCount":22,"googleAuthor":"DE Magee","doi":"10.1016/j.annonc.2019.10.008","elsevierAuthor":"Magee D.E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"January 2020","elsevierCitationCount":"13","altmetricAuthors":["D.E. Magee","A.E. Hird","Z. Klaassen","S.S. Sridhar","R.K. Nam","C.J.D. Wallis","G.S. Kulkarni"],"twitterCount":1,"altmetricId":73785625,"statusesArray":["1215228996427730944"]},{"title":"Cancer-related fatigue: ESMO Clinical Practice Guidelines for diagnosis and treatment","googleId":"agJEFPIBxlUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)36077-4/pdf","googleCitationCount":16,"googleAuthor":"","statusesArray":[]},{"title":"Analysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: Prognostic and predictive value for adjuvant treatment …","googleId":"O-BA9Uz0KpgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603790","googleCitationCount":30,"googleAuthor":"J Taieb","doi":"10.1093/annonc/mdz394.019","elsevierAuthor":"Schraa S.J.","publicationName":"BMC Cancer","elsevierCoverDate":"2020-08-20","elsevierCoverDisplayDate":"20 August 2020","elsevierCitationCount":"1","altmetricAuthors":["J. Taieb","V. Taly","D. Vernerey","C. Bourreau","J. Bennouna","R. Faroux","J. Desrame","O. Bouche","C. Borg","J. Egreteau","L. Mineur","C. Lepere","G. Deplanque","C. Mulot","C. Louvet","M. Mabro","M. Ychou","A. de Gramont","T. Andre","P. Laurent-Puig"],"twitterCount":0,"altmetricId":68179400,"statusesArray":[]},{"title":"Intratumoral IL17-producing cells infiltration correlate with antitumor immune contexture and improved response to adjuvant chemotherapy in gastric cancer","googleId":"3EZHtU2FiRAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310233","googleCitationCount":30,"googleAuthor":"","doi":"10.1093/annonc/mdy505","elsevierAuthor":"Wang J.T.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-02-01","elsevierCoverDisplayDate":"1 February 2019","elsevierCitationCount":"20","altmetricAuthors":["J.T. Wang","H. Li","H. Zhang","Y.F. Chen","Y.F. Cao","R.C. Li","C. Lin","Y.C. Wei","X.N. Xiang","H.J. Fang","H.Y. Zhang","Y. Gu","X. Liu","R.J. Zhou","H. Liu","H.Y. He","W.J. Zhang","Z.B. Shen","J. Qin","J.J. Xu"],"twitterCount":4,"altmetricId":51600572,"statusesArray":["1066009584240754688","1066009448970219520","1065954583460093953","1065938295174152192","1065938261644902400"]},{"title":"Cancer-related cognitive impairment: an update on state of the art, detection, and management strategies in cancer survivors","googleId":"stJ-r3IG89wJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375342032562X","googleCitationCount":33,"googleAuthor":"J Vardy","doi":"10.1093/annonc/mdz410","elsevierAuthor":"Lange M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-12-01","elsevierCoverDisplayDate":"1 December 2019","elsevierCitationCount":"18","altmetricAuthors":["M. Lange","F. Joly","J Vardy","T. Ahles","M. Dubois","L. Tron","G. Winocur","M.B. De Ruiter","H. Castel"],"twitterCount":32,"altmetricId":68809692,"statusesArray":["1224238680476454912","1223697558494642191","1223569370611355648","1223549516416241665","1223547983238770688","1223533596851560448","1223521186862321664","1223504983762575361","1223429519240908800","1223424893657600000","1223386066666840064","1223380370080423936","1223350100497317888","1223350073318244352","1223335271300837378","1223326315895578626","1223267209981714432","1223213946733322240","1223174216473772032","1223173477307494401","1223167177139924992","1223151274595704833","1223145543410601985","1222468479657267201","1221789336087277569","1216408513343369231","1194150525945733120","1193972534791811073","1193967584175149056","1193966854013894656","1187281844942917634","1186601843981467648","1186271641761992704","1184777785946132485"]},{"title":"Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group","googleId":"ShcmN2lrzUAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312700","googleCitationCount":31,"googleAuthor":"M Donoghue","doi":"10.1093/annonc/mdz136","elsevierAuthor":"Mandelker D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-08-01","elsevierCoverDisplayDate":"1 August 2019","elsevierCitationCount":"18","altmetricAuthors":["D. Mandelker","M. Donoghue","S. Talukdar","C. Bandlamudi","P. Srinivasan","M. Vivek","S. Jezdic","H. Hanson","K. Snape","A. Kulkarni","L. Hawkes","J.-Y Douillard","S.E. Wallace","E. Rial-Sebbag","F. Meric-Bersntam","A. George","D. Chubb","C. Loveday","M. Ladanyi","M.F. Berger","B.S. Taylor","C. Turnbull"],"twitterCount":76,"altmetricId":59892898,"statusesArray":["1334096942410858496","1334084615070355459","1211097656560369665","1211085370919727106","1210977727500541954","1210948571442417665","1210903927832678401","1210858288411271168","1210662563928821762","1210636621542035457","1191328269305614337","1190678899233087495","1190555769495867392","1190531147094036480","1190371818017820673","1190370672301760512","1190323942348722177","1174634283253882880","1174606230087536642","1174569347328729088","1174563887024357376","1166695858236268545","1162795821026414592","1161535180387082240","1161339273318162433","1160995746935705600","1160916362878783488","1159440224285597698","1156154022409252864","1156147986742874112","1151629755239809024","1151090937084334082","1128670004302483458","1128003382977925121","1127290698254909442","1127274590449950720","1127256158367113217","1127208357004283904","1127112608589520896","1127050308822024192","1127049930563104768","1127001510418710528","1126958302930382849","1126924868832960512","1126839539924983809","1126412267854159872","1126098307137146880","1125961907779686400","1125640582217568256","1125640547262033920","1125566711422279680","1125472829095456769","1125456461021241344","1125440980767977474","1125399362690080774","1125398021020237827","1125396601273561088","1125394043205292032","1125228662775672832","1125159218045235202","1124998079172583424","1124993704786300930","1124980063194292224","1124980019795845121","1124978128336637953","1124897532029464576","1124822544333312000","1124797818126970882","1124780928730042368","1124780875479179264","1124779430847700993","1124773902788497408","1124771440652427271","1124750978069217281","1124730898522312705","1124695338361614336","1124671427855175681","1124655729162489856","1124655076277137408","1124650368678318080","1124644187104661504","1124640667806859264","1124627174114258944","1124600997601583104","1124599709300154368","1124597339648294912","1124594939353079808","1124591769872752640","1124586636296192000","1124583587821563904","1124573902431297536","1124568685560176641","1124566587544100864","1124565779276546048","1124564637842853890","1124561991732027392","1124561135133450240","1124555648920846336","1124554655441326080","1124553990442823685"]},{"title":"HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L) 1 blockade in advanced non-small …","googleId":"IiJECdi4WTIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420392954","googleCitationCount":18,"googleAuthor":"HS Kim","doi":"10.1016/j.annonc.2020.04.004","elsevierAuthor":"Shim J.H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-07-01","elsevierCoverDisplayDate":"July 2020","elsevierCitationCount":"15","altmetricAuthors":["J.H. Shim","H.S. Kim","H. Cha","S. Kim","T.M. Kim","V. Anagnostou","Y.-L. Choi","H.A. Jung","J.-M. Sun","J.S. Ahn","M.-J. Ahn","K. Park","W.-Y. Park","S.-H. Lee"],"twitterCount":4,"altmetricId":80386576,"statusesArray":["1275177362464833537","1265542964287283200","1253470213019820033","1253263737722560516"]},{"title":"Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast …","googleId":"aPOX45bC4y0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310877","googleCitationCount":29,"googleAuthor":"AA Brandes","doi":"10.1093/annonc/mdz007","elsevierAuthor":"Dieci M.V.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-03-01","elsevierCoverDisplayDate":"1 March 2019","elsevierCitationCount":"16","altmetricAuthors":["M.V. Dieci","P. Conte","G. Bisagni","A.A. Brandes","A. Frassoldati","L. Cavanna","A. Musolino","F. Giotta","A. Rimanti","O. Garrone","E. Bertone","K. Cagossi","S. Sarti","A. Ferro","F. Piacentini","A. Maiorana","E. Orvieto","M. Sanders","F. Miglietta","S. Balduzzi","R. D’Amico","V. Guarneri"],"twitterCount":95,"altmetricId":54061583,"statusesArray":["1169484021040066562","1124243784294912001","1116063532808900608","1116062998366433280","1116062069042962443","1115697304407875587","1115695205460717578","1115694706669903872","1115693869893603328","1115690605915648001","1115665095026196480","1115653655523414016","1115614352394993664","1115599278959763458","1115595931368353792","1115570979109867520","1115541139774496768","1115534738830372865","1115534387993546752","1115525905588400128","1115524921751474176","1115524767048552449","1111093543509082114","1110029523842674688","1109985464130265088","1109952382413225984","1109863536472346625","1109758793242554368","1109758591374905344","1109757494778384385","1109756657670737921","1109723057969680384","1094747778427822080","1093998273113796608","1093990593657749506","1093969229068595202","1093913119125049345","1093866570668036096","1093826203763556354","1093820623728623617","1093807481271214081","1093801102120706054","1093796596238569473","1091453597647200256","1090171832395812864","1088560283738664960","1088501626610929664","1088403352172613632","1088398694561579010","1088395671927803905","1088390959468036096","1088071946267385856","1088018537749405696","1087989560645177344","1087818296244748288","1087739427877781504","1087708665715585025","1087693810270916609","1087690127466512385","1087639650683027457","1087638565440364544","1087632715967594496","1087622784044347394","1087620544130961409","1087557221720875008","1087554037183119360","1087544639534628865","1087524778884378624","1087455457063591936","1087454054450688007","1087439734518018049","1087437306837884928","1087423576288837632","1087422926612299777","1087406992443011073","1087386728892153857","1087378013132451841","1087375628935065600","1087374163197730816","1087373977159417856","1087370872061599744","1087365106818781185","1087364979609620480","1087364846826545153","1087364532404736001","1087351343919042560","1087342377575026688","1087342314249486336","1087336687301259265","1087324433977614337","1087302859048263681","1087300348694482944","1087285427801796608","1087285050541043712","1087282116453376001","1087050505820475399","1086770953479163904","1086596424954007555","1086585617536950272","1086242777644650496"]},{"title":"Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized …","googleId":"js2-M_CPsvEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311585","googleCitationCount":30,"googleAuthor":"","doi":"10.1093/annonc/mdz058","elsevierAuthor":"Vienot A.","publicationName":"Clinics and Research in Hepatology and Gastroenterology","elsevierCoverDate":"2020-11-01","elsevierCoverDisplayDate":"November 2020","elsevierCitationCount":"0","altmetricAuthors":["S.T. Kim","J.H. Kang","J. Lee","H.W. Lee","S.Y. Oh","J.S. Jang","M.A. Lee","B.S. Sohn","S.Y. Yoon","H.J. Choi","J.H. Hong","M.-J. Kim","S. Kim","Y.S. Park","J.O. Park","H.Y. Lim"],"twitterCount":18,"altmetricId":55805741,"statusesArray":["1167366374450180098","1167366336349114369","1140303030069407744","1137905545107640321","1103640836619698177","1103624036926533632","1103620434233384960","1103585277539278848","1103584572246237184","1101637851412873222","1101443979592245249","1099894759366119424","1099752378620887040","1099350956632915968","1099024640050122753","1098754270000640000","1098590806477336577","1098583452453167104","1098575002692141056","1098488104820842496","1098242396733755392"]},{"title":"Overall survival (OS) in KATE2, a phase II study of programmed death ligand 1 (PD-L1) inhibitor atezolizumab (atezo)+ trastuzumab emtansine (T-DM1) vs …","googleId":"Mg52z8zrtAgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419585271","googleCitationCount":29,"googleAuthor":"LA Emens","doi":"10.1093/annonc/mdz242","elsevierAuthor":"Donahue B.S.","publicationName":"Clinical Journal of Oncology Nursing","elsevierCoverDate":"2020-12-01","elsevierCoverDisplayDate":"December 2020","elsevierCitationCount":"0","altmetricAuthors":["L.A. Emens","F.J. Esteva","M. Beresford","C. Saura","M. De Laurentiis","S.-B. Kim","S.-A. Im","Y. Wang","A. Mani","J. Shah","H. Liu","S. de Haas","M. Patre","S. Loi"],"twitterCount":0,"altmetricId":67710000,"statusesArray":[]},{"title":"Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives","googleId":"flJXLGG9SjQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354146","googleCitationCount":20,"googleAuthor":"D Ciardiello","doi":"10.1016/j.annonc.2019.10.007","elsevierAuthor":"Martinelli E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"January 2020","elsevierCitationCount":"17","altmetricAuthors":["E. Martinelli","D. Ciardiello","G. Martini","T. Troiani","C. Cardone","P.P. Vitiello","N. Normanno","A.M. Rachiglio","E. Maiello","T. Latiano","F. De Vita","F. Ciardiello"],"twitterCount":3,"altmetricId":75148502,"statusesArray":["1225782653376454656","1225642246562709504","1225508504938713089"]},{"title":"Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K …","googleId":"3xJWImk5ue0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420343726","googleCitationCount":25,"googleAuthor":"D Eiger","doi":"10.1093/annonc/mdz280","elsevierAuthor":"Xu X.","publicationName":"Journal of Cellular Physiology","elsevierCoverDate":"2021-02-01","elsevierCoverDisplayDate":"February 2021","elsevierCitationCount":"0","altmetricAuthors":["M. Brandão","R. Caparica","D. Eiger","E. de Azambuja"],"twitterCount":16,"altmetricId":73049327,"statusesArray":["1217389165576278016","1213012862173687808","1210766085143719936","1209291838047293440","1208711788180779008","1208705019001933825","1208357191457095680","1208300212193652736","1208221694935977991","1208202061973770241","1208155622404956164","1208078017286811648","1208072093943902208","1208068544308666374","1208066120881586176","1208065912705814529","1208065868149723137","1208063027947413505","1208062662363504643","1208017590636941312"]},{"title":"Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial","googleId":"vFcPTKK-fD0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420363742","googleCitationCount":25,"googleAuthor":"","doi":"10.1016/j.annonc.2020.03.287","elsevierAuthor":"Paz-Ares L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-06-01","elsevierCoverDisplayDate":"June 2020","elsevierCitationCount":"17","altmetricAuthors":["L. Paz-Ares","A. Spira","D. Raben","D. Planchard","B.C. Cho","M. Özgüroğlu","D. Daniel","A. Villegas","D. Vicente","R. Hui","S. Murakami","D. Spigel","S. Senan","C.J. Langer","B.A. Perez","A-M. Boothman","H. Broadhurst","C. Wadsworth","P.A. Dennis","S.J. Antonia","C. Faivre-Finn"],"twitterCount":2,"altmetricId":79187908,"statusesArray":["1264155318621257728","1264154469106941953","1264147882489282561"]},{"title":"FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer","googleId":"IhQez76oQiEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312918","googleCitationCount":25,"googleAuthor":"P Nuciforo","doi":"10.1093/annonc/mdz177","elsevierAuthor":"Oliveira M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-08-01","elsevierCoverDisplayDate":"1 August 2019","elsevierCitationCount":"17","altmetricAuthors":["M. Oliveira","C. Saura","P. Nuciforo","I. Calvo","J. Andersen","J.L. Passos-Coelho","M. Gil Gil","B. Bermejo","D.A. Patt","E. Ciruelos","L. de la Peña","N. Xu","M. Wongchenko","Z. Shi","S.M. Singel","S.J. Isakoff"],"twitterCount":8,"altmetricId":61440986,"statusesArray":["1137350741440499712","1137195386928414722","1137193900408369152","1136953194796453888","1136949494375997440","1136947244853338117","1136943382079582208","1135436850695417857"]},{"title":"Pembrolizumab with or without chemotherapy vs chemotherapy in patients with advanced G/GEJ cancer (GC) including outcomes according to Microsatellite …","googleId":"x98I5RIl2xEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603959","googleCitationCount":27,"googleAuthor":"K Shitara","doi":"10.1093/annonc/mdz394.035","elsevierAuthor":"Petrelli F.","publicationName":"JAMA Oncology","elsevierCoverDate":"2020-07-01","elsevierCoverDisplayDate":"July 2020","elsevierCitationCount":"6","altmetricAuthors":["K. Shitara","E. Van Cutsem","Y.-J. Bang","C.S. Fuchs","L. Wyrwicz","K.W. Lee","I. Kudaba","M. Garrido","H. Cheol Chung","H.R. Castro","W. Mansoor","M I F M Braghiroli","E. Goekkurt","J. Chao","Z.A. Wainberg","U. Kher","S. Shah","S.P. Kang","J. Tabernero"],"twitterCount":0,"altmetricId":68179427,"statusesArray":[]},{"title":"Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression≥ 50%","googleId":"4ppXofhhqZMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419417213","googleCitationCount":19,"googleAuthor":"JF Gainor","doi":"10.1016/j.annonc.2019.11.015","elsevierAuthor":"Gainor J.F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-03-01","elsevierCoverDisplayDate":"March 2020","elsevierCitationCount":"11","altmetricAuthors":["J.F. Gainor","H. Rizvi","E. Jimenez Aguilar","F. Skoulidis","B.Y. Yeap","J. Naidoo","S. Khosrowjerdi","M. Mooradian","C. Lydon","P. Illei","J. Zhang","R. Peterson","B. Ricciuti","M. Nishino","J. Zhang","J.A. Roth","J. Grishman","D. Anderson","B.P. Little","B.W. Carter","K. Arbour","J.L. Sauter","M. Mino-Kenudson","J.V. Heymach","S. Digumarthy","A.T. Shaw","M.M. Awad","M.D. Hellmann"],"twitterCount":19,"altmetricId":76102028,"statusesArray":["1230113351562223616","1230107355620220929","1229046402707124224","1228767727906643969","1228750144289505281","1228738711782858752","1228737474224148480","1228726858189017091","1228724371600158721","1228715701373931521","1228699259123441664","1228697312127586305","1228685031238971392","1228682524500668416","1228682490690363392","1228607275226607616","1228604976747839489","1228580129061965827","1228556999647993858","1228516370511515650"]},{"title":"Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)","googleId":"ZWpnw0ZzBBQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310920","googleCitationCount":33,"googleAuthor":"","doi":"10.1093/annonc/mdz036","elsevierAuthor":"Condorelli R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-03-01","elsevierCoverDisplayDate":"1 March 2019","elsevierCitationCount":"23","altmetricAuthors":["R. Condorelli","F. Mosele","B. Verret","T. Bachelot","P.L. Bedard","J. Cortes","D.M. Hyman","D. Juric","I. Krop","I. Bieche","C. Saura","C. Sotiriou","F. Cardoso","S. Loibl","F. Andre","N.C. Turner"],"twitterCount":67,"altmetricId":54809487,"statusesArray":["1205982490785017856","1204487852849090566","1195291999630442498","1195265983428071424","1195262645710073856","1132279759868715008","1130673895307120641","1130574081219280901","1130528557128671232","1130502423456432128","1130415570946527232","1130405434190385154","1130360926056722432","1130359154290376704","1130322324790611968","1130291054111019008","1130057748799004672","1097218981243568131","1094751495784972288","1094746036017360897","1094529220988948481","1094443966550999040","1094413149162344448","1094404185691348992","1094374127660494848","1094374091430248448","1093050281733079040","1093045930025279488","1092839778523979776","1092616681472569347","1092615862559875072","1092615674030116864","1091850478684725248","1091836665432297472","1091765538592829440","1091760672193564672","1091716345295790080","1091688592039182338","1091684342986825728","1091677379926331393","1091674024529326080","1091657918758506496","1091640916018896896","1091638270021246976","1091622030687068161","1091616844832755712","1091605662562439168","1091600803729674240","1091582177676910593","1091575429260103680","1091552000838254592","1091517274094227456","1091467854514405379","1091435054977503232","1091426679816368129","1091385785243205634","1091383319319711744","1091376856920670209","1091376503772737536","1091362203599396864","1091358069538373632","1091356216364879872","1091355798003949568","1091353449210540032","1091342787122028545","1091342050786766848","1091341874068185088","1091341308868861954","1091340606368997381","1091340447874715650"]},{"title":"Prognostic value of circulating tumour cells in limited-stage small-cell lung cancer: analysis of the concurrent once-daily versus twice-daily radiotherapy …","googleId":"mkEum991BwIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341931230X","googleCitationCount":23,"googleAuthor":"","doi":"10.1093/annonc/mdz122","elsevierAuthor":"Tamminga M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-07-01","elsevierCoverDisplayDate":"1 July 2019","elsevierCitationCount":"1","altmetricAuthors":["R.Y. Tay","F. Fernández-Gutiérrez","V. Foy","K. Burns","J. Pierce","K. Morris","L. Priest","J. Tugwood","L. Ashcroft","C.R. Lindsay","C. Faivre-Finn","C. Dive","F. Blackhall"],"twitterCount":23,"altmetricId":59548932,"statusesArray":["1275731924678557699","1159467185607233536","1156387125463584771","1156283930020130817","1156247918770294784","1156240344528244736","1156228914643165184","1156215001469739010","1156214981760704512","1127188537760043008","1126461556840071168","1126455726531072000","1125049323866284033","1124291184866799616","1123832810681307136","1123712641388679168","1123694707899498499","1123674714201821184","1123639743307177984","1123562643418222592","1123548167218372609","1123531256048779264","1123494816699101186","1121738511374327808","1121696586235547648"]},{"title":"PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: Results from …","googleId":"b3kGa1DtEb8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604497","googleCitationCount":22,"googleAuthor":"MC Garassino","doi":"10.1093/annonc/mdz394.089","elsevierCitationCount":0,"altmetricAuthors":["L. Paz-Ares","J.W. Goldman","M.C. Garassino","M. Dvorkin","D. Trukhin","G. Statsenko","K. Hotta","J.H. Ji","M.J. Hochmair","O. Voitko","L. Havel","A. Poltoratskiy","G. Losonczy","N. Reinmuth","Y. Shrestha","N. Patel","H. Mann","H. Jiang","M. Özgüroğlu","Y. Chen"],"twitterCount":0,"altmetricId":68818517,"statusesArray":[]},{"title":"COVID-19 infection in cancer patients: early observations and unanswered questions","googleId":"1wS454AcwJMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)36384-5/pdf","googleCitationCount":26,"googleAuthor":"","statusesArray":[]},{"title":"Gender medicine and oncology: report and consensus of an ESMO workshop","googleId":"NxybZTWA4R0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325643","googleCitationCount":25,"googleAuthor":"S Oertelt-Prigione","doi":"10.1093/annonc/mdz414","elsevierAuthor":"Wagner A.D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-12-01","elsevierCoverDisplayDate":"1 December 2019","elsevierCitationCount":"16","altmetricAuthors":["A.D. Wagner","S. Oertelt-Prigione","A. Adjei","T. Buclin","V. Cristina","C. Csajka","G. Coukos","U. Dafni","G.-P. Dotto","M. Ducreux","J. Fellay","J. Haanen","A. Hocquelet","I. Klinge","V. Lemmens","A. Letsch","M. Mauer","M. Moehler","S. Peters","B.C. Özdemir"],"twitterCount":67,"altmetricId":68747829,"statusesArray":["1288379047232311296","1225522602845843470","1223523995754082306","1222757156933525504","1222661258576572416","1222624689354420225","1222590466375540737","1222575360539353088","1222574612925550596","1222555682873827328","1222490151366090752","1222483940704845825","1222476899382972417","1222476529558605825","1222473919191535617","1222467340631187456","1222464229116141569","1222463389420617728","1222462202239758336","1222461868012396544","1222460150218399744","1191694720323477504","1187282071548497920","1186646189875388422","1186215481189064704","1185518126630363141","1185233844930260992","1185136899691810816","1185088829985869830","1184976614091841536","1184848275461070850","1184833249404751873","1184820175683506176","1184819748162301953","1184815593079398401","1184802621074395138","1184801441883574272","1184799723808579584","1184798675102552064","1184796224643354625","1184796163549081602","1184794627209072640","1184794172022312960","1184776333462835201","1184759329066573824","1184756787834163200","1184754415040913408","1184749446451683328","1184748266929434624","1184745591433302016","1184745402622468097","1184745046278656000","1184744918062981120","1184744422191325184","1184743624346652672","1184743543090417664","1184743426354495489","1184743198104657920","1184742928863891457","1184742798500749312","1184739951637913600","1184734517153669121","1184724261807804418","1184723508988792833","1184723449173794818","1184709192889843712","1184709141278920704","1184707394565263360","1184707147285880832","1184703822423318528","1184574697809293313","1184573691830648832","1184561396203315202","1184557130411429888","1184544847170027520","1184409181350236161"]},{"title":"Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients","googleId":"6tfIGvxzDlcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311640","googleCitationCount":28,"googleAuthor":"JH Lee","doi":"10.1093/annonc/mdz075","elsevierAuthor":"Keller L.","publicationName":"British Journal of Cancer","elsevierCoverDate":"2021-01-19","elsevierCoverDisplayDate":"19 January 2021","elsevierCitationCount":"2","altmetricAuthors":["J.H. Lee","R.P. Saw","J.F. Thompson","S. Lo","A.J. Spillane","K.F. Shannon","J.R. Stretch","J. Howle","A.M. Menzies","M.S. Carlino","R.F. Kefford","G.V. Long","R.A. Scolyer","H. Rizos"],"twitterCount":76,"altmetricId":56942134,"statusesArray":["1271786416368836608","1174714053995966470","1174705216912076800","1157674008114028544","1156868290519715840","1154151162473373698","1150561381294456832","1150457885769588736","1150394667835580417","1150272848482598913","1150258152517976065","1124067744222195712","1124004092316135425","1123908671845675017","1123803414427729920","1123694457583484928","1123688480477990915","1123683772703084546","1123677088345657345","1123591506592321543","1123587912010829824","1113316085082861569","1112507724439437312","1111627809745788928","1111342525942517762","1109088847734992897","1108565047624826880","1108522986338803712","1108360103810355200","1108359906703212544","1108222597181771777","1108041234784890881","1108036407405277184","1107973801835458560","1107935053122887681","1107916617088827392","1107205903822905344","1107195282591117313","1107066303020298240","1107049388138848256","1107032848601497600","1106889625937707010","1106887809883762688","1106410425166508032","1106323747697418240","1106209526292742144","1106158887420473344","1106155428214423554","1106129645391540225","1106104651999576070","1106103205195333632","1106096662177636357","1106030463775174657","1106030225266102272","1105997390950121473","1105982994945318919","1105971110028431360","1105944102800113664","1105943799052800002","1105942839886782471","1105895972788412421","1105888645309853697","1105880873709326337","1105872593423343616","1105867732824711168","1105860567644979200","1105859554045251584","1105851143710801921","1105842736932872198","1105835317020512258","1105831058770194432","1105828507563839488","1105821973945430017","1105821065052344320","1105817465550856194","1105814706512637953","1105814704453271553","1105814513050370054","1105773257330839553","1105769629765394432","1105764225044107265","1105748590369091584","1105740401540022272","1105731295202734080"]},{"title":"Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis","googleId":"MwOJQ9vxOyEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325941","googleCitationCount":27,"googleAuthor":"AR Ferreira","doi":"10.1093/annonc/mdz298","elsevierAuthor":"Ferreira A.R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-11-01","elsevierCoverDisplayDate":"November 2019","elsevierCitationCount":"20","altmetricAuthors":["A.R. Ferreira","A. Di Meglio","B. Pistilli","A.S. Gbenou","M. El-Mouhebb","S. Dauchy","C. Charles","F. Joly","S. Everhard","M. Lambertini","C. Coutant","P. Cottu","F. Lerebours","T. Petit","F. Dalenc","P. Rouanet","A. Arnaud","A. Martin","J. Berille","P.A. Ganz","A.H. Partridge","S. Delaloge","S. Michiels","F. Andre","I. Vaz-Luis"],"twitterCount":62,"altmetricId":68071659,"statusesArray":["1263510688204574720","1225712206488199168","1196549805293654016","1196549340292100097","1191674051061829632","1191095596519690241","1189929439255089152","1189860365263425536","1189857874404659200","1189845715050090496","1189835913427398656","1189577413237317632","1189537686261923841","1189511953380716545","1189506504279412737","1189484549941710848","1189476974852329473","1189448967420960770","1189428144400457728","1189427299730546688","1189427186526240769","1189427132079972353","1189422231673278464","1189418924254908416","1189277944314847232","1189209396427005956","1189189584128659461","1189186333517860865","1189146273896685568","1189112191976382464","1189105948880769025","1189101015297081344","1189098368716410880","1189083832999395328","1189067008727498752","1188976623011483648","1188975465631047682","1188947713599201280","1188943046211244035","1188937123048689670","1188917824615583744","1188913850709630977","1188900978159951874","1188882159475527680","1188878261155254275","1188872129154093060","1188871033023074304","1188869879279038465","1188866996286431233","1188866377995735040","1188864566236721152","1184491537796927488","1183695250835038208","1183628039520829441","1183627841491083265","1183603471636807680","1183601150697734145","1183232416401350656","1183206150201847808","1183200350695837696","1183200259146686464","1183199301314330625","1183021962223902722","1182985651102326790","1182968262159671297","1182957179952873472","1182766511309709312","1182763850157961216","1182760649992130560","1182758885301608448","1182697950004350976","1182606501048995843","1182361837612027907","1182347561270726663","1181964495691898881","1181954532177256451","1181902657226772482","1181869796092186624","1181826068002562048","1181817849733668865","1181803526428729344","1181683486446510084"]},{"title":"Phase II study of olaparib (O) and durvalumab (D)(MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast …","googleId":"TydcdbeVsAsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594030","googleCitationCount":23,"googleAuthor":"S Postel-Vinay","doi":"10.1093/annonc/mdz253.017","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Overview of the relevance of PI3K pathway in HR-positive breast cancer","googleId":"r3cKMq3JT7EJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420343738","googleCitationCount":24,"googleAuthor":"N Vasan","doi":"10.1093/annonc/mdz281","elsevierAuthor":"Vasan N.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-04-01","elsevierCoverDisplayDate":"April 2020","elsevierCitationCount":"0","altmetricAuthors":["N. Vasan","E. Toska","M. Scaltriti"],"twitterCount":13,"altmetricId":73059115,"statusesArray":["1217388930665828358","1213106240462692352","1213012981455433728","1213012915068047360","1209406724005933057","1208739806945128448","1208625140755582976","1208622622222770176","1208095285047640065","1208088292543123456","1208079323451854851","1208077442327498752","1208077172268847111","1208075776802861057"]},{"title":"Recent advances in circulating nucleic acids in oncology","googleId":"llW4tJsV08sJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310919","googleCitationCount":27,"googleAuthor":"","doi":"10.1093/annonc/mdz031","elsevierAuthor":"Otandault A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-03-01","elsevierCoverDisplayDate":"1 March 2019","elsevierCitationCount":"22","altmetricAuthors":["A. Otandault","P. Anker","Z. Al Amir Dache","V. Guillaumon","R. Meddeb","B. Pastor","E. Pisareva","C. Sanchez","R. Tanos","G. Tousch","H. Schwarzenbach","A.R. Thierry"],"twitterCount":2,"altmetricId":59251483,"statusesArray":["1119428729271353344","1119308892578598912"]},{"title":"MonarcHER: A randomized phase II study of abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy …","googleId":"KXK8bYznZqIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603728","googleCitationCount":21,"googleAuthor":"","doi":"10.1093/annonc/mdz394.012","elsevierCitationCount":0,"altmetricAuthors":["S.M. Tolaney","A.M. Wardley","S. Zambelli","J. Hilton","T. Troso-Sandoval","F. Ricci","S.-A. Im","S.-B. Kim","S.R.D. Johnston","A. Chan","S. Goel","K. Catron","Z. Yang","C. Gainford","F. André"],"twitterCount":0,"altmetricId":67755514,"statusesArray":[]},{"title":"Molecular pathology of tumors of the central nervous system","googleId":"-OSUrllH0x0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312839","googleCitationCount":28,"googleAuthor":"","doi":"10.1093/annonc/mdz164","elsevierAuthor":"Kristensen B.W.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-08-01","elsevierCoverDisplayDate":"1 August 2019","elsevierCitationCount":"12","altmetricAuthors":["B.W. Kristensen","L.P. Priesterbach-Ackley","J.K. Petersen","P. Wesseling"],"twitterCount":25,"altmetricId":61245987,"statusesArray":["1197598389875224577","1194289359169761280","1192183986245767169","1192064599228657664","1192007999784706048","1192006670081306625","1192006614531874816","1191996951786598400","1191992990644023296","1191967592128401408","1191953967514898433","1166695783393046528","1161907008813096960","1161904713933234177","1161835591815839745","1161679177172627456","1161638266094751744","1136376625334013958","1136360094336258051","1136322385978822657","1136295689686781952","1136273356024688640","1136266631699750918","1136230486370607105","1136229949814140928","1133956598131580928","1133956170115309568","1133731130052620290"]},{"title":"Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO–ESMO initiative …","googleId":"tFwE2CDFyu4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310002","googleCitationCount":23,"googleAuthor":"F Lordick","doi":"10.1093/annonc/mdy498","elsevierAuthor":"Muro K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-01-01","elsevierCoverDisplayDate":"1 January 2019","elsevierCitationCount":"22","altmetricAuthors":["K. Muro","F. Lordick","T. Tsushima","G. Pentheroudakis","E. Baba","Z. Lu","B.C. Cho","I.M. Nor","M. Ng","L -T Chen","K. Kato","J. Li","M -H Ryu","W I Wan Zamaniah","W -P Yong","K -H Yeh","T.E. Nakajima","K. Shitara","H. Kawakami","Y. Narita","T. Yoshino","E. Van Cutsem","E. Martinelli","E.C. Smyth","D. Arnold","H. Minami","J. Tabernero","J -Y Douillard"],"twitterCount":9,"altmetricId":51601317,"statusesArray":["1133871834015961088","1133750895177621509","1133750608614137856","1133356486510415872","1068936196875796480","1068553745754189827","1067731042545463296","1067557124601896960","1067556149593989120","1067549389319692288","1065943022624493569"]},{"title":"Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial","googleId":"LIsqyzgs5LIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420363808","googleCitationCount":16,"googleAuthor":"R Berardi","doi":"10.1016/j.annonc.2020.03.293","elsevierAuthor":"Schuler M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-06-01","elsevierCoverDisplayDate":"June 2020","elsevierCitationCount":"9","altmetricAuthors":["M. Schuler","R. Berardi","W.-T. Lim","M. de Jonge","T.M. Bauer","A. Azaro","M. Gottfried","J.-Y. Han","D.H. Lee","M. Wollner","D.S. Hong","A. Vogel","A. Delmonte","M. Akimov","S. Ghebremariam","X. Cui","N. Nwana","M. Giovannini","T.M. Kim"],"twitterCount":2,"altmetricId":78691421,"statusesArray":["1274780465707323396","1244851667960582144"]},{"title":"Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo","googleId":"UJPt7EO5QPwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420398367","googleCitationCount":13,"googleAuthor":"T Karn","doi":"10.1016/j.annonc.2020.05.015","elsevierAuthor":"Karn T.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-09-01","elsevierCoverDisplayDate":"September 2020","elsevierCitationCount":"6","altmetricAuthors":["T. Karn","C. Denkert","K.E. Weber","U. Holtrich","C. Hanusch","B.V. Sinn","B.W. Higgs","P. Jank","H.P. Sinn","J. Huober","C. Becker","J.-U. Blohmer","F. Marmé","W.D. Schmitt","S. Wu","M. van Mackelenbergh","V. Müller","C. Schem","E. Stickeler","P.A. Fasching","C. Jackisch","M. Untch","A. Schneeweiss","S. Loibl"],"twitterCount":17,"altmetricId":82748985,"statusesArray":["1300761062082572290","1300754144496676864","1300752664679067651","1299361818826153987","1299310457900142592","1299310390141165569","1267715358506582016","1265978209209847809","1265727097747714049","1265390916111663106","1265359315147292679","1265327248007065600","1265272630241787905","1265245334621609984","1265226778408185857","1265224289550303233","1265215921146097665","1265210591708434437","1265208152020189185","1265203990750470145","1265203883028201472"]},{"title":"French Sarcoma Group proposals for management of sarcoma patients during the COVID-19 outbreak","googleId":"7KKlQ2brJZ0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)36413-9/pdf","googleCitationCount":19,"googleAuthor":"S Bonvalot","statusesArray":[]},{"title":"Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small-cell lung cancer","googleId":"sWJkGW2cAN0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419459942","googleCitationCount":28,"googleAuthor":"J Zhang","doi":"10.1093/annonc/mdz207","elsevierAuthor":"Kudo Y.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-09-01","elsevierCoverDisplayDate":"1 September 2019","elsevierCitationCount":"22","altmetricAuthors":["Y. Kudo","C. Haymaker","J. Zhang","A. Reuben","D.Y. Duose","J. Fujimoto","S. Roy-Chowdhuri","L.M. Solis Soto","H. Dejima","E.R. Parra","B. Mino","R. Abraham","N. Ikeda","A. Vaporcyan","D. Gibbons","J. Zhang","F.F. Lang","R. Luthra","J.J. Lee","C. Moran","J.T. Huse","H. Kadara","I.I. Wistuba"],"twitterCount":19,"altmetricId":63415578,"statusesArray":["1268751154852384771","1222515998151962625","1193363221413081088","1193309883988430849","1193031713301155840","1191461108428820490","1191373907883806720","1191370581716811777","1191368654178246656","1191353954573209601","1191349785632133125","1191326394866749445","1191320805466083328","1191309323378425857","1191306086675910656","1149370406652055552","1149327567955955712","1149316815929126913","1149309867514945538"]},{"title":"Different shades of pancreatic ductal adenocarcinoma, different paths towards precision therapeutic applications","googleId":"8Lhub5gERssJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419459814","googleCitationCount":20,"googleAuthor":"R Nicolle","doi":"10.1093/annonc/mdz181","elsevierAuthor":"Martens S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-09-01","elsevierCoverDisplayDate":"1 September 2019","elsevierCitationCount":"9","altmetricAuthors":["S. Martens","P. Lefesvre","R. Nicolle","A.V. Biankin","F. Puleo","J.L. Van Laethem","I. Rooman"],"twitterCount":2,"altmetricId":62257344,"statusesArray":["1141414441818513413","1140175883141046273"]},{"title":"BEACON CRC: a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab …","googleId":"_pbYZDbSygEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30959-7/abstract","googleCitationCount":25,"googleAuthor":"S Kopetz","statusesArray":[]},{"title":"Extrachromosomal DNA–relieving heredity constraints, accelerating tumour evolution","googleId":"hbrHEmWXqcQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420363924","googleCitationCount":12,"googleAuthor":"C Bailey","doi":"10.1016/j.annonc.2020.03.303","elsevierAuthor":"Bailey C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-07-01","elsevierCoverDisplayDate":"July 2020","elsevierCitationCount":"7","altmetricAuthors":["C. Bailey","M.J. Shoura","P.S. Mischel","C. Swanton"],"twitterCount":33,"altmetricId":79343881,"statusesArray":["1347206623631003650","1275800541193482248","1275673014793908224","1275653399128813570","1275609744292675584","1275602663623872512","1275521163276533760","1275515564778283014","1275466507624079366","1275341817752453121","1254950673742876673","1254948479442604033","1254948344889139201","1249478250994135041","1248942505577472001","1248914700110192640","1248277329094283265","1248267064156061699","1248211878397931521","1248169581685772288","1248165806967578624","1248165473771909120","1248150700477071361","1248149674021847040","1248148754999508993","1248148124457144321","1248147001889492992","1248122419719495680","1248119954500657153","1247999195627347971","1247992530991566849","1247949261054119937","1247945381280972800","1247941127421988865","1247939639404609537","1247925820775153671"]},{"title":"Evolutionary dynamics of residual disease in human glioblastoma","googleId":"2tBZ5ry8hPEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310725","googleCitationCount":23,"googleAuthor":"G Caravagna","doi":"10.1093/annonc/mdy506","elsevierAuthor":"Spiteri I.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-03-01","elsevierCoverDisplayDate":"1 March 2019","elsevierCitationCount":"9","altmetricAuthors":["I. Spiteri","G. Caravagna","G.D. Cresswell","A. Vatsiou","D. Nichol","A. Acar","L. Ermini","K. Chkhaidze","B. Werner","R. Mair","E. Brognaro","R.G.W. Verhaak","G. Sanguinetti","S.G.M. Piccirillo","C. Watts","A. Sottoriva"],"twitterCount":125,"altmetricId":51782352,"statusesArray":["1118005707142508544","1117848925392625666","1117726316739084288","1117716872818982912","1117701970750390277","1117699112961363969","1106940044357574658","1102516003857199104","1102196605745156096","1102104623970689024","1101979922686451713","1101935808251133952","1101887724783575040","1101471850318782464","1099071556226072577","1096415525968797697","1096393041680715777","1096273268049436673","1096138211087343616","1096092397245730817","1096084424838529033","1096063548546039808","1096061553248333826","1094794739663040513","1094781067893051394","1094734255924613120","1094726687491833856","1094680276146573313","1094647009422856193","1094630899847577602","1094622771265495045","1094556918570471427","1094523472687124480","1094498573058756609","1094484224416059392","1094442722432335878","1094366711975985153","1094358902001549312","1094352186769895425","1094327492662439937","1094251545229701120","1094247553237803008","1094237359535804416","1094235016454959106","1094235004283031552","1094233340826259458","1094227581845544960","1094222517231853568","1094194557380640769","1094191795121078273","1094189685021261824","1094160575393865728","1094157233338925056","1094154952136642560","1094151705581834240","1094145537220042758","1094143494099255296","1094135746267631616","1094132337296711680","1094127473741254656","1094115789874102272","1094085822771429377","1094077074007093249","1094066923317415937","1094045353014378499","1094034119594594304","1094008947365814273","1094007816879169536","1094005263294709760","1094004112809779200","1093998999319789568","1093996247239835648","1093991731513692160","1093982404480401409","1093961357630820353","1093954032945823744","1093930417328140288","1093928525348913153","1093928395455455232","1093928169311227904","1093924743491678208","1093924678563958785","1093906648459083776","1093906331755532288","1093904121688702976","1093903146353594369","1093898698734559232","1093887398575046656","1093884622780256256","1093877142641917954","1093864118858272773","1093858350310309888","1093856644918845442","1093847993583849473","1093847786301415424","1093845421426860033","1093844570977259520","1093841095530868736","1093840725022859264","1093840242824617986","1093838163645218816","1093837168596996097","1093832417067048960","1093832263836598272","1093818778725568513","1093813573569134593","1093810865151856640","1093808301014466560","1093806904470577152","1093804354266636288","1093803825876619265","1093803689742139392","1093801237009612800","1093800344474304512","1093798129911169025","1093796652442365955","1093796114883641344","1087351764851011586","1087268991180115968","1087178496147968224","1086810584803409920","1086766311680684032","1086740086761373702","1086712411065929728","1086653952966434818","1086588228570877952","1086584088662888448","1086523283095384064","1086394631863107584","1086370046476238848","1086297285338845184","1086296556683386881","1086290676491288578","1086276728480092160","1086272550450024448","1086268042345046021","1086268042303160321","1086205640605761538","1086194827971256320","1086187862331138049","1086186459856396289","1068859479779725315","1068763896910032896","1068558240135479296","1068552546585763840","1068551141221384192","1068533296026529792","1068533078593802242","1068532634026999808","1068531864862904322"]},{"title":"Incidence and mortality from cervical cancer and other malignancies after treatment of cervical intraepithelial neoplasia: a systematic review and meta …","googleId":"8eJgY7p9cccJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419390854","googleCitationCount":14,"googleAuthor":"A Athanasiou","doi":"10.1016/j.annonc.2019.11.004","elsevierAuthor":"Kalliala I.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-02-01","elsevierCoverDisplayDate":"February 2020","elsevierCitationCount":"10","altmetricAuthors":["I. Kalliala","A. Athanasiou","A.A. Veroniki","G. Salanti","O. Efthimiou","N. Raftis","S. Bowden","M. Paraskevaidi","K. Aro","M. Arbyn","P. Bennett","P. Nieminen","E. Paraskevaidis","M. Kyrgiou"],"twitterCount":11,"altmetricId":73750183,"statusesArray":["1224146109674741764","1220914259896332288","1220861956485255169","1220846150372220928","1220844177740660743","1220241600217075712","1215964634018127873","1215643649427546112","1215399481342152707","1215234239991599105","1214887692246360065"]},{"title":"Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label …","googleId":"lyFoqwPuSNEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420364346","googleCitationCount":17,"googleAuthor":"RL Ferris","doi":"10.1016/j.annonc.2020.04.001","elsevierAuthor":"Ferris R.L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-07-01","elsevierCoverDisplayDate":"July 2020","elsevierCitationCount":"13","altmetricAuthors":["R.L. Ferris","R. Haddad","C. Even","M. Tahara","M. Dvorkin","T.E. Ciuleanu","P.M. Clement","R. Mesia","S. Kutukova","L. Zholudeva","A. Daste","J. Caballero-Daroqui","B. Keam","I. Vynnychenko","C. Lafond","J. Shetty","H. Mann","J. Fan","S. Wildsmith","N. Morsli","J. Fayette","L. Licitra"],"twitterCount":14,"altmetricId":79917415,"statusesArray":["1288822208102567936","1288100762963316736","1288092784336023554","1288087611492507651","1288087172176908288","1274777925011804161","1273271811711602689","1253891781814390789","1252206971664633861","1252144927066079233","1251466169552375808","1251238353124634626","1250906252718325760","1250839628443054080","1250805914346549248"]},{"title":"Phase II study of olaparib+ durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)","googleId":"FfyCXormmyoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594029","googleCitationCount":21,"googleAuthor":"","doi":"10.1093/annonc/mdz253.016","elsevierAuthor":"Gupta N.","publicationName":"Oncotarget","elsevierCoverDate":"2021-01-05","elsevierCoverDisplayDate":"5 January 2021","elsevierCitationCount":"0","altmetricAuthors":["Y. Drew","B. Kaufman","S. Banerjee","A. Lortholary","S.H. Hong","Y.H. Park","S. Zimmermann","P. Roxburgh","M. Ferguson","R.H. Alvarez","S. Domchek","C. Gresty","H.K. Angell","V Rocher Ros","K. Meyer","M. Lanasa","P. Herbolsheimer","M. de Jonge"],"twitterCount":0,"altmetricId":68179394,"statusesArray":[]},{"title":"REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer …","googleId":"0IyMIZT1uYUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310336","googleCitationCount":25,"googleAuthor":"K Shitara","doi":"10.1093/annonc/mdy526","elsevierAuthor":"Shitara K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-02-01","elsevierCoverDisplayDate":"1 February 2019","elsevierCitationCount":"10","altmetricAuthors":["K. Shitara","T. Yamanaka","T. Denda","Y. Tsuji","K. Shinozaki","Y. Komatsu","Y. Kobayashi","J. Furuse","H. Okuda","M. Asayama","K. Akiyoshi","Y. Kagawa","T. Kato","E. Oki","T. Ando","Y. Hagiwara","Y. Ohashi","T. Yoshino"],"twitterCount":10,"altmetricId":52264645,"statusesArray":["1078882301147316224","1073968278903644160","1073240242050732034","1073175390766751745","1072056005251411970","1071906484320174080","1071830240928894977","1071813301145927680","1071757929169203201","1071081985135796225","1070636733413376002"]},{"title":"Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC","googleId":"jQjwSZkTEPgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603984","googleCitationCount":25,"googleAuthor":"DG Duda","doi":"10.1093/annonc/mdz394.038","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Phase II study of pertuzumab and trastuzumab-emtansine (T-DM1) in patients with HER2-positive metastatic colorectal cancer: The HERACLES-B (HER2 …","googleId":"xnKXuBOa33kJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603844","googleCitationCount":20,"googleAuthor":"A Sartore-Bianchi","doi":"10.1093/annonc/mdz394.024","elsevierAuthor":"Rizzetto F.","publicationName":"European Radiology Experimental","elsevierCoverDate":"2020-12-01","elsevierCoverDisplayDate":"December 2020","elsevierCitationCount":"1","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Durability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer","googleId":"YFb0XUsUREUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419580139","googleCitationCount":17,"googleAuthor":"D Hyman","doi":"10.1093/annonc/mdz431.002","elsevierAuthor":"Harada G.","publicationName":"Current Treatment Options in Oncology","elsevierCoverDate":"2020-05-01","elsevierCoverDisplayDate":"1 May 2020","elsevierCitationCount":"2","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer","googleId":"_enP7C4XwBgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420360555","googleCitationCount":18,"googleAuthor":"O Cohen","doi":"10.1016/j.annonc.2020.02.008","elsevierAuthor":"Waks A.G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-05-01","elsevierCoverDisplayDate":"May 2020","elsevierCitationCount":"13","altmetricAuthors":["A.G. Waks","O. Cohen","B. Kochupurakkal","D. Kim","C.E. Dunn","J. Buendia Buendia","S. Wander","K. Helvie","M.R. Lloyd","L. Marini","M.E. Hughes","S.S. Freeman","S.P. Ivy","J. Geradts","S. Isakoff","P. LoRusso","V.A. Adalsteinsson","S.M. Tolaney","U. Matulonis","I.E. Krop","A.D. D’Andrea","E.P. Winer","N.U. Lin","G.I. Shapiro","N. Wagle"],"twitterCount":57,"altmetricId":76794249,"statusesArray":["1255292465420140545","1246925717268357120","1241133330684313600","1237592935094308865","1237138270590504965","1234345697601781762","1234054794635030528","1233963028212834306","1233890663436914689","1233862789967511561","1233862776805888000","1233860089724882944","1233797697158746113","1233771617681125376","1233768224656850951","1233751318243749889","1233740735905701889","1233730425325080578","1233730346421772294","1233728929778847746","1233728136241713152","1233728099809943553","1233726980996128770","1233716018222190592","1233713097048756225","1233699557747429376","1233685295331041280","1233685023963873281","1233683375489212422","1233682903953027072","1233673570812940288","1233673545177325568","1233668827138973698","1233664599448342528","1233647973847969795","1233643644805992449","1233641334470270976","1233639163678736385","1233639110125867008","1233635512113647616","1233609605017751553","1233599397889560580","1233585876719919104","1233538430493188097","1233532284088832001","1233523488541028354","1233506289025798151","1233494487252570115","1233474896979779586","1233474366144438277","1233458698799996928","1233449278523105280","1233448970317418497","1233437712100646914","1233427765086621698","1233420092127485953","1233408387779584001","1233407212686495745","1233404519330959361","1233393983461695488","1233391701336584193","1233378025368162308","1233376991010787328","1233364975000772608","1233361329609740293","1233358812037382144","1233357052694626306","1233354126534348800","1233351183022116865","1233350947126071298"]},{"title":"Efficacy and safety of nivolumab (Nivo)+ ipilimumab (Ipi) in patients (pts) with recurrent/metastatic (R/M) cervical cancer: results from CheckMate 358","googleId":"zMFU0IFcgp8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604199","googleCitationCount":21,"googleAuthor":"RW Naumann","doi":"10.1093/annonc/mdz394.059","elsevierCitationCount":0,"altmetricAuthors":["R.W. Naumann","A. Oaknin","T. Meyer","J.M. Lopez-Picazo","C. Lao","Y.-J. Bang","V. Boni","W.H. Sharfman","J.C. Park","L.A. Devriese","K. Harano","C.H. Chung","S.L. Topalian","K. Zaki","T. Chen","J. Gu","B. Li","A. Barrows","A. Horvath","K.N. Moore"],"twitterCount":0,"altmetricId":93776674,"statusesArray":[]},{"title":"Deep learning radiomic nomogram can predict the number of lymph node metastasis in locally advanced gastric cancer: an international multicenter study","googleId":"cc7yeXPHCcUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420392942","googleCitationCount":16,"googleAuthor":"D Dong","doi":"10.1016/j.annonc.2020.04.003","elsevierAuthor":"Dong D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-07-01","elsevierCoverDisplayDate":"July 2020","elsevierCitationCount":"15","altmetricAuthors":["D. Dong","M.-J. Fang","L. Tang","X.-H. Shan","J.-B. Gao","F. Giganti","R.-P. Wang","X. Chen","X.-X. Wang","D. Palumbo","J. Fu","W.-C. Li","J. Li","L.-Z. Zhong","F. De Cobelli","J.-F. Ji","Z.-Y. Liu","J. Tian"],"twitterCount":15,"altmetricId":80101025,"statusesArray":["1255874113438089216","1252591428871450624","1252571572625260544","1252567354136920064","1252565028202442752","1252563355107131393","1252562209000976384","1252562072409264128","1252562004868386817","1252561334169829377","1252559854134112256","1252559591474266112","1251852563806162944","1251819119420334083","1251818892080668672"]},{"title":"Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS …","googleId":"ABZjXaoc-0gJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419532240","googleCitationCount":13,"googleAuthor":"G Pentheroudakis","doi":"10.1016/j.annonc.2019.12.001","elsevierAuthor":"Chen L.T.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-03-01","elsevierCoverDisplayDate":"March 2020","elsevierCitationCount":"9","altmetricAuthors":["L.-T. Chen","E. Martinelli","A.-L. Cheng","G. Pentheroudakis","S. Qin","G.S. Bhattacharyya","M. Ikeda","H.-Y. Lim","G.F. Ho","S.P. Choo","Z. Ren","H. Malhotra","M. Ueno","B.-Y. Ryoo","T.C. Kiang","D. Tai","A. Vogel","A. Cervantes","S.-N. Lu","C.-J. Yen","Y.-H. Huang","S.-C. Chen","C. Hsu","Y.-C. Shen","J. Tabernero","Y. Yen","C.-H. Hsu","T. Yoshino","J.-Y. Douillard"],"twitterCount":2,"altmetricId":73845359,"statusesArray":["1230125891100930049","1215644133735501825"]},{"title":"Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the …","googleId":"cvwh9Cb_5EAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420397969","googleCitationCount":24,"googleAuthor":"","doi":"10.1016/j.annonc.2020.04.478","elsevierAuthor":"Mok T.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-08-01","elsevierCoverDisplayDate":"August 2020","elsevierCitationCount":"13","altmetricAuthors":["T. Mok","D.R. Camidge","S.M. Gadgeel","R. Rosell","R. Dziadziuszko","D.-W. Kim","M. Pérol","S.-H.I. Ou","J.S. Ahn","A.T. Shaw","W. Bordogna","V. Smoljanović","M. Hilton","T. Ruf","J. Noé","S. Peters"],"twitterCount":1,"altmetricId":95961777,"statusesArray":["1338489261755158528"]},{"title":"The forefront of ovarian cancer therapy: update on PARP inhibitors","googleId":"A2wPDo9ojcQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420398914","googleCitationCount":19,"googleAuthor":"MR Mirza","doi":"10.1016/j.annonc.2020.06.004","elsevierAuthor":"Mirza M.R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-09-01","elsevierCoverDisplayDate":"September 2020","elsevierCitationCount":"10","altmetricAuthors":["M.R. Mirza","R.L. Coleman","A. González-Martín","K.N. Moore","N. Colombo","I. Ray-Coquard","S. Pignata"],"twitterCount":31,"altmetricId":84387486,"statusesArray":["1304330138675417088","1303355854897532931","1303295002399961094","1303205725662064645","1303184949822980097","1303105588931506176","1303092745427456000","1303077026086047744","1303074501186318336","1303072926527152128","1303070028468756487","1303063043916656640","1303028641694208001","1303013442014580736","1303001390365593602","1302999117795262466","1302987269608034305","1302986610867425283","1302977343154257921","1302975718096338947","1302975606376796162","1302975348385210368","1286346439094829057","1286330967519625216","1275385495086698498","1274466407309348866","1274429645916700674","1274419850652405762","1274389175186403328","1274388269220978689","1274387266975252482","1274386865567793152"]},{"title":"An adaptive, biomarker directed platform study in metastatic urothelial cancer (BISCAY) with durvalumab in combination with targeted therapies","googleId":"nnpcydVVlxkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591189","googleCitationCount":19,"googleAuthor":"R Jones","doi":"10.1093/annonc/mdz249.001","elsevierCitationCount":0,"altmetricAuthors":["T. Powles","A. Balar","G. Gravis","R. Jones","A. Ravaud","J. Florence","P. Grivas","D.P. Petrylak","M. Galsky","J. Carles","S. Sridhar","H.-T. Arkenau","D. Carroll","J. DeCesare","F. Mercier","D. Hodgson","J. Stone","J. Cosaert","D. Landers"],"twitterCount":0,"altmetricId":68179462,"statusesArray":[]},{"title":"Preserving fertility in female patients with hematological malignancies: a multidisciplinary oncofertility approach","googleId":"x1D2NaIvnm0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325862","googleCitationCount":14,"googleAuthor":"A Anazodo","doi":"10.1093/annonc/mdz284","elsevierAuthor":"Salama M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-11-01","elsevierCoverDisplayDate":"November 2019","elsevierCitationCount":"6","altmetricAuthors":["M. Salama","A. Anazodo","T.K. Woodruff"],"twitterCount":29,"altmetricId":65057913,"statusesArray":["1222489197031890944","1167725340942225409","1167482230802923520","1164209085069373440","1164068406393548800","1163557995864895488","1163510723147915264","1163434181436817409","1163261840169807872","1163158420477874177","1163116297447718912","1163112655265026048","1163070897886048259","1163065046408159233","1163049089241681920","1163048854335500288","1163027948070268930","1162999484592402432","1162993328394317824","1162991098710634496","1162989472100708352","1162856965854257153","1162722038458593281","1162667306570473472","1162608502197706752","1162538058291400704","1162521064842248192","1162520282143215616","1162446779864014853","1162438716838809600","1162357644021121024"]},{"title":"LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC …","googleId":"w-nteMbYxsQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42378-6/abstract","googleCitationCount":39,"googleAuthor":"K Shitara","statusesArray":[]},{"title":"696O_PR Nivolumab+ cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER …","googleId":"LOeyRQQr1TEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42339-7/abstract","googleCitationCount":37,"googleAuthor":"TK Choueiri","statusesArray":[]},{"title":"Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for …","googleId":"smZ_tgrg7msJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310257","googleCitationCount":21,"googleAuthor":"","doi":"10.1093/annonc/mdy512","elsevierAuthor":"Zugazagoitia J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-02-01","elsevierCoverDisplayDate":"1 February 2019","elsevierCitationCount":"17","altmetricAuthors":["J. Zugazagoitia","I. Ramos","J.M. Trigo","M. Palka","A. Gómez-Rueda","E. Jantus-Lewintre","C. Camps","D. Isla","P. Iranzo","S. Ponce-Aix","R. García-Campelo","M. Provencio","F. Franco","R. Bernabé","O. Juan-Vidal","E. Felip","J. de Castro","J.M. Sanchez-Torres","I. Faul","R.B. Lanman","P. Garrido","L. Paz-Ares"],"twitterCount":28,"altmetricId":52471600,"statusesArray":["1235563222763102209","1235562842113245185","1222519273966321670","1099702167387164674","1099473999317352448","1099261161214750720","1075780419306618880","1074413410224431107","1073170669356150784","1073103609125052416","1073091866172776448","1073086653026263045","1073044345941446656","1072956024909250560","1072814588721213440","1072765269490237440","1072750913360748546","1072597532663054336","1072568128075427842","1072417692383145985","1072411241300279298","1072411210350542849","1072393653413470208","1072390549846548480","1072389000143482880","1072371228340568064","1072258901658091520","1072235930164084740","1072232829688401920","1072202040070299648"]},{"title":"Pre-operative ipilimumab and nivolumab in locoregionally advanced, stage III, urothelial cancer (NABUCCO)","googleId":"7e4fZViTeOkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591207","googleCitationCount":17,"googleAuthor":"","doi":"10.1093/annonc/mdz249.003","elsevierCitationCount":0,"altmetricAuthors":["M.S. Van der Heijden","N. van Dijk","L. Smit","K. Hendricksen","J.M. de Feijter","E. Bekers","E. Hooijberg","C.C.N. van Rooijen","A. Broeks","Y. Lubeck","K. Sikorska","T.N. Schumacher","P. Kvistborg","T. Boellaard","C.U. Blank","B.W. van Rhijn"],"twitterCount":0,"altmetricId":68179457,"statusesArray":[]},{"title":"Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers","googleId":"UlTYYiNbI9EJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312384","googleCitationCount":24,"googleAuthor":"K Nones","doi":"10.1093/annonc/mdz132","elsevierAuthor":"Foulkes W.D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-07-01","elsevierCoverDisplayDate":"1 July 2019","elsevierCitationCount":"0","altmetricAuthors":["K. Nones","J. Johnson","F. Newell","A.M. Patch","H. Thorne","S.H. Kazakoff","X.M. de Luca","M.T. Parsons","K. Ferguson","L.E. Reid","A.E. McCart Reed","S. Srihari","V. Lakis","A.L. Davidson","P. Mukhopadhyay","O. Holmes","Q. Xu","S. Wood","C. Leonard","J. Beesley","J.M. Harris","D. Barnes","A. Degasperi","M.A. Ragan","A.B. Spurdle","K.K. Khanna","S.R. Lakhani","J.V. Pearson","S. Nik-Zainal","G. Chenevix-Trench","N. Waddell","P.T. Simpson"],"twitterCount":57,"altmetricId":60525683,"statusesArray":["1275809836874125312","1275773301093089280","1275770669427331072","1222499138882785285","1177910394146496513","1162799125584392195","1162797404506206210","1156634464426123265","1156578865768292354","1156574622378352640","1156554769265287169","1156401612472107009","1156394422793383938","1155882358731681792","1155159314585145344","1155117975474724866","1155107323171561474","1155096724031102976","1155066837001916416","1155061127983837184","1155040341378174976","1155028398751780864","1155028155087970304","1155026501013823489","1155016430691213312","1155007945542963200","1154972075771277312","1154964881205948416","1154963900506529793","1154929156636860417","1154888502443745288","1154872499278139392","1154866966613639168","1154826789237207047","1154789358186225667","1154787679172616194","1154780595760848896","1154753778983329792","1154743375809187840","1154743237485027328","1154741113011539968","1154740687579099138","1154740426235977729","1154107832867799040","1135455152121556992","1135398905103831040","1135363347514241024","1133114259418812417","1132083496279613440","1132041731287994369","1132033671853031426","1132028985666359297","1132006397284102144","1131941795183636481","1131937902290595840","1131349133409832961","1129836330886795264","1129810090481967104","1129805148073660417","1128938778318393344"]},{"title":"Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung …","googleId":"8z2OHoHDekkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311603","googleCitationCount":22,"googleAuthor":"","doi":"10.1093/annonc/mdz060","elsevierAuthor":"Blumenthal G.M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-05-01","elsevierCoverDisplayDate":"May 2019","elsevierCitationCount":"16","altmetricAuthors":["G.M. Blumenthal","Y. Gong","K. Kehl","P. Mishra-Kalyani","K.B. Goldberg","S. Khozin","P.G. Kluetz","G.R. Oxnard","R. Pazdur"],"twitterCount":66,"altmetricId":55943907,"statusesArray":["1159775855993851905","1155700796287258625","1119251460473131014","1119153452314021888","1118560045736841218","1118531983687208961","1118497550833569792","1118460312607440896","1118460005852880896","1118459243802300417","1118447772321976320","1118419664038764545","1118394651210407938","1118321599005057024","1118306859453177856","1118272644095315968","1118272536813260801","1118269425797533697","1118268514312380423","1114167894793949184","1114092137237368832","1113861842181423104","1113854317092638720","1113854265087483907","1113525949239160832","1113496201683304450","1113490265065566209","1113489806896640000","1113479277369077760","1113454271197011968","1113447233238728704","1113410840026210305","1103779465786781707","1103779168712568839","1101181373413507072","1101172779397853190","1100771933979693056","1100767215056535552","1100718364219994113","1100713504724668416","1100641938460553218","1100550792996683777","1100421834686844933","1100386139259715584","1100380759519571969","1100378982522998784","1100369129830268929","1100363780985417729","1100272778547204097","1100202550018625542","1100197678573674496","1100191619154931713","1100187184550821889","1100167456549531648","1100133429298036737","1100133017417404417","1100122030458966016","1100111816598814720","1100067825975095296","1100065630349275136","1100065393480220673","1100058528616800257","1100051675564466176","1100051024276934661","1100050152411275265","1100049625170526208","1099965502502420480","1099965365260562433","1099733526881206272","1099722789626540036","1099721799565279232","1099601433358258176","1099601375007191040","1099510496921899009","1099381536955092992","1099301549900218368","1099286984957284352","1099286872658980864","1099286090823929856","1099262313939566592","1099247465583312896"]},{"title":"The Macrophage 'Do not eat me'signal, CD47, is a clinically validated cancer immunotherapy target","googleId":"ld6xbcHXvWcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31086-5/abstract","googleCitationCount":22,"googleAuthor":"","statusesArray":[]},{"title":"Liquid biopsy assay for lung carcinoma using centrifuged supernatants from fine-needle aspiration specimens","googleId":"grujUqpfw64J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311974","googleCitationCount":19,"googleAuthor":"W Ye","doi":"10.1093/annonc/mdz102","elsevierAuthor":"Hannigan B.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-06-01","elsevierCoverDisplayDate":"1 June 2019","elsevierCitationCount":"13","altmetricAuthors":["B. Hannigan","W. Ye","M. Mehrotra","V. Lam","A. Bolivar","S. Zalles","B.A. Barkoh","D. Duose","P.C. Hu","R. Broaddus","J. Stewart","J. Heymach","L.J. Medeiros","I. Wistuba","R. Luthra","S. Roy-Chowdhuri"],"twitterCount":26,"altmetricId":57319578,"statusesArray":["1308428326151872514","1139131862385876992","1109916246517129218","1109843457823178752","1109543418567512069","1109206858676535296","1109184493892583424","1108706044715454464","1108465872174235649","1108464636796592133","1108408686412791808","1108400443993018369","1108389880596439041","1108380559842177024","1108369189943808001","1108366348768497666","1108348069614112769","1108336834214588416","1108335438815772672","1108333738449092610","1108323172607279104","1108318904487682049","1108312536347279360","1108244111910289408","1108241793630593024","1108212308394672128","1108210810097205254","1108204417122254850","1108200513475096576","1108198176568328193"]},{"title":"Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer","googleId":"lNFfQDkVvhIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419551171","googleCitationCount":21,"googleAuthor":"A Amatu","doi":"10.1093/annonc/mdz383","elsevierAuthor":"Amatu A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-11-01","elsevierCoverDisplayDate":"1 November 2019","elsevierCitationCount":"17","altmetricAuthors":["A. Amatu","A. Sartore-Bianchi","K. Bencardino","E.G. Pizzutilo","F. Tosi","S. Siena"],"twitterCount":32,"altmetricId":70762900,"statusesArray":["1203811679806599169","1201811351741579264","1200045122496421894","1199973141310783488","1199967539905908737","1199963245056016384","1199961630798430210","1199886907708264448","1199847909086416898","1199723521582100480","1199721387755048960","1199699504712302592","1199699097403437056","1199685804110614528","1199668568218054656","1199641620439871488","1199623848985088001","1199512810570469377","1199465524939370496","1199456737696374784","1199403447029776385","1199402232086716417","1199391362371723264","1199367229168467969","1199362353432846336","1199360015309688832","1199356697535483907","1199356250258997248","1199331355181670400","1199331126722084869","1199326298688098304","1199322957669122048","1199293664125739009","1199264384658419712","1196745826220924934"]},{"title":"Head and neck cancer prevention: from primary prevention to impact of clinicians on reducing burden","googleId":"dqOK4yydhNEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311706","googleCitationCount":22,"googleAuthor":"","doi":"10.1093/annonc/mdz084","elsevierAuthor":"Sabatini M.E.","publicationName":"British Journal of Cancer","elsevierCoverDate":"2020-02-04","elsevierCoverDisplayDate":"4 February 2020","elsevierCitationCount":"6","altmetricAuthors":["D. Hashim","E. Genden","M. Posner","M. Hashibe","P. Boffetta"],"twitterCount":12,"altmetricId":56641788,"statusesArray":["1357220529938259970","1357080777993957376","1357070278883495939","1357030593213714435","1272133192867147779","1222499390427787269","1138932671902552065","1138541171628748802","1138456378350166019","1131883043935989761","1130494697154068480","1130466051030806528","1130461982950400006","1103620263877459969"]},{"title":"IMpower133: Updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo)+ carboplatin+ etoposide in extensive-stage SCLC (ES-SCLC)","googleId":"xdN7rYsjtF8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419598702","googleCitationCount":30,"googleAuthor":"AS Mansfield","doi":"10.1093/annonc/mdz264","elsevierCitationCount":0,"altmetricAuthors":["M. Reck","S.V. Liu","A.S. Mansfield","T.S.K. Mok","A. Scherpereel","N. Reinmuth","M.C. Garassino","JCastro De Carpeno","R. Califano","M. Nishio","F. Orlandi","J A Alatorre Alexander","T.A. Leal","Y. Cheng","J.-S. Lee","S. Lam","M. McCleland","Y. Deng","S. Phan","L. Horn"],"twitterCount":0,"altmetricId":68818519,"statusesArray":[]},{"title":"De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study","googleId":"ZhfooX04w4QJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311937","googleCitationCount":26,"googleAuthor":"","doi":"10.1093/annonc/mdz055","elsevierAuthor":"Goldner M.","publicationName":"Future Oncology","elsevierCoverDate":"2020-07-01","elsevierCoverDisplayDate":"July 2020","elsevierCitationCount":"0","altmetricAuthors":["V. Guarneri","M.V. Dieci","G. Bisagni","A. Frassoldati","G.V. Bianchi","G.L. De Salvo","E. Orvieto","L. Urso","T. Pascual","L. Paré","P. Galván","M. Ambroggi","C.A. Giorgi","G. Moretti","G. Griguolo","R. Vicini","A. Prat","P.F. Conte"],"twitterCount":25,"altmetricId":55762168,"statusesArray":["1100386462200147968","1100249570351738881","1099600742246240256","1099001224844767234","1098713154664652800","1098698612312363008","1098562661397217280","1098481805018255360","1098479008277237760","1098462294508474368","1098388263016878080","1098358129501356033","1098355031294832640","1098351753068720133","1098349739819626497","1098341636856262656","1098339898946453504","1098339832680587265","1098335137123713024","1098333221199187968","1098331175175753736","1098328563756032000","1098264368842600449","1098181368775958529","1098161335664291840","1098132408149442560","1098129247565213697","1097989823170834432","1097952578002972672","1097946519217549312","1097930290528468993"]},{"title":"Tailored immunotherapy approach with nivolumab in advanced renal cell carcinoma (TITAN-RCC)","googleId":"a2ySe8Qr7Z8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604114","googleCitationCount":25,"googleAuthor":"MO Grimm","doi":"10.1093/annonc/mdz394.051","elsevierAuthor":"Ravi P.","publicationName":"JAMA Oncology","elsevierCoverDate":"2020-10-01","elsevierCoverDisplayDate":"October 2020","elsevierCitationCount":"4","altmetricAuthors":["M.-O. Grimm","M. Schmidinger","I. Duran Martinez","G. Schinzari","E. Esteban","M. Schmitz","U. Schumacher","G. Baretton","P. Barthelemy","B. Melichar","N. Charnley","D. Schrijvers","L. Albiges"],"twitterCount":0,"altmetricId":68179443,"statusesArray":[]},{"title":"Risk profiling based on p16 and HPV DNA more accurately predicts location of disease relapse in patients with oropharyngeal squamous cell carcinoma","googleId":"ueg1xNLivs4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311093","googleCitationCount":17,"googleAuthor":"JH Rasmussen","doi":"10.1093/annonc/mdz010","elsevierAuthor":"Dickinsoni A.","publicationName":"PLoS ONE","elsevierCoverDate":"2020-06-01","elsevierCoverDisplayDate":"June 2020","elsevierCitationCount":"0","altmetricAuthors":["J.H. Rasmussen","C. Grønhøj","K. Håkansson","J. Friborg","E. Andersen","G. Lelkaitis","J.P. Klussmann","C. Wittekindt","S. Wagner","I.R. Vogelius","C. von Buchwald"],"twitterCount":13,"altmetricId":54330471,"statusesArray":["1252719194703040520","1252550406107836416","1130085106406821889","1130069466665181185","1129991148829925377","1129835758855106561","1129820886079610880","1095766134672941056","1088102708010192896","1088084129353220102","1088066436029915136","1088064363775344640","1088062543833092102"]},{"title":"INVICTUS: a Phase III, interventional, double-blind, placebo-controlled study to assess the safety and efficacy of ripretinib as≥ 4th-line therapy in patients with …","googleId":"DYN4OGko_wYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604473","googleCitationCount":19,"googleAuthor":"H Gelderblom","doi":"10.1093/annonc/mdz394.087","elsevierCitationCount":0,"altmetricAuthors":["M. von Mehren","C. Serrano","S. Bauer","H. Gelderblom","S. George","M. Heinrich","P. Schöffski","J. Zalcberg","P. Chi","R.L. Jones","P. Reichardt","S. Attia","G. D’Amato","J. Meade","K. Shi","R. Ruiz-Soto","J.-Y. Blay"],"twitterCount":0,"altmetricId":94802418,"statusesArray":[]},{"title":"Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanoma","googleId":"2GN65pCEtmUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354067","googleCitationCount":13,"googleAuthor":"S Ugurel","doi":"10.1016/j.annonc.2019.09.005","elsevierAuthor":"Ugurel S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"January 2020","elsevierCitationCount":"11","altmetricAuthors":["S. Ugurel","D. Schadendorf","K. Horny","A. Sucker","S. Schramm","J. Utikal","C. Pföhler","R. Herbst","B. Schilling","C. Blank","J.C. Becker","A. Paschen","L. Zimmer","E. Livingstone","P.A. Horn","V. Rebmann"],"twitterCount":5,"altmetricId":73785388,"statusesArray":["1217370757937786881","1215429554740662272","1215368596039307265","1215367022176919552","1215227749004038145"]},{"title":"Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on adjuvant therapy","googleId":"jRlAdvzt20cJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604205","googleCitationCount":17,"googleAuthor":"","doi":"10.1093/annonc/mdz394.060","elsevierCitationCount":0,"altmetricAuthors":["C.L. Creutzberg","A. Leon-Castillo","S.M. de Boer","M.E. Powell","L.R. Mileshkin","H.J. Mackay","A. Leary","H.W. Nijman","N. Singh","P. Pollock","A. Fyles","C. Haie-Meder","V T H B M Smit","R.J. Edmondson","H. Putter","H.C. Kitchener","E.J. Crosbie","M. de Bruyn","R. Nout","T. Bosse"],"twitterCount":0,"altmetricId":69765980,"statusesArray":[]},{"title":"Advances in targeted alpha therapy for prostate cancer","googleId":"qeZvW6dmJH4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325850","googleCitationCount":14,"googleAuthor":"G De Vincentis","doi":"10.1093/annonc/mdz270","elsevierAuthor":"De Vincentis G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-11-01","elsevierCoverDisplayDate":"November 2019","elsevierCitationCount":"8","altmetricAuthors":["G. De Vincentis","W. Gerritsen","J.E. Gschwend","M. Hacker","V. Lewington","J.M. O’Sullivan","M. Oya","M. Pacilio","C. Parker","N. Shore","O. Sartor"],"twitterCount":15,"altmetricId":65058034,"statusesArray":["1222925879220850690","1219341908138438656","1219328146950033408","1216408825114349568","1210482335516377096","1210450435120742401","1166695736123240449","1165401328065175553","1164540799012474883","1163747861575733248","1163746659723022336","1163480205903589376","1163458154664996871","1163438223260913665","1162358676038062080"]},{"title":"Management of hepatocellular carcinoma in the time of COVID-19","googleId":"v5bGX8EiKCwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39304-2/abstract","googleCitationCount":17,"googleAuthor":"M Iavarone","statusesArray":[]},{"title":"Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of …","googleId":"MSh6nWxhVTkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311159","googleCitationCount":20,"googleAuthor":"L Danilova","doi":"10.1093/annonc/mdz019","elsevierAuthor":"Stein J.E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-04-01","elsevierCoverDisplayDate":"April 2019","elsevierCitationCount":"17","altmetricAuthors":["J.E. Stein","A. Soni","L. Danilova","T.R. Cottrell","T.F. Gajewski","F.S. Hodi","S. Bhatia","W.J. Urba","W.H. Sharfman","M. Wind-Rotolo","R. Edwards","E.J. Lipson","J.M. Taube"],"twitterCount":2,"altmetricId":54661642,"statusesArray":["1090271623628808193","1090257899979325440"]},{"title":"Final efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for …","googleId":"Ly-xjGYuG7wJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604412","googleCitationCount":16,"googleAuthor":"V Velcheti","doi":"10.1093/annonc/mdz394.081","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Epigenetic modulations and lineage plasticity in advanced prostate cancer","googleId":"UZi_jLmBMpwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420360348","googleCitationCount":13,"googleAuthor":"R Montironi","doi":"10.1016/j.annonc.2020.02.002","elsevierAuthor":"Ge R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-04-01","elsevierCoverDisplayDate":"April 2020","elsevierCitationCount":"9","altmetricAuthors":["R. Ge","Z. Wang","R. Montironi","Z. Jiang","M. Cheng","M. Santoni","K. Huang","F. Massari","X. Lu","A. Cimadamore","A. Lopez-Beltran","L. Cheng"],"twitterCount":9,"altmetricId":78094274,"statusesArray":["1275185223873986562","1245721193736482816","1244596380674514944","1244587805436608513","1244587753507033089","1244585417434976257","1244557209188683776","1243155834131152896","1242103340655312896"]},{"title":"Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer","googleId":"F6TcQAXKdLkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419390945","googleCitationCount":24,"googleAuthor":"A Lusque","doi":"10.1016/j.annonc.2019.11.006","elsevierAuthor":"Mosele F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-03-01","elsevierCoverDisplayDate":"March 2020","elsevierCitationCount":"11","altmetricAuthors":["F. Mosele","B. Stefanovska","A. Lusque","A. Tran Dien","I. Garberis","N. Droin","C. Le Tourneau","M.-P. Sablin","L. Lacroix","D. Enrico","I. Miran","C. Jovelet","I. Bièche","J.-C. Soria","F. Bertucci","H. Bonnefoi","M. Campone","F. Dalenc","T. Bachelot","A. Jacquet","M. Jimenez","F. André"],"twitterCount":0,"altmetricId":78607740,"statusesArray":[]},{"title":"Overall survival (OS) from the AURA3 phase III study: Osimertinib vs platinum-pemetrexed (plt-pem) in patients (pts) with EGFR T790M advanced non-small …","googleId":"52y4nZCSp3UJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419581212","googleCitationCount":17,"googleAuthor":"","doi":"10.1093/annonc/mdz437.001","elsevierAuthor":"Chiang C.L.","publicationName":"Targeted Oncology","elsevierCoverDate":"2020-08-01","elsevierCoverDisplayDate":"1 August 2020","elsevierCitationCount":"1","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer","googleId":"lS8eu5BjU1IJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419309998","googleCitationCount":21,"googleAuthor":"YX Feng","doi":"10.1093/annonc/mdy497","elsevierAuthor":"Sokol E.S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-01-01","elsevierCoverDisplayDate":"1 January 2019","elsevierCitationCount":"10","altmetricAuthors":["E.S. Sokol","Y.X. Feng","D.X. Jin","A. Basudan","A.V. Lee","J.M. Atkinson","J. Chen","P.J. Stephens","G.M. Frampton","P.B. Gupta","J.S. Ross","J.H. Chung","S. Oesterreich","S.M. Ali","R.J. Hartmaier"],"twitterCount":46,"altmetricId":51499493,"statusesArray":["1161219007946641409","1160977019758370821","1160716209387712513","1160667786340917249","1160591867911823361","1160585601843912704","1160575749084127235","1160575600181968896","1160323607979089921","1090309418833661955","1090264622207135750","1090262956078653441","1090155575751700480","1090153572837322752","1090099057748516864","1090065343916240896","1089993304844972035","1089989021336358913","1089945768537063424","1089900956035084288","1071237139445231618","1071139515874598912","1070671733240274945","1070584570532253697","1070571634145271813","1070520669715226626","1070487230366580737","1070442382901035010","1070410916343308289","1070390352849321984","1070383866530201602","1070370513472638977","1070359549163593728","1070351244135403520","1070349928059293696","1070348657990471680","1067073430422466560","1065734530898714625","1065688106001723392","1065581551570878466","1065574916131643393","1065535856801394688","1065523316033765378","1065461297930792961","1065337941936009216","1065322146539495424","1065279800384737280","1065236048551337984","1065234522982268928","1065233831366746113","1065232108724068357"]},{"title":"Incidence and mortality of nasopharyngeal carcinoma: interim analysis of a cluster randomized controlled screening trial (PRO-NPC-001) in southern China","googleId":"o7MGi_c7O-EJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419609750","googleCitationCount":14,"googleAuthor":"","doi":"10.1093/annonc/mdz231","elsevierAuthor":"Ji M.F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-10-01","elsevierCoverDisplayDate":"1 October 2019","elsevierCitationCount":"11","altmetricAuthors":["M.F. Ji","W. Sheng","W.M. Cheng","M.H. Ng","B.H. Wu","X. Yu","K.R. Wei","F.G. Li","S.F. Lian","P.P. Wang","W. Quan","L. Deng","X.H. Li","X.D. Liu","Y.L. Xie","S.J. Huang","S.X. Ge","S.L. Huang","X.J. Liang","S.M. He","H.W. Huang","S.L. Xia","P.S. Ng","H.L. Chen","S.H. Xie","Q. Liu","M.H. Hong","J. Ma","Y. Yuan","N.S. Xia","J. Zhang","S.M. Cao"],"twitterCount":19,"altmetricId":64484932,"statusesArray":["1201817443053768706","1201502867355578369","1201450977993342980","1197936810942500864","1197706667716227072","1197607103315283968","1197600779995140104","1197600488415383552","1197515218865262592","1197467960253788161","1197463681564475392","1157593076602482689","1157558911337226242","1157531775020797953","1157401818563055621","1157379672910548993","1157379087821869061","1157375840579129345","1157375650258477061"]},{"title":"Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer","googleId":"9rmS9po1tKgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325989","googleCitationCount":24,"googleAuthor":"","doi":"10.1093/annonc/mdz390","elsevierAuthor":"Tarazona N.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-11-01","elsevierCoverDisplayDate":"November 2019","elsevierCitationCount":"16","altmetricAuthors":["N. Tarazona","F. Gimeno-Valiente","V. Gambardella","S. Zuñiga","P. Rentero-Garrido","M. Huerta","S. Roselló","C. Martinez-Ciarpaglini","J.A. Carbonell-Asins","F. Carrasco","A. Ferrer-Martínez","G. Bruixola","T. Fleitas","J. Martín","R. Tébar-Martínez","D. Moro","J. Castillo","A. Espí","D. Roda","A. Cervantes"],"twitterCount":58,"altmetricId":67409608,"statusesArray":["1185931566544867328","1185499382512324609","1185497653465047040","1180859487286169600","1180503484212244481","1180500292720136193","1180476014918545408","1180439942679465985","1180394872760684544","1180385396221517824","1180326016306352128","1180325334354403329","1180223546964037632","1180221174384615424","1180205427063169025","1180205113362849793","1180191155809439744","1180182885879484417","1180170283400994817","1180166937688645642","1180155745289084928","1180120085849153537","1180111591217520640","1180111447029932033","1180110854454419457","1180105300046729216","1180105269017272326","1180101051262750720","1180100861579546625","1180100179321671681","1180098978462994432","1180096971853434881","1180096318758363142","1180094598439477248","1180090006020472837","1180089228568535040","1179857371516026880","1179744501348405248","1179559070040301568","1179543542156451841","1179503887637716992","1179444840540577792","1179424884423827458","1179409090755403777","1179408674734968832","1179406885562327040","1179200353859825664","1178638435306921984","1178601413762539520","1178562388750151680","1178521610761818112","1178451137797722112","1178444536546316288","1178425849600602112","1178312493522915328","1178219574937948161","1178213237759922177","1178211132772945921","1178209098292174848","1178208102941970432","1178197113617948673","1178193639098462208","1178050249555791872","1178000498315542528","1177990182404083712","1177983776095424512","1177975767893983232","1177962282556391424","1177962026515259392","1177961575220568068","1177960762247204864","1177960661176987648"]},{"title":"Triumph: primary efficacy of a phase II trial of trastuzumab (T) and pertuzumab (P) in patients (PTS) with metastatic colorectal cancer (mCRC) with HER2 …","googleId":"n9BfcJJvHrIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419587476","googleCitationCount":20,"googleAuthor":"Y Nakamura","doi":"10.1093/annonc/mdz246.004","elsevierCitationCount":0,"altmetricAuthors":["Y. Nakamura","W. Okamoto","T. Kato","H. Hasegawa","K. Kato","S. Iwasa","T. Esaki","Y. Komatsu","T. Masuishi","T. Nishina","S. Nomura","M. Fukui","S. Matsuda","A. Sato","S. Fujii","J.I. Odegaard","S. Olsen","T. Yoshino"],"twitterCount":0,"altmetricId":68179403,"statusesArray":[]},{"title":"The phase 3 KEYNOTE-181 study: pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer","googleId":"42c2AQFuvg0J","googleLink":"https://www.researchgate.net/profile/Gianluca_Masi/publication/334295334_O-013Impact_of_age_and_gender_on_safety_and_efficacy_of_first-line_FOLFOXIRIbevacizumab_in_mCRC_a_pooled_analysis_of_TRIBE_and_TRIBE2_studies/links/5dd2cbc3299bf1b74b4e18ec/O-013Impact-of-age-and-gender-on-safety-and-efficacy-of-first-line-FOLFOXIRI-bevacizumab-in-mCRC-a-pooled-analysis-of-TRIBE-and-TRIBE2-studies.pdf","googleCitationCount":19,"googleAuthor":"M Shah","statusesArray":[]},{"title":"MONARCH 2: overall survival of abemaciclib plus fulvestrant in patients with HR+, HER2-advanced breast cancer","googleId":"PVTN2slrZ5QJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603662","googleCitationCount":18,"googleAuthor":"J Sohn","doi":"10.1093/annonc/mdz394.006","elsevierCitationCount":0,"altmetricAuthors":["G.W. Sledge","M. Toi","P. Neven","J. Sohn","K. Inoue","X. Pivot","O. Burdaeva","M. Okera","N. Masuda","P.A. Kaufman","H. Koh","E.-M. Grischke","P.F. Conte","Y. Lu","S. Barriga","K. Hurt","M. Frenzel","S.R.D. Johnston","A. Llombart-Cussac"],"twitterCount":0,"altmetricId":67755513,"statusesArray":[]},{"title":"Efficacy and biomarker analysis of patients (pts) with advanced renal cell carcinoma (aRCC) with sarcomatoid histology (sRCC): Subgroup analysis from the …","googleId":"TuSfcSrt8BYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591268","googleCitationCount":17,"googleAuthor":"TK Choueiri","doi":"10.1093/annonc/mdz249.009","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patients","googleId":"FLQZU05i39wJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420398732","googleCitationCount":10,"googleAuthor":"Y Nakamura","doi":"10.1016/j.annonc.2020.05.031","elsevierAuthor":"Nakamura Y.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-09-01","elsevierCoverDisplayDate":"September 2020","elsevierCitationCount":"7","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Genomic and transcriptional heterogeneity of multifocal hepatocellular carcinoma","googleId":"6b-CHagAf4oJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311986","googleCitationCount":17,"googleAuthor":"J Yu","doi":"10.1093/annonc/mdz103","elsevierAuthor":"Huang A.","publicationName":"Signal Transduction and Targeted Therapy","elsevierCoverDate":"2020-12-01","elsevierCoverDisplayDate":"1 December 2020","elsevierCitationCount":"3","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Current status of immune checkpoint inhibition in early-stage NSCLC","googleId":"F5k74PO6DsAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341931289X","googleCitationCount":20,"googleAuthor":"","doi":"10.1093/annonc/mdz175","elsevierAuthor":"Vansteenkiste J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-08-01","elsevierCoverDisplayDate":"1 August 2019","elsevierCitationCount":"12","altmetricAuthors":["J. Vansteenkiste","E. Wauters","B. Reymen","C.J. Ackermann","S. Peters","D. De Ruysscher"],"twitterCount":6,"altmetricId":61322183,"statusesArray":["1270662134947430401","1270658099058073600","1270658039050383371","1168607692648304642","1135228169987022848","1134327163828809728"]},{"title":"ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer","googleId":"acxHqv6UDloJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420360415","googleCitationCount":16,"googleAuthor":"S Orlov","doi":"10.1016/j.annonc.2020.02.006","elsevierAuthor":"Planchard D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-05-01","elsevierCoverDisplayDate":"May 2020","elsevierCitationCount":"12","altmetricAuthors":["D. Planchard","N. Reinmuth","S. Orlov","J.R. Fischer","S. Sugawara","S. Mandziuk","D. Marquez-Medina","S. Novello","Y. Takeda","R. Soo","K. Park","M. McCleod","S.L. Geater","M. Powell","R. May","U. Scheuring","P. Stockman","D. Kowalski"],"twitterCount":30,"altmetricId":77044484,"statusesArray":["1258156150580805632","1257200071004901376","1257126277720363009","1257050471849537536","1256956942230192128","1256903137497100288","1256859454492065792","1256841739106758656","1256841521103622144","1256827952886460416","1256700131585515521","1256688557667823623","1256684126998011906","1256660246405185538","1256619000479412226","1256561148901634048","1256530917771878402","1256529400247586817","1256528534908125184","1256521194905440256","1256516927985459200","1256516449432199168","1256513113236451329","1256512885225926657","1256512095736266753","1256512094511529984","1256511962541932545","1256508617462702080","1256501192827469824","1256499750213496832","1256499475654246400"]},{"title":"An adaptive population enrichment phase III trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS trial)","googleId":"6Zw2I3UKrooJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419309810","googleCitationCount":21,"googleAuthor":"","doi":"10.1093/annonc/mdy464","elsevierAuthor":"Mehta C.R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-01-01","elsevierCoverDisplayDate":"1 January 2019","elsevierCitationCount":"14","altmetricAuthors":["C.R. Mehta","L. Liu","C. Theuer"],"twitterCount":16,"altmetricId":50255900,"statusesArray":["1118371717322280960","1118308948338204673","1118301279954984961","1103006154458828802","1102989284083154945","1102945513891078145","1102942370528743424","1102681467300261888","1102548988006449153","1102494052929466368","1102493909769281537","1092818762414338048","1092800045186011137","1078267332882059266","1078231560774733824","1078214478104166400","1055472569573347328","1055468182633435136"]},{"title":"Randomized phase III ANGEL study of rivoceranib (apatinib)+ best supportive care (BSC) vs placebo+ BSC in patients with advanced/metastatic gastric …","googleId":"1A8_QawQBrMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603947","googleCitationCount":19,"googleAuthor":"YK Kang","doi":"10.1093/annonc/mdz394.034","elsevierCitationCount":0,"altmetricAuthors":["Y.-K. Kang","W.K. Kang","M. Di Bartolomeo","I. Chau","H.H. Yoon","S. Cascinu","M.-H. Ryu","J.G. Kim","K.-W. Lee","S.C. Oh","A. Takashima","A. Kryzhanivska","Y. Chao","V. Vladimirov","L. Evesque","M. Schenker","A. McGinn","N. Sankar","L. Wyrwicz","N. Boku"],"twitterCount":0,"altmetricId":68179421,"statusesArray":[]},{"title":"A randomized phase III trial comparing primary tumor resection plus chemotherapy with chemotherapy alone in incurable stage IV colorectal cancer: Updated results …","googleId":"KI1-fpoSKj8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40538-1/abstract","googleCitationCount":18,"googleAuthor":"K Shitara","statusesArray":[]},{"title":"Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic …","googleId":"7hFAPDMoQdsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419309792","googleCitationCount":20,"googleAuthor":"G Bodoky","doi":"10.1093/annonc/mdy461","elsevierAuthor":"Yoshino T.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-01-01","elsevierCoverDisplayDate":"1 January 2019","elsevierCitationCount":"13","altmetricAuthors":["T. Yoshino","D.C. Portnoy","R. Obermannová","G. Bodoky","J. Prausová","R. Garcia-Carbonero","T. Ciuleanu","P. García-Alfonso","A.L. Cohn","E. Van Cutsem","K. Yamazaki","S. Lonardi","K. Muro","T.W. Kim","K. Yamaguchi","A. Grothey","J. O’Connor","J. Taieb","S.R. Wijayawardana","R.R. Hozak","F. Nasroulah","J. Tabernero"],"twitterCount":28,"altmetricId":49972736,"statusesArray":["1103888148457709569","1103709716239319042","1103611826217078784","1103578571073826816","1103347297604259841","1103340546980904961","1103309989605707777","1103309278004170752","1101350916005990400","1098481883707596800","1098445651212451840","1098371396743368705","1098330891175235585","1098328976454488072","1098258954767949825","1098243441107132416","1098237703093669889","1098235859470405632","1093575888812298240","1093423453015818241","1093269880537866240","1093236043527188482","1093208934809137152","1093186276507799553","1093172878105812993","1093167393642303493","1093166492433043456","1093164843685892098","1093162420078399488","1055653241919299586","1055623444480454656","1055549651112333312","1055528856650764288","1055523171049398281","1055497998329962496","1055494809513791488","1055481613113532417","1053600923874942981","1053599150393253888"]},{"title":"Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study","googleId":"ouf4Iu9Igh4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419417249","googleCitationCount":9,"googleAuthor":"R Kurzrock","doi":"10.1016/j.annonc.2019.11.018","elsevierAuthor":"Kurzrock R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-03-01","elsevierCoverDisplayDate":"March 2020","elsevierCitationCount":"9","altmetricAuthors":["R. Kurzrock","D.W. Bowles","H. Kang","F. Meric-Bernstam","J. Hainsworth","D.R. Spigel","R. Bose","H. Burris","C.J. Sweeney","M.S. Beattie","S. Blotner","K. Schulze","V. Cuchelkar","C. Swanton"],"twitterCount":57,"altmetricId":76348180,"statusesArray":["1347206619457671170","1331847912712769536","1331829814723039232","1301054124302139392","1300774829398855681","1300667636187979782","1300638298797346817","1300625426734342145","1300622630001586176","1300615129629827072","1283153184744255491","1283105248756867075","1283082193569329152","1283015973843415041","1282999410704687105","1282924192116006913","1282898397754621958","1282881966300250114","1282876739883020288","1282864700603031553","1234947181792108547","1233288900002668544","1233139706478702595","1233137536215789579","1233088839553617920","1233084302805676033","1233083179701063681","1231963763865051137","1231855243673133057","1231853139181129728","1231796541020569601","1231796464612974594","1231707980099391496","1231701634259931138","1231671874419073024","1231656428844220421","1231612901435301888","1231483324562051073","1231469133520351232","1231430772000772096","1231376416765349888","1231352407713386496","1231344766782255106","1231343623356153857","1231178850735923206","1231171930826432512","1231167824044838912","1231153205851181056","1231150004770934784","1231147033953808384","1231143355163324416","1231141600505540608","1231005537849860096","1230914577589665792","1230913892429090816","1230899985660563457","1230632251240501248","1230454191597944833","1230454011767197696","1230389222411915265","1230378372427124737","1230373507533561857","1230337576281702400","1230335302432149506","1230333880084779009","1230315488686665730","1230315171320492032","1230315113988739072","1230288554271617026","1230283103014309890","1230144390577807361"]},{"title":"Multicenter randomized controlled trial to evaluate the efficacy and tolerability of frozen gloves for the prevention of chemotherapy-induced peripheral …","googleId":"NPgTkgPAclkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354080","googleCitationCount":12,"googleAuthor":"F Mols","doi":"10.1016/j.annonc.2019.09.006","elsevierAuthor":"Beijers A.J.M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"January 2020","elsevierCitationCount":"10","altmetricAuthors":["A.J.M. Beijers","C.S. Bonhof","F. Mols","J. Ophorst","J. de Vos-Geelen","E.M.G. Jacobs","L.V. van de Poll-Franse","G. Vreugdenhil"],"twitterCount":2,"altmetricId":73788502,"statusesArray":["1298237476369133568","1215247383241596929"]},{"title":"Nivolumab (NIVO)+ low-dose ipilimumab (IPI) vs platinum-doublet chemotherapy (chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung …","googleId":"M1pTCaU6dAYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604357","googleCitationCount":15,"googleAuthor":"S Peters","doi":"10.1093/annonc/mdz394.075","elsevierAuthor":"Dong A.","publicationName":"Journal of Gene Medicine","elsevierCoverDate":"2021-02-01","elsevierCoverDisplayDate":"February 2021","elsevierCitationCount":"0","altmetricAuthors":["S. Peters","S.S. Ramalingam","L. Paz-Ares","R. Bernabe Caro","B. Zurawski","S.-W. Kim","A. Alexandru","L. Lupinacci","E. de la Mora Jimenez","H. Sakai","I. Albert","A. Vergnenegre","M. Reck","H. Borghaei","J.R. Brahmer","K.J. O’Byrne","W.J. Geese","P. Bhagavatheeswaran","F.E. Nathan","M.D. Hellmann"],"twitterCount":0,"altmetricId":68179412,"statusesArray":[]},{"title":"Pilot randomized trial of an electronic symptom monitoring intervention for hospitalized patients with cancer","googleId":"58qX7XXIVQgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341931021X","googleCitationCount":17,"googleAuthor":"RD Nipp","doi":"10.1093/annonc/mdy488","elsevierAuthor":"Nipp R.D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-02-01","elsevierCoverDisplayDate":"1 February 2019","elsevierCitationCount":"12","altmetricAuthors":["R.D. Nipp","A. El-Jawahri","M. Ruddy","C. Fuh","B. Temel","S.M. D'Arpino","B.J. Cashavelly","V.A. Jackson","D.P. Ryan","E.P. Hochberg","J.A. Greer","J.S. Temel"],"twitterCount":37,"altmetricId":56035411,"statusesArray":["1235522033171169282","1222478757828624386","1204801160504381440","1191530557601189888","1188565606750216192","1187728698432249857","1178495838022180866","1178004229321105408","1176827880619331585","1176730716496777216","1176730704173907968","1176715031687229440","1176710370079252481","1176630402057981953","1176606088776601600","1176602201348874242","1176599889351827457","1176590334308028417","1176587937716346883","1176563402593964033","1176533421528629251","1176511618039128068","1176509327881986048","1176508718009200641","1176508440576966661","1176505613603475456","1117657804574212097","1117655262674993152","1117363954534240256","1117355259448516608","1117350835871211520","1117341108957274112","1103275407166619648","1102831443816767488","1101651925613842432","1100378064561803268","1100373578892099585","1100361136594137089","1100337028703481856","1100322481183838208","1100269692244111360","1100263534695460864","1100153977843269633","1100152403830157312","1100147378164707328","1100127118346895360","1100116554442727424","1059748654901350401"]},{"title":"FORWARD I (GOG 3011): A phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus …","googleId":"yvVADTcEIYAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419592055","googleCitationCount":15,"googleAuthor":"N Colombo","doi":"10.1093/annonc/mdz250","elsevierAuthor":"Fabrizio D.A.","publicationName":"JAMA Oncology","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"0","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Anti-epidermal growth factor receptor (EGFR) monoclonal antibody combined with cisplatin and 5-fluorouracil in patients with metastatic nasopharyngeal …","googleId":"rrb4MMBTzvUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311160","googleCitationCount":18,"googleAuthor":"","doi":"10.1093/annonc/mdz020","elsevierAuthor":"Ning X.","publicationName":"Journal of Biochemical and Molecular Toxicology","elsevierCoverDate":"2020-07-01","elsevierCoverDisplayDate":"1 July 2020","elsevierCitationCount":"1","altmetricAuthors":["C. Zhao","J. Miao","G. Shen","J. Li","M. Shi","N. Zhang","G. Hu","X. Chen","X. Hu","S. Wu","J. Chen","X. Shao","L. Wang","F. Han","H. Mai","M.L.K. Chua","C. Xie"],"twitterCount":3,"altmetricId":54590126,"statusesArray":["1090278529814556672","1089933989811372034","1089770650112311296"]},{"title":"ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer","googleId":"2c57VdqfLgkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420421647","googleCitationCount":7,"googleAuthor":"V Serra","doi":"10.1016/j.annonc.2020.08.2102","elsevierAuthor":"Miller R.E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-12-01","elsevierCoverDisplayDate":"December 2020","elsevierCitationCount":"6","altmetricAuthors":["R.E. Miller","A. Leary","C.L. Scott","V. Serra","C.J. Lord","D. Bowtell","D.K. Chang","D.W. Garsed","J. Jonkers","J.A. Ledermann","S. Nik-Zainal","I. Ray-Coquard","S.P. Shah","X. Matias-Guiu","E.M. Swisher","L.R. Yates"],"twitterCount":14,"altmetricId":91494302,"statusesArray":["1363187757519171589","1362519870462713856","1362478289336606728","1335603850267381766","1328477180280508417","1320987539570716677","1313044922711367681","1312824190802817024","1312823190545207298","1312823161931608066","1312552932567592968","1312535939957186560","1312412141794844681","1312411887217315840","1312411027976278017","1312409975772401665","1312409838090096641"]},{"title":"Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy","googleId":"X3FpqKpxPOQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312438","googleCitationCount":22,"googleAuthor":"","doi":"10.1093/annonc/mdz139","elsevierAuthor":"Hamfjord J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-07-01","elsevierCoverDisplayDate":"1 July 2019","elsevierCitationCount":"14","altmetricAuthors":["J. Hamfjord","T.K. Guren","O. Dajani","J.S. Johansen","B. Glimelius","H. Sorbye","P. Pfeiffer","O.C. Lingjærde","K.M. Tveit","E.H. Kure","N. Pallisgaard","K.-L.G. Spindler"],"twitterCount":27,"altmetricId":60084286,"statusesArray":["1160186406704177152","1153611892310646784","1153544465992302593","1153528169896566784","1153429372424085504","1153347787670597633","1153346524887183360","1153336949916049409","1153287051212574720","1153270247585124352","1153259383234551809","1153226470715736064","1153223026353278976","1153221930910175232","1153216345506570244","1153211607742394369","1153165615806349312","1153079701927165952","1153067127521337346","1129661207290494977","1129359262805835777","1126880777898287106","1126305637724332032","1126304752956952576","1126255795522473984","1126224564097363970","1126197871672463360","1126185081276653569","1126179529599459328","1126178877364162565","1126178449033293824"]},{"title":"Meeting report from the joint IARC–NCI International cancer seminar series: a focus on colorectal cancer","googleId":"DsrZK-Rp-gUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311251","googleCitationCount":17,"googleAuthor":"MJ Gunter","doi":"10.1093/annonc/mdz044","elsevierAuthor":"Gunter M.J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-04-01","elsevierCoverDisplayDate":"April 2019","elsevierCitationCount":"8","altmetricAuthors":["M.J. Gunter","S. Alhomoud","M. Arnold","H. Brenner","J. Burn","G. Casey","A.T. Chan","A.J. Cross","E. Giovannucci","R. Hoover","R. Houlston","M. Jenkins","P. Laurent-Puig","U. Peters","D. Ransohoff","E. Riboli","R. Sinha","Z.K. Stadler","P. Brennan","S.J. Chanock"],"twitterCount":11,"altmetricId":55071294,"statusesArray":["1127778410309275649","1108055518113869827","1107090431739920384","1107056733212545025","1107040573855318016","1107040308582330370","1107027322497101826","1105946303455002632","1105945686435086337","1105845994996916224","1093448914953486337"]},{"title":"Pembrolizumab in microsatellite instability high cancers: Updated analysis of the phase II KEYNOTE-164 and KEYNOTE-158 studies","googleId":"swBGN60j_j8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419593863","googleCitationCount":15,"googleAuthor":"D Le","doi":"10.1093/annonc/mdz253","elsevierAuthor":"Gupta N.","publicationName":"Oncotarget","elsevierCoverDate":"2021-01-05","elsevierCoverDisplayDate":"5 January 2021","elsevierCitationCount":"0","altmetricAuthors":["L.A. Diaz","D. Le","M. Maio","P.A. Ascierto","R. Geva","D. Motola-Kuba","T. André","E. Van Cutsem","M. Gottfried","E. Elez","J.-P. Delord","D. Jäger","T.W. Kim","R. Guimbaud","T. Yoshino","M. Chen","K. Norwood","P. Marinello","A. Marabelle"],"twitterCount":0,"altmetricId":69537240,"statusesArray":[]},{"title":"Initial results from TROPHY-U-01: A phase II open-label study of sacituzumab govitecan in patients (Pts) with metastatic urothelial cancer (mUC) after failure of …","googleId":"iIQVL6SPcWkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604096","googleCitationCount":15,"googleAuthor":"N Agarwal","doi":"10.1093/annonc/mdz394.049","elsevierAuthor":"Cardillo T.M.","publicationName":"Oncotarget","elsevierCoverDate":"2020-10-27","elsevierCoverDisplayDate":"27 October 2020","elsevierCitationCount":"0","altmetricAuthors":["S.T. Tagawa","A. Balar","D.P. Petrylak","P. Grivas","N. Agarwal","C.N. Sternberg","Q. Hong","A. Gladden","C. Kanwal","P. Siemon-Hryczyk","T. Goswami","L.M. Itri","Y. Loriot"],"twitterCount":0,"altmetricId":68179460,"statusesArray":[]},{"title":"Perioperative chemotherapy of oxaliplatin combined with S-1 (SOX) versus postoperative chemotherapy of SOX or oxaliplatin with capecitabine (XELOX) in …","googleId":"Nyb_mj5OEWoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603935","googleCitationCount":20,"googleAuthor":"","doi":"10.1093/annonc/mdz394.033","elsevierAuthor":"Ikegame K.","publicationName":"Japanese Journal of Cancer and Chemotherapy","elsevierCoverDate":"2020-04-01","elsevierCoverDisplayDate":"April 2020","elsevierCitationCount":"0","altmetricAuthors":["J. Ji","L. Shen","Z. Li","X. Zhang","H. Liang","Y. Xue","Y. Wang","Z. Zhou","J. Yu","L. Chen","Y. Du","G. Li","G. Xiao","D. Wu","Y. Zhou","C. Dang","Y. He","Z. Zhang","Y. Sun","Y. Li"],"twitterCount":0,"altmetricId":68179425,"statusesArray":[]},{"title":"Differential effects of an electronic symptom monitoring intervention based on the age of patients with advanced cancer","googleId":"NKeaDsv_3u4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354043","googleCitationCount":11,"googleAuthor":"RD Nipp","doi":"10.1016/j.annonc.2019.09.003","elsevierAuthor":"Nipp R.D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"January 2020","elsevierCitationCount":"5","altmetricAuthors":["R.D. Nipp","N.K. Horick","A.M. Deal","L.J. Rogak","C. Fuh","J.A. Greer","A.C. Dueck","E. Basch","J.S. Temel","A. El-Jawahri"],"twitterCount":47,"altmetricId":73769182,"statusesArray":["1271430454281977856","1236075319079002112","1220456456979472403","1220445318489178112","1219881568740823040","1219472496107442177","1219184456734593024","1218186693343358976","1217280250243158016","1217277859875708928","1217268492598161410","1215909185113726977","1215745052170956805","1215626076090748928","1215622534286184448","1215452671236300801","1215416198537588736","1215400397029945344","1215343983771226112","1215330261941899264","1215326406714019848","1215283850823262209","1215255147342778373","1215242361309147137","1215234952507404288","1215233502423257099","1215214963318513665","1215192212440567809","1215187468217135105","1215174006468419584","1215171594634461184","1215171577010171904","1215170236313288704","1215170202150887427","1215168991506944000","1215161907075780610","1215146542312624128","1215138932406378496","1215134905098809344","1215120042871808000","1215107141603921921","1215102712494333954","1215092536081108992","1215085865350754309","1215085781313699840","1215075232563679232","1215073349564616705","1215070371398942722","1215068085469749254","1215067599412908032","1215065227110289408","1215064086431588354"]},{"title":"Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib","googleId":"M-zIDvNotN8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375342032559X","googleCitationCount":12,"googleAuthor":"P Hammel","doi":"10.1093/annonc/mdz406","elsevierAuthor":"Hammel P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-12-01","elsevierCoverDisplayDate":"1 December 2019","elsevierCitationCount":"9","altmetricAuthors":["P. Hammel","H.L. Kindler","M. Reni","E. Van Cutsem","T. Macarulla","M.J. Hall","J.O. Park","D. Hochhauser","D. Arnold","D.-Y. Oh","A. Reinacher-Schick","G. Tortora","H. Algül","E.M. O’Reilly","D. McGuinness","K.Y. Cui","S. Joo","H.K. Yoo","N. Patel","T. Golan"],"twitterCount":10,"altmetricId":67471721,"statusesArray":["1288380840368640002","1225041534078328832","1224370694680653824","1224360729274454016","1222478792385495041","1178850608658305025","1178735907995881472","1178670982992662530","1178659207777832962","1178651906341773312","1178647769290039296","1178644227342962688","1178599688947322880"]},{"title":"Use of aspirin, other nonsteroidal anti-inflammatory drugs and acetaminophen and risk of endometrial cancer: the Epidemiology of Endometrial Cancer …","googleId":"I0p5ITwTiz4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310373","googleCitationCount":17,"googleAuthor":"PM Webb","doi":"10.1093/annonc/mdy541","elsevierAuthor":"Webb P.M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-02-01","elsevierCoverDisplayDate":"1 February 2019","elsevierCitationCount":"12","altmetricAuthors":["P.M. Webb","R. Na","E. Weiderpass","H.O. Adami","K.E. Anderson","K.A. Bertrand","E. Botteri","T.M. Brasky","L.A. Brinton","C. Chen","J.A. Doherty","L. Lu","S.E. McCann","K.B. Moysich","S. Olson","S. Petruzella","J.R. Palmer","A.E. Prizment","C. Schairer","V.W. Setiawan","A.B. Spurdle","B. Trabert","N. Wentzensen","L. Wilkens","H.P. Yang","H. Yu","H.A. Risch","S.J. Jordan"],"twitterCount":11,"altmetricId":54968060,"statusesArray":["1235521206436032512","1224346398448971776","1112834509454491648","1112566632621051904","1112513320873914368","1105054361305186305","1105023709788758016","1103611435962130432","1103588875249696768","1103477209686204417","1101933795899592704","1101831985465573376"]},{"title":"Characterizing diversity in the tumor-immune microenvironment of distinct subclasses of gastroesophageal adenocarcinomas","googleId":"tgqXxm9e9RMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420393108","googleCitationCount":7,"googleAuthor":"LK de Klerk","doi":"10.1016/j.annonc.2020.04.011","elsevierAuthor":"Derks S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-08-01","elsevierCoverDisplayDate":"August 2020","elsevierCitationCount":"5","altmetricAuthors":["S. Derks","L.K. de Klerk","X. Xu","T. Fleitas","K.X. Liu","Y. Liu","F. Dietlein","C. Margolis","A.M. Chiaravalli","A.C. Da Silva","S. Ogino","F.G. Akarca","G.J. Freeman","S.J. Rodig","J.L. Hornick","E. van Allen","B. Li","S.X. Liu","V. Thorsson","A.J. Bass"],"twitterCount":7,"altmetricId":81704783,"statusesArray":["1347409966265556994","1347197437794865152","1294176303797633024","1259786589066018816","1259165118979428353","1259162427754721284","1259151988203405314","1259144869211189254"]},{"title":"Recommendation for supportive care in patients receiving concurrent chemotherapy and radiotherapy for lung cancer","googleId":"2OoMY_m35EEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354092","googleCitationCount":12,"googleAuthor":"D De Ruysscher","doi":"10.1016/j.annonc.2019.10.003","elsevierAuthor":"De Ruysscher D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"January 2020","elsevierCitationCount":"9","altmetricAuthors":["D. De Ruysscher","C. Faivre-Finn","K. Nackaerts","K. Jordan","J. Arends","J.Y. Douillard","U. Ricardi","S. Peters"],"twitterCount":1,"altmetricId":73810341,"statusesArray":["1215437732194840578"]},{"title":"Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion","googleId":"SIU1amTP2bwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419551195","googleCitationCount":21,"googleAuthor":"EM O'reilly","doi":"10.1093/annonc/mdz385","elsevierAuthor":"O'Reilly E.M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-11-01","elsevierCoverDisplayDate":"1 November 2019","elsevierCitationCount":"17","altmetricAuthors":["E.M. O’Reilly","J.F. Hechtman"],"twitterCount":23,"altmetricId":68309417,"statusesArray":["1362413422881734657","1245291578895163394","1197230153094639616","1197178437137567744","1189886280588562433","1183936079390527493","1183776766789181440","1183764422428418048","1183724263003557889","1183715676734836737","1183704773662515200","1183669314920112128","1183640236804464640","1183625796801499136","1183625765000073217","1183624433455501313","1183598555975557120","1183564958279389184","1183559333738680320","1183546794745253889","1183518047962710016","1183517811076993025","1183498153250578432","1183452016850296832","1183431997953335301","1183397467200602118"]},{"title":"LBA43 spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600–mutant unresectable or metastatic …","googleId":"7WMCEEMWtEwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42355-5/abstract","googleCitationCount":12,"googleAuthor":"GV Long","statusesArray":[]},{"title":"A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal …","googleId":"rtNp8qsBolcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420399270","googleCitationCount":14,"googleAuthor":"S Park","doi":"10.1016/j.annonc.2020.06.017","elsevierAuthor":"Park S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-10-01","elsevierCoverDisplayDate":"October 2020","elsevierCitationCount":"8","altmetricAuthors":["S. Park","M.-H. Lee","M. Seong","S.T. Kim","J.-H. Kang","B.C. Cho","K.H. Lee","E.K. Cho","J.-M. Sun","S.-H. Lee","J.S. Ahn","K. Park","M.-J. Ahn"],"twitterCount":2,"altmetricId":85416306,"statusesArray":["1349699033736966146","1280805358416523266"]},{"title":"KRAS mutational status and efficacy in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as first-line therapy for …","googleId":"UIRHWToeoOoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420345506","googleCitationCount":13,"googleAuthor":"","doi":"10.1093/annonc/mdz453.002","elsevierCitationCount":0,"altmetricAuthors":["S. Gadgeel","D. Rodriguez-Abreu","E. Felip","E. Esteban","G. Speranza","M. Reck","R. Hui","M. Boyer","E.B. Garon","H. Horinouchi","R. Cristescu","D. Aurora-Garg","J. Lunceford","J. Kobie","M. Ayers","B. Piperdi","M.C. Pietanza","M.C. Garassino"],"twitterCount":0,"altmetricId":73140505,"statusesArray":[]},{"title":"5-year survival outcomes of the CheckMate 067 phase III trial of nivolumab plus ipilimumab (NIVO+ IPI) combination therapy in advanced melanoma","googleId":"3GXbb48SKIEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604254","googleCitationCount":11,"googleAuthor":"JMG Larkin","doi":"10.1093/annonc/mdz394.065","elsevierCitationCount":0,"altmetricAuthors":["J.M.G. Larkin","V. Chiarion-Sileni","R. Gonzalez","J.J. Grob","P. Rutkowski","C. Lao","C.L. Cowey","D. Schadendorf","J. Wagstaff","R. Dummer","P.F. Ferrucci","M. Smylie","D. Hogg","A. Hill","I. Marquez-Rodas","J B A G Haanen","J. Rizzo","A. Balogh","F.S. Hodi","J. Wolchok"],"twitterCount":0,"altmetricId":94102418,"statusesArray":[]},{"title":"Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for …","googleId":"uKQP4Wz61dgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325540","googleCitationCount":16,"googleAuthor":"","doi":"10.1093/annonc/mdz399","elsevierAuthor":"Yoshioka H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-12-01","elsevierCoverDisplayDate":"1 December 2019","elsevierCitationCount":"7","altmetricAuthors":["H. Yoshioka","M. Shimokawa","T. Seto","S. Morita","Y. Yatabe","I. Okamoto","J. Tsurutani","M. Satouchi","T. Hirashima","S. Atagi","K. Shibata","H. Saito","S. Toyooka","N. Yamamoto","K. Nakagawa","T. Mitsudomi"],"twitterCount":7,"altmetricId":67341095,"statusesArray":["1184011629190533121","1181309791794323457","1181151445103497216","1181150681840918529","1181144822297575424","1181144639811833856","1177577929536167936"]},{"title":"Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: REACHIN, a randomized, double-blind …","googleId":"5IIjn9Orx44J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420398392","googleCitationCount":10,"googleAuthor":"I Borbath","doi":"10.1016/j.annonc.2020.05.018","elsevierAuthor":"Demols A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-09-01","elsevierCoverDisplayDate":"September 2020","elsevierCitationCount":"8","altmetricAuthors":["A. Demols","I. Borbath","M. Van den Eynde","G. Houbiers","M. Peeters","R. Marechal","T. Delaunoit","J.-C. Goemine","S. Laurent","S. Holbrechts","M. Paesmans","J.-L. Van Laethem"],"twitterCount":3,"altmetricId":83005358,"statusesArray":["1266348109765971968","1266344285919739909","1266344160010829825"]},{"title":"Primary efficacy analysis results from the SORCE trial (RE05): Adjuvant sorafenib for renal cell carcinoma at intermediate or high risk of relapse: An …","googleId":"cZ5XBovNdmwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604102","googleCitationCount":14,"googleAuthor":"RS Kaplan","doi":"10.1093/annonc/mdz394.050","elsevierAuthor":"Greco F.","publicationName":"Current Drug Targets","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"1","altmetricAuthors":["T.Q.G. Eisen","E. Frangou","B. Smith","A. Ritchie","R.S. Kaplan","B. Oza","I.D. Davis","M.R. Stockler","L. Albiges","B. Escudier","J.M.G. Larkin","A. Bex","S. Joniau","B.W. Hancock","G.G. Hermann","J. Bellmunt","E. Hodgkinson","P. Hanlon","M.K.B. Parmar","A.M. Meade"],"twitterCount":1,"altmetricId":68179439,"statusesArray":["1337449566048751617"]},{"title":"Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients","googleId":"oxFPf2cdQdwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420359251","googleCitationCount":18,"googleAuthor":"A Algazi","doi":"10.1016/j.annonc.2019.12.008","elsevierAuthor":"Algazi A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-04-01","elsevierCoverDisplayDate":"April 2020","elsevierCitationCount":"14","altmetricAuthors":["A. Algazi","S. Bhatia","S. Agarwala","M. Molina","K. Lewis","M. Faries","L. Fong","L.P. Levine","M. Franco","A. Oglesby","C. Ballesteros-Merino","C.B. Bifulco","B.A. Fox","D. Bannavong","R. Talia","E. Browning","M.H. Le","R.H. Pierce","S. Gargosky","K.K. Tsai","C. Twitty","A.I. Daud"],"twitterCount":2,"altmetricId":77309255,"statusesArray":["1284042808081301504","1237443312149127168"]},{"title":"Timing of HPV16-E6 antibody seroconversion before OPSCC: findings from the HPVC3 consortium","googleId":"8FMktI4iiF8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312712","googleCitationCount":17,"googleAuthor":"","doi":"10.1093/annonc/mdz138","elsevierAuthor":"Kreimer A.R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-08-01","elsevierCoverDisplayDate":"1 August 2019","elsevierCitationCount":"12","altmetricAuthors":["A.R. Kreimer","A. Ferreiro-Iglesias","M. Nygard","N. Bender","L. Schroeder","A. Hildesheim","H.A. Robbins","M. Pawlita","H. Langseth","N.F. Schlecht","L.F. Tinker","I. Agalliu","S.W. Smoller","E. Ness-Jensen","K. Hveem","G. D’Souza","K. Visvanathan","B. May","G. Ursin","E. Weiderpass","G.G. Giles","R.L. Milne","Q. Cai","W.J. Blot","W. Zheng","S.J. Weinstein","D. Albanes","N. Brenner","J. Hoffman-Bolton","R. Kaaks","A. Barricarte","A. Tjønneland","C. Sacerdote","A. Trichopoulou","R.C.H. Vermeulen","W.-Y. Huang","N.D. Freedman","P. Brennan","T. Waterboer","M. Johansson"],"twitterCount":47,"altmetricId":61929719,"statusesArray":["1168847397419659264","1166695471441686529","1164646087493378049","1164449693860093952","1164417974893236224","1164370617497530369","1164357722969694208","1164282793549021191","1164224671539224577","1164205841555361792","1164167126510444545","1164165928101306369","1164162647052263425","1164161478615818246","1164161018274205696","1164160791232204800","1160084698216968192","1159948399682232320","1157660311207456770","1146196087822278657","1145584207130853376","1139830041309634562","1139284403476189184","1139281618139582475","1139269962646925313","1139187959238991872","1139174541404659712","1139157725823361024","1139106317900177408","1139017455177801728","1138910195634069505","1138907896387948544","1138905510676242433","1138873276921470977","1138872845851877376","1138867334406270976","1138840275990798338","1138835525194932224","1138787089116520448","1138783096726327298","1138770596584677376","1138767864675078144","1138757271289257986","1138752310992154625","1138751567497027584","1138743407323598848","1138725527798407168","1138724209469861889","1138723492550074368","1138723378364387330","1138720261220577280","1138717827693797376","1138716081424654336","1138715081934376960","1138714308974714880","1138711076869201920","1138596306069446657"]},{"title":"Insulin-like growth factor-1, insulin-like growth factor-binding protein-3, and breast cancer risk: observational and Mendelian randomization analyses with∼ …","googleId":"qSPVtGMofikJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420360191","googleCitationCount":16,"googleAuthor":"A Knuppel","doi":"10.1016/j.annonc.2020.01.066","elsevierAuthor":"Murphy N.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-05-01","elsevierCoverDisplayDate":"May 2020","elsevierCitationCount":"10","altmetricAuthors":["N. Murphy","A. Knuppel","N. Papadimitriou","R.M. Martin","K.K. Tsilidis","K. Smith-Byrne","G. Fensom","A. Perez-Cornago","R.C. Travis","T.J. Key","M.J. Gunter"],"twitterCount":14,"altmetricId":77320430,"statusesArray":["1239543072217858051","1239250037730926594","1239182948831604738","1239155207575089153","1237712019190689793","1237698636240297986","1237690948328488960","1237683453233172480","1237681272161525760","1237681230319104001","1237680037240938496","1237679852590968832","1237679814854746115","1237679456686419969","1237678994369150977","1237665899592679424","1237665318966788096","1237664546854244352","1237663977955561472"]},{"title":"Prognostic gene expression signature for high-grade serous ovarian cancer","googleId":"A2_DJVg4SMYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420398410","googleCitationCount":11,"googleAuthor":"J Millstein","doi":"10.1016/j.annonc.2020.05.019","elsevierAuthor":"Millstein J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-09-01","elsevierCoverDisplayDate":"September 2020","elsevierCitationCount":"5","altmetricAuthors":["J. Millstein","T. Budden","E.L. Goode","M.S. Anglesio","A. Talhouk","M.P. Intermaggio","H.S. Leong","S. Chen","W. Elatre","B. Gilks","T. Nazeran","M. Volchek","R.C. Bentley","C. Wang","D.S. Chiu","S. Kommoss","S.C.Y. Leung","J. Senz","A. Lum","V. Chow","H. Sudderuddin","R. Mackenzie","J. George","S. Fereday","J. Hendley","N. Traficante","H. Steed","J.M. Koziak","M. Köbel","I.A. McNeish","T. Goranova","D. Ennis","G. Macintyre","D. Silva De Silva","T. Ramón y Cajal","J. García-Donas","S. Hernando Polo","G.C. Rodriguez","K.L. Cushing-Haugen","H.R. Harris","C.S. Greene","R.A. Zelaya","S. Behrens","R.T. Fortner","P. Sinn","E. Herpel","J. Lester","J. Lubiński","O. Oszurek","A. Tołoczko","C. Cybulski","J. Menkiszak","C.L. Pearce","M.C. Pike","C. Tseng","J. Alsop","V. Rhenius","H. Song","M. Jimenez-Linan","A.M. Piskorz","A. Gentry-Maharaj","C. Karpinskyj","M. Widschwendter","N. Singh","C.J. Kennedy","R. Sharma","P.R. Harnett","B. Gao","S.E. Johnatty","R. Sayer","J. Boros","S.J. Winham","G.L. Keeney","S.H. Kaufmann","M.C. Larson","H. Luk","B.Y. Hernandez","P.J. Thompson","L.R. Wilkens","M.E. Carney","B. Trabert","J. Lissowska","L. Brinton","M.E. Sherman","C. Bodelon","S. Hinsley","L.A. Lewsley","R. Glasspool","S.N. Banerjee","E.A. Stronach","P. Haluska","I. Ray-Coquard","S. Mahner","B. Winterhoff","D. Slamon","D.A. Levine","L.E. Kelemen","J. Benitez","J. Chang-Claude","J. Gronwald","A.H. Wu","U. Menon","M.T. Goodman","J.M. Schildkraut","N. Wentzensen","R. Brown","A. Berchuck","G. Chenevix-Trench","A. deFazio","S.A. Gayther","M.J. García","M.J. Henderson","M.A. Rossing","A. Beeghly-Fadiel","P.A. Fasching","S. Orsulic","B.Y. Karlan","G.E. Konecny","D.G. Huntsman","D.D. Bowtell","J.D. Brenton","J.A. Doherty","P.D.P. Pharoah","S.J. Ramus","D. Bowtell","G. Chenevix-Trench","A. Green","P. Webb","A. DeFazio","D. Gertig","N. Traficante","S. Fereday","S. Moore","J. Hung","K. Harrap","T. Sadkowsky","N. Pandeya","M. Malt","A. Mellon","R. Robertson","T. Vanden Bergh","M. Jones","P. Mackenzie","J. Maidens","K. Nattress","Y.E. Chiew","A. Stenlake","H. Sullivan","B. Alexander","P. Ashover","S. Brown","T. Corrish","L. Green","L. Jackman","K. Ferguson","K. Martin","A. Martyn","B. Ranieri","J. White","V. Jayde","P. Mamers","L. Bowes","L. Galletta","D. Giles","J. Hendley","K. Alsop","T. Schmidt","H. Shirley","C. Ball","C. Young","S. Viduka","Hoa Tran","Sanela Bilic","Lydia Glavinas","Julia Brooks","R. Stuart-Harris","F. Kirsten","J. Rutovitz","P. Clingan","A. Glasgow","A. Proietto","S. Braye","G. Otton","J. Shannon","T. Bonaventura","J. Stewart","S. Begbie","M. Friedlander","D. Bell","S. Baron-Hay","A. Ferrier,a","G. Gard","D. Nevell","N. Pavlakis","S. Valmadre","B. Young","C. Camaris","R. Crouch","L. Edwards","N. Hacker","D. Marsden","G. Robertson","P. Beale","J. Beith","J. Carter","C. Dalrymple","R. Houghton","P. Russell","M. Links","J. Grygiel","J. Hill","A. Brand","K. Byth","R. Jaworski","P. Harnett","R. Sharma","G. Wain","B. Ward","D. Papadimos","A. Crandon","M. Cummings","K. Horwood","A. Obermair","L. Perrin","D. Wyld","J. Nicklin","M. Davy","M.K. Oehler","C. Hall","T. Dodd","T. Healy","K. Pittman","D. Henderson","J. Miller","J. Pierdes","P. Blomfield","D. Challis","R. McIntosh","A. Parker","B. Brown","R. Rome","D. Allen","P. Grant","S. Hyde","R. Laurie","M. Robbie","D. Healy","T. Jobling","T. Manolitsas","J. McNealage","P. Rogers","B. Susil","E. Sumithran","I. Simpson","K. Phillips","D. Rischin","S. Fox","D. Johnson","S. Lade","M. Loughrey","N. O’Callaghan","W. Murray","P. Waring","V. Billson","J. Pyman","D. Neesham","M. Quinn","C. Underhill","R. Bell","L.F. Ng","R. Blum","V. Ganju","I. Hammond","Y. Leung","A. McCartney","M. Buck","I. Haviv","D. Purdie","D. Whiteman","N. Zeps"],"twitterCount":20,"altmetricId":83144282,"statusesArray":["1341643169193099265","1321556111850430466","1319007590618222592","1318931572163284998","1318930757092593666","1316144207497756672","1315657610910146563","1315620630331498497","1315597292506759168","1315594308389543936","1313843656047161351","1304326439911583746","1304178045608230912","1297821765721350146","1297790702999482369","1297185913378877441","1295632134116261889","1295572261097807877","1295469948286820352","1295430260821905408","1295427114762551296","1280804693736853504","1270345969289375745","1267034481996652550"]},{"title":"Simultaneous multi-cancer detection and tissue of origin (TOO) localization using targeted bisulfite sequencing of plasma cell-free DNA (cfDNA)","googleId":"BzXj6JTEc9EJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604345","googleCitationCount":14,"googleAuthor":"GR Oxnard","doi":"10.1093/annonc/mdz394.074","elsevierCitationCount":0,"altmetricAuthors":["G.R. Oxnard","E.A. Klein","M.V. Seiden","E. Hubbell","O. Venn","A. Jamshidi","N. Zhang","J.F. Beausang","S. Gross","K.N. Kurtzman","E.T. Fung","B. Allen","A.P. Fields","H. Liu","M.A. Sekeres","D.A. Richards","P.P. Yu","A.M. Aravanis","A.-R. Hartman","M.C. Liu"],"twitterCount":1,"altmetricId":67530415,"statusesArray":["1187166348260102144","1181256934630072320","1180092756120788992","1179048106224164864","1179034183190138880","1179033931074723840"]},{"title":"EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort …","googleId":"DKytDmeaZZMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325928","googleCitationCount":21,"googleAuthor":"J Bellmunt","doi":"10.1093/annonc/mdz296","elsevierAuthor":"Horwich A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-11-01","elsevierCoverDisplayDate":"November 2019","elsevierCitationCount":"15","altmetricAuthors":["A. Horwich","M. Babjuk","J. Bellmunt","H.M. Bruins","T.M. De Reijke","M. De Santis","S. Gillessen","N. James","S. Maclennan","J. Palou","T. Powles","M.J. Ribal","S.F. Shariat","T. Van Der Kwast","E. Xylinas","N. Agarwal","T. Arends","A. Bamias","A. Birtle","P.C. Black","B.H. Bochner","M. Bolla","J.L. Boormans","A. Bossi","A. Briganti","I. Brummelhuis","M. Burger","D. Castellano","R. Cathomas","A. Chiti","A. Choudhury","E. Compérat","S. Crabb","S. Culine","B. De Bari","W. DeBlok","P.J.L. De Visschere","K. Decaestecker","K. Dimitropoulos","J.L. Dominguez-Escrig","S. Fanti","V. Fonteyne","M. Frydenberg","J.J. Futterer","G. Gakis","B. Geavlete","P. Gontero","B. Grubmüller","S. Hafeez","D.E. Hansel","A. Hartmann","D. Hayne","A.M. Henry","V. Hernandez","H. Herr","K. Herrmann","P. Hoskin","J. Huguet","B.A. Jereczek-Fossa","R. Jones","A.M. Kamat","V. Khoo","A.E. Kiltie","S. Krege","S. Ladoire","P.C. Lara","A. Leliveld","E. Linares-Espinós","V. Løgager","A. Lorch","Y. Loriot","R. Meijer","M. Carmen Mir","M. Moschini","H. Mostafid","A.-C. Müller","C.R. Müller","J. N’Dow","A. Necchi","Y. Neuzillet","J.R. Oddens","J. Oldenburg","S. Osanto","W.J.G. Oyen","L. Pacheco-Figueiredo","H. Pappot","M.I. Patel","B.R. Pieters","K. Plass","M. Remzi","M. Retz","J. Richenberg","M. Rink","F. Roghmann","J.E. Rosenberg","M. Rouprêt","O. Rouvière","C. Salembier","A. Salminen","P. Sargos","S. Sengupta","A. Sherif","R.J. Smeenk","A. Smits","A. Stenzl","G.N. Thalmann","B. Tombal","B. Turkbey","S. Vahr Lauridsen","R. Valdagni","A.G. Van Der Heijden","H. Van Poppel","M.D. Vartolomei","E. Veskimäe","A. Vilaseca","F.A. Vives Rivera","T. Wiegel","P. Wiklund","A. Williams","R. Zigeuner","J.A. Witjes"],"twitterCount":98,"altmetricId":70779014,"statusesArray":["1220735333769392128","1220587285231685633","1220585058144325635","1220432430311583751","1220432286178594816","1219333468129087488","1219327458471751683","1212580968420147202","1210556372800167937","1210506542375677954","1210457666021199872","1202146343424339968","1201832295495168001","1201806600400453633","1201649648286535681","1201572833924657152","1201558562633334785","1201557942153228288","1201248934519287808","1200479802416713728","1199697544495845378","1199696881020002304","1198993409270255616","1197681102984556546","1197630389021491201","1197535337679138816","1197465511023517697","1197449734752890882","1197426749866422272","1197391401371217920","1197350467761836032","1197281032480968704","1197280634730881026","1197280471794749441","1197271716386484224","1197260908290039810","1197219574585925634","1197192864322727936","1197176812255662081","1197174247212208130","1197164906954592256","1197154665542144001","1197153299004346369","1197145515491823618","1197143971241349120","1197143814336589826","1197133444440117248","1197122076282363905","1197121987719696386","1197121767514488832","1197120633278210048","1197119855654244352","1197117669633339393","1197112535394246658","1197107016575201281","1197103480164507648","1197097697297068032","1197094791047200769","1197078321890308096","1197071117208317952","1197060409511030786","1197048510081884160","1197042177899143168","1197039599937347584","1197037593231278080","1197037572914139137","1197032242381574144","1197032114656546816","1197027553409740801","1197025860299177984","1197023773444186112","1197010146855018496","1196983052242739202","1196956785166319616","1196954069765623808","1196953984222691328","1196937464163848198","1196934925192175616","1196930053415874567","1196930052962836480","1196925944784719872","1196921805149265920","1196919920539373568","1196894015460954112","1196892266473967618","1196889834612297728","1196885497404153857","1196883089051439104","1196875546883440647","1196869494024671236","1196868443603161088","1196868400066301952","1196862883214348288","1196861972689629185","1196860183600869376","1196851536032411650","1196848640901484546","1196847474113155073","1196846330536243200","1196842341283368961"]},{"title":"Does androgen deprivation therapy protect against severe complications from COVID-19?","googleId":"R1H_v4qaLfQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39933-6/abstract","googleCitationCount":13,"googleAuthor":"X Zhong","statusesArray":[]},{"title":"Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK+ NSCLC: Updated results from the phase III ALTA-1L trial","googleId":"3LMeyIHHBPYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419582254","googleCitationCount":14,"googleAuthor":"HR Kim","doi":"10.1093/annonc/mdz446","elsevierAuthor":"Nault J.C.","publicationName":"Hepatology","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"January 2021","elsevierCitationCount":"4","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB)≥ 10: a decision centered on empowering patients and their …","googleId":"D7CdjGBq4Q4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534%2820%2939936-1/fulltext","googleCitationCount":13,"googleAuthor":"V Subbiah","statusesArray":[]},{"title":"Cancer mortality in Europe in 2015 and an overview of trends since 1990","googleId":"DmXfIFSav7MJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312931","googleCitationCount":12,"googleAuthor":"P Bertuccio","doi":"10.1093/annonc/mdz179","elsevierAuthor":"Bertuccio P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-08-01","elsevierCoverDisplayDate":"1 August 2019","elsevierCitationCount":"12","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Integrating postradiotherapy plasma Epstein–Barr virus DNA and TNM stage for risk stratification of nasopharyngeal carcinoma to adjuvant therapy","googleId":"07zg0H1-SUYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420363766","googleCitationCount":10,"googleAuthor":"BB Ma","doi":"10.1016/j.annonc.2020.03.289","elsevierAuthor":"Hui E.P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-06-01","elsevierCoverDisplayDate":"June 2020","elsevierCitationCount":"4","altmetricAuthors":["E.P. Hui","W.F. Li","B.B. Ma","W.K.J. Lam","K.C.A. Chan","F. Mo","Q.Y.H. Ai","A.D. King","C.H. Wong","R. Guo","D.M.C. Poon","M. Tong","L. Li","T.K.H. Lau","K.C.W. Wong","D.C.M. Lam","Y.M.D. Lo","J. Ma","A.T.C. Chan"],"twitterCount":1,"altmetricId":78569388,"statusesArray":["1244333378695880704"]},{"title":"Prophylactic irradiation to the contralateral breast for BRCA mutation carriers with early-stage breast cancer","googleId":"Ss2zX1CeqbQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310749","googleCitationCount":18,"googleAuthor":"AM Ben-David","doi":"10.1093/annonc/mdy515","elsevierAuthor":"Evron E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-03-01","elsevierCoverDisplayDate":"1 March 2019","elsevierCitationCount":"15","altmetricAuthors":["E. Evron","A.M. Ben-David","H. Goldberg","G. Fried","B. Kaufman","R. Catane","M.R. Pfeffer","D.B. Geffen","P. Chernobelsky","T. Karni","R. Abdah-Bortnyak","O. Rosengarten","D. Matceyevsky","M. Inbar","A. Kuten","B.W. Corn"],"twitterCount":35,"altmetricId":51816640,"statusesArray":["1195167228733349888","1195105169660416001","1195102539433172992","1194832135636471809","1163980871172575233","1163774782913097728","1141234327453413376","1130914196663615488","1130903991792164864","1130903045276147712","1130866059588841477","1130863259979001861","1076196820420911104","1076038656517984257","1075492084218503168","1069940067131645954","1068814499464007680","1068813758678605824","1068355860227747840","1068079415983259649","1068076046191345664","1068074588796592129","1067865632455237633","1067807061520654336","1067738090402402304","1067693183897882624","1067654512620367872","1067637970486874112","1067565883915202560","1067492666143895553","1067481490370498560","1067415790385864704","1067412694096072706","1067410043149012992","1067400204528349185","1067395799909392384","1067394177166688256"]},{"title":"CDK12-altered prostate cancer: clinical features and therapeutic outcomes to standard systemic therapies, PARP inhibitors, and PD1 inhibitors","googleId":"-U42AytoZk0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419590615","googleCitationCount":14,"googleAuthor":"ES Antonarakis","doi":"10.1093/annonc/mdz248.002","elsevierCitationCount":0,"altmetricAuthors":["E.S. Antonarakis","P Isaacsson Velho","N. Agarwal","V Sacristan Santos","B.L. Maughan","R. Pili","N. Adra","C.N. Sternberg","P.J. Vlachostergios","S.T. Tagawa","A.H. Bryce","A.L. McNatty","Z.R. Reichert","R. Dreicer","O. Sartor","T.L. Lotan","M. Hussain"],"twitterCount":15,"altmetricId":71393076,"statusesArray":["1201559627990585345","1201559358137454592","1201473810664431622","1201153317851795458","1200987188206301184","1200941148367413254","1200867996618698752","1200805619911057408","1200661982153601024","1200650758158467073","1200601216650231808","1200513131648372736","1200494028174823426","1200491570958602242","1200487728959246337"]},{"title":"Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer","googleId":"FfvSFLjg4xsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420424652","googleCitationCount":8,"googleAuthor":"","doi":"10.1016/j.annonc.2020.09.015","elsevierAuthor":"Lin J.J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-12-01","elsevierCoverDisplayDate":"December 2020","elsevierCitationCount":"6","altmetricAuthors":["J.J. Lin","S.V. Liu","C.E. McCoach","V.W. Zhu","A.C. Tan","S. Yoda","J. Peterson","A. Do","K. Prutisto-Chang","I. Dagogo-Jack","L.V. Sequist","L.J. Wirth","J.K. Lennerz","A.N. Hata","M. Mino-Kenudson","V. Nardi","S.-H.I. Ou","D.S.-W. Tan","J.F. Gainor"],"twitterCount":6,"altmetricId":91691228,"statusesArray":["1351294176487383041","1351182044492140549","1351181390495297543","1345386625904373763","1313860251884625920","1312332586111299584"]},{"title":"Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK …","googleId":"XQR-ImLJkfIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325953","googleCitationCount":29,"googleAuthor":"HJ Lenz","doi":"10.1093/annonc/mdz387","elsevierAuthor":"Stintzing S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-11-01","elsevierCoverDisplayDate":"November 2019","elsevierCitationCount":"14","altmetricAuthors":["S. Stintzing","P. Wirapati","H.-J. Lenz","D. Neureiter","L. Fischer von Weikersthal","T. Decker","A. Kiani","F. Kaiser","S. Al-Batran","T. Heintges","C. Lerchenmüller","C. Kahl","G. Seipelt","F. Kullmann","M. Moehler","W. Scheithauer","S. Held","D.P. Modest","A. Jung","T. Kirchner","D. Aderka","S. Tejpar","V. Heinemann"],"twitterCount":48,"altmetricId":70346696,"statusesArray":["1210850788500787200","1210652659314810880","1210627681307570176","1210627609484288000","1210529703670484993","1197929956401188866","1197923809010929664","1197493673300238336","1197374827297939456","1197319391756595200","1197280320934031363","1197248103352393728","1197240203225845760","1197208966801039362","1197183072774565894","1197176717221064706","1197176297455116288","1197176271697932288","1197000569342304256","1196911142884372480","1196904111687557121","1196857829908500483","1196811274694168576","1196776615608500224","1196729096367030272","1196728111704027136","1196721358584999936","1196719492987904002","1196697451606007809","1196563093297471488","1196529790930636800","1196508372943671296","1196505838682173440","1196504291579703297","1196502357242195974","1196500174945673218","1196481285058781185","1196479959730184192","1196479560960937990","1196112107277864960","1195621038123552768","1195619760161132545","1195489481018753025","1195392876185821184","1195391809620496386","1195381475203411969","1195380693406076928","1195316221677391872","1195314900769419273","1195107973959503872","1195049221352820738","1195043278502191104"]},{"title":"Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer","googleId":"WI68VFTWPK4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310798","googleCitationCount":18,"googleAuthor":"R Sundar","doi":"10.1093/annonc/mdy550","elsevierAuthor":"Sundar R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-03-01","elsevierCoverDisplayDate":"1 March 2019","elsevierCitationCount":"14","altmetricAuthors":["R. Sundar","K.K. Huang","A. Qamra","K.-M. Kim","S.T. Kim","W.K. Kang","A.L.K. Tan","J. Lee","P. Tan"],"twitterCount":18,"altmetricId":53743119,"statusesArray":["1146720479429976064","1117645256642715648","1116307034779996160","1116282820232732672","1116256727043854336","1116206880890601472","1116154613625950209","1115984222504804353","1115977771992223744","1085803674260000769","1085591416812625920","1085582455065595904","1083566915107336193","1083553371124944896","1083519437309804545","1083515090761105409","1083506820948287488","1083383626039881728","1083381880806952960","1083380374745436160"]},{"title":"Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAFv600 mutation–positive melanoma …","googleId":"9xXOv_5K8hAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354079","googleCitationCount":9,"googleAuthor":"PA Ascierto","doi":"10.1016/j.annonc.2019.10.002","elsevierAuthor":"Ascierto P.A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"January 2020","elsevierCitationCount":"8","altmetricAuthors":["P.A. Ascierto","K.D. Lewis","A.M. Di Giacomo","L. Demidov","M. Mandalà","I. Bondarenko","C. Herbert","A. Mackiewicz","P. Rutkowski","A. Guminski","B. Simmons","C. Ye","G. Hooper","M.J. Wongchenko","G.R. Goodman","Y. Yan","D. Schadendorf"],"twitterCount":3,"altmetricId":73785490,"statusesArray":["1215332068420390912","1215235024653443073","1215227750652317696"]},{"title":"Clinicopathological and genomic correlates of programmed cell death ligand 1 (PD-L1) expression in nonsquamous non-small-cell lung cancer","googleId":"aLbkOt9viK0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420360786","googleCitationCount":12,"googleAuthor":"G Lamberti","doi":"10.1016/j.annonc.2020.02.017","elsevierAuthor":"Lamberti G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-06-01","elsevierCoverDisplayDate":"June 2020","elsevierCitationCount":"5","altmetricAuthors":["G. Lamberti","L.F. Spurr","Y. Li","B. Ricciuti","G. Recondo","R. Umeton","M. Nishino","L.M. Sholl","M.L. Meyerson","A.D. Cherniack","M.M. Awad"],"twitterCount":41,"altmetricId":80802828,"statusesArray":["1257311709284298755","1256760538211643393","1256604392150536193","1256593453082988545","1256439204034166784","1256063753621307392","1256009044562546688","1255985911399018496","1255877080845373442","1255832542483267584","1255784348453867522","1255756596300460034","1255749292041670656","1255711910412107780","1255695274774839299","1255658292237352961","1255639897832132614","1255634847479074824","1255609009073201161","1255608902017744897","1255607890104246272","1255607866406436870","1255607491330740225","1255587481665273858","1255586209742667779","1255585593280659457","1255575003652935683","1255569700903411713","1255528931668697088","1255527014343327744","1255523699744178179","1255522959483166725","1255517146790219784","1255483758893023234","1255480394046201857","1255470704469979143","1255440104082071553","1255439866952892424","1255429410938896384","1255414237154992128","1255324312258654210","1255323969466630145","1255322600131244033","1255321439328141314"]},{"title":"A systematic review and meta-analysis of the 2007 WCRF/AICR score in relation to cancer-related health outcomes","googleId":"J8z9-MWXHUsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420319219","googleCitationCount":12,"googleAuthor":"","doi":"10.1016/j.annonc.2020.01.001","elsevierAuthor":"Solans M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-03-01","elsevierCoverDisplayDate":"March 2020","elsevierCitationCount":"10","altmetricAuthors":["M. Solans","D.S.M. Chan","P. Mitrou","T. Norat","D. Romaguera"],"twitterCount":4,"altmetricId":76343934,"statusesArray":["1230515432492294145","1230382048747147264","1230346906091565056","1230125392779862016"]},{"title":"3-year relapse-free survival (RFS), overall survival (OS) and long-term toxicity of (neo) adjuvant ipilimumab (IPI)+ nivolumab (NIVO) in macroscopic stage III …","googleId":"EIlLpk01leoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419595242","googleCitationCount":13,"googleAuthor":"CU Blank","doi":"10.1093/annonc/mdz255.003","elsevierAuthor":"Fountzila E.","publicationName":"ecancermedicalscience","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"0","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non …","googleId":"E7cPqiQtX3UJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375342034549X","googleCitationCount":12,"googleAuthor":"RS Herbst","doi":"10.1093/annonc/mdz453.001","elsevierCitationCount":0,"altmetricAuthors":["R.S. Herbst","G. Lopes","D.M. Kowalski","K. Kasahara","Y.-L. Wu","G. De Castro","B.C. Cho","H.Z. Turna","R. Cristescu","D. Aurora-Garg","J. Lunceford","J. Kobie","M. Ayers","M.C. Pietanza","B. Piperdi","T.S.K. Mok"],"twitterCount":2,"altmetricId":73717671,"statusesArray":["1214588722727018503","1214588049952256000"]},{"title":"Phase II/III blood first assay screening trial (BFAST) in patients (pts) with treatment-naïve NSCLC: Initial results from the ALK+ cohort","googleId":"QDf00-oG_A0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604394","googleCitationCount":17,"googleAuthor":"S Peters","doi":"10.1093/annonc/mdz394.079","elsevierCitationCount":0,"altmetricAuthors":["S.M. Gadgeel","T.S.K. Mok","S. Peters","J.A.A. Alexander","N.B. Leighl","V. Sriuranpong","M. Perol","G. De Castro","E. Nadal","F. De Marinis","J.-Y. Han","M. Yan","T. Riehl","E. Schleifman","S.M. Paul","S. Mocci","D. Shames","M.S. Mathisen","R. Dziadziuszko"],"twitterCount":0,"altmetricId":68179415,"statusesArray":[]},{"title":"Phase III randomized study of neoadjuvant chemotherapy (CT) with docetaxel (D), oxaliplatin (O) and S-1 (S)(DOS) followed by surgery and adjuvant S-1, vs …","googleId":"Td3McEwog0kJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603923","googleCitationCount":16,"googleAuthor":"YK Kang","doi":"10.1093/annonc/mdz394.032","elsevierAuthor":"Oshima T.","publicationName":"Oncotarget","elsevierCoverDate":"2020-07-28","elsevierCoverDisplayDate":"28 July 2020","elsevierCitationCount":"0","altmetricAuthors":["Y.-K. Kang","J.H. Yook","Y.-K. Park","Y.-W. Kim","J. Kim","M.-H. Ryu","S.Y. Rha","I.-J. Chung","I.-H. Kim","S.C. Oh","C.-H. Yoo","J.-H. Choi","D.Y. Zang","G. Kim","Y. Lee","S.-H. Noh"],"twitterCount":0,"altmetricId":68179423,"statusesArray":[]},{"title":"Primary 2-year (yr) results of a phase II, multicenter, randomized, open-label trial of efficacy and safety for talimogene laherparepvec (T-VEC) neoadjuvant …","googleId":"MZkk_g1ZvK0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604230","googleCitationCount":12,"googleAuthor":"DE Gyorki","doi":"10.1093/annonc/mdz394.063","elsevierCitationCount":0,"altmetricAuthors":["R. Dummer","D.E. Gyorki","J. Hyngstrom","A. Berger","R. Conry","L. Demidov","A. Sharma","S.A. Treichel","K. Gorski","A. Anderson","M. Faries","M.I. Ross"],"twitterCount":0,"altmetricId":68179432,"statusesArray":[]},{"title":"TPX-0046 is a novel and potent RET/SRC inhibitor for RET-driven cancers","googleId":"XRSQh-bBR4EJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419587282","googleCitationCount":13,"googleAuthor":"A Drilon","doi":"10.1093/annonc/mdz244.068","elsevierAuthor":"Dadu R.","publicationName":"Endocrine-Related Cancer","elsevierCoverDate":"2020-08-01","elsevierCoverDisplayDate":"August 2020","elsevierCitationCount":"0","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)","googleId":"DiJw6z1VjykJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42460-3/abstract","googleCitationCount":27,"googleAuthor":"F Cardoso","statusesArray":[]},{"title":"A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ …","googleId":"fRhXJknAZ0cJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311949","googleCitationCount":18,"googleAuthor":"J Veeraraghavan","doi":"10.1093/annonc/mdz076","elsevierAuthor":"Veeraraghavan J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-06-01","elsevierCoverDisplayDate":"1 June 2019","elsevierCitationCount":"16","altmetricAuthors":["J. Veeraraghavan","C. De Angelis","R. Mao","T. Wang","S. Herrera","A.C. Pavlick","A. Contreras","P. Nuciforo","I.A. Mayer","A. Forero","R. Nanda","M.P. Goetz","J.C. Chang","A.C. Wolff","I.E. Krop","S.A.W. Fuqua","A. Prat","S.G. Hilsenbeck","B. Weigelt","J.S. Reis-Filho","C. Gutierrez","C.K. Osborne","M.F. Rimawi","R. Schiff"],"twitterCount":27,"altmetricId":57587642,"statusesArray":["1120381905797406720","1111617723304423425","1111384696267522049","1111104806683332608","1111069972531478528","1111059407826235392","1111015063446540289","1111006784410521611","1110996617879060481","1110970248868581387","1110952702853505026","1110915512404332545","1110915479067975681","1110905790053974019","1110893776095141890","1110869725054156800","1110830994523865089","1110799227423256576","1110781341463924736","1110776530240786432","1110759859199373312","1110741004062093317","1110740994301935616","1110712694431272960","1110685294754480129","1109784356124536838","1109711140295241729"]},{"title":"Complementary roles of MRI and endoscopic examination in the early detection of nasopharyngeal carcinoma","googleId":"R2Qwv5iK2DUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312001","googleCitationCount":14,"googleAuthor":"AD King","doi":"10.1093/annonc/mdz106","elsevierAuthor":"King A.D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-06-01","elsevierCoverDisplayDate":"1 June 2019","elsevierCitationCount":"13","altmetricAuthors":["A.D. King","J.K.S. Woo","Q.Y. Ai","J.S.M. Chan","W.K.J. Lam","I.O.L. Tse","K.S. Bhatia","B.C.Y. Zee","E.P. Hui","B.B.Y. Ma","R.W.K. Chiu","A.C. van Hasselt","A.T.C. Chan","Y.M.D. Lo","K.C.A. Chan"],"twitterCount":14,"altmetricId":62926320,"statusesArray":["1146016169092157440","1145991466621308929","1145848986898751488","1145769366476247041","1145719147353071617","1145683740364070917","1145678039822602242","1145662887253434368","1145641542683639808","1145627470642761728","1145622795285667840","1145585352612208640","1145585133904441344","1145580542550781952"]},{"title":"Development of adaptive immune effector therapies in solid tumors","googleId":"pn7jB1r8bZIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325874","googleCitationCount":10,"googleAuthor":"F Lanza","doi":"10.1093/annonc/mdz285","elsevierAuthor":"Comoli P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-11-01","elsevierCoverDisplayDate":"November 2019","elsevierCitationCount":"12","altmetricAuthors":["P. Comoli","C. Chabannon","U. Koehl","F. Lanza","A. Urbano-Ispizua","M. Hudecek","A. Ruggeri","S. Secondino","C. Bonini","P. Pedrazzoli"],"twitterCount":6,"altmetricId":65366901,"statusesArray":["1290905280423890952","1166023678385098754","1166018180961230849","1165974300400078848","1165956500138921985","1164971952215216128"]},{"title":"Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO …","googleId":"dUGfUJzYiOsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419360831","googleCitationCount":7,"googleAuthor":"KH Lee","doi":"10.1016/j.annonc.2019.10.026","elsevierAuthor":"Park K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-02-01","elsevierCoverDisplayDate":"February 2020","elsevierCitationCount":"7","altmetricAuthors":["K. Park","J. Vansteenkiste","K.H. Lee","G. Pentheroudakis","C. Zhou","K. Prabhash","T. Seto","P.J. Voon","D.S.W. Tan","J.C.H. Yang","J. Wang","K. Govind Babu","Y. Nakayama","A. Alip","K.L.M. Chua","J.C.-H. Cheng","S. Senan","Y.C. Ahn","T.-Y. Kim","H.K. Ahn","S. Peters","T. Yoshino","J.-Y. Douillard"],"twitterCount":35,"altmetricId":73845116,"statusesArray":["1245109419630886922","1233328874802384898","1223249724943355905","1222948302049697792","1222803904326459392","1222468531079520256","1222466997662949376","1222438637981356039","1222422157889806336","1222419296334184448","1222406370252808197","1222385438679347201","1222338181036572672","1222336861168947200","1222311961808994305","1222297848236191744","1222297077809668096","1222284691903901696","1222282238982795267","1222233595227656192","1222230266241900544","1222229577600323586","1222191992605573120","1222176331443724290","1222176316293877765","1222132254203416576","1222127347937112067","1222125337955299328","1222122223114366976","1222120502845530112","1222112123171622912","1222110304307298304","1222110072886693893","1222099103104086016","1222097907358355456","1222097000541364225","1215949437295636480","1215642500439990273"]},{"title":"Bone health in cancer: ESMO clinical practice guidelines","googleId":"yjXVVOyuOQIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39995-6/abstract","googleCitationCount":14,"googleAuthor":"R Coleman","statusesArray":[]},{"title":"Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO–EONS–EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and …","googleId":"rhmbclHXLbcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39938-5/abstract","googleCitationCount":6,"googleAuthor":"F Cardoso","statusesArray":[]},{"title":"Neuronal autoantibodies associated with cognitive impairment in melanoma patients","googleId":"ZfHJQDb-fMYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341931169X","googleCitationCount":16,"googleAuthor":"","doi":"10.1093/annonc/mdz083","elsevierAuthor":"Bartels F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-05-01","elsevierCoverDisplayDate":"May 2019","elsevierCitationCount":"9","altmetricAuthors":["F. Bartels","T. Strönisch","K. Farmer","K. Rentzsch","F. Kiecker","C. Finke"],"twitterCount":20,"altmetricId":56644744,"statusesArray":["1162824478675615744","1141594594448199680","1141571956535418880","1141332084247674881","1141332015352025088","1141331748036534272","1141298437293559808","1141298341885517824","1111606607190867968","1111327057840005120","1111324459959545857","1111303961204719616","1111283936758501377","1111283706549940224","1111281550618959872","1104411481771261952","1104386036061401089","1103870602547355652","1103870476642709504","1103734575933534208","1103635421097996289"]},{"title":"Treating HER2-mutant advanced biliary tract cancer with neratinib: benefits of HER2-directed targeted therapy in the phase 2 SUMMIT 'basket'trial","googleId":"pi-01BkZC7QJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30513-7/abstract","googleCitationCount":17,"googleAuthor":"J Harding","statusesArray":[]},{"title":"Pembrolizumab (pembro)+ chemotherapy (chemo) in metastatic squamous NSCLC: Final analysis and progression after the next line of therapy (PFS2) in …","googleId":"L7XK79b7QqIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604400","googleCitationCount":13,"googleAuthor":"","doi":"10.1093/annonc/mdz394.080","elsevierCitationCount":0,"altmetricAuthors":["L. Paz-Ares","D. Vicente","A. Tafreshi","A. Robinson","H. Soto Parra","J. Mazières","B. Hermes","I. Cicin","B. Medgyasszay","B. Beatrix","J. Rodríguez Cid","I. Okamoto","S. Lee","R. Ramlau","V. Vladimirov","Y. Cheng","X. Deng","T. Bas","B. Piperdi","B. Halmos"],"twitterCount":1,"altmetricId":67579432,"statusesArray":["1179410802761228290"]},{"title":"BACCI: A phase II randomized, double-blind, multicenter, placebo-controlled study of capecitabine (C) bevacizumab (B) plus atezolizumab (A) or placebo (P) …","googleId":"u-bpLVJKA18J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419587543","googleCitationCount":11,"googleAuthor":"TR Halfdanarson","doi":"10.1093/annonc/mdz246.011","elsevierAuthor":"Chen E.X.","publicationName":"JAMA Oncology","elsevierCoverDate":"2020-06-01","elsevierCoverDisplayDate":"June 2020","elsevierCitationCount":"13","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Cancer mortality in the elderly in 11 countries worldwide, 1970–2015","googleId":"9nB-JV49mk4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341931292X","googleCitationCount":11,"googleAuthor":"M Malvezzi","doi":"10.1093/annonc/mdz178","elsevierAuthor":"Carioli G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-08-01","elsevierCoverDisplayDate":"1 August 2019","elsevierCitationCount":"7","altmetricAuthors":["G. Carioli","M. Malvezzi","P. Bertuccio","D. Hashim","S. Waxman","E. Negri","P. Boffetta","C. La Vecchia"],"twitterCount":1,"altmetricId":72747787,"statusesArray":["1205625548631879681"]},{"title":"Interpretation of time-to-event outcomes in randomized trials: an online randomized experiment","googleId":"QrolSTmxn5IJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419309809","googleCitationCount":16,"googleAuthor":"IR Weir","doi":"10.1093/annonc/mdy462","elsevierAuthor":"Weir I.R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-01-01","elsevierCoverDisplayDate":"1 January 2019","elsevierCitationCount":"11","altmetricAuthors":["I.R. Weir","G.D. Marshall","J.I. Schneider","J.A. Sherer","E.M. Lord","B. Gyawali","M.K. Paasche-Orlow","E.J. Benjamin","L. Trinquart"],"twitterCount":84,"altmetricId":49889013,"statusesArray":["1109426829360807937","1109098810226159616","1094291893222076418","1094252944361512960","1094238816016175104","1094168506843779072","1094036018095894529","1093966667196129282","1093965267028398080","1093964788395327489","1093962674612908032","1093950469469286400","1093940190731739136","1093938862567567361","1093937413238521857","1093892153804242944","1093824781479227392","1093756760807100416","1093649901555249152","1093342229291286528","1092879558372704264","1092860182173007879","1092786286463717377","1092782729886945281","1092781997771100160","1092161128074043392","1091378478736240640","1091329465899208705","1091315441526550528","1091313737552646149","1091294059379998721","1091281250596388864","1091264588887121921","1091259885117792256","1087568020376088577","1087093145781850114","1059410124438233089","1059175662701985792","1059152692763918336","1059130147444613122","1059129585009418240","1059114272393957376","1059108297410838528","1059106491020517376","1059098891591794693","1059088369458790400","1059080147335307264","1059044187268673536","1059039610771267584","1058952505533566976","1058944825549119490","1058801171022991361","1058784949061476353","1058770458370301952","1058745033678045184","1058729986268520448","1058724486139273216","1058722321035214848","1058716718821007360","1058688475438989317","1058683987999240192","1058675025862111232","1058672158845603840","1058629932178276357","1058619549245939712","1058578371410571264","1058538677524201472","1058442813153648640","1058406731670261760","1058401805367791616","1058400574033592321","1058400305178648576","1058395707500085248","1058319902661066752","1058319878174707712","1058316646580998145","1058314249573986304","1058312348191150082","1058229313953099776","1058096674407677952","1058091346756599810","1055846783849385986","1055085390682603524","1054942556767862784","1054928946112815104","1054897928882528257","1054897754227556353","1054853631864901633","1054853298254110720","1054853002408931335","1054844214142427136","1054822571710078976","1054635680092090373","1054202904419147777","1053601670461116417","1053322989029203973","1053285598708948992","1053284207785582593","1053282620950355974","1053151150151778304"]},{"title":"Body size and obesity during adulthood, and risk of lympho-haematopoietic cancers: an update of the WCRF-AICR systematic review of published prospective …","googleId":"W4mtmUjUBisJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311263","googleCitationCount":15,"googleAuthor":"L Abar","doi":"10.1093/annonc/mdz045","elsevierAuthor":"Abar L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-04-01","elsevierCoverDisplayDate":"April 2019","elsevierCitationCount":"12","altmetricAuthors":["L. Abar","J.G. Sobiecki","M. Cariolou","N. Nanu","A.R. Vieira","C. Stevens","D. Aune","D.C. Greenwood","D.S.M. Chan","T. Norat"],"twitterCount":4,"altmetricId":55392621,"statusesArray":["1222489199028379649","1222476263689838592","1096107051409903617","1095643082811428869","1095639919517683713"]},{"title":"Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients …","googleId":"rVaraWt_ov4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420397982","googleCitationCount":12,"googleAuthor":"F André","doi":"10.1016/j.annonc.2020.05.001","elsevierAuthor":"Rugo H.S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-08-01","elsevierCoverDisplayDate":"August 2020","elsevierCitationCount":"7","altmetricAuthors":["H.S. Rugo","F. André","T. Yamashita","H. Cerda","I. Toledano","S.M. Stemmer","J.C. Jurado","D. Juric","I. Mayer","E.M. Ciruelos","H. Iwata","P. Conte","M. Campone","C. Wilke","D. Mills","A. Lteif","M. Miller","F. Gaudenzi","S. Loibl"],"twitterCount":4,"altmetricId":82212538,"statusesArray":["1262267109515681795","1262122489053761537","1262122028263526400","1262117916805300224"]},{"title":"Adjuvant immunotherapy with nivolumab (NIVO) alone or in combination with ipilimumab (IPI) versus placebo in stage IV melanoma patients with no evidence …","googleId":"rKo_d3VxsaYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604242","googleCitationCount":10,"googleAuthor":"D Schadendorf","doi":"10.1093/annonc/mdz394.064","elsevierCitationCount":0,"altmetricAuthors":["D. Schadendorf","J.C. Hassel","M. Fluck","T. Eigentler","C. Loquai","M. Berneburg","R. Gutzmer","F. Meier","P. Mohr","A. Hauschild","J.C. Becker","C. Menzer","F. Kiecker","E. Dippel","J.-C. Simon","B. Conrad","C. Garbe","S. Körner","E. Livingstone","L. Zimmer"],"twitterCount":0,"altmetricId":68179433,"statusesArray":[]},{"title":"EV-103: initial results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma","googleId":"LjYPNpazzngJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591177","googleCitationCount":12,"googleAuthor":"","doi":"10.1093/annonc/mdz249","elsevierAuthor":"Joshi M.","publicationName":"Cancer Medicine","elsevierCoverDate":"2020-12-01","elsevierCoverDisplayDate":"December 2020","elsevierCitationCount":"0","altmetricAuthors":["C.J. Hoimes","J.E. Rosenberg","S. Srinivas","D.P. Petrylak","M. Milowsky","J.R. Merchan","M.A. Bilen","S. Gupta","A.-S. Carret","N. Yuan","A. Melhem-Bertrandt","T. Flaig"],"twitterCount":0,"altmetricId":68179459,"statusesArray":[]},{"title":"LBA3 Nivolumab (NIVO)+ platinum-doublet chemotherapy (chemo) vs chemo as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (aNSCLC …","googleId":"UB47kBIJdJ8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375342034552X","googleCitationCount":10,"googleAuthor":"","doi":"10.1093/annonc/mdz453.004","elsevierAuthor":"Remon J.","publicationName":"Translational Cancer Research","elsevierCoverDate":"2020-04-01","elsevierCoverDisplayDate":"1 April 2020","elsevierCitationCount":"2","altmetricAuthors":["L. Paz-Ares","T.E. Ciuleanu","X. Yu","P. Salman","A. Pluzanski","A. Nagrial","L. Havel","R. Kowalyszyn","C. Audigier-Valette","Y.-L. Wu","H. Borghaei","M.D. Hellmann","J. Brahmer","M. Reck","S. Ramalingam","L. Zhang","P. Bhagavatheeswaran","F.E. Nathan","K.J. O'Byrne"],"twitterCount":1,"altmetricId":72849082,"statusesArray":["1206612580590116869"]},{"title":"Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1–4 inhibitor in patients with advanced solid tumors","googleId":"NENwnyRoHAoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420399282","googleCitationCount":8,"googleAuthor":"F Meric-Bernstam","doi":"10.1016/j.annonc.2020.06.018","elsevierAuthor":"Bahleda R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-10-01","elsevierCoverDisplayDate":"October 2020","elsevierCitationCount":"6","altmetricAuthors":["R. Bahleda","F. Meric-Bernstam","L. Goyal","B. Tran","Y. He","I. Yamamiya","K.A. Benhadji","I. Matos","H.-T. Arkenau"],"twitterCount":3,"altmetricId":85303123,"statusesArray":["1282524716561924096","1281971787342008320","1280087830375645184"]},{"title":"Prediction of response to anti-PD-1 therapy in patients with non-small-cell lung cancer by electronic nose analysis of exhaled breath","googleId":"YhpGzTX_1DcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419609828","googleCitationCount":17,"googleAuthor":"M Muller","doi":"10.1093/annonc/mdz279","elsevierAuthor":"De Vries R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-10-01","elsevierCoverDisplayDate":"1 October 2019","elsevierCitationCount":"14","altmetricAuthors":["R. de Vries","M. Muller","V. van der Noort","W.S.M.E. Theelen","R.D. Schouten","K. Hummelink","S.H. Muller","M. Wolf-Lansdorf","J.W.F. Dagelet","K. Monkhorst","A.H. Maitland-van der Zee","P. Baas","P.J. Sterk","M.M. van den Heuvel"],"twitterCount":78,"altmetricId":66757648,"statusesArray":["1225882775007395840","1222440218520969216","1222417844480012288","1212723337732009984","1212694033279135744","1200774899268280320","1200773790080360448","1198415107824537600","1198192515247149056","1178829379360698369","1178526587832225792","1178525839182503936","1177619389874671617","1177345700734087171","1177345583025197056","1177196493884858368","1177183534211112960","1177168101022097408","1177167466977472512","1177160919018823680","1177140031212929024","1177048575202811904","1176963186345545729","1176961271314468872","1176961215131803650","1176961179522146304","1176960845504483334","1176960427105902592","1176950282300715008","1176861564198162433","1176861541934800897","1176861460762374146","1176851070951337984","1176850903921545217","1176850532419457024","1176809697195757573","1176641094270029824","1176591714762575872","1176587150286118912","1176584793137414144","1176575292426661890","1176514735514279936","1176504006849572865","1176459587035074566","1176448724593184770","1176379932353662977","1176373175892029440","1176339360960208896","1176299303016509440","1176284755320430593","1176283059475439616","1176122251906732039","1175460329230393346","1175175843850727427","1175137618700447744","1175134035087101952","1175107468868890633","1175065844117889024","1174614611271868416","1174595036006289410","1174591325154480129","1174463865314103296","1174460149727203342","1174459907699105792","1174420715338158083","1174401103653482502","1174393247004839938","1174357260388241409","1174355218609274880","1174352850161459200","1174345241396154368","1174341561737498624","1174334566640828417","1174332106325073920","1174318922914512901","1174312839206592512","1174311128349978624","1174309157127651328","1174306710116134912","1174305057984188416","1174303532645867520","1174302071505543168","1174298764753944576","1174298125680467969","1174288745182486529","1174286293599051776","1174279205493837824","1174274024064598017","1174272490085990402","1174255555050913792","1174253077966274562","1174253015756394501","1174252564902232064","1174250790535536643","1174249856564629504","1174249791469051906","1174245244436660229","1174235496429604864","1174232394213277702","1174229207762788352"]},{"title":"Final analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) …","googleId":"wEhNMgAOtrQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30051-1/abstract","googleCitationCount":16,"googleAuthor":"","statusesArray":[]},{"title":"Noninvasive imaging evaluation of tumor immune microenvironment to predict outcomes in gastric cancer","googleId":"PwNrlAJv6UUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420363821","googleCitationCount":7,"googleAuthor":"Y Jiang","doi":"10.1016/j.annonc.2020.03.295","elsevierAuthor":"Jiang Y.","publicationName":"Annals of Oncology","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"2021","elsevierCitationCount":"0","altmetricAuthors":["Y. Jiang","H. Wang","J. Wu","C. Chen","Q. Yuan","W. Huang","T. Li","S. Xi","Y. Hu","Z. Zhou","Y. Xu","G. Li","R. Li"],"twitterCount":5,"altmetricId":78691397,"statusesArray":["1265412007894769664","1263923588555575298","1263922834759442438","1261027138301378562","1244851516969811969"]},{"title":"Measures of body fatness and height in early and mid-to-late adulthood and prostate cancer: risk and mortality in The Pooling Project of Prospective Studies of …","googleId":"kvlFRvbPn1sJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354134","googleCitationCount":8,"googleAuthor":"JM Genkinger","doi":"10.1016/j.annonc.2019.09.007","elsevierAuthor":"Genkinger J.M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"January 2020","elsevierCitationCount":"4","altmetricAuthors":["J.M. Genkinger","K. Wu","M. Wang","D. Albanes","A. Black","P.A. van den Brandt","K.A. Burke","M.B. Cook","S.M. Gapstur","G.G. Giles","E. Giovannucci","G.G. Goodman","P.J. Goodman","N. Håkansson","T.J. Key","S. Männistö","L. Le Marchand","L.M. Liao","R.J. MacInnis","M.L. Neuhouser","E.A. Platz","N. Sawada","J.M. Schenk","V.L. Stevens","R.C. Travis","S. Tsugane","K. Visvanathan","L.R. Wilkens","A. Wolk","S.A. Smith-Warner"],"twitterCount":10,"altmetricId":73816369,"statusesArray":["1252581214902517760","1237306132475019264","1237037069035122690","1237032540705177601","1237024318107701248","1236988826083643392","1233366750772813826","1231877685804195841","1227603851060006912","1227204242802429953","1215485365169147904"]},{"title":"A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower …","googleId":"jvU9psOBTO4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419459905","googleCitationCount":19,"googleAuthor":"O Türeci","doi":"10.1093/annonc/mdz199","elsevierAuthor":"Türeci O.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-09-01","elsevierCoverDisplayDate":"1 September 2019","elsevierCitationCount":"15","altmetricAuthors":["O. Türeci","U. Sahin","H. Schulze-Bergkamen","Z. Zvirbule","F. Lordick","D. Koeberle","P. Thuss-Patience","T. Ettrich","D. Arnold","F. Bassermann","S.E. Al-Batran","K. Wiechen","K. Dhaene","D. Maurus","M. Gold","C. Huber","A. Krivoshik","A. Arozullah","J.W. Park","M. Schuler"],"twitterCount":17,"altmetricId":62903590,"statusesArray":["1222474998872330240","1204069098877050882","1187410933196316672","1187373238558396416","1164936496555745280","1146938650472505344","1146346591927717889","1146109603907682304","1146039646511611904","1145757490501566465","1145756214837616645","1145753668249161730","1145753504868438017","1145692286505738241","1145664970878849025","1145591994674290688","1145579685134393345","1145502489959157761","1145305269519433728"]},{"title":"Clinical development of therapies targeting TGFβ: current knowledge and future perspectives.","googleId":"R1UXAr4PW90J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420399464","googleCitationCount":5,"googleAuthor":"D Ciardiello","doi":"10.1016/j.annonc.2020.07.009","elsevierAuthor":"Ciardiello D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-10-01","elsevierCoverDisplayDate":"October 2020","elsevierCitationCount":"4","altmetricAuthors":["D. Ciardiello","E. Elez","J. Tabernero","J. Seoane"],"twitterCount":1,"altmetricId":86718454,"statusesArray":["1288424235099201539"]},{"title":"Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials","googleId":"Nz2kQiOi_LgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354110","googleCitationCount":10,"googleAuthor":"","doi":"10.1016/j.annonc.2019.10.005","elsevierAuthor":"Yoshino T.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"January 2020","elsevierCitationCount":"8","altmetricAuthors":["T. Yoshino","J.M. Cleary","E. Van Cutsem","R.J. Mayer","A. Ohtsu","E. Shinozaki","A. Falcone","K. Yamazaki","T. Nishina","R. Garcia-Carbonero","Y. Komatsu","H. Baba","G. Argilés","A. Tsuji","A. Sobrero","K. Yamaguchi","M. Peeters","K. Muro","A. Zaniboni","N. Sugimoto","Y. Shimada","Y. Tsuji","H.S. Hochster","T. Moriwaki","B. Tran","T. Esaki","C. Hamada","T. Tanase","F. Benedetti","L. Makris","F. Yamashita","H.-J. Lenz"],"twitterCount":4,"altmetricId":73787757,"statusesArray":["1258728415928168449","1215678206096769029","1215623084234956807","1215242125241126912"]},{"title":"811MO maintenance olaparib for patients (PTS) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (Y) follow-up (f/u) from …","googleId":"oi9w_cO8PGsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40946-9/abstract","googleCitationCount":11,"googleAuthor":"N Colombo","statusesArray":[]},{"title":"Model-informed drug development approach supporting approval of the 4-week (Q4W) dosing schedule for nivolumab (Opdivo) across multiple indications: a …","googleId":"v-VNA55SDYYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311226","googleCitationCount":18,"googleAuthor":"Y Bi","doi":"10.1093/annonc/mdz037","elsevierAuthor":"Czarnecka A.M.","publicationName":"Expert Opinion on Drug Safety","elsevierCoverDate":"2020-04-02","elsevierCoverDisplayDate":"2 April 2020","elsevierCitationCount":"1","altmetricAuthors":["Y. Bi","J. Liu","B. Furmanski","H. Zhao","J. Yu","C. Osgood","A. Ward","P. Keegan","B.P. Booth","A. Rahman","Y. Wang"],"twitterCount":18,"altmetricId":54902761,"statusesArray":["1131285678384394241","1131195981398253568","1131194414250901505","1131184455333269504","1129733772432347137","1106491251044564992","1106260697632161794","1106210004829433856","1105945593116008448","1105934686575038468","1105919399658209280","1105770847787048967","1105766564052246529","1105694952833540098","1105663578701348864","1105660554952228864","1105646963150802944","1105589176198676485","1092821762620960770","1092162697054044160"]},{"title":"Results of the ASCEND-7 phase II study evaluating ALK inhibitor (ALKi) ceritinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) metastatic to …","googleId":"KOG_AcRQSzsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419596867","googleCitationCount":11,"googleAuthor":"","doi":"10.1093/annonc/mdz260","elsevierAuthor":"Vavala T.","publicationName":"Journal of Clinical Pathology","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"2021","elsevierCitationCount":"0","altmetricAuthors":["L.Q. Chow","F. Barlesi","E.M. Bertino","M.J. van den Bent","H. Wakelee","P.Y. Wen","C.-H. Chiu","S. Orlov","M. Majem","R. Chiari","M. McKeage","C.-J. Yu","F.K. Hurtado","P Cazorla Arratia","Y. Song","F. Branle","M. Shi","D.-W. Kim"],"twitterCount":0,"altmetricId":68976397,"statusesArray":[]},{"title":"Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the …","googleId":"ZfAaBXFIBvIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420421064","googleCitationCount":8,"googleAuthor":"","doi":"10.1016/j.annonc.2020.08.2098","elsevierAuthor":"Litton J.K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-11-01","elsevierCoverDisplayDate":"November 2020","elsevierCitationCount":"5","altmetricAuthors":["J.K. Litton","S.A. Hurvitz","L.A. Mina","H.S. Rugo","K.-H. Lee","A. Gonçalves","S. Diab","N. Woodward","A. Goodwin","R. Yerushalmi","H. Roché","Y.-H. Im","W. Eiermann","R.G.W. Quek","T. Usari","S. Lanzalone","A. Czibere","J.L. Blum","M. Martin","J. Ettl"],"twitterCount":2,"altmetricId":88982250,"statusesArray":["1299117949836570628","1299026108218830853"]},{"title":"Long lasting major response to pembrolizumab in a thoracic malignant rhabdoid-like SMARCA4-deficient tumor","googleId":"vrXLOmpkcssJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31280-3/abstract","googleCitationCount":14,"googleAuthor":"JY Blay","statusesArray":[]},{"title":"Outcomes with pembrolizumab (pembro) monotherapy in patients (pts) with PD-L1–positive NSCLC with brain metastases: pooled analysis of KEYNOTE-001 …","googleId":"Xn06f8Ktfq0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419596909","googleCitationCount":11,"googleAuthor":"AS Mansfield","doi":"10.1093/annonc/mdz260.004","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Analysis of tumor microenvironmental features to refine prognosis by T, N risk group in patients with stage III colon cancer (NCCTG N0147)(Alliance)","googleId":"CpTWaK4cMO8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420359445","googleCitationCount":7,"googleAuthor":"TC Smyrk","doi":"10.1016/j.annonc.2020.01.011","elsevierAuthor":"Lee H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-04-01","elsevierCoverDisplayDate":"April 2020","elsevierCitationCount":"6","altmetricAuthors":["H. Lee","D. Sha","N.R. Foster","Q. Shi","S.R. Alberts","T.C. Smyrk","F.A. Sinicrope"],"twitterCount":13,"altmetricId":76689041,"statusesArray":["1283223882883792896","1238760104738140161","1235079524322168833","1234730333943107585","1234699504802291718","1234636952013541377","1234489954270576640","1232925690112151552","1232706798328504320","1232654047238381568","1232626216387084288","1232625371201314817","1232622275679010816","1232621368694407169"]},{"title":"Combination treatment with cobimetinib (C) and atezolizumab (A) vs pembrolizumab (P) in previously untreated patients (pts) with BRAFV600 wild type (wt) …","googleId":"7OjVEeecLcYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604266","googleCitationCount":12,"googleAuthor":"H Gogas","doi":"10.1093/annonc/mdz394.066","elsevierCitationCount":0,"altmetricAuthors":["A.M. Arance","H. Gogas","B. Dreno","K.T. Flaherty","L. Demidov","D. Stroyakovskiy","Z. Eroglu","P.F. Ferrucci","J. Pigozzo","P. Rutkowski","J. Mackiewicz","I. Rooney","A. Voulgari","S. Troutman","B. Pitcher","Y. Yan","J.M.G. Larkin"],"twitterCount":0,"altmetricId":68179437,"statusesArray":[]},{"title":"Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) in NSCLC with brain metastases: Pooled analysis of KEYNOTE-021, 189, and 407","googleId":"whQ4QbeLsfYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419596910","googleCitationCount":14,"googleAuthor":"","doi":"10.1093/annonc/mdz260.005","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"On the need to adjust for multiplicity in confirmatory clinical trials with master protocols","googleId":"YN3bWWuIEqMJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6503623/","googleCitationCount":13,"googleAuthor":"","doi":"10.1093/annonc/mdz038","elsevierAuthor":"Stallard N.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-04-01","elsevierCoverDisplayDate":"April 2019","elsevierCitationCount":"10","altmetricAuthors":["N. Stallard","S. Todd","D. Parashar","P.K. Kimani","L.A. Renfro"],"twitterCount":4,"altmetricId":57071495,"statusesArray":["1107114195793829888","1106629510081011712","1106573314019987461","1106570773081186304"]},{"title":"Identification of an excellent prognosis subset of human papillomavirus-associated oropharyngeal cancer patients by quantification of intratumoral CD103+ …","googleId":"HHxIrzN0D90J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419609804","googleCitationCount":8,"googleAuthor":"RJ Young","doi":"10.1093/annonc/mdz271","elsevierAuthor":"Solomon B.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-10-01","elsevierCoverDisplayDate":"1 October 2019","elsevierCitationCount":"7","altmetricAuthors":["B. Solomon","R.J. Young","M. Bressel","J. Cernelc","P. Savas","H. Liu","D. Urban","A. Thai","C. Cooper","T. Fua","P. Neeson","S. Loi","S.V. Porceddu","D. Rischin"],"twitterCount":22,"altmetricId":64842426,"statusesArray":["1201637769711431680","1201502867833544704","1201451086843973634","1163540267225538561","1163027818659270656","1163008676967395329","1162012435961827328","1162012317682266113","1161969498879959040","1161585503960887297","1161435328969760768","1161383271290138624","1161334667590676480","1161227035412434944","1161145007656411136","1160956403089104898","1160917797930721280","1160898710873812992","1160898275316240384","1160885594924470272","1160871094846283776","1160861921836490752","1160454125651410945"]},{"title":"ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee","googleId":"TDALFMKmFZIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420399397","googleCitationCount":5,"googleAuthor":"PA Ascierto","doi":"10.1016/j.annonc.2020.07.004","elsevierAuthor":"Keilholz U.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-11-01","elsevierCoverDisplayDate":"November 2020","elsevierCitationCount":"1","altmetricAuthors":["U. Keilholz","P.A. Ascierto","R. Dummer","C. Robert","P. Lorigan","A. van Akkooi","A. Arance","C.U. Blank","V. Chiarion Sileni","M. Donia","M.B. Faries","C. Gaudy-Marqueste","H. Gogas","J.J. Grob","M. Guckenberger","J. Haanen","A.J. Hayes","C. Hoeller","C. Lebbé","I. Lugowska","M. Mandalà","I. Márquez-Rodas","P. Nathan","B. Neyns","R. Olofsson Bagge","S. Puig","P. Rutkowski","B. Schilling","V.K. Sondak","H. Tawbi","A. Testori","O. Michielin"],"twitterCount":2,"altmetricId":87130048,"statusesArray":["1292090718702522375","1290592615935639552"]},{"title":"Enrichment of kinase fusions in ESR1 wild-type, metastatic breast cancer revealed by a systematic analysis of 4854 patients","googleId":"FnoShPpOI6MJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420393066","googleCitationCount":5,"googleAuthor":"P Razavi","doi":"10.1016/j.annonc.2020.04.008","elsevierAuthor":"Ross D.S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-08-01","elsevierCoverDisplayDate":"August 2020","elsevierCitationCount":"3","altmetricAuthors":["D.S. Ross","B. Liu","A.M. Schram","P. Razavi","S.M. Lagana","Y. Zhang","M. Scaltriti","J.F. Bromberg","M. Ladanyi","D.M. Hyman","A. Drilon","A. Zehir","R. Benayed","S. Chandarlapaty","J.F. Hechtman"],"twitterCount":32,"altmetricId":80891059,"statusesArray":["1283251197281890304","1265028557035757568","1263251108203503616","1262774136952193029","1262509203022917638","1262410144136204288","1262368610707820544","1262308190106071040","1262305785956184064","1262262867195244549","1262255464915570688","1262254529233530880","1262247061531000836","1262246563973398528","1258679925747453953","1258554762946998278","1258541851344121856","1257644772124168193","1257606835248513024","1257517219258433537","1257503307163189248","1257496162770264069","1257496060873920518","1257491420559994881","1257477583777693698","1257409020953911296","1257367259376504834","1257349512970076172","1257333779884015616","1257320367422468096","1257317317500735490","1255800958115655681"]},{"title":"Central, prospective detection of homologous recombination repair gene mutations (HRRm) in tumour tissue from> 4000 men with metastatic castration …","googleId":"h-isco5sVRMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419590639","googleCitationCount":10,"googleAuthor":"JS de Bono","doi":"10.1093/annonc/mdz248.004","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Three-versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology …","googleId":"C5docYF6XnQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312980","googleCitationCount":11,"googleAuthor":"J Souglakos","doi":"10.1093/annonc/mdz193","elsevierAuthor":"Souglakos J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-08-01","elsevierCoverDisplayDate":"1 August 2019","elsevierCitationCount":"8","altmetricAuthors":["J. Souglakos","I. Boukovinas","S. Kakolyris","S. Xynogalos","N. Ziras","A. Athanasiadis","N. Androulakis","A. Christopoulou","M. Vaslamatzis","A. Ardavanis","C. Emmanouilides","I. Bompolaki","C. Kourousis","P. Makrantonakis","C. Christofyllakis","E. Athanasiadis","N. Kentepozidis","A. Karampeazis","U. Katopodi","A. Anagnosopoulos","G. Papadopoulos","E. Prinarakis","A. Kalisperi","D. Mavroudis","V. Georgoulias"],"twitterCount":9,"altmetricId":62595012,"statusesArray":["1144230580223012865","1144140930490011649","1143940154161340416","1143929782855319552","1143925356048633857","1143911800838197249","1143222184749535232","1142899425674768384","1142891882978189317"]},{"title":"An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45","googleId":"AbplPkpSoYwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419360843","googleCitationCount":8,"googleAuthor":"F Cardoso","doi":"10.1016/j.annonc.2019.10.027","elsevierAuthor":"Bjelic-Radisic V.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-04-01","elsevierCoverDisplayDate":"April 2020","elsevierCitationCount":"0","altmetricAuthors":["V. Bjelic-Radisic","F. Cardoso","D. Cameron","E. Brain","K. Kuljanic","R.A. da Costa","T. Conroy","E.C. Inwald","S. Serpentini","M. Pinto","J. Weis","O. Morag","G. Lindviksmoen Astrup","K.A. Tomaszweksi","K. Pogoda","P. Sinai","M. Sprangers","N. Aaronson","G. Velikova","E. Greimel","J. Arraras","A. Bottomley","Eveline Bleiker","Brigitte Bliem","Weichu Chie","Carien Creutzberg","Valerie Deville","Francois Duhoux","Kirsten Eilf","Sue Hartup","Michael Koller","Eva Nagele","Ourania Nicolatou-Galitis","Anne Oberguggenberger","Claudia Schmalz","Zoe Winters"],"twitterCount":1,"altmetricId":76426645,"statusesArray":["1235629007724572674"]},{"title":"Treatment with abiraterone and enzalutamide does not overcome poor outcome from metastatic castration-resistant prostate cancer in men with the germline …","googleId":"hWLeihe80qMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420397908","googleCitationCount":6,"googleAuthor":"D Dolling","doi":"10.1016/j.annonc.2020.04.473","elsevierAuthor":"Lu C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-09-01","elsevierCoverDisplayDate":"September 2020","elsevierCitationCount":"4","altmetricAuthors":["C. Lu","A. Terbuch","D. Dolling","J. Yu","H. Wang","Y. Chen","J. Fountain","C. Bertan","A. Sharp","S. Carreira","W.B. Isaacs","E.S. Antonarakis","J.S. De Bono","J. Luo"],"twitterCount":2,"altmetricId":81787574,"statusesArray":["1262455380552101889","1259787090247643136"]},{"title":"Cognitive behavioral therapy or graded exercise therapy compared with usual care for severe fatigue in patients with advanced cancer during treatment: a …","googleId":"aqixsgI_sh0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354031","googleCitationCount":8,"googleAuthor":"WTA Van Der Graaf","doi":"10.1016/j.annonc.2019.09.002","elsevierAuthor":"Poort H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"January 2020","elsevierCitationCount":"3","altmetricAuthors":["H. Poort","M.E.W.J. Peters","W.T.A. van der Graaf","P.T. Nieuwkerk","A.J. van de Wouw","M.W.G. Nijhuis-van der Sanden","G. Bleijenberg","C.A.H.H.V.M. Verhagen","H. Knoop"],"twitterCount":88,"altmetricId":73772928,"statusesArray":["1347202140461281281","1224724651437367297","1224045015258804224","1222131172748267521","1218020755625140225","1216992396581490688","1216977916044677120","1216860217641721856","1216814466400182272","1216667186455924736","1216650753579851776","1216647246533611520","1216641557811679233","1216361693061664768","1216282073067085829","1216274557897707520","1216108313022279681","1216081314857869314","1216060242066206720","1216043876961673216","1216034210298966016","1215808035844771840","1215805560198778880","1215730159216734209","1215724957579259904","1215723747757391872","1215642292360372229","1215624488106242048","1215623519708569600","1215622715270406144","1215622631577346048","1215615394536480768","1215582272188870657","1215516595264507905","1215484779526750208","1215449308952178689","1215409864152731648","1215400865701552128","1215398354047455232","1215373946276777997","1215373931965628416","1215371548799799296","1215364963931430912","1215362284329017344","1215357862345658369","1215357487085281280","1215356622479847424","1215349229364961284","1215349103972044800","1215344617773621248","1215316068211810310","1215296149206249472","1215290243613462531","1215288471666847751","1215287366568382464","1215284731119579136","1215284425761656833","1215282713004953605","1215279164711936003","1215276732397367296","1215275519480074241","1215269955408666625","1215267244885725190","1215260991488962562","1215258508918083584","1215257803738185728","1215257311171751936","1215254156023345153","1215243231933489152","1215242449460834311","1215232841627381760","1215232283768127489","1215231277563109376","1215224223666450432","1215220634902499329","1215212498632298497","1215212452578648064","1215210612856446977","1215205958055530496","1215195880128729088","1215191478659698689","1215190004403769345","1215189186531266560","1215184103072550912","1215182207771447296","1215180863438303232","1215179913965248513","1215170424897769473","1215170255355555840","1215148387810439168","1215146941215997952","1215146370908049409","1215145955873280000","1215144601192931329","1215128131582873600","1215123514115575809","1215119726759874560","1215107637341233153"]},{"title":"Entrectinib in NTRK fusion-positive non-small cell lung cancer (NSCLC): integrated analysis of patients (pts) enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001","googleId":"28wh4aQLRL0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30062-6/abstract","googleCitationCount":13,"googleAuthor":"RC Doebele","statusesArray":[]},{"title":"Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"F85io6vBVUoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39898-7/abstract","googleCitationCount":30,"googleAuthor":"E Castro","statusesArray":[]},{"title":"LBA-5 ANCHOR CRC: a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600E-mutant metastatic colorectal …","googleId":"lIt1mjYEfB4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39379-0/pdf","googleCitationCount":8,"googleAuthor":"A Grothey","statusesArray":[]},{"title":"Characterization of on-target adverse events caused by TRK inhibitor therapy","googleId":"IMp4OwIpN5UJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420398203","googleCitationCount":5,"googleAuthor":"","doi":"10.1016/j.annonc.2020.05.006","elsevierAuthor":"Liu D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-09-01","elsevierCoverDisplayDate":"September 2020","elsevierCitationCount":"3","altmetricAuthors":["D. Liu","J. Flory","A. Lin","M. Offin","C.J. Falcon","Y.R. Murciano-Goroff","E. Rosen","R. Guo","E. Basu","B.T. Li","J.J. Harding","G. Iyer","K. Jhaveri","M.M. Gounder","N.N. Shukla","S.S. Roberts","J. Glade-Bender","L. Kaplanis","A. Schram","D.M. Hyman","A. Drilon"],"twitterCount":33,"altmetricId":82632764,"statusesArray":["1301621239153397760","1301242327613280256","1301168864995221506","1301153092742926336","1301147599521673216","1301127701512814593","1301115131422748674","1301108517353517056","1301093461991419904","1301091329812951047","1301091060807020546","1268584537245790210","1268426124452859904","1268426080857325568","1268426028478857223","1265911475685797888","1265528419825131520","1265527848862912512","1265380811685019648","1265361527185555457","1265360054569644034","1265359262970232834","1265359164307574787","1265301002267299843","1265295350589386752","1265267729407381504","1265253760722284545","1265246915421241344","1265226523570733056","1265223579144278016","1265210648104964096","1265210473512939520","1265202501520961536","1265200344377819136","1265200200240582657","1264720445552701440","1264676260841652224","1264368632244719617"]},{"title":"ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee","googleId":"gC33zBCdAngJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420399403","googleCitationCount":8,"googleAuthor":"PA Ascierto","doi":"10.1016/j.annonc.2020.07.005","elsevierAuthor":"Michielin O.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-11-01","elsevierCoverDisplayDate":"November 2020","elsevierCitationCount":"4","altmetricAuthors":["O. Michielin","A. van Akkooi","P. Lorigan","P.A. Ascierto","R. Dummer","C. Robert","A. Arance","C.U. Blank","V. Chiarion Sileni","M. Donia","M.B. Faries","C. Gaudy-Marqueste","H. Gogas","J.J. Grob","M. Guckenberger","J. Haanen","A.J. Hayes","C. Hoeller","C. Lebbé","I. Lugowska","M. Mandalà","I. Márquez-Rodas","P. Nathan","B. Neyns","R. Olofsson Bagge","S. Puig","P. Rutkowski","B. Schilling","V.K. Sondak","H. Tawbi","A. Testori","U. Keilholz"],"twitterCount":5,"altmetricId":87130134,"statusesArray":["1292386933491077121","1292369137021456384","1292131335948165120","1292090691502460929","1290592913639055360"]},{"title":"Impact of compliance to chemoradiation on long-term outcomes in squamous cell carcinoma of the anus: results of a post hoc analysis from the randomised phase III …","googleId":"X2tuCjW7ZykJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420398999","googleCitationCount":5,"googleAuthor":"R Glynne-Jones","doi":"10.1016/j.annonc.2020.06.012","elsevierAuthor":"Glynne-Jones R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-10-01","elsevierCoverDisplayDate":"October 2020","elsevierCitationCount":"5","altmetricAuthors":["R. Glynne-Jones","H.M. Meadows","A. Lopes","R. Muirhead","D. Sebag-Montefiore","R. Adams"],"twitterCount":6,"altmetricId":85301223,"statusesArray":["1280492896391761925","1280424959421165568","1280265006072938498","1280264918378274817","1280264895364304902","1280090827193188359"]},{"title":"New hints towards a precision medicine strategy for IDH wild-type glioblastoma","googleId":"WRk3KBIrvfQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420424287","googleCitationCount":4,"googleAuthor":"BM Murphy","doi":"10.1016/j.annonc.2020.08.2336","elsevierAuthor":"White K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-12-01","elsevierCoverDisplayDate":"December 2020","elsevierCitationCount":"2","altmetricAuthors":["K. White","K. Connor","J. Clerkin","B.M. Murphy","M. Salvucci","A.C. O'Farrell","M. Rehm","D. O'Brien","J.H.M. Prehn","S.P. Niclou","M.L.M. Lamfers","M. Verreault","A. Idbaih","R. Verhaak","A. Golebiewska","A.T. Byrne"],"twitterCount":8,"altmetricId":89896337,"statusesArray":["1306140963010686976","1305231784939008008","1305046264451661824","1305043324542353409","1304444569233379329","1304438407544868865","1304418005389017088","1304411040231428096"]},{"title":"138O CNS metastases in HER2-positive metastatic breast cancer treated with trastuzumab deruxtecan: DESTINY-Breast01 subgroup analyses","googleId":"ZK5O7LqaH-EJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)36318-3/abstract","googleCitationCount":14,"googleAuthor":"","statusesArray":[]},{"title":"Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial","googleId":"uQKssSgFJl4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420398331","googleCitationCount":9,"googleAuthor":"JA Di Palma","doi":"10.1016/j.annonc.2020.05.012","elsevierAuthor":"Barcenas C.H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-09-01","elsevierCoverDisplayDate":"September 2020","elsevierCitationCount":"4","altmetricAuthors":["C.H. Barcenas","S.A. Hurvitz","J.A. Di Palma","R. Bose","A.J. Chien","N. Iannotti","G. Marx","A. Brufsky","A. Litvak","E. Ibrahim","R.H. Alvarez","M. Ruiz-Borrego","N. Chan","Y. Manalo","A. Kellum","M. Trudeau","M. Thirlwell","J. Garcia Saenz","D. Hunt","R. Bryce","L. McCulloch","H.S. Rugo","D. Tripathy","A. Chan","L. Carcas","A. Castrellon","D. Chan","K. Cheong","B. Choi","M. Coleman","A. Conlin","R. Dichmann","D. Ellison","N. Erickson","I. Gore","V. Hansen","D. Huang","D. Hufnagel","F. Kass","S.D. Kendall","M. Kozloff","W. Lawler","K.D. Nahum","B. Pistilli","E. Reyes","J. Seeger","R. Somer","E. Tan Chiu","G. Thomas","K. Tkaczuk","I. Vaziri","J. Wade","M. Wilkinson"],"twitterCount":4,"altmetricId":82803026,"statusesArray":["1280197411617615876","1273218340077670401","1267581859564830720","1266310093877866499","1265630947267018755","1265435012297605120"]},{"title":"Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR …","googleId":"E4X5KINOBgcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354018","googleCitationCount":7,"googleAuthor":"M Saigi","doi":"10.1016/j.annonc.2019.09.001","elsevierAuthor":"Pros E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-02-01","elsevierCoverDisplayDate":"February 2020","elsevierCitationCount":"6","altmetricAuthors":["E. Pros","M. Saigi","D. Alameda","G. Gomez-Mariano","B. Martinez-Delgado","J.J. Alburquerque-Bejar","J. Carretero","R. Tonda","A. Esteve-Codina","I. Catala","R. Palmero","M. Jove","C. Lazaro","A. Patiño-Garcia","I. Gil-Bazo","S. Verdura","A. Teulé","J. Torres-Lanzas","D. Sidransky","N. Reguart","R. Pio","O. Juan-Vidal","E. Nadal","E. Felip","L.M. Montuenga","M. Sanchez-Cespedes"],"twitterCount":2,"altmetricId":74353136,"statusesArray":["1220398379399819270","1220017057422594054"]},{"title":"A multicentre, randomised trial comparing schedules of G-CSF (filgrastim) administration for primary prophylaxis of chemotherapy-induced febrile neutropenia …","googleId":"sNkXhUwUOCUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420392966","googleCitationCount":9,"googleAuthor":"M Clemons","doi":"10.1016/j.annonc.2020.04.005","elsevierAuthor":"Clemons M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-07-01","elsevierCoverDisplayDate":"July 2020","elsevierCitationCount":"4","altmetricAuthors":["M. Clemons","D. Fergusson","D. Simos","M. Mates","A. Robinson","N. Califaretti","L. Zibdawi","M. Bahl","J. Raphael","M.F.K. Ibrahim","R. Fernandes","L. Pitre","O. Aseyev","C. Stober","L. Vandermeer","D. Saunders","B. Hutton","R. Mallick","G.R. Pond","A. Awan","J. Hilton"],"twitterCount":53,"altmetricId":80464234,"statusesArray":["1347268284169682949","1288840761258246151","1281198288256077825","1281178365689561088","1279383238797152257","1277938938229993472","1277703188603375619","1277683269094572034","1277655262791372805","1277628127322177537","1277604843230822400","1277576214862061573","1277576064240402433","1277562467149918210","1277560600416129025","1277543088785895426","1277502071957336065","1277498846637993985","1277493558463868933","1277490420344373249","1277485819268411396","1277463790284492800","1277458552748154884","1277443194242752512","1277441118750244864","1277392088577880064","1277375361010016259","1277372391002431489","1277365916607676417","1277364929155252226","1277353460292296705","1277353018154012672","1277350863288389635","1277347425351589888","1277346008964509697","1277341860005117953","1277334682825195520","1277334418797899776","1277333663915683841","1274778265463463939","1273001668603514880","1272992824053641217","1272900487725977600","1260012013327015936","1259968271186571265","1259911407304413194","1259851167129092097","1259834287148290050","1259831809615040512","1259779899944042497","1259747374462730240","1259744645547991041","1259742187413213185","1259732741152800769","1259730960192544768","1259715568686567425","1259705135846043649","1259705009396203521","1253625244188696577"]},{"title":"A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the …","googleId":"LIavQYLN_vsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420424597","googleCitationCount":7,"googleAuthor":"U Dafni","doi":"10.1016/j.annonc.2020.09.009","elsevierAuthor":"Popat S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-12-01","elsevierCoverDisplayDate":"December 2020","elsevierCitationCount":"8","altmetricAuthors":["S. Popat","A. Curioni-Fontecedro","U. Dafni","R. Shah","M. O'Brien","A. Pope","P. Fisher","J. Spicer","A. Roy","D. Gilligan","O. Gautschi","E. Nadal","W.D. Janthur","R. López Castro","R. García Campelo","S. Rusakiewicz","I. Letovanec","V. Polydoropoulou","H. Roschitzki-Voser","B. Ruepp","A. Gasca-Ruchti","S. Peters","R.A. Stahel"],"twitterCount":2,"altmetricId":91714901,"statusesArray":["1363990970723950592","1363927837342916615"]},{"title":"Single agent activity of U3-1402, a HER3-targeting antibody-drug conjugate, in HER3-overexpressing metastatic breast cancer: Updated results from a phase I/II trial","googleId":"68rXpXmeGXsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30419-3/abstract","googleCitationCount":14,"googleAuthor":"","statusesArray":[]},{"title":"Financial toxicity in lung cancer: an assessment of magnitude, perception, and impact on quality of life","googleId":"GVryPl7ojioJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354122","googleCitationCount":8,"googleAuthor":"W Fu","doi":"10.1016/j.annonc.2019.10.006","elsevierAuthor":"Hazell S.Z.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"January 2020","elsevierCitationCount":"7","altmetricAuthors":["S.Z. Hazell","W. Fu","C. Hu","K.R. Voong","B. Lee","V. Peterson","J.L. Feliciano","L.H. Nicholas","T.R. McNutt","P. Han","R.K. Hales"],"twitterCount":32,"altmetricId":73863216,"statusesArray":["1262727241676529664","1256916931082424320","1232055958051991554","1225253500000624640","1218947376163041280","1218293139879931904","1218170408496701440","1218169663139516417","1218129378225348608","1217475736346546177","1216672044714057728","1216642021303209986","1216585288337805313","1216423145785167873","1216371362647945218","1216357218792001536","1216291906654740482","1216234601804443648","1216073429171896321","1216039709132173312","1216019961291755522","1216017875590209536","1215989381351313408","1215988960566169600","1215980571727474689","1215977719453962240","1215968233347584001","1215932738705948672","1215898445971513344","1215895086095130625","1215876502501384193","1215869845008461827","1215802855228985345","1215799356801970176","1215794918007832576","1215794500192415744","1215794347146465281"]},{"title":"Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy","googleId":"bYVAfJ7ElAsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310853","googleCitationCount":12,"googleAuthor":"J Vidal","doi":"10.1093/annonc/mdz005","elsevierAuthor":"Vidal J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-03-01","elsevierCoverDisplayDate":"1 March 2019","elsevierCitationCount":"6","altmetricAuthors":["J. Vidal","B. Bellosillo","C. Santos Vivas","P. García-Alfonso","A. Carrato","M.T. Cano","R. García-Carbonero","E. Élez","F. Losa","B. Massutí","M. Valladares-Ayerbes","J.M. Viéitez","J.L. Manzano","D. Azuara","J. Gallego","S. Pairet","G. Capellá","R. Salazar","J. Tabernero","E. Aranda","C. Montagut"],"twitterCount":4,"altmetricId":57816501,"statusesArray":["1243256277679181825","1243105796046630914","1242807275301023744","1110747138571620352"]},{"title":"Conversion rate in locally advanced pancreatic cancer (LAPC) after nab-paclitaxel/gemcitabine-or FOLFIRINOX-based induction chemotherapy (NEOLAP) …","googleId":"ljWYHnSvVyMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419588913","googleCitationCount":13,"googleAuthor":"","doi":"10.1093/annonc/mdz247","elsevierAuthor":"Pinter M.","publicationName":"JAMA Oncology","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"January 2021","elsevierCitationCount":"3","altmetricAuthors":["V. Kunzmann","H. Algül","E. Goekkurt","G.M. Siegler","U.M. Martens","D. Waldschmidt","U. Pelzer","E. Hennes","M. Fuchs","J. Siveke","F. Kullmann","S. Boeck","T.J. Ettrich","P. Ferenczy","R. Keller","C.-T. Germer","H. Stein","I. Hartlapp","I. Klein","V. Heinemann"],"twitterCount":0,"altmetricId":69058759,"statusesArray":[]},{"title":"Activity of larotrectinib in TRK fusion lung cancer","googleId":"XIBRQdmZkL8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30060-2/abstract","googleCitationCount":12,"googleAuthor":"A Drilon","statusesArray":[]},{"title":"A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant …","googleId":"NTcg08-mTIIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420360373","googleCitationCount":10,"googleAuthor":"","doi":"10.1016/j.annonc.2020.01.074","elsevierAuthor":"Kolinsky M.P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-05-01","elsevierCoverDisplayDate":"May 2020","elsevierCitationCount":"2","altmetricAuthors":["M.P. Kolinsky","P. Rescigno","D. Bianchini","Z. Zafeiriou","N. Mehra","J. Mateo","V. Michalarea","R. Riisnaes","M. Crespo","I. Figueiredo","S. Miranda","D. Nava Rodrigues","P. Flohr","N. Tunariu","U. Banerji","R. Ruddle","A. Sharp","J. Welti","M. Lambros","S. Carreira","F.I. Raynaud","K.E. Swales","S. Plymate","J. Luo","H. Tovey","N. Porta","R. Slade","L. Leonard","E. Hall","J.S. de Bono"],"twitterCount":15,"altmetricId":78655049,"statusesArray":["1348562935124258816","1344676327002169344","1264891302111588352","1260996027408101377","1260690175165968389","1260683956695052293","1260679187955888129","1260626017389088768","1260620141513097219","1260594968550400002","1260589424943026177","1260587425975472129","1244714938553315332","1244675101825609730","1244675014399528960","1244654773892263945","1244643064179757057","1244625355299786755"]},{"title":"Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a …","googleId":"d83tG3ZZQn4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)32591-6/abstract","googleCitationCount":11,"googleAuthor":"J Remon","statusesArray":[]},{"title":"The DNA damage response pathway as a land of therapeutic opportunities for colorectal cancer","googleId":"gCdulKRKST0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420398690","googleCitationCount":5,"googleAuthor":"G Mauri","doi":"10.1016/j.annonc.2020.05.027","elsevierAuthor":"Mauri G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-09-01","elsevierCoverDisplayDate":"September 2020","elsevierCitationCount":"5","altmetricAuthors":["G. Mauri","S. Arena","S. Siena","A. Bardelli","A. Sartore-Bianchi"],"twitterCount":1,"altmetricId":94760798,"statusesArray":["1330599034311028737"]},{"title":"Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy☆","googleId":"J6RlTDboOUIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375342039788X","googleCitationCount":5,"googleAuthor":"","doi":"10.1016/j.annonc.2020.04.471","elsevierAuthor":"Owen C.N.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-08-01","elsevierCoverDisplayDate":"August 2020","elsevierCitationCount":"5","altmetricAuthors":["C.N. Owen","A.N. Shoushtari","D. Chauhan","D.J. Palmieri","B. Lee","M.W. Rohaan","J. Mangana","V. Atkinson","F. Zaman","A. Young","C. Hoeller","P. Hersey","R. Dummer","M.A. Khattak","M. Millward","S.P. Patel","A. Haydon","D.B. Johnson","S. Lo","C.U. Blank","S. Sandhu","M.S. Carlino","J.M.G. Larkin","A.M. Menzies","G.V. Long"],"twitterCount":2,"altmetricId":81787525,"statusesArray":["1260162354106466304","1259786838643863552"]},{"title":"Durvalumab activity in previously treated patients who stopped durvalumab without disease progression","googleId":"ZDJIpcmjKtsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419593875","googleCitationCount":7,"googleAuthor":"JC Soria","doi":"10.1093/annonc/mdz253.001","elsevierCitationCount":0,"altmetricAuthors":["S. Sheth","C. Gao","N. Mueller","P. Martinez","J.-C. Soria"],"twitterCount":1,"altmetricId":67588144,"statusesArray":["1179484649887809537"]},{"title":"Long-term outcomes from the randomized phase II study of nivolumab (nivo) or nivo+ ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets) …","googleId":"8pwtEE2GtV0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419595229","googleCitationCount":10,"googleAuthor":"GV Long","doi":"10.1093/annonc/mdz255.001","elsevierAuthor":"Phadke M.","publicationName":"Experimental Dermatology","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"2021","elsevierCitationCount":"0","altmetricAuthors":["G.V. Long","V.G. Atkinson","S. Lo","S.K. Sandhu","M. Brown","M. Gonzalez","A. Guminski","R.A. Scolyer","L. Emmett","A.M. Menzies","G.A. McArthur"],"twitterCount":0,"altmetricId":68179435,"statusesArray":[]},{"title":"Genomewide copy number alteration screening of circulating plasma DNA: potential for the detection of incipient tumors","googleId":"hmakyT2ThpwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419309901","googleCitationCount":12,"googleAuthor":"","doi":"10.1093/annonc/mdy476","elsevierAuthor":"Lenaerts L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-01-01","elsevierCoverDisplayDate":"1 January 2019","elsevierCitationCount":"8","altmetricAuthors":["L. Lenaerts","P. Vandenberghe","N. Brison","H. Che","M. Neofytou","M. Verheecke","L. Leemans","C. Maggen","B. Dewaele","L. Dehaspe","S. Vanderschueren","D. Dierickx","V. Vandecaveye","F. Amant","J.R. Vermeesch"],"twitterCount":12,"altmetricId":50524777,"statusesArray":["1065545716758654976","1058727624598528000","1058711655629185024","1058488768305422337","1058452974513442816","1058417718817443842","1058404186742677504","1058389984028188672","1058375456355954689","1058358070743449600","1057215304390995969","1057210947423690752"]},{"title":"Genomic origin and EGFR-TKI treatments of pulmonary adenosquamous carcinoma","googleId":"fSxC-lbZ3fYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420359470","googleCitationCount":5,"googleAuthor":"","doi":"10.1016/j.annonc.2020.01.014","elsevierAuthor":"Lin G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-04-01","elsevierCoverDisplayDate":"April 2020","elsevierCitationCount":"4","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain metastases","googleId":"1LpLr0Wqv9IJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420398355","googleCitationCount":5,"googleAuthor":"O Metzger Filho","doi":"10.1016/j.annonc.2020.05.014","elsevierAuthor":"Metzger Filho O.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-09-01","elsevierCoverDisplayDate":"September 2020","elsevierCitationCount":"4","altmetricAuthors":["O. Metzger Filho","J.P. Leone","T. Li","Z. Tan-Wasielewski","L. Trippa","W.T. Barry","J. Younger","E. Lawler","L. Walker","R.A. Freedman","S.M. Tolaney","I. Krop","E.P. Winer","N.U. Lin"],"twitterCount":36,"altmetricId":83393029,"statusesArray":["1296609324333228034","1296537493697900544","1296450730748936192","1296436409893519360","1271432632623140867","1269256089159077894","1269217173051867136","1268857780984832007","1268804461440491521","1268755595823325185","1268700481741885440","1268689341129375749","1268639969788284928","1268634183976574976","1268617271783677952","1268613291128942593","1268611845155426305","1268602266816315392","1268599328190365696","1268594071154700289","1268593488003768321","1268592957613096961","1268590452929892356","1268587092180897792","1268578900445147147","1268553145111793665","1268550150106071044","1268546473177894912","1268543166833209345","1268526890563878912","1268526679355527170","1268526358180900864","1268517187616210944","1268504048795254784","1268497060690567168","1268487683569070080","1268484427660668928","1268482514546569218","1268480127500984320"]},{"title":"Final PFS, updated OS and safety data from the randomised, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ …","googleId":"_IUT7LbfCD8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419596922","googleCitationCount":8,"googleAuthor":"","doi":"10.1093/annonc/mdz260.006","elsevierCitationCount":0,"altmetricAuthors":["T.S.K. Mok","A.T. Shaw","R.D. Camidge","S.M. Gadgeel","R. Rosell","R. Dziadziuszko","D.-W. Kim","M. Perol","S.-H. Ou","W. Bordogna","V. Smoljanović","M. Hilton","S. Peters"],"twitterCount":0,"altmetricId":67768424,"statusesArray":[]},{"title":"Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic …","googleId":"VF5Q4gDycQIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419360740","googleCitationCount":9,"googleAuthor":"","doi":"10.1016/j.annonc.2019.10.018","elsevierAuthor":"Moehler M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-02-01","elsevierCoverDisplayDate":"February 2020","elsevierCitationCount":"8","altmetricAuthors":["M. Moehler","A. Maderer","P.C. Thuss-Patience","B. Brenner","J. Meiler","T.J. Ettrich","R.-D. Hofheinz","S.E. Al-Batran","A. Vogel","L. Mueller","M.P. Lutz","F. Lordick","M. Alsina","K. Borchert","R. Greil","W. Eisterer","A. Schad","J. Slotta-Huspenina","E. Van Cutsem","S. Lorenzen"],"twitterCount":10,"altmetricId":74361831,"statusesArray":["1223249753783312385","1221544203592916993","1221438829061705728","1221333913077014528","1221327390930034689","1221298416317353986","1221022636546850816","1221015920879030272","1221009833987596288","1220018300522041346"]},{"title":"On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2","googleId":"kB5DSvDfPcAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39892-6/abstract","googleCitationCount":7,"googleAuthor":"","statusesArray":[]},{"title":"NGS-based profiling reveals a critical contributing role of somatic D-loop mtDNA mutations in HBV-related hepatocarcinogenesis","googleId":"W6HxnPjeaW0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311998","googleCitationCount":8,"googleAuthor":"","doi":"10.1093/annonc/mdz105","elsevierAuthor":"Yin C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-06-01","elsevierCoverDisplayDate":"1 June 2019","elsevierCitationCount":"5","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Prognostic significance of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in non-small cell lung cancer (NSCLC) treated with immune …","googleId":"N0YY9E9vWZ0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30016-X/abstract","googleCitationCount":14,"googleAuthor":"","statusesArray":[]},{"title":"First birth achieved after fertility preservation using vitrification of in vitro matured oocytes in a woman with breast cancer","googleId":"8f7oF_DdXqoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)35923-8/abstract","googleCitationCount":9,"googleAuthor":"","statusesArray":[]},{"title":"LBA75 Defining COVID-19 outcomes in thoracic cancer patients: TERAVOLT (Thoracic cancERs international coVid 19 cOLlaboraTion)","googleId":"bOP91W2he0cJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/pmc7506419/","googleCitationCount":6,"googleAuthor":"FR Hirsch","doi":"10.1016/j.annonc.2020.08.2316","elsevierCitationCount":0,"altmetricAuthors":["J. Baena Espinar","V. Torri","J. Whisenant","F.R. Hirsch","J. Rogado","J. de Castro Carpeño","B. Halmos","G.L. Ceresoli","A. Gomez Rueda","M. Tiseo","E. Felip","M. Majem Tarruella","I. Monnet","U. Tapan","H. Wakelee","L-C. Huang","M.C. Garassino","S. Peters","L. Horn","M. Hellmann"],"twitterCount":0,"altmetricId":93976201,"statusesArray":[]},{"title":"Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1/TRK fusion-positive solid tumors (TRIDENT-1 study)","googleId":"SUZ9CGVFySsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586665","googleCitationCount":8,"googleAuthor":"A Drilon","doi":"10.1093/annonc/mdz244.006","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden","googleId":"xtbxe2Q-DBcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420421702","googleCitationCount":4,"googleAuthor":"D Marinelli","doi":"10.1016/j.annonc.2020.08.2105","elsevierAuthor":"Marinelli D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-12-01","elsevierCoverDisplayDate":"December 2020","elsevierCitationCount":"2","altmetricAuthors":["D. Marinelli","M. Mazzotta","S. Scalera","I. Terrenato","F. Sperati","L. D'Ambrosio","M. Pallocca","G. Corleone","E. Krasniqi","L. Pizzuti","M. Barba","S. Carpano","P. Vici","M. Filetti","R. Giusti","A. Vecchione","M. Occhipinti","A. Gelibter","A. Botticelli","F. De Nicola","L. Ciuffreda","F. Goeman","E. Gallo","P. Visca","E. Pescarmona","M. Fanciulli","R. De Maria","P. Marchetti","G. Ciliberto","M. Maugeri-Saccà"],"twitterCount":18,"altmetricId":89111944,"statusesArray":["1358954593472958465","1303304523293896705","1300757301666541570","1300737219380916226","1299778809282138112","1299771564905373701","1299766159156416512","1299661073176498176","1299655530307350529","1299655507620311041","1299648639413948416","1299648018044551169","1299636504587841539","1299623632168198144","1299622617993957377","1299601942663041026","1299596735451455488","1299596237705039872"]},{"title":"Germline and sporadic cancers driven by the RAS pathway: parallels and contrasts","googleId":"YVYtYKIrbOsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375342036378X","googleCitationCount":6,"googleAuthor":"E Burkitt-Wright","doi":"10.1016/j.annonc.2020.03.291","elsevierAuthor":"Dunnett-Kane V.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-07-01","elsevierCoverDisplayDate":"July 2020","elsevierCitationCount":"3","altmetricAuthors":["V. Dunnett-Kane","E. Burkitt-Wright","F.H. Blackhall","A. Malliri","D.G. Evans","C.R. Lindsay"],"twitterCount":6,"altmetricId":79070003,"statusesArray":["1272611049729134595","1272424531815260160","1272271263227154434","1257704862760009728","1257190378924630019","1257078752594604035","1246457338850131973","1246439327179169793"]},{"title":"Avoiding over-and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet?","googleId":"tnCSfKiAFEYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312347","googleCitationCount":12,"googleAuthor":"A Matikas","doi":"10.1093/annonc/mdz126","elsevierAuthor":"Zerdes I.","publicationName":"Molecular Oncology","elsevierCoverDate":"2020-05-01","elsevierCoverDisplayDate":"1 May 2020","elsevierCitationCount":"3","altmetricAuthors":["A. Matikas","T. Foukakis","S. Swain","J. Bergh"],"twitterCount":3,"altmetricId":61553153,"statusesArray":["1153606356156522501","1153329173106188289","1136289619215958019"]},{"title":"Chemotherapy plus local-regional radiotherapy versus chemotherapy alone in primary metastatic nasopharyngeal carcinoma: A randomized, open-label, phase III trial","googleId":"rI-CjIc7UEoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)59320-6/abstract","googleCitationCount":9,"googleAuthor":"","statusesArray":[]},{"title":"Deep androgen receptor suppression in prostate cancer exploits sexually dimorphic renal expression for systemic glucocorticoid exposure","googleId":"91b7HY1ETPYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419532252","googleCitationCount":6,"googleAuthor":"M Alyamani","doi":"10.1016/j.annonc.2019.12.002","elsevierAuthor":"Alyamani M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-03-01","elsevierCoverDisplayDate":"March 2020","elsevierCitationCount":"3","altmetricAuthors":["M. Alyamani","J. Li","M. Patel","S. Taylor","F. Nakamura","M. Berk","C. Przybycin","E.M. Posadas","R.A. Madan","J.L. Gulley","B. Rini","J.A. Garcia","E.A. Klein","N. Sharifi"],"twitterCount":29,"altmetricId":75950997,"statusesArray":["1255042100724367361","1254887227680854018","1254866841455022080","1254863458635354112","1254863021567959040","1254859703269507072","1254065013922377730","1236415542107549696","1230616762087018501","1229485793518989318","1229414926197936128","1228672065042911234","1228641446317547520","1228637354753085441","1228473908032090117","1228361904340557825","1228358996916101121","1228358924249763841","1228349679282376704","1228319707905875976","1228318601188446213","1228314705741041664","1228312579744915456","1228311436423843842","1228311426160353280","1228311378697555968","1228073680552378368","1228038145029156866","1227975002097479688","1227972408205815810","1227965628675264513","1227953786578063360","1227833967589707776","1227791197197832192","1227733051062575104","1227726420442583040","1227720322952114177","1227707587665309702","1227705210027507712"]},{"title":"18-months relapse-free survival (RFS) and biomarker analyses of OpACIN-neo: A study to identify the optimal dosing schedule of neoadjuvant (neoadj) …","googleId":"PRMOPP4n9DYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604321","googleCitationCount":8,"googleAuthor":"AM Menzies","doi":"10.1093/annonc/mdz394.072","elsevierAuthor":"Pelster M.S.","publicationName":"Current Treatment Options in Oncology","elsevierCoverDate":"2020-02-01","elsevierCoverDisplayDate":"1 February 2020","elsevierCitationCount":"5","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Overall survival (OS) update in ALTER 1202: Anlotinib as third-line or further-line treatment in relapsed small-cell lung cancer (SCLC)","googleId":"IIGNdluRZEwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419598726","googleCitationCount":9,"googleAuthor":"","doi":"10.1093/annonc/mdz264.002","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Phase II study of 2 dosing regimens of cemiplimab, a human monoclonal anti–PD-1, in metastatic cutaneous squamous cell carcinoma (mCSCC)","googleId":"wI2O4utGDfcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341959528X","googleCitationCount":8,"googleAuthor":"D Rischin","doi":"10.1093/annonc/mdz255.007","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Lenvatinib (LEN) and pembrolizumab (PEMBRO) in advanced endometrial cancer (EC)","googleId":"Jy3jJ8va4gMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419592079","googleCitationCount":8,"googleAuthor":"V Makker","doi":"10.1093/annonc/mdz250.002","elsevierCitationCount":0,"altmetricAuthors":["V. Makker","M.H. Taylor","C. Aghajanian","A. Oaknin","J. Mier","A.L. Cohn","M Romeo Marin","R Bratos Lorenzo","M.S. Brose","C. DiSimone","M.J. Messing","D.E. Stepan","C.E. Dutcus","J. Wu","E.V. Schmidt","R.J. Orlowski","P. Sachdev","R. Shumaker","A Casado Herraez"],"twitterCount":0,"altmetricId":68179395,"statusesArray":[]},{"title":"Supporting clinical decision making in advanced melanoma by preclinical testing in personalized immune-humanized xenograft mouse models","googleId":"yA3kiA1zyioJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419390830","googleCitationCount":5,"googleAuthor":"H Jespersen","doi":"10.1016/j.annonc.2019.11.002","elsevierAuthor":"Ny L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-05-01","elsevierCoverDisplayDate":"May 2020","elsevierCitationCount":"0","altmetricAuthors":["L. Ny","L.Y. Rizzo","V. Belgrano","J. Karlsson","H. Jespersen","L. Carstam","R.O. Bagge","L.M. Nilsson","J.A. Nilsson"],"twitterCount":8,"altmetricId":73711313,"statusesArray":["1358094350157287432","1252997051220099072","1215066306329772032","1214832825188274181","1214828922602500096","1214678248485007360","1214615842899595264","1214552972664946688","1214547227554844672"]},{"title":"Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and …","googleId":"oV6uMfar37cJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354055","googleCitationCount":7,"googleAuthor":"","doi":"10.1016/j.annonc.2019.09.004","elsevierAuthor":"Kundranda M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-08-01","elsevierCoverDisplayDate":"August 2020","elsevierCitationCount":"0","altmetricAuthors":["M. Kundranda","A.C. Gracian","S.F. Zafar","E. Meiri","J. Bendell","H. Algül","F. Rivera","E.R. Ahn","D. Watkins","U. Pelzer","V. Charu","A. Zalutskaya","G. Kuesters","J.M. Pipas","S. Santillana","V. Askoxylakis","A.H. Ko"],"twitterCount":1,"altmetricId":73785684,"statusesArray":["1215229244529422337"]},{"title":"Model-based evaluation of the efficacy and safety of nivolumab once every 4 weeks across multiple tumor types","googleId":"vIN32Nud6uEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419360703","googleCitationCount":5,"googleAuthor":"V Ivaturi","doi":"10.1016/j.annonc.2019.10.015","elsevierAuthor":"Zhao X.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-02-01","elsevierCoverDisplayDate":"February 2020","elsevierCitationCount":"2","altmetricAuthors":["X. Zhao","J. Shen","V. Ivaturi","M. Gopalakrishnan","Y. Feng","B.J. Schmidt","P. Statkevich","V. Goodman","J. Gobburu","A. Bello","A. Roy","S. Agrawal"],"twitterCount":12,"altmetricId":74351416,"statusesArray":["1227993445781864450","1227930797786763264","1227895574038536193","1227840901650829312","1227837252568526849","1227821184638750720","1227819965388075011","1227796794169602048","1227791763135270913","1223823364961132545","1223823238687363074","1219948372808949760"]},{"title":"Randomized phase II (RP2) study of ATR inhibitor M6620 in combination with gemcitabine versus gemcitabine alone in platinum-resistant high grade serous …","googleId":"QH2-VdfZMYsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604175","googleCitationCount":7,"googleAuthor":"PA Konstantinopoulos","doi":"10.1093/annonc/mdz394.057","elsevierAuthor":"Schleicher E.M.","publicationName":"PLoS Genetics","elsevierCoverDate":"2020-11-02","elsevierCoverDisplayDate":"2 November 2020","elsevierCitationCount":"0","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancer","googleId":"QHmAlpzWXncJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420364140","googleCitationCount":3,"googleAuthor":"S Dutta","doi":"10.1016/j.annonc.2020.03.309","elsevierAuthor":"Halabi S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-07-01","elsevierCoverDisplayDate":"July 2020","elsevierCitationCount":"2","altmetricAuthors":["S. Halabi","S. Dutta","C.M. Tangen","M. Rosenthal","D.P. Petrylak","I.M. Thompson","K.N. Chi","J.S. De Bono","J.C. Araujo","C. Logothetis","M.A. Eisenberger","D.I. Quinn","K. Fizazi","M.J. Morris","C.S. Higano","I.F. Tannock","E.J. Small","W.K. Kelly"],"twitterCount":11,"altmetricId":79834251,"statusesArray":["1276183374319804416","1256213091672559617","1256049656389349377","1255944525085802497","1255944321376927744","1253680305409527808","1250961032215818240","1250866873970950144","1250789631395868672","1250786364322246657","1250785123903197185","1250364257402630145"]},{"title":"Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: Pooled analysis of 6501 patients treated with fluorouracil …","googleId":"u1LOP2qmqCEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375342035924X","googleCitationCount":5,"googleAuthor":"J Yin","doi":"10.1016/j.annonc.2019.12.007","elsevierAuthor":"Salem M.E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-04-01","elsevierCoverDisplayDate":"April 2020","elsevierCitationCount":"5","altmetricAuthors":["M.E. Salem","J. Yin","R.M. Goldberg","L.D. Pederson","N. Wolmark","S.R. Alberts","J. Taieb","J.L. Marshall","S. Lonardi","T. Yoshino","R.S. Kerr","G. Yothers","A. Grothey","T. Andre","A. De Gramont","Q. Shi"],"twitterCount":5,"altmetricId":76551115,"statusesArray":["1259494676551303169","1249810797401911305","1244317981447835648","1244254578260000768","1244254545208840193","1244254241612607490","1244252481057705984","1231502281176166404"]},{"title":"Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer","googleId":"XU9SkaKn8nwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420398902","googleCitationCount":5,"googleAuthor":"F Ruiz-Pace","doi":"10.1016/j.annonc.2020.06.003","elsevierAuthor":"Serna G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-10-01","elsevierCoverDisplayDate":"October 2020","elsevierCitationCount":"4","altmetricAuthors":["G. Serna","F. Ruiz-Pace","J. Hernando","L. Alonso","R. Fasani","S. Landolfi","R. Comas","J. Jimenez","E. Elez","S. Bullman","J. Tabernero","J. Capdevila","R. Dienstmann","P. Nuciforo"],"twitterCount":30,"altmetricId":84535116,"statusesArray":["1290682414562385921","1290681332742279168","1284783366869590016","1277554258884415490","1276560991229100035","1276075050261712896","1276033460801540096","1275841842815414272","1275829173848809473","1275799890577240065","1275799325235392512","1275797229979283456","1275648406053101568","1275646767451734023","1275617446091608065","1275575463860150272","1275573481690685440","1275563139694841860","1275559230116937729","1275443722885328896","1275427152255541248","1275426045198512129","1275422843069743106","1275418112939241473","1275418028931457024","1275412423533449217","1275394309903114240","1275368656751357952","1275368035684020224","1275338266858999810"]},{"title":"Combinatorial immunotherapy strategies: most gods throw dice, but fate plays chess","googleId":"CxpwHk0n__EJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)32593-X/abstract","googleCitationCount":7,"googleAuthor":"J Ciccolini","statusesArray":[]},{"title":"Associations of early life and adulthood adiposity with risk of epithelial ovarian cancer","googleId":"AyA8rab9h-YJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310415","googleCitationCount":9,"googleAuthor":"T Huang","doi":"10.1093/annonc/mdy546","elsevierAuthor":"Huang T.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-02-01","elsevierCoverDisplayDate":"1 February 2019","elsevierCitationCount":"5","altmetricAuthors":["T. Huang","S.S. Tworoger","W.C. Willett","M.J. Stampfer","B.A. Rosner"],"twitterCount":3,"altmetricId":53259501,"statusesArray":["1079298479661465600","1078951007634243596","1077179597496606721"]},{"title":"Efficacy and safety of nivolumab in combination with docetaxel in men with metastatic castration-resistant prostate cancer in checkmate 9KD","googleId":"6ZJbXrwKE1wJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604059","googleCitationCount":6,"googleAuthor":"","doi":"10.1093/annonc/mdz394.045","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"LBA15 Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel (PAC)±atezolizumab (atezo) for …","googleId":"0EHi1GzH994J","googleLink":"https://www.researchgate.net/profile/Margarita_Donica/publication/345371639_LBA15_Primary_results_from_IMpassion131_a_double-blind_placebo-controlled_randomised_phase_III_trial_of_first-line_paclitaxel_PAC_atezolizumab_atezo_for_unresectable_locally_advancedmetastatic_triple-/links/5fd27161299bf188d40afe50/LBA15-Primary-results-from-IMpassion131-a-double-blind-placebo-controlled-randomised-phase-III-trial-of-first-line-paclitaxel-PAC-atezolizumab-atezo-for-unresectable-locally-advanced-metastatic-trip.pdf","googleCitationCount":6,"googleAuthor":"F André","statusesArray":[]},{"title":"Safety and efficacy of TRIplet combination of nivolumab (N) with dabrafenib (D) and trametinib (T) in patients (pts) with BRAF-mutated metastatic …","googleId":"hKdrcqMzaLcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419595230","googleCitationCount":9,"googleAuthor":"","doi":"10.1093/annonc/mdz255.002","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Safety and efficacy of pembrolizumab (Pembro) monotherapy in elderly patients (Pts) with PD-L1–positive advanced NSCLC: pooled analysis from KEYNOTE-010 …","googleId":"ZLNLGxi6yekJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30052-3/abstract","googleCitationCount":12,"googleAuthor":"P Baas","statusesArray":[]},{"title":"Hyperprogression during immunotherapy: do we really want to know?","googleId":"ZmOi6P0b4ekJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31252-9/abstract","googleCitationCount":8,"googleAuthor":"S Champiat","statusesArray":[]},{"title":"Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma","googleId":"3_YgXegM5ekJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375342036381X","googleCitationCount":5,"googleAuthor":"V Moreno","doi":"10.1016/j.annonc.2020.03.294","elsevierAuthor":"Moreno V.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-06-01","elsevierCoverDisplayDate":"June 2020","elsevierCitationCount":"3","altmetricAuthors":["V. Moreno","J.M. Sepulveda","M. Vieito","T. Hernández-Guerrero","B. Doger","O. Saavedra","O. Ferrero","R. Sarmiento","M. Arias","J. De Alvaro","J. Di Martino","M. Zuraek","T. Sanchez-Pérez","I. Aronchik","E.H. Filvaroff","M. Lamba","B. Hanna","Z. Nikolova","I. Braña"],"twitterCount":4,"altmetricId":78957917,"statusesArray":["1282162180033359873","1247106340050423808","1247104277941751809","1246015476066484224"]},{"title":"LBA45 First report of efficacy and safety from the phase II study SECOMBIT (SEquential COMBo Immuno and Targeted therapy study)","googleId":"kAcGkVgOBLYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42357-9/abstract","googleCitationCount":5,"googleAuthor":"PA Ascierto","statusesArray":[]},{"title":"Pembrolizumab in patients with MSI-H advanced endometrial cancer from the KEYNOTE-158 study","googleId":"uNP2m2WV8e8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419592572","googleCitationCount":6,"googleAuthor":"","doi":"10.1093/annonc/mdz250.052","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Niraparib therapy in patients with newly diagnosed advanced ovarian cancer (PRIMA/ENGOT-OV26/GOG-3012 study)","googleId":"QcO9t0yY9KkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604126","googleCitationCount":8,"googleAuthor":"IB Vergote","doi":"10.1093/annonc/mdz394.052","elsevierCitationCount":0,"altmetricAuthors":["A. González Martín","B. Pothuri","I.B. Vergote","R.D. Christensen","W. Graybill","M.R. Mirza","C. McCormick","D. Lorusso","P. Hoskins","G. Freyer","F. Backes","K. Baumann","A. Redondo","R.G. Moore","C. Vulsteke","R.E. O’Cearbhaill","B. Lund","Y. Li","D. Gupta","B.J. Monk"],"twitterCount":0,"altmetricId":68011604,"statusesArray":[]},{"title":"Primary results from TAIL, a global single-arm safety study of atezolizumab (atezo) monotherapy in a diverse population of patients with previously treated …","googleId":"axZKfNw5nEwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604424","googleCitationCount":7,"googleAuthor":"S Azevedo","doi":"10.1093/annonc/mdz394.082","elsevierCitationCount":0,"altmetricAuthors":["A. Ardizzoni","S. Azevedo","B. Rubio Viquiera","D. Rodriguez Abreu","J. Alatorre-Alexander","H.J. Smit","J. Yu","K. Syrigos","H. Patel","J. Tolson","A. Cardona","P. Perez Moreno","T. Newsom-Davis"],"twitterCount":1,"altmetricId":67584403,"statusesArray":["1179450323305455617"]},{"title":"Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase …","googleId":"I3igMxL0WfMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420432211","googleCitationCount":2,"googleAuthor":"","doi":"10.1016/j.annonc.2020.12.013","elsevierAuthor":"Martin M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"2021","elsevierCitationCount":"0","altmetricAuthors":["M. Martin","C. Zielinski","M. Ruiz-Borrego","E. Carrasco","N. Turner","E.M. Ciruelos","M. Muñoz","B. Bermejo","M. Margeli","A. Anton","Z. Kahan","T. Csöszi","M.I. Casas","L. Murillo","S. Morales","E. Alba","E. Gal-Yam","A. Guerrero-Zotano","L. Calvo","J. de la Haba-Rodriguez","M. Ramos","I. Alvarez","A. Garcia-Palomo","C. Huang Bartlett","M. Koehler","R. Caballero","M. Corsaro","X. Huang","J.A. Garcia-Sáenz","J.I. Chacón","C. Swift","C. Thallinger","M. Gil-Gil"],"twitterCount":24,"altmetricId":96844915,"statusesArray":["1351206546647220231","1351131832327266314","1351104417676861443","1349808513640488962","1345670747746922496","1345521124528984065","1345439249118576641","1345422348263034886","1345383067402326016","1345381012675715072","1345369529241763842","1345328399380692996","1345324620837056512","1345098986856841216","1344409364627644418","1344370588534640643","1344345824101191682","1344342041245986819","1344341559270113292","1344338978502225921","1344316083780644865","1344308886082301953","1344307720325918720","1344306892097552389","1344276062855974913","1344243463143960578","1344242489046097921"]},{"title":"Trilaciclib (T) decreases myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy plus atezolizumab","googleId":"cMlfn6VU-ysJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419598751","googleCitationCount":6,"googleAuthor":"D Daniel","doi":"10.1093/annonc/mdz264.006","elsevierCitationCount":0,"altmetricAuthors":["D. Daniel","V. Kuchava","I. Bondarenko","O. Ivashchuk","D. Spigel","A. Dasgupta","S. Reddy","T. Melkadze","J. Jaal","I. Kudaba","L. Hart","A. Matitashvili","K.D. Koynov","Z. Yang","S.G. Wolfe","R. Malik","S.R. Morris","J.M. Antal","J. Goldschmidt"],"twitterCount":0,"altmetricId":100059240,"statusesArray":[]},{"title":"Benefit of prostate radiotherapy for patients with lymph node only or< 4 bone metastasis and no visceral metastases: Exploratory analyses of metastatic site …","googleId":"SpuphOViGsoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419590664","googleCitationCount":8,"googleAuthor":"ND James","doi":"10.1093/annonc/mdz248.007","elsevierCitationCount":0,"altmetricAuthors":["S.A. Ali","A. Hoyle","N.D. James","C. Parker","C. Brawley","G. Attard","H. Douis","M.D. Mason","M.K.B. Parmar","M.R. Sydes","N.W. Clarke"],"twitterCount":10,"altmetricId":68933720,"statusesArray":["1186012269794099201","1185946802115076096","1185832234260938752","1185651808125050881","1185607914230374400","1185589992107626496","1185576135272419329","1185570606202400770","1185544010913538048","1185530382160142336","1185429781191393280","1185333844037242882"]},{"title":"LBA17 ASCENT: A randomized phase III study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with previously treated …","googleId":"6OIi3uM_3HcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42327-0/abstract","googleCitationCount":16,"googleAuthor":"K Punie","statusesArray":[]},{"title":"Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option","googleId":"GH5N_3OE6AoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311767","googleCitationCount":10,"googleAuthor":"SN Westin","doi":"10.1093/annonc/mdz104","elsevierAuthor":"Buechel M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-05-01","elsevierCoverDisplayDate":"May 2019","elsevierCitationCount":"7","altmetricAuthors":["M. Buechel","T.J. Herzog","S.N. Westin","R.L. Coleman","B.J. Monk","K.N. Moore"],"twitterCount":2,"altmetricId":57337328,"statusesArray":["1109711011119017985","1108327205405261824"]},{"title":"NRG1 fusion-driven tumors: biology, detection and the therapeutic role of afatinib and other ErbB-targeting agents","googleId":"wFZhWfqIjIAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420424275","googleCitationCount":2,"googleAuthor":"K Tolba","doi":"10.1016/j.annonc.2020.08.2335","elsevierAuthor":"Laskin J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-12-01","elsevierCoverDisplayDate":"December 2020","elsevierCitationCount":"1","altmetricAuthors":["J. Laskin","S.V. Liu","K. Tolba","C. Heining","R.F. Schlenk","P. Cheema","J. Cadranel","M.R. Jones","A. Drilon","A. Cseh","S. Gyorffy","F. Solca","M. Duruisseaux"],"twitterCount":3,"altmetricId":89960698,"statusesArray":["1363551265230376975","1304932914178797573","1304756571717726208"]},{"title":"Relation of cetuximab-induced skin toxicity and early tumor shrinkage in metastatic colorectal cancer patients: results of the randomized phase 3 trial FIRE-3 …","googleId":"XV2yr0JKKhsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341935402X","googleCitationCount":9,"googleAuthor":"","doi":"10.1016/j.annonc.2019.10.001","elsevierAuthor":"Holch J.W.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"January 2020","elsevierCitationCount":"4","altmetricAuthors":["J.W. Holch","S. Held","S. Stintzing","L. Fischer von Weikersthal","T. Decker","A. Kiani","F. Kaiser","T. Heintges","C. Kahl","F. Kullmann","W. Scheithauer","M. Moehler","J.C. von Einem","M. Michl","V. Heinemann"],"twitterCount":3,"altmetricId":73786751,"statusesArray":["1347202142793302018","1215331998757216258","1215235026670899202"]},{"title":"Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase …","googleId":"2hoJ72fIdV8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311123","googleCitationCount":10,"googleAuthor":"S Delaloge","doi":"10.1093/annonc/mdz016","elsevierAuthor":"Delaloge S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-04-01","elsevierCoverDisplayDate":"April 2019","elsevierCitationCount":"7","altmetricAuthors":["S. Delaloge","D. Cella","Y. Ye","M. Buyse","A. Chan","C.H. Barrios","F.A. Holmes","J. Mansi","H. Iwata","B. Ejlertsen","B. Moy","S.K.L. Chia","M. Gnant","S. Smichkoska","A. Ciceniene","N. Martinez","S. Filipović","N.E. Ben-Baruch","A.A. Joy","S.T. Langkjer","F. Senecal","R.H. de Boer","S. Moran","B. Yao","R. Bryce","A. Auerbach","L. Fallowfield","M. Martin"],"twitterCount":17,"altmetricId":54336549,"statusesArray":["1095719879544659969","1095719612778467331","1089540228816093184","1089014279251087360","1088536592187355136","1088366406289117185","1088333432646709248","1088250635621974022","1088174576398405632","1088155792304427008","1088129932440584193","1088129758825725952","1088125266457780224","1088117044262899713","1088113579381981185","1088112071617724416","1088100128404193280"]},{"title":"SO-26 Clinical efficacy of combined BRAF, MEK, and PD-1 inhibition in BRAFV600E colorectal cancer patients","googleId":"Zqj5W-2vcvcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39340-6/pdf","googleCitationCount":6,"googleAuthor":"","statusesArray":[]},{"title":"LBA71 Systemic cancer treatment-related outcomes in patients with SARS-CoV-2 infection: A CCC19 registry analysis","googleId":"EZWUlpk9zG4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42394-4/abstract","googleCitationCount":6,"googleAuthor":"A Desai","statusesArray":[]},{"title":"Results of REARRANGE trial: A randomized phase 2 study comparing different dosing approaches for regorafenib (REG) during the first cycle of treatment in patients …","googleId":"Mqc4-PyeEJkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30534-4/abstract","googleCitationCount":13,"googleAuthor":"","statusesArray":[]},{"title":"LBA16 IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab+ nab-paclitaxel vs placebo+ nab-paclitaxel in previously untreated …","googleId":"pGEc_Be6CZoJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506448/","googleCitationCount":7,"googleAuthor":"LA Emens","doi":"10.1016/j.annonc.2020.08.2244","elsevierCitationCount":0,"altmetricAuthors":["L.A. Emens","S. Adams","C.H. Barrios","V.C. Dieras","H. Iwata","S. Loi","H.S. Rugo","A. Schneeweiss","E.P. Winer","S. Patel","V. Henschel","A. Swat","M. Kaul","L. Molinero","S.Y. Chui","P. Schmid"],"twitterCount":0,"altmetricId":96978182,"statusesArray":[]},{"title":"Phase (Ph) II study of MBG453+ spartalizumab in patients (pts) with non-small cell lung cancer (NSCLC) and melanoma pretreated with anti–PD-1/L1 therapy","googleId":"1iXmwrgh7_gJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594145","googleCitationCount":7,"googleAuthor":"DW Kim","doi":"10.1093/annonc/mdz253.028","elsevierAuthor":"Morganti S.","publicationName":"ecancermedicalscience","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"0","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study☆","googleId":"IyIuWeNxY80J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420424615","googleCitationCount":4,"googleAuthor":"M Bandini","doi":"10.1016/j.annonc.2020.09.011","elsevierAuthor":"Bandini M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-12-01","elsevierCoverDisplayDate":"December 2020","elsevierCitationCount":"2","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Molecular screening to select therapy for advanced cancer?","googleId":"7DkpRHL1apYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31172-X/abstract","googleCitationCount":11,"googleAuthor":"IF Tannock","statusesArray":[]},{"title":"A phase III, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non-small-cell lung cancer","googleId":"u31LmrWx5v0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312359","googleCitationCount":10,"googleAuthor":"RJ Kelly","doi":"10.1093/annonc/mdz128","elsevierAuthor":"Kelly R.J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-07-01","elsevierCoverDisplayDate":"1 July 2019","elsevierCitationCount":"7","altmetricAuthors":["R.J. Kelly","F.A. Shepherd","A. Krivoshik","F. Jie","L. Horn"],"twitterCount":28,"altmetricId":60228860,"statusesArray":["1130343757738643456","1129006130565402625","1128953641677795328","1128946452410052608","1128926384703889408","1128890057593708544","1128836744936169472","1128781501330546695","1128724966642520064","1128724270304169984","1128722472415780864","1128722079992504322","1128716343719673856","1128715653362462720","1128715574694088706","1128708485611388933","1128690796868321280","1128688515166949376","1128688113423749122","1128661595591196673","1128658381584179201","1128655384221241345","1128475476727599104","1128458215996280833","1128414258247733248","1128333052524892160","1128324046867664897","1128321500207968261","1128317796646039552","1127626497932578818","1127506873035448320","1126719894722994178","1126710562535104513"]},{"title":"Phase II study of osimertinib in NSCLC patients with EGFR exon 20 insertion mutation: A multicenter trial of the Korean Cancer Study Group (LU17-19)","googleId":"Fh_YjwOALCUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419597368","googleCitationCount":7,"googleAuthor":"TM Kim","doi":"10.1093/annonc/mdz260.051","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration …","googleId":"x-7m5RVTDDYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419609762","googleCitationCount":6,"googleAuthor":"R Kurzrock","doi":"10.1093/annonc/mdz232","elsevierAuthor":"Kurzrock R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-10-01","elsevierCoverDisplayDate":"1 October 2019","elsevierCitationCount":"5","altmetricAuthors":["R. Kurzrock","L.A. Gurski","R.W. Carlson","D.S. Ettinger","S.M. Horwitz","S.K. Kumar","L. Million","M. von Mehren","A.B. Benson"],"twitterCount":48,"altmetricId":64567083,"statusesArray":["1278346816551940097","1278165981114691584","1201430123393757184","1201343149064499201","1201325513769283584","1201313600016650242","1201309762136236038","1201265997749071877","1200036943347814402","1199842282448605184","1199792079943143425","1199790013518635010","1199789075995254785","1199777596973694984","1199763664976465921","1199723688830152705","1199708916055203840","1199691601531981825","1199685466460692480","1199672065772720129","1199671596992081924","1199670967187972096","1199646904558206977","1199642418343301120","1199642281185140737","1159804492830904320","1159716893185458177","1159663745909567488","1159591635321274368","1159590863258783744","1159556843720663040","1159506098619068422","1159498718602641408","1159498446904053760","1159460444194648065","1159459900986146816","1159459686397161472","1159454520356872192","1159450364871139331","1159447833965203457","1159447802877030401","1159440259492581376","1159435361921249280","1159432430102577152","1159430373991993344","1159425687520010240","1159423696966225921","1159419243282219008","1159412020237803520","1159410710180323328","1159400104765394944","1158448659538817024","1158320770973675520","1158259165015490560","1158232663418789888"]},{"title":"Impact of early introduction of steroid on immune-checkpoint inhibitors (ICI) in patients with advanced non-small cell lung cancer treated","googleId":"eJ5hosmQbnQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420344252","googleCitationCount":6,"googleAuthor":"A De Giglio","doi":"10.1093/annonc/mdz449","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Updated overall survival (OS) from extended follow up in ARCHER 1050: a randomized Phase III study comparing dacomitinib with gefitinib as first-line …","googleId":"YN1Kh9RfAu4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419582230","googleCitationCount":6,"googleAuthor":"","doi":"10.1093/annonc/mdz446.018","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Extended induction chemotherapy does not improve the outcome for high-risk neuroblastoma patients: results of the randomized open-label GPOH trial …","googleId":"BcY_nKhaYsAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419406996","googleCitationCount":9,"googleAuthor":"","doi":"10.1016/j.annonc.2019.11.011","elsevierAuthor":"Berthold F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-03-01","elsevierCoverDisplayDate":"March 2020","elsevierCitationCount":"8","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Validation of a clinicopathological and gene expression profile (CP-GEP) model for sentinel lymph node metastasis in primary cutaneous melanoma","googleId":"lckIDNYs8wgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419595357","googleCitationCount":7,"googleAuthor":"D Tempel","doi":"10.1093/annonc/mdz255.014","elsevierAuthor":"Grossman D.","publicationName":"JAMA Dermatology","elsevierCoverDate":"2020-09-01","elsevierCoverDisplayDate":"September 2020","elsevierCitationCount":"7","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Using methylation signatures on cell-free DNA for early cancer detection: a new era in liquid biopsy?","googleId":"3NGeYrZpslsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)36411-5/pdf","googleCitationCount":4,"googleAuthor":"","statusesArray":[]},{"title":"Management of toxicity to isoform α-specific PI3K inhibitors","googleId":"9TTVrHvfHxAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420343763","googleCitationCount":12,"googleAuthor":"","doi":"10.1093/annonc/mdz440","elsevierAuthor":"Nunnery S.E.","publicationName":"Annals of oncology : official journal of the European Society for Medical Oncology","elsevierCoverDate":"2019-12-01","elsevierCoverDisplayDate":"1 December 2019","elsevierCitationCount":"5","altmetricAuthors":["S.E. Nunnery","I.A. Mayer"],"twitterCount":15,"altmetricId":68916417,"statusesArray":["1217389233465262080","1187244371353243649","1187142523917160450","1187104025331851266","1186978647371997185","1186971859591598081","1186952318937391104","1186949210773446656","1186944361315160065","1186938587729797120","1186928559123828736","1186927136910786561","1186926050313297922","1186657378357276673","1185203674647322625"]},{"title":"Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3–5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK …","googleId":"i0zThZVYZvUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420398379","googleCitationCount":2,"googleAuthor":"","doi":"10.1016/j.annonc.2020.05.016","elsevierAuthor":"McMillan A.K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-09-01","elsevierCoverDisplayDate":"September 2020","elsevierCitationCount":"1","altmetricAuthors":["A.K. McMillan","E.H. Phillips","A.A. Kirkwood","S. Barrans","C. Burton","S. Rule","R. Patmore","R. Pettengell","K.M. Ardeshna","A. Lawrie","S. Montoto","S. Paneesha","L. Clifton-Hadley","D.C. Linch"],"twitterCount":3,"altmetricId":82998103,"statusesArray":["1266630572295716864","1266346056377237505","1266310075171233792"]},{"title":"Preoperative cisplatin, fluorouracil, and docetaxel with or without radiotherapy after poor early response to cisplatin and fluorouracil for resectable oesophageal …","googleId":"UlM1IW-p1Y4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419360764","googleCitationCount":7,"googleAuthor":"","doi":"10.1016/j.annonc.2019.10.019","elsevierAuthor":"Barbour A.P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-02-01","elsevierCoverDisplayDate":"February 2020","elsevierCitationCount":"6","altmetricAuthors":["A.P. Barbour","E.T. Walpole","G.T. Mai","E.H. Barnes","D.I. Watson","S.P. Ackland","J.M. Martin","M. Burge","R. Finch","C.S. Karapetis","J. Shannon","L.M. Nott","S. Varma","G. Marx","G.L. Falk","V. Gebski","M. Oostendorp","K. Wilson","J. Thomas","G. Lampe","J.R. Zalcberg","J. Simes","B.M. Smithers","A. Barbour","J. Simes","E. Walpole","T. Mai","D. Watson","C. Karapetis","V. Gebski","L. Barnes","M. Oostendorp","K. Wilson"],"twitterCount":7,"altmetricId":74373005,"statusesArray":["1234267533689024512","1222773387199533056","1222463416838680578","1222297036369719296","1222295998233399298","1222273413571432448","1220136326000832512","1220113799694340096"]},{"title":"A cost-effectiveness analysis of consolidation immunotherapy with durvalumab in stage III NSCLC responding to definitive radiochemotherapy in Switzerland","googleId":"v3_4HwlBkOgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420359287","googleCitationCount":4,"googleAuthor":"","doi":"10.1016/j.annonc.2020.01.007","elsevierAuthor":"Panje C.M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-04-01","elsevierCoverDisplayDate":"April 2020","elsevierCitationCount":"3","altmetricAuthors":["C.M. Panje","J.E. Lupatsch","M. Barbier","E. Pardo","M. Lorez","K.J. Dedes","D.M. Aebersold","L. Plasswilm","O. Gautschi","M. Schwenkglenks"],"twitterCount":26,"altmetricId":74897915,"statusesArray":["1224536862334824449","1224422893200855041","1224413068593111041","1224402526113542144","1224394187094876161","1224347874730766338","1224298968282214400","1224219810445303808","1224192787895201793","1224183173459791872","1224140473637359616","1224116149358682112","1224099275740712964","1224080949559939072","1224051978239647745","1224051416764944387","1224051032474284032","1224050500703870977","1224034499547320320","1224030813278416896","1224000480269013000","1223997307152162817","1223994984090808320","1223989327538966528","1223912576029011968","1223902412957614081","1223878777387802630"]},{"title":"Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm …","googleId":"iZS6BqeHw0oJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420424457","googleCitationCount":5,"googleAuthor":"","doi":"10.1016/j.annonc.2020.09.004","elsevierAuthor":"Kalinsky K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-12-01","elsevierCoverDisplayDate":"December 2020","elsevierCitationCount":"3","altmetricAuthors":["K. Kalinsky","J.R. Diamond","L.T. Vahdat","S.M. Tolaney","D. Juric","J. O'Shaughnessy","R.L. Moroose","I.A. Mayer","V.G. Abramson","D.M. Goldenberg","R.M. Sharkey","P. Maliakal","Q. Hong","T. Goswami","W.A. Wegener","A. Bardia"],"twitterCount":11,"altmetricId":92299517,"statusesArray":["1334030893883781120","1333753147127455744","1333712053303988226","1333678582204420096","1333640861352161280","1333580483209342976","1333517883880554496","1333472403108880386","1333464638952968193","1333426349051174912","1333378037421903877"]},{"title":"Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network","googleId":"ovIZTPCnhxIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420422975","googleCitationCount":6,"googleAuthor":"B Bjerkehagen","doi":"10.1016/j.annonc.2020.08.2232","elsevierAuthor":"Demetri G.D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-11-01","elsevierCoverDisplayDate":"November 2020","elsevierCitationCount":"1","altmetricAuthors":["G.D. Demetri","C.R. Antonescu","B. Bjerkehagen","J.V.M.G. Bovée","K. Boye","M. Chacón","A.P. Dei Tos","J. Desai","J.A. Fletcher","H. Gelderblom","S. George","A. Gronchi","R.L. Haas","N. Hindi","P. Hohenberger","H. Joensuu","R.L. Jones","I. Judson","Y.-K. Kang","A. Kawai","A.J. Lazar","A. Le Cesne","R. Maestro","R.G. Maki","J. Martín","S. Patel","F. Penault-Llorca","C. Premanand Raut","P. Rutkowski","A. Safwat","M. Sbaraglia","I.-M. Schaefer","L. Shen","C. Serrano","P. Schöffski","S. Stacchiotti","K. Sundby Hall","W.D. Tap","D.M. Thomas","J. Trent","C. Valverde","W.T.A. van der Graaf","M. von Mehren","A. Wagner","E. Wardelmann","Y. Naito","J. Zalcberg","J.-Y. Blay"],"twitterCount":7,"altmetricId":89644708,"statusesArray":["1319936319297040384","1319387436494053376","1319230892846600193","1318869284660137985","1303304394830688258","1303277003941072896","1303242307869704192"]},{"title":"610O Final overall survival (OS) analysis of PROfound: Olaparib vs physician's choice of enzalutamide or abiraterone in patients (pts) with metastatic castration …","googleId":"xKUe8dng_18J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40866-X/abstract","googleCitationCount":7,"googleAuthor":"JS De Bono","statusesArray":[]},{"title":"1670O Prospective data of first 1,797 hospitalised patients with cancer and COVID-19 derived from the COVID-19 Clinical Information Network and international …","googleId":"6nXSg6NqKoEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41731-4/abstract","googleCitationCount":5,"googleAuthor":"L Turtle","statusesArray":[]},{"title":"Comprehensive genomic profiling and clinical outcomes in patients (pts) with fibroblast growth factor receptor rearrangement-positive (FGFR2+) …","googleId":"aPKEGScWGv4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419589372","googleCitationCount":5,"googleAuthor":"A Hollebecque","doi":"10.1093/annonc/mdz247.047","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Outcomes based on plasma biomarkers for the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma …","googleId":"l6JJo1kXZW4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419588974","googleCitationCount":7,"googleAuthor":"T Meyer","doi":"10.1093/annonc/mdz247.006","elsevierAuthor":"Nault J.C.","publicationName":"Hepatology","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"January 2021","elsevierCitationCount":"4","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"FOxTROT: An international randomised controlled trial in 1053 patients evaluating neoadjuvant chemotherapy (NAC) for colon cancer. On behalf of the …","googleId":"k_cjYQxhFnYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419587440","googleCitationCount":5,"googleAuthor":"D Morton","doi":"10.1093/annonc/mdz246.001","elsevierCitationCount":0,"altmetricAuthors":["D. Morton"],"twitterCount":0,"altmetricId":68179398,"statusesArray":[]},{"title":"Apalutamide (APA) and overall survival (OS) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Updated results from the …","googleId":"isw9la_ioCYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419590597","googleCitationCount":9,"googleAuthor":"MR Smith","doi":"10.1093/annonc/mdz248","elsevierAuthor":"Vlachostergios P.J.","publicationName":"Prostate","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"2021","elsevierCitationCount":"0","altmetricAuthors":["M.R. Smith","F. Saad","S. Chowdhury","S. Oudard","B.A. Hadaschik","J.N. Graff","D. Olmos","P.N. Mainwaring","J.Y. Lee","H. Uemura","P. De Porre","A. Smith","K. Zhang","A. Lopez-Gitlitz","E.J. Small"],"twitterCount":0,"altmetricId":67711678,"statusesArray":[]},{"title":"Nivolumab versus chemotherapy in advanced esophageal squamous cell carcinoma (ESCC): the phase III ATTRACTION-3 study","googleId":"N0EdnZcrUSEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603881","googleCitationCount":7,"googleAuthor":"M Takahashi","doi":"10.1093/annonc/mdz394.028","elsevierCitationCount":0,"altmetricAuthors":["B.C. Cho","K. Kato","M. Takahashi","M. Okada","C.-Y. Lin","K. Chin","S. Kadowaki","M.-J. Ahn","Y. Hamamoto","Y. Doki","C.-C. Yen","Y. Kubota","S.-B. Kim","C.-H. Hsu","E. Holtved","I. Xynos","M. Kodani","Y. Kitagawa"],"twitterCount":0,"altmetricId":68179422,"statusesArray":[]},{"title":"Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and …","googleId":"gIQR-2j1Y6gJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325588","googleCitationCount":10,"googleAuthor":"S Lonardi","doi":"10.1093/annonc/mdz403","elsevierAuthor":"Marmorino F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-12-01","elsevierCoverDisplayDate":"1 December 2019","elsevierCitationCount":"7","altmetricAuthors":["F. Marmorino","D. Rossini","S. Lonardi","R. Moretto","G. Zucchelli","G. Aprile","E. Dell’Aquila","M. Ratti","F. Bergamo","G. Masi","F. Urbano","M. Ronzoni","M. Libertini","B. Borelli","G. Randon","A. Buonadonna","G. Allegrini","N. Pella","V. Ricci","A. Boccaccino","T.P. Latiano","S. Cordio","A. Passardi","E. Tamburini","L. Boni","A. Falcone","C. Cremolini"],"twitterCount":5,"altmetricId":67958321,"statusesArray":["1182247656283889665","1182236721129381888","1182232031045898240","1182226765596495872","1181462217696395264"]},{"title":"LBA33 Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced high‐grade ovarian carcinoma (HGOC): Final analysis …","googleId":"kq7OkdAsJe4J","googleLink":"https://www.clearityfoundation.org/wp-content/uploads/2020/10/PAOLA-ESMO-2020-PFS2-abstract.pdf","googleCitationCount":4,"googleAuthor":"F Heitz","statusesArray":[]},{"title":"Association between depth of response and overall survival: exploratory analysis in patients with previously untreated advanced renal cell carcinoma (aRCC) …","googleId":"l9k_1iz6fEoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591633","googleCitationCount":5,"googleAuthor":"TK Choueiri","doi":"10.1093/annonc/mdz249.046","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"IMpower150: an exploratory analysis of efficacy outcomes in patients with EGFR mutations","googleId":"2yPh6yh2ulIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30053-5/abstract","googleCitationCount":11,"googleAuthor":"DWT Lim","statusesArray":[]},{"title":"Making immunotherapy 'cold'tumours 'hot'by chemotherapy-induced mutations—a misconception","googleId":"P2_ewO_wzVsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31089-0/abstract","googleCitationCount":9,"googleAuthor":"T Helleday","statusesArray":[]},{"title":"Circulating breast-derived DNA allows universal detection and monitoring of localized breast cancer","googleId":"l1i8PadHgp0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419417201","googleCitationCount":10,"googleAuthor":"J Moss","doi":"10.1016/j.annonc.2019.11.014","elsevierAuthor":"Moss J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-03-01","elsevierCoverDisplayDate":"March 2020","elsevierCitationCount":"6","altmetricAuthors":["J. Moss","A. Zick","A. Grinshpun","E. Carmon","M. Maoz","B.L. Ochana","O. Abraham","O. Arieli","L. Germansky","K. Meir","B. Glaser","R. Shemer","B. Uziely","Y. Dor"],"twitterCount":1,"altmetricId":76222604,"statusesArray":["1229476880962793474"]},{"title":"Updated overall survival (OS) and quality of life (QoL) in premenopausal patients (pts) with advanced breast cancer (ABC) who received ribociclib (RIB) or …","googleId":"The5kMy8YSkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419585301","googleCitationCount":6,"googleAuthor":"MA Colleoni","doi":"10.1093/annonc/mdz242.003","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"INSIGHT 2: Tepotinib plus osimertinib in patients with EGFR-mutant NSCLC having acquired resistance to EGFR TKIs due to MET-amplification: A phase II …","googleId":"VdNs2SrAoL8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419581819","googleCitationCount":7,"googleAuthor":"JCH Yang","doi":"10.1093/annonc/mdz437.061","elsevierAuthor":"Johne A.","publicationName":"Investigational New Drugs","elsevierCoverDate":"2020-10-01","elsevierCoverDisplayDate":"1 October 2020","elsevierCitationCount":"2","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"A first-in-human phase I/II trial of the oral HIF-2a inhibitor PT2977 in patients with advanced RCC","googleId":"46Bv31sYuJEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341959127X","googleCitationCount":5,"googleAuthor":"E Jonasch","doi":"10.1093/annonc/mdz249.010","elsevierCitationCount":0,"altmetricAuthors":["E. Jonasch","E.R. Plimack","T. Bauer","J.R. Merchan","K.P. Papadopoulos","D.F. McDermott","M.D. Michaelson","L.J. Appleman","S. Thamake","N. Zojwalla","T.K. Choueiri"],"twitterCount":0,"altmetricId":72883858,"statusesArray":[]},{"title":"Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma: interim results of the open-label …","googleId":"q1UetUI2wV8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420424627","googleCitationCount":2,"googleAuthor":"L Marandino","doi":"10.1016/j.annonc.2020.09.012","elsevierAuthor":"Giannatempo P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-12-01","elsevierCoverDisplayDate":"December 2020","elsevierCitationCount":"2","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Tocilizumab for refractory severe immune checkpoint inhibitor-associated myocarditis","googleId":"c05vsIrp3r4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39819-7/abstract","googleCitationCount":5,"googleAuthor":"JO Prior","statusesArray":[]},{"title":"LBA-3 CheckMate 459: Long-term (minimum follow-up 33.6 months) survival outcomes with nivolumab versus sorafenib as first-line treatment in patients with …","googleId":"-v0Tk5oGjH0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39377-7/pdf","googleCitationCount":4,"googleAuthor":"B Sangro","statusesArray":[]},{"title":"First case of persistent pancytopenia associated with SARS-CoV-2 bone marrow infiltration in an immunocompromised patient","googleId":"tIxXVvHlttgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39926-9/abstract","googleCitationCount":7,"googleAuthor":"","statusesArray":[]},{"title":"Efficacy and safety of surufatinib in patients with well-differentiated advanced extrapancreatic neuroendocrine tumors (NETs): results from the randomized …","googleId":"yR1dG1NTmbQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604333","googleCitationCount":7,"googleAuthor":"","statusesArray":[]},{"title":"807O Nivolumab versus gemcitabine or pegylated liposomal doxorubicin for patients with platinum-resistant (advanced or recurrent) ovarian cancer: Open-label …","googleId":"TRWintnmUhMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40942-1/abstract","googleCitationCount":6,"googleAuthor":"J Hamanishi","statusesArray":[]},{"title":"MONARCHplus: a phase III trial of abemaciclib plus nonsteroidal aromatase inhibitor (NSAI) or fulvestrant (F) for women with HR+/HER2-advanced breast …","googleId":"lkSmc2IP4c8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603741","googleCitationCount":6,"googleAuthor":"","doi":"10.1093/annonc/mdz394.014","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Health-related quality of life (HRQoL) in patients (pts) treated with pembrolizumab (pembro) vs chemotherapy as first-line treatment in microsatellite instability-high …","googleId":"8DPJXcTZz80J","googleLink":"https://portal.findresearcher.sdu.dk/en/publications/health-related-quality-of-life-hrqol-in-patients-pts-treated-with","googleCitationCount":4,"googleAuthor":"T André","doi":"10.1016/j.annonc.2020.08.507","elsevierAuthor":"van Oorschot B.","publicationName":"Onkologe","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"0","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"LBA1 Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood …","googleId":"rphT06jAE5oJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420345488","googleCitationCount":4,"googleAuthor":"RS Herbst","doi":"10.1093/annonc/mdz453","elsevierAuthor":"Remon J.","publicationName":"Translational Cancer Research","elsevierCoverDate":"2020-04-01","elsevierCoverDisplayDate":"1 April 2020","elsevierCitationCount":"2","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"An enhanced prognostic score for overall survival of patients with cancer derived from a large real-world cohort","googleId":"TfnNe6HwQuwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420399701","googleCitationCount":3,"googleAuthor":"T Becker","doi":"10.1016/j.annonc.2020.07.013","elsevierAuthor":"Becker T.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-11-01","elsevierCoverDisplayDate":"November 2020","elsevierCitationCount":"2","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Choice of control tissue impacts designation of germline variants in a cohort of papillary thyroid carcinoma patients","googleId":"_e6JKDqnzZEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420360749","googleCitationCount":3,"googleAuthor":"JC Rubinstein","doi":"10.1016/j.annonc.2020.02.013","elsevierAuthor":"Rubinstein J.C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-06-01","elsevierCoverDisplayDate":"June 2020","elsevierCitationCount":"2","altmetricAuthors":["J.C. Rubinstein","N.G. Nicolson","D. Rottmann","R. Morotti","R. Korah","T. Carling","E.R. Christison-Lagay"],"twitterCount":1,"altmetricId":77499686,"statusesArray":["1239337614164946944"]},{"title":"Keynote-407 China extension study: pembrolizumab (pembro) plus chemotherapy in Chinese patients with metastatic squamous NSCLC","googleId":"Fe-OFza8cSYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419582242","googleCitationCount":6,"googleAuthor":"","doi":"10.1093/annonc/mdz446.019","elsevierCitationCount":0,"altmetricAuthors":["Y. Cheng","L. Zhang","J. Hu","D. Wang","C. Hu","J. Zhou","L. Wu","L. Cao","J. Liu","H. Zhang","H. Sun","Z. Wang","H. Gao","J. Ge","H. Wang","Y. Tian","B. Piperdi","L. Paz-Ares"],"twitterCount":0,"altmetricId":71576429,"statusesArray":[]},{"title":"Association of systemic corticosteroids with overall survival in patients receiving cancer immunotherapy for advanced melanoma, non-small cell lung cancer …","googleId":"6sYSgzh7bLMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420344264","googleCitationCount":7,"googleAuthor":"A Drakaki","doi":"10.1093/annonc/mdz449.001","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Neoantigen prediction and computational perspectives towards clinical benefit: recommendations from the ESMO Precision Medicine Working Group","googleId":"iCJbfUNKaOAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420398240","googleCitationCount":2,"googleAuthor":"M Vazquez","doi":"10.1016/j.annonc.2020.05.008","elsevierAuthor":"De Mattos-Arruda L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-08-01","elsevierCoverDisplayDate":"August 2020","elsevierCitationCount":"0","altmetricAuthors":["L. De Mattos-Arruda","M. Vazquez","F. Finotello","R. Lepore","E. Porta","J. Hundal","P. Amengual-Rigo","C.K.Y. Ng","A. Valencia","J. Carrillo","T.A. Chan","V. Guallar","N. McGranahan","J. Blanco","M. Griffith"],"twitterCount":15,"altmetricId":84898338,"statusesArray":["1306247772207800322","1278631405258301440","1278286987783520259","1277613121847386114","1277602904514363393","1277565826934112256","1277558811272847361","1277546992332345344","1277542536333099008","1277542346465427456","1277541732717117443","1277541545927946240","1277539688132345857","1277528842186481665","1277527447475572736","1277526268922204160","1277526052546523137","1277523140621582336"]},{"title":"Nivolumab plus low-dose IPILIMUMAB as first-line treatment of advanced NSCLC: Overall survival analysis of checkmate 817","googleId":"ICPr6eSAdRUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420344793","googleCitationCount":6,"googleAuthor":"","doi":"10.1093/annonc/mdz451.001","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer","googleId":"0vkxjvhVkyQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420360385","googleCitationCount":4,"googleAuthor":"CH Barrios","doi":"10.1016/j.annonc.2020.02.003","elsevierAuthor":"Adams S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-05-01","elsevierCoverDisplayDate":"May 2020","elsevierCitationCount":"2","altmetricAuthors":["S. Adams","V. Diéras","C.H. Barrios","E.P. Winer","A. Schneeweiss","H. Iwata","S. Loi","S. Patel","V. Henschel","S.Y. Chui","H.S. Rugo","L.A. Emens","P. Schmid"],"twitterCount":53,"altmetricId":76565337,"statusesArray":["1263822080291647490","1256132699170893825","1253255719152955393","1253213380350967810","1253128374022737924","1253110208890417152","1253104033407160321","1253082591273660419","1253070076829487111","1253063767002361858","1253050305907953677","1253046459311759360","1253031887137898498","1253031456974176259","1253024498753966087","1253001422695735297","1252998219912695808","1252998053994381314","1252996577498628099","1252973079921332226","1252968668331417601","1252968192760152072","1252965681164886016","1252955573420687360","1252952167268249600","1252951813218852865","1252951106898079744","1252949508016803841","1252945910759374848","1252942794332700672","1252942425464672256","1252941250476552193","1252940906526883840","1252939864645013506","1252938315717844992","1252937425418178562","1252936689355546625","1234377747968991233","1233330946834944000","1232670508182888448","1232670466411827200","1231838216635977730","1231837336012410880","1231804568679350273","1231796726866030592","1231747211828105216","1231720998476619777","1231720093710766081","1231705606983057408","1231699997734785024","1231690147931938816","1231671756429123584","1231665247825645569","1231663209976696832","1231659415746596864","1231656240125747203","1231655879969267714","1231655741016154112","1231654390722891776","1231650601727119360","1231650046975905792"]},{"title":"Phase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent/metastatic (R/M) HPV-16+ cancers","googleId":"uxWyi4nJSngJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594224","googleCitationCount":5,"googleAuthor":"","doi":"10.1093/annonc/mdz253.036","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Redefining the IGCCCG classification in advanced non-seminoma","googleId":"snClG7sVDIwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591190","googleCitationCount":7,"googleAuthor":"G Daugaard","doi":"10.1093/annonc/mdz249.002","elsevierCitationCount":0,"altmetricAuthors":["S. Gillessen","L. Collette","G. Daugaard","R. de Wit","A. Tryakin","C. Albany","O. Stahl","K. Fizazi","J.A. Gietema","U.F.F. De Giorgi","A.R. Hansen","D. Feldman","F. Cafferty","T. Tandstad","X. Garcia del Muro","R.A. Huddart","C.J. Sweeney","D.Y.C. Heng","N. Sauve","J. Beyer"],"twitterCount":3,"altmetricId":80845509,"statusesArray":["1352082786459521024","1255638384841822210","1255545704073834497"]},{"title":"Bone health in childhood cancer: review of the literature and recommendations for the management of bone health in childhood cancer survivors","googleId":"EbBelKVZwlkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312086","googleCitationCount":8,"googleAuthor":"","doi":"10.1093/annonc/mdz120","elsevierAuthor":"Marcucci G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-06-01","elsevierCoverDisplayDate":"1 June 2019","elsevierCitationCount":"4","altmetricAuthors":["G. Marcucci","G. Beltrami","A. Tamburini","J.J. Body","C.B. Confavreux","P. Hadji","G. Holzer","D. Kendler","N. Napoli","D.D. Pierroz","R. Rizzoli","M.L. Brandi"],"twitterCount":44,"altmetricId":60762353,"statusesArray":["1362127786622689281","1151163167495598084","1151160684106997760","1149666416515092480","1149138537205231617","1148926221675368449","1148909231376146433","1148896489307082754","1148889019171950592","1144893111757414400","1142877565134286849","1142805061480931329","1142767871157776384","1142247456689647616","1142133390549946368","1142075904971161600","1142075617178898433","1138811002525573121","1138796410470621187","1138692402724687873","1138661386739826689","1138549352639676417","1138412747203469312","1138393112387248129","1138368750728732678","1138366169717661696","1138351244911751168","1138350420454252544","1138348886660194304","1138348709626994688","1138348269426368513","1138345316233699328","1138336645806206976","1138324916217028608","1138310596326252552","1138204908065296384","1138140733255430144","1138129969706614784","1136677454825828352","1136653777933520896","1136652761653792769","1133096506901368832","1133093034193821696","1131916120317923328","1131188214377664512","1131072467911544832","1130849830106910723"]},{"title":"Immunogenicity and safety of influenza vaccination in cancer patients receiving checkpoint inhibitors targeting PD-1 or PD-L1","googleId":"B2CW9FEl4vAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)36377-8/pdf","googleCitationCount":8,"googleAuthor":"M Khettab","statusesArray":[]},{"title":"Clonal haematopoiesis: a source of biological noise in cell-free DNA analyses","googleId":"aGs7bdOwwdwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31080-4/abstract","googleCitationCount":8,"googleAuthor":"C Abbosh","statusesArray":[]},{"title":"First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (nccRCC): Updated follow-up for KEYNOTE-427 cohort B","googleId":"ZCyxD4-GM8wJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341959161X","googleCitationCount":7,"googleAuthor":"RA Gafanov","doi":"10.1093/annonc/mdz249.044","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Updated efficacy and safety of entrectinib in patients with NTRK fusion-positive tumors: Integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001","googleId":"-tZuKFYzY_AJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586987","googleCitationCount":5,"googleAuthor":"C Rolfo","doi":"10.1093/annonc/mdz244.038","elsevierAuthor":"Russo A.","publicationName":"Current Oncology Reports","elsevierCoverDate":"2020-05-01","elsevierCoverDisplayDate":"1 May 2020","elsevierCitationCount":"6","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated follow-up for KEYNOTE-427 cohort A","googleId":"1lFDicpHL2sJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591621","googleCitationCount":5,"googleAuthor":"JMG Larkin","doi":"10.1093/annonc/mdz249.045","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Lurbinectedin as second-or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16)","googleId":"-1v6hkpFctIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420359263","googleCitationCount":5,"googleAuthor":"M Pless","doi":"10.1016/j.annonc.2019.12.009","elsevierAuthor":"Metaxas Y.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-04-01","elsevierCoverDisplayDate":"April 2020","elsevierCitationCount":"4","altmetricAuthors":["Y. Metaxas","M. Früh","E.I. Eboulet","F. Grosso","M. Pless","P.A. Zucali","G.L. Ceresoli","M. Mark","M. Schneider","A. Maconi","M. Perrino","C. Biaggi-Rudolf","P. Froesch","S. Schmid","C. Waibel","C. Appenzeller","D. Rauch","R. von Moos"],"twitterCount":1,"altmetricId":74764232,"statusesArray":["1347202146253598720"]},{"title":"Co-occurrence of NTRK fusions with other genomic biomarkers in cancer patients","googleId":"bVK78XT20YIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419583338","googleCitationCount":6,"googleAuthor":"","doi":"10.1093/annonc/mdz239.013","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"The immune profile of small HER2-positive breast cancers: A secondary analysis from the APT trial","googleId":"EVWrH3BmzFwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311287","googleCitationCount":7,"googleAuthor":"R Barroso-Sousa","doi":"10.1093/annonc/mdz047","elsevierAuthor":"Barroso-Sousa R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-04-01","elsevierCoverDisplayDate":"April 2019","elsevierCitationCount":"4","altmetricAuthors":["R. Barroso-Sousa","W.T. Barry","H. Guo","D. Dillon","Y.B. Tan","K. Fuhrman","W. Osmani","A. Getz","M. Baltay","C. Dang","D. Yardley","B. Moy","P.K. Marcom","E.A. Mittendorf","I.E. Krop","E.P. Winer","S.M. Tolaney"],"twitterCount":17,"altmetricId":55174996,"statusesArray":["1096054062322237440","1095962988035469314","1095926143612583937","1095874809907630081","1095855918581985280","1095841408366317569","1095831105905836033","1095822280184209410","1095810111644319745","1095739477136457728","1095733617500667907","1095724861916360704","1095721694436700160","1095719496730456065","1095711748596948992","1095699117358108673","1095697914754711552","1093947571784040449"]},{"title":"LBA49 Durvalumab after chemoradiotherapy in stage III NSCLC: 4-year survival update from the phase III PACIFIC trial","googleId":"Dvs8Q7w8S3kJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42363-4/abstract","googleCitationCount":8,"googleAuthor":"C Faivre-Finn","statusesArray":[]},{"title":"Results of the TAPPAS trial: An adaptive enrichment phase III trial of TRC105 and pazopanib (P) versus pazopanib alone in patients with advanced …","googleId":"2VaILcEkmnwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419602899","googleCitationCount":6,"googleAuthor":"RL Jones","doi":"10.1093/annonc/mdz283","elsevierAuthor":"Chen H.","publicationName":"Aging","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"January 2021","elsevierCitationCount":"0","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"LBA86 Durvalumab (D)±tremelimumab (T)+ platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden …","googleId":"TM6Pc7WbER0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42419-6/abstract","googleCitationCount":3,"googleAuthor":"MC Garassino","statusesArray":[]},{"title":"Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"GxLLSD4jr_0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42107-6/abstract","googleCitationCount":5,"googleAuthor":"M Fassnacht","statusesArray":[]},{"title":"Updated data of epitopes-HPV02 trial and external validation of efficacy of DCF in prospective epitopes-HPV01 study in advanced anal squamous cell …","googleId":"RkiRlFEsgJUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419587555","googleCitationCount":5,"googleAuthor":"S Kim","doi":"10.1093/annonc/mdz246.012","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Association between antibiotics use and outcome in patients with NSCLC treated with immunotherapeutics","googleId":"dpNkqauvhCoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31117-2/abstract","googleCitationCount":9,"googleAuthor":"H Hackl","statusesArray":[]},{"title":"Bevacizumab plus chemotherapy versus chemotherapy alone as first-line treatment for patients with RAS mutant unresectable colorectal liver-limited metastases: A …","googleId":"w0gnXY9HLy4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)60380-7/abstract","googleCitationCount":6,"googleAuthor":"","statusesArray":[]},{"title":"Efficacy evaluation of concurrent nivolumab addition to a first-line, concurrent chemo-radiotherapy regimen in unresectable locally advanced NSCLC: Results …","googleId":"95YtTGz5SEgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341959665X","googleCitationCount":7,"googleAuthor":"S Peters","doi":"10.1093/annonc/mdz259","elsevierAuthor":"Geng Y.","publicationName":"Cancer Medicine","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"2021","elsevierCitationCount":"0","altmetricAuthors":["S. Peters","E. Felip","U. Dafni","A. Tufman","M. Guckenberger","A. Irigoyen","E. Nadal","A. Becker","H. Vees","M. Pless","A. Martinez-Marti","M. Lambrecht","N. Andratschke","Z. Tsourti","A.-C. Piguet","H. Roschitzki-Voser","M. Rabaglio-Poretti","R.A. Stahel","J.F. Vansteenkiste","D. De Ruysscher"],"twitterCount":0,"altmetricId":68179416,"statusesArray":[]},{"title":"Quantitative lymph node burden as a 'very-high-risk'factor identifying head and neck cancer patients benefiting from postoperative chemoradiation","googleId":"Q1WS5orRUmcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419309949","googleCitationCount":8,"googleAuthor":"ZS Zumsteg","doi":"10.1093/annonc/mdy490","elsevierAuthor":"Zumsteg Z.S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-10-01","elsevierCoverDisplayDate":"1 October 2019","elsevierCitationCount":"0","altmetricAuthors":["Z.S. Zumsteg","M. Luu","S. Kim","M. Tighiouart","A. Mita","K.S. Scher","D.J. Lu","S.L. Shiao","J. Mallen-St. Clair","A.S. Ho"],"twitterCount":1,"altmetricId":63984554,"statusesArray":["1235527113584697346"]},{"title":"Oral THC: CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial","googleId":"jN_4phlgsKIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420399968","googleCitationCount":4,"googleAuthor":"N Lintzeris","doi":"10.1016/j.annonc.2020.07.020","elsevierAuthor":"Grimison P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-11-01","elsevierCoverDisplayDate":"November 2020","elsevierCitationCount":"1","altmetricAuthors":["P. Grimison","A. Mersiades","A. Kirby","N. Lintzeris","R. Morton","P. Haber","I. Olver","A. Walsh","I. McGregor","Y. Cheung","A. Tognela","C. Hahn","K. Briscoe","M. Aghmesheh","P. Fox","E. Abdi","S. Clarke","S. Della-Fiorentina","J. Shannon","C. Gedye","S. Begbie","J. Simes","M. Stockler"],"twitterCount":53,"altmetricId":88279557,"statusesArray":["1355467886584860673","1303068894488399873","1303068881867636738","1302532824315113477","1302364157128445953","1301288789499883521","1300457185500188674","1299240514076762112","1298418796114448385","1298372341508972546","1298370057886556161","1298311274737086472","1298205668550348800","1298092326267412480","1298035084524691456","1298023708158656513","1298023506198724609","1298022027123658754","1298021092561432583","1297971652584710145","1297944303675809794","1297939069469679629","1297898700912693248","1297871753406971906","1297869843325235201","1297837765758001152","1297836560562388994","1297833424745529344","1297476886897942529","1297474358818955266","1297473954118959106","1296791363636416513","1296732346469752832","1296455686746931202","1296434731815444481","1296409859727020033","1296406922749517824","1296406738627960833","1296375061264441345","1296353389748449280","1296346959653900288","1296338656890953731","1296312854769885184","1296310453103030272","1296220419381317633","1296218110559580161","1296213039633633280","1296211838959382528","1295672104952766466","1295273007590649857","1295248812487966720","1294764506598510593","1294763378171416577","1294550518321168386","1294530291722145792","1294529684294623232","1294495500775743493","1294409036259930112","1294397395791425536"]},{"title":"Efficacy of lung cancer screening appears to increase with prolonged intervention: results from the MILD trial and a meta-analysis","googleId":"3j03RdQHacEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31245-1/abstract","googleCitationCount":7,"googleAuthor":"M Rota","statusesArray":[]},{"title":"VELIA/GOG-3005: Integration of veliparib with front-line chemotherapy and maintenance in women with high-grade serous carcinoma of ovarian, fallopian …","googleId":"2ewGa1j8zuAJ","googleLink":"https://portal.findresearcher.sdu.dk/en/publications/veliagog-3005-integration-of-veliparib-with-front-line-chemothera","googleCitationCount":7,"googleAuthor":"","doi":"10.1093/annonc/mdz394","elsevierAuthor":"Demartino P.C.","publicationName":"JAMA Internal Medicine","elsevierCoverDate":"2021-02-01","elsevierCoverDisplayDate":"February 2021","elsevierCitationCount":"0","altmetricAuthors":["K. Fizazi","A. Maillard","N. Penel","G. Baciarello","D. Allouache","G. Daugaard","A. Van de Wouw","G. Soler","E. Vauleon","L. Chaigneau","R. Janssen","F. Losa Gaspa","R. Morales Barrera","C. Balana","D. Tosi","B. Chauffert","C.A. Schnabel","G. Martineau","S. Culine","I. Borget"],"twitterCount":1,"altmetricId":67579395,"statusesArray":["1179410536875864064"]},{"title":"Reproducibility and concordance of 4 clinically developed programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) assays in triple negative breast …","googleId":"K-dNdkkiFYYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419585817","googleCitationCount":5,"googleAuthor":"C Denkert","doi":"10.1093/annonc/mdz242.054","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"711P Nivolumab+ ipilimumab (N+ I) vs sunitinib (S) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and …","googleId":"aOAvqOoWvWwJ","googleLink":"https://www.researchgate.net/profile/Shruti_Saggi3/publication/345365652_711P_Nivolumab_ipilimumab_NI_vs_sunitinib_S_for_first-line_treatment_of_advanced_renal_cell_carcinoma_aRCC_in_CheckMate_214_4-year_follow-up_and_subgroup_analysis_of_patients_pts_without_nephrectomy/links/5fd7f6ad299bf140880f5a58/711P-Nivolumab-ipilimumab-N-I-vs-sunitinib-S-for-first-line-treatment-of-advanced-renal-cell-carcinoma-aRCC-in-CheckMate-214-4-year-follow-up-and-subgroup-analysis-of-patients-pts-without-nephrectom.pdf","googleCitationCount":5,"googleAuthor":"","statusesArray":[]},{"title":"LBA70_PR The impact of COVID-19 on oncology professionals: Initial results of the ESMO resilience task force survey collaboration","googleId":"fQ1BwQoC3VMJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506393/","googleCitationCount":2,"googleAuthor":"S Banerjee","doi":"10.1016/j.annonc.2020.08.2311","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Entrectinib in locally advanced/metastatic ROS1 and NTRK fusion-positive non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2 …","googleId":"EEfgpRzu7cUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341959696X","googleCitationCount":6,"googleAuthor":"S Siena","doi":"10.1093/annonc/mdz260.010","elsevierAuthor":"Russo A.","publicationName":"Current Oncology Reports","elsevierCoverDate":"2020-05-01","elsevierCoverDisplayDate":"1 May 2020","elsevierCitationCount":"6","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Inducible T cell costimulatory (ICOS) receptor agonist, GSK3359609 (GSK609) alone and in combination with pembrolizumab (pembro): Preliminary results …","googleId":"YMmdJZltyYkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419593310","googleCitationCount":7,"googleAuthor":"D Rischin","doi":"10.1093/annonc/mdz252.011","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Pembrolizumab vs chemotherapy in patients with advanced/metastatic adenocarcinoma (AC) or squamous cell carcinoma (SCC) of the esophagus as second …","googleId":"EABTlbOmLvcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419589761","googleCitationCount":5,"googleAuthor":"","doi":"10.1093/annonc/mdz247.086","elsevierCitationCount":0,"altmetricAuthors":["J. Chen","S. Luo","S. Qin","Y. Cheng","Z. Li","Y. Fan","X. Yuan","W. Li","Y. Sun","X. Yin","X. Lin","Y. Bai","T. Liu","J. Zhang","Y. Cui","P. Bhagia","S.P. Kang","W. Lu","Y. Zhou","L. Shen"],"twitterCount":0,"altmetricId":68179429,"statusesArray":[]},{"title":"A phase Ib study of pembrolizumab following trans-arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): PETAL","googleId":"QE0S46-Aj7UJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419589669","googleCitationCount":7,"googleAuthor":"DJ Pinato","doi":"10.1093/annonc/mdz247.076","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Chemotherapy in localized soft tissue sarcoma: will we soon have to treat grade 1 tumors? Update on CINSARC performances","googleId":"cIUIuJvEg3UJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30982-2/abstract","googleCitationCount":8,"googleAuthor":"T Valentin","statusesArray":[]},{"title":"Cancer mortality and predictions for 2018 in selected Australasian countries and Russia","googleId":"dvPl-t3kVGYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419309937","googleCitationCount":5,"googleAuthor":"M Malvezzi","doi":"10.1093/annonc/mdy489","elsevierAuthor":"Carioli G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-01-01","elsevierCoverDisplayDate":"1 January 2019","elsevierCitationCount":"5","altmetricAuthors":["G. Carioli","M. Malvezzi","P. Bertuccio","F. Levi","P. Boffetta","E. Negri","C. La Vecchia"],"twitterCount":8,"altmetricId":52481649,"statusesArray":["1141717334069063680","1072801969708912640","1072801414089453568","1072556642888282112","1072476940777463810","1072460878610608128","1072456871930486786","1072449731425656832","1072419997643882497","1072418187558469632","1072417884691931136"]},{"title":"Switch maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma: a multicenter open label phase II trial (NVALT19)","googleId":"_LTLTO-_LPQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604527","googleCitationCount":5,"googleAuthor":"R Cornelissen","doi":"10.1093/annonc/mdz394.092","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Comparison of patient populations identified by different PD-L1 assays in in triple-negative breast cancer (TNBC)","googleId":"uG702wmLxQkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30282-0/abstract","googleCitationCount":11,"googleAuthor":"","statusesArray":[]},{"title":"Talimogene laherparepvec (T-VEC) in combination (combo) with ipilimumab (ipi) versus ipi alone for advanced melanoma: 3-year landmark analysis of a …","googleId":"OoQCIphKtwsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604278","googleCitationCount":5,"googleAuthor":"","doi":"10.1093/annonc/mdz394.067","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Height as a mediator of sex differences in cancer risk","googleId":"ksLu85g_VUQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420360579","googleCitationCount":1,"googleAuthor":"BC Fu","doi":"10.1016/j.annonc.2020.02.010","elsevierAuthor":"Fu B.C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-05-01","elsevierCoverDisplayDate":"May 2020","elsevierCitationCount":"1","altmetricAuthors":["B.C. Fu","M. Song","X. Li","J. Han","H.O. Adami","E.L. Giovannucci","L.A. Mucci"],"twitterCount":3,"altmetricId":78552317,"statusesArray":["1244461858498592770","1244461731599933441","1244180822288224256"]},{"title":"Anti-PD1 treatment of advanced melanoma: development of criteria for a safe stop","googleId":"Emp4rT3XMzQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31251-7/abstract","googleCitationCount":5,"googleAuthor":"AMM Eggermont","statusesArray":[]},{"title":"Phase I study of gefitinib (G)+ durvalumab (D) for locally advanced/metastatic non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR …","googleId":"wj4LaT7SnicJ","googleLink":"https://mdanderson.elsevierpure.com/en/publications/phase-i-study-of-gefitinib-g-durvalumab-d-for-locally-advancedmet","googleCitationCount":6,"googleAuthor":"SW Kim","doi":"10.1093/annonc/mdz067.001","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the 1st-and 2nd-line treatment of unresectable mCRC","googleId":"MYOX_PG4AKsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30960-3/abstract","googleCitationCount":7,"googleAuthor":"S Lonardi","statusesArray":[]},{"title":"Treatment-free survival, with and without toxicity, as a novel outcome applied to immuno-oncology agents in advanced renal cell carcinoma","googleId":"JmMefyRg44YJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591840","googleCitationCount":4,"googleAuthor":"MM Regan","doi":"10.1093/annonc/mdz249.067","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Preliminary results of STELLAR-001, a dose escalation phase I study of the anti-C5aR, IPH5401, in combination with durvalumab in advanced solid tumours","googleId":"8DHg7aJj4n4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594157","googleCitationCount":4,"googleAuthor":"C Massard","doi":"10.1093/annonc/mdz253.029","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Efficacy of derazantinib (DZB) in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) expressing FGFR2-fusion or FGFR2 mutations/amplifications","googleId":"eoj7gEV92hMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419589384","googleCitationCount":4,"googleAuthor":"","doi":"10.1093/annonc/mdz247.048","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Defining COVID-19 outcomes in thoracic cancer patients: TERAVOLT (Thoracic cancERs international coVid 19 cOLlaboraTion)","googleId":"DUSRbOqE4pcJ","googleLink":"https://search.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/en/covidwho-804086","googleCitationCount":3,"googleAuthor":"","doi":"10.1016/j.annonc.2020.08.2316","elsevierCitationCount":0,"altmetricAuthors":["J. Baena Espinar","V. Torri","J. Whisenant","F.R. Hirsch","J. Rogado","J. de Castro Carpeño","B. Halmos","G.L. Ceresoli","A. Gomez Rueda","M. Tiseo","E. Felip","M. Majem Tarruella","I. Monnet","U. Tapan","H. Wakelee","L-C. Huang","M.C. Garassino","S. Peters","L. Horn","M. Hellmann"],"twitterCount":0,"altmetricId":93976201,"statusesArray":[]},{"title":"Safety and Efficacy of Quavonlimab, a Novel Anti–CTLA-4 Antibody (MK-1308), in Combination with Pembrolizumab in First-Line Advanced Non–Small Cell …","googleId":"EMt4b0AZKioJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420431758","googleCitationCount":1,"googleAuthor":"J Bar","doi":"10.1016/j.annonc.2020.11.020","elsevierAuthor":"Perets R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"2021","elsevierCitationCount":"1","altmetricAuthors":["R. Perets","J. Bar","D.W. Rasco","M.-J. Ahn","K. Yoh","D.-W. Kim","A. Nagrial","M. Satouchi","D.H. Lee","D.R. Spigel","D. Kotasek","M. Gutierrez","J. Niu","S. Siddiqi","X. Li","J. Cyrus","A. Chackerian","A. Chain","R.A. Altura","B.C. Cho"],"twitterCount":3,"altmetricId":95487764,"statusesArray":["1336077658380177409","1335222779386314753","1335178111168565248"]},{"title":"Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and …","googleId":"btiWx0H14-kJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39949-X/abstract","googleCitationCount":3,"googleAuthor":"JP Machiels","statusesArray":[]},{"title":"Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from …","googleId":"hSYq1dqDOMAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420399300","googleCitationCount":17,"googleAuthor":"F Montemurro","doi":"10.1016/j.annonc.2020.06.020","elsevierAuthor":"Montemurro F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-10-01","elsevierCoverDisplayDate":"October 2020","elsevierCitationCount":"6","altmetricAuthors":["F. Montemurro","S. Delaloge","C.H. Barrios","R. Wuerstlein","A. Anton","E. Brain","T. Hatschek","C.M. Kelly","C. Peña-Murillo","M. Yilmaz","M. Donica","P. Ellis"],"twitterCount":33,"altmetricId":85266009,"statusesArray":["1313793759142834184","1293688863836315648","1285706719952343040","1280821649965830144","1280767865616883712","1280626938936254467","1280591828266422274","1280527893274247168","1280483291246858240","1280481270061907970","1280470354935365633","1280466456535318530","1280426451674845186","1280418818662293504","1280415535117803520","1280409720424140800","1280402612718886914","1280302668213338112","1280283117497077761","1280250815740076032","1280182868564639744","1280177198163529731","1280176124031569925","1280168217709854720","1280162092822257664","1280144503668707331","1280144230913056768","1280128111015866368","1280103474475094016","1280096990215446529","1280074729974530048","1280065706244157442","1280064790149431296","1279821370608816128"]},{"title":"Docetaxel for hormone-naïve prostate cancer (PCa): Results from long-term follow-up of non-metastatic (M0) patients in the STAMPEDE randomised trial","googleId":"46_DHhXzPr0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419590688","googleCitationCount":4,"googleAuthor":"ND James","doi":"10.1093/annonc/mdz248.008a","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Myeloid derived suppressor cells but not regulatory T cells are associated with adaptive immunity and clinical outcomes in anal squamous cell carcinoma","googleId":"qfBg97Wo8Q8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419600323","googleCitationCount":4,"googleAuthor":"C Borg","doi":"10.1093/annonc/mdz268.030","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma","googleId":"NBQeKINiMXQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419459899","googleCitationCount":4,"googleAuthor":"","doi":"10.1093/annonc/mdz198","elsevierAuthor":"Mayer E.L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-09-01","elsevierCoverDisplayDate":"1 September 2019","elsevierCitationCount":"4","altmetricAuthors":["E.L. Mayer","A. DeMichele","H.S. Rugo","K. Miller","A.G. Waks","S.E. Come","T. Mulvey","R. Jeselsohn","B. Overmoyer","H. Guo","W.T. Barry","C. Huang Bartlett","M. Koehler","E.P. Winer","H.J. Burstein"],"twitterCount":47,"altmetricId":62879509,"statusesArray":["1183465123408699396","1175777210982174720","1175175267125518336","1148941769020772352","1148565231611863040","1147872999791648768","1147412178556915712","1147281612515627008","1147096979790426112","1146858288073596928","1146820560296583169","1146702611254562816","1146690105664389120","1146291906520997888","1146203401820262407","1146192568822181888","1146177977576820738","1146149109973303301","1146138457019805696","1146110350917455872","1146088550879944705","1146069062008672256","1146068726669647873","1146057654072041472","1146045404011814912","1145962375440412672","1145960970877054978","1145955959535296514","1145859284984463360","1145803319060967424","1145785418044116992","1145771712413196288","1145771599326396416","1145745225773658113","1145673798622072835","1145612968639574016","1145569396334702592","1145536600128069632","1145490395037655040","1145457370761445378","1145457240465391618","1145393638295445505","1145368729200541696","1145363573624848386","1145363421174480896","1145359222995128320","1145308602971938818","1145308379927261184","1145304778513276928","1145300382886899712","1145166215838457856","1145146620645916673","1145123923220148225","1145106514476093440","1145102378489790464","1145066094069260288"]},{"title":"The FDA approval of pembrolizumab for patients with TMB> 10 mut/Mb: was it a wise decision? No","googleId":"5auEc2zWw9YJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534%2820%2939935-X/fulltext","googleCitationCount":5,"googleAuthor":"V Prasad","statusesArray":[]},{"title":"A multi-center phase IIA trial to assess the safety and efficacy of BL-8040 (a CXCR4 inhibitor) in combination with pembrolizumab and chemotherapy in …","googleId":"WxMK8lvpk1MJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420344781","googleCitationCount":5,"googleAuthor":"M Hidalgo","doi":"10.1093/annonc/mdz451","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Activity of EGFR antibody in non-V600 BRAF mutant metastatic colorectal cancer","googleId":"CTBYx5KxG54J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30991-3/abstract","googleCitationCount":8,"googleAuthor":"Y Wang","statusesArray":[]},{"title":"HER2: Defining a Neu target in non-small-cell lung cancer","googleId":"qxVMKBjHj2EJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31096-8/abstract","googleCitationCount":5,"googleAuthor":"","statusesArray":[]},{"title":"HSD3B1 (1245A> C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide …","googleId":"5sMQNP-womEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420398938","googleCitationCount":3,"googleAuthor":"","doi":"10.1016/j.annonc.2020.06.006","elsevierAuthor":"Khalaf D.J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-09-01","elsevierCoverDisplayDate":"September 2020","elsevierCitationCount":"2","altmetricAuthors":["D.J. Khalaf","I.M. Aragón","M. Annala","R. Lozano","S. Taavitsainen","D. Lorente","D.L. Finch","N. Romero-Laorden","J. Vergidis","Y. Cendón","C. Oja","M.I. Pacheco","M. Zulfiqar","M.E. Gleave","A.W. Wyatt","D. Olmos","K.N. Chi","E. Castro","E. Almagro","J.Á. Arranz","E.G. Billalabeitia","P. Borrega","E. Castro","J.A. Contreras","M. Domenech","R. Escribano","E. Fernández-Parra","E. Gallardo","I. García-Carbonero","R. García","J. Garde","A. González del Alba","B. González","A. Hernández","S. Hernando","P. Jiménez","N. Laínez","D. Lorente","R. Luque","E. Martínez","A. Medina","M.J. Méndez-Vidal","A. Montesa","R. Morales","Olmos David","J.L. Pérez-Gracia","B. Pérez-Valderrama","Á. Pinto","J. Piulats","J. Puente","R. Querol","A. Rodríguez-Vida","N. Romero-Laorden","M.I. Sáez","S. Vázquez","E. Vélez","J.C. Villa-Guzmán","R. Villatoro","C. Zambrana"],"twitterCount":2,"altmetricId":84599307,"statusesArray":["1276160279118823426","1275731437619163150"]},{"title":"VELIA/GOG-3005: Integration of veliparib (V) with front-line chemotherapy and maintenance in women with high-grade serous carcinoma of ovarian, fallopian …","googleId":"lpARJ9VcD0kJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341960414X","googleCitationCount":5,"googleAuthor":"E Swisher","doi":"10.1093/annonc/mdz394.054","elsevierAuthor":"Henriksen J.R.","publicationName":"Journal of Ovarian Research","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"1","altmetricAuthors":["R.L. Coleman","G.F. Fleming","M.F. Brady","E. Swisher","K.D. Steffensen","M. Friedlander","A. Okamoto","K. Moore","N. Ben-Baruch","T.L. Werner","A. Oaknin","J.-H. Nam","C.A. Leath","S. Nicum","D. Cella","D.M. Sullivan","P.J. Ansell","M. Dinh","C. Aghajanian","M.A. Bookman"],"twitterCount":0,"altmetricId":68846535,"statusesArray":[]},{"title":"Sperm count in Swedish clinical stage I testicular cancer patients following adjuvant treatment","googleId":"kanofeyHxO4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311135","googleCitationCount":5,"googleAuthor":"","doi":"10.1093/annonc/mdz017","elsevierAuthor":"Weibring K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-04-01","elsevierCoverDisplayDate":"April 2019","elsevierCitationCount":"1","altmetricAuthors":["K. Weibring","C. Nord","O. Ståhl","J. Eberhard","K. Sandberg","H. Johansson","S. Arver","A. Giwercman","G. Cohn-Cedermark"],"twitterCount":28,"altmetricId":56011586,"statusesArray":["1252550410553851904","1123333665180803072","1122700486237462528","1122049802559283200","1122032513319358464","1121775987199340544","1111515733765341184","1111515503799918594","1111377671441641475","1111321281822158848","1111321075563012096","1110919431012540417","1107192293075927040","1107011672517038080","1104419791614423040","1101486043042320385","1100304625016729600","1100240278508711942","1100229431807959045","1100036578129465346","1100022055565697030","1100009527074672640","1099993561834184704","1099991194854219781","1099991179649736704","1099991023995052033","1099990294366470149","1099989115238576128","1099987731181174785","1099982390276120577","1099975538041647106","1099974639697178626","1099974610861330434"]},{"title":"First report of AURORA, the Breast International Group (BIG) molecular screening initiative for metastatic breast cancer (MBC) patients (pts)","googleId":"6wd0BT809esJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30420-X/abstract","googleCitationCount":6,"googleAuthor":"F Hilbers","statusesArray":[]},{"title":"TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) …","googleId":"7qknh2GRQdEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420420617","googleCitationCount":3,"googleAuthor":"R Jankowitz","doi":"10.1016/j.annonc.2020.08.2064","elsevierAuthor":"Mayer E.L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-11-01","elsevierCoverDisplayDate":"November 2020","elsevierCitationCount":"0","altmetricAuthors":["E.L. Mayer","V. Abramson","R. Jankowitz","C. Falkson","P.K. Marcom","T. Traina","L. Carey","M. Rimawi","J. Specht","K. Miller","V. Stearns","N. Tung","C. Perou","A.L. Richardson","K. Componeschi","L. Trippa","Z. Tan-Wasielewski","K. Timms","I. Krop","A.C. Wolff","E.P. Winer"],"twitterCount":11,"altmetricId":88510493,"statusesArray":["1348626051656802307","1348239739594432513","1348215315621171200","1348052452680073219","1347957296295510018","1328853506330038272","1296129788755705858","1296127238027513858","1296083618230566912","1296082398455595009","1296081978085855233"]},{"title":"Efficacy and safety of nintedanib+ docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): Updated …","googleId":"xu0f8S430HYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419597125","googleCitationCount":6,"googleAuthor":"S Haas","doi":"10.1093/annonc/mdz260.027","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Androgen receptor (AR) aberrations in patients (Pts) with metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) plus …","googleId":"1GV9Brp-_yAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419590998","googleCitationCount":5,"googleAuthor":"KN Chi","doi":"10.1093/annonc/mdz248.040","elsevierAuthor":"Merseburger A.S.","publicationName":"Aktuelle Urologie","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"0","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: further results from the prospective PANTHER study with focus on …","googleId":"IJmeWtf8n5UJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419309895","googleCitationCount":6,"googleAuthor":"A Matikas","doi":"10.1093/annonc/mdy475","elsevierAuthor":"Matikas A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-01-01","elsevierCoverDisplayDate":"1 January 2019","elsevierCitationCount":"6","altmetricAuthors":["A. Matikas","T. Foukakis","V. Moebus","R. Greil","N. -O. Bengtsson","G.G. Steger","M. Untch","H. Johansson","M. Hellström","P. Malmström","M. Gnant","S. Loibl","J. Bergh"],"twitterCount":2,"altmetricId":50255927,"statusesArray":["1055472558781407232","1055468269606449152"]},{"title":"Effect of post-study immunotherapy (IO) on overall survival (OS) outcome in patients with metastatic (m) NSCLC treated with first-line durvalumab (D) vs chemotherapy …","googleId":"9Lx0s8HabOQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30262-5/abstract","googleCitationCount":6,"googleAuthor":"","statusesArray":[]},{"title":"Effect of second-line cabozantinib on health states for patients with advanced hepatocellular carcinoma (aHCC) after sorafenib: QTWiST analysis from the …","googleId":"_2RJZjMbiYsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419589700","googleCitationCount":4,"googleAuthor":"","doi":"10.1093/annonc/mdz247.080","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Pembrolizumab for recurrent/metastatic cutaneous squamous cell carcinoma (cSCC): Efficacy and safety results from the phase II KEYNOTE-629 study","googleId":"22cY5a_u7iwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604291","googleCitationCount":4,"googleAuthor":"","doi":"10.1093/annonc/mdz394.069","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally …","googleId":"sgwxApH68sUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310786","googleCitationCount":6,"googleAuthor":"K Hutcheson","doi":"10.1093/annonc/mdy549","elsevierAuthor":"Haddad R.I.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-03-01","elsevierCoverDisplayDate":"1 March 2019","elsevierCitationCount":"4","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Early detection of pancreatic ductal adenocarcinoma using methylation signatures in circulating tumour DNA","googleId":"mUSHNspINhkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419589049","googleCitationCount":4,"googleAuthor":"","doi":"10.1093/annonc/mdz247.013","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Exaggeration of PFS by blinded, independent, central review (BICR)","googleId":"OrG4tubPNTsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310269","googleCitationCount":6,"googleAuthor":"V Gebski","doi":"10.1093/annonc/mdy514","elsevierAuthor":"Stone A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-02-01","elsevierCoverDisplayDate":"1 February 2019","elsevierCitationCount":"5","altmetricAuthors":["A. Stone","V. Gebski","R. Davidson","R. Bloomfield","J.W. Bartlett","A. Sabin"],"twitterCount":19,"altmetricId":51615515,"statusesArray":["1159467245581623297","1156210492291129344","1156164526951325697","1155986541912526853","1155935277359099904","1155934570069446656","1155866060681179136","1155575817264672768","1155347616038825989","1155341743958700033","1155320946175045633","1155212822181289984","1155081672007794688","1155066542863855616","1067302891956969472","1066185771336384512","1066119149506752518","1066053947201331200","1066044232052334592","1066043738038915074"]},{"title":"Double-blind randomized phase II results comparing concurrent high-dose cisplatin chemorradiation (CRT) plus debio 1143 or placebo in high-risk patients …","googleId":"cOXfWgY_1T0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604229","googleCitationCount":4,"googleAuthor":"","doi":"10.1093/annonc/mdz394.062","elsevierAuthor":"Walker A.J.","publicationName":"JAMA Oncology","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"0","altmetricAuthors":["J. Bourhis","X. Sun","Y. Pointreau","C. Sire","C. Le Tourneau","A. Coutte","M.-C. Kaminsky-Forrett","M. Alfonsi","P. Boisselier","L. Martin","J.-P. Delord","F. Clatot","J. Miroir","F. Rolland","P. Crompton","S. Brienza","S.A. Szyldergemajn","C. Even","Y. Tao"],"twitterCount":0,"altmetricId":68179410,"statusesArray":[]},{"title":"Frequency and clinicopathological characteristics of biliary tract carcinomas harboring the FGFR2-fusion gene: a prospective observational study (PRELUDE …","googleId":"ac0K3DdcUUcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419589402","googleCitationCount":5,"googleAuthor":"A Naganuma","doi":"10.1093/annonc/mdz247.050","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Outcomes based on Albumin‐Bilirubin (ALBI) grade in the phase 3 CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular …","googleId":"NL7MyRiTDTIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30530-7/abstract","googleCitationCount":5,"googleAuthor":"R Miksad","statusesArray":[]},{"title":"Prognostic impact of the use of antibiotics in patients with advanced non-small cell lung cancer (NSCLC) receiving PD-(L) 1 targeting monoclonal antibodies","googleId":"rk7Uk4nTELAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30106-1/abstract","googleCitationCount":8,"googleAuthor":"LA Mauti","statusesArray":[]},{"title":"The potential influence of human Y-chromosome haplogroup on COVID-19 prevalence and mortality","googleId":"AMtRNMqPWowJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42104-0/abstract","googleCitationCount":4,"googleAuthor":"","statusesArray":[]},{"title":"Phase Ib, open-label, dose-escalation study of M9241 (NHS-IL12) plus avelumab in patients (pts) with advanced solid tumours","googleId":"fxCno9y9_nQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594364","googleCitationCount":3,"googleAuthor":"","doi":"10.1093/annonc/mdz253.050","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Genomic landscape of entrectinib resistance from ctDNA analysis in STARTRK-2","googleId":"OShqCjpI3AEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603777","googleCitationCount":5,"googleAuthor":"RC Doebele","doi":"10.1093/annonc/mdz394.017","elsevierAuthor":"Russo A.","publicationName":"Current Oncology Reports","elsevierCoverDate":"2020-05-01","elsevierCoverDisplayDate":"1 May 2020","elsevierCitationCount":"6","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Pembrolizumab (Pembro) therapy vs best supportive care (BSC) in advanced hepatocellular carcinoma (HCC): KEYNOTE-240","googleId":"MqbuC3LLxu0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30535-6/abstract","googleCitationCount":6,"googleAuthor":"","statusesArray":[]},{"title":"High-risk neuroblastoma: where do we go?","googleId":"rivzS4g5HZ0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)53226-4/abstract","googleCitationCount":3,"googleAuthor":"","statusesArray":[]},{"title":"A randomised double-blind placebo-controlled phase II trial of palbociclib combined with letrozole (L) in patients (pts) with oestrogen receptor-positive (ER+) …","googleId":"ZqggrHkLv20J","googleLink":"https://vbn.aau.dk/en/publications/a-randomised-double-blind-placebo-controlled-phase-ii-trial-of-pa","googleCitationCount":2,"googleAuthor":"MR Mirza","doi":"10.1016/j.annonc.2020.08.2258","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Longitudinal circulating tumour DNA (ctDNA) monitoring for early detection of disease progression and resistance in advanced NSCLC in FLAURA","googleId":"-Gqh8RNS8v0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604436","googleCitationCount":4,"googleAuthor":"N Peled","doi":"10.1093/annonc/mdz394.083","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"T-cell bispecific antibodies in node-positive breast cancer: novel therapeutic avenue for MHC class I loss variants","googleId":"rg4aRYHymYIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312050","googleCitationCount":4,"googleAuthor":"TP Mourikis","doi":"10.1093/annonc/mdz112","elsevierAuthor":"Marra A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-06-01","elsevierCoverDisplayDate":"1 June 2019","elsevierCitationCount":"1","altmetricAuthors":["M. Messaoudene","T.P. Mourikis","J. Michels","Y. Fu","M. Bonvalet","M. Lacroix-Trikki","B. Routy","A. Fluckiger","S. Rusakiewicz","M.P. Roberti","S. Cotteret","C. Flament","V. Poirier-Colame","N. Jacquelot","F. Ghiringhelli","A. Caignard","A.M.M. Eggermont","G. Kroemer","A. Marabelle","M. Arnedos","C. Vicier","S. Dogan","F. Jaulin","S -J Sammut","W. Cope","C. Caldas","S. Delaloge","N. McGranahan","F. André","L. Zitvogel"],"twitterCount":24,"altmetricId":58642604,"statusesArray":["1263430560254484480","1115647508586176512","1115593420221763585","1115590194281971712","1115588610550587397","1115577056602087424","1115310285471068165","1115167199520546817","1115122312116940800","1114829124005236736","1114807157365575680","1114750859903025157","1114576378052141056","1114563588490964993","1114563347079421952","1114541230262816769","1114529711143694336","1114525911267909632","1114517044182048768","1114487561794273281","1114478125637877760","1114475609298755584","1114466158231654400","1114458087337934849"]},{"title":"Breaking avelumab resistance with combined ipilimumab and nivolumab in metastatic Merkel cell carcinoma?","googleId":"ZzWJpOxPQq4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)60974-9/abstract","googleCitationCount":4,"googleAuthor":"M Goebeler","statusesArray":[]},{"title":"BAROCCO: A randomized phase II study of weekly paclitaxel vs cediranib-olaparib combination given with continuous or intermittent schedule in patients with …","googleId":"EoK116VmAIQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604151","googleCitationCount":5,"googleAuthor":"N Colombo","doi":"10.1093/annonc/mdz394.055","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Long-term fatigue and quality of life among epithelial ovarian cancer survivors: a GINECO case/control VIVROVAIRE I study","googleId":"Ke1NtfewcV0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311639","googleCitationCount":8,"googleAuthor":"","doi":"10.1093/annonc/mdz074","elsevierAuthor":"Joly F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-05-01","elsevierCoverDisplayDate":"May 2019","elsevierCitationCount":"6","altmetricAuthors":["F. Joly","D. Ahmed-Lecheheb","E. Kalbacher","N. Heutte","B. Clarisse","J.M. Grellard","F. Gernier","D. Berton-Rigaud","O. Tredan","M. Fabbro","A.M. Savoye","J.E. Kurtz","J. Alexandre","P. Follana","V. Delecroix","N. Dohollou","C. Roemer-Becuwe","G. De Rauglaudre","A. Lortholary","K. Prulhiere","A. Lesoin","A. Zannetti","S. N’Guyen","S. Trager-Maury","L. Chauvenet","S. Abadie Lacourtoisie","A. Gompel","C. Lhommé","A. Floquet","P. Pautier"],"twitterCount":13,"altmetricId":56910071,"statusesArray":["1112015965192110081","1112014114199650304","1111995127743107072","1111798827709882369","1109794189213122560","1109619687913070594","1109237285244100608","1109135204407373824","1108913242699677696","1108898003740512258","1108830055034056706","1106257748906397696","1106217262141313025","1106136638344724480","1105494387285475328"]},{"title":"IPATential150: Phase III study of ipatasertib (ipat) plus abiraterone (abi) vs placebo (pbo) plus abi in metastatic castration-resistant prostate cancer (mCRPC)","googleId":"QS1ZZ_zaKpIJ","googleLink":"https://elibrary.ru/item.asp?id=43977890","googleCitationCount":3,"googleAuthor":"JS de Bono","statusesArray":[]},{"title":"Pexidartinib (Pex) for locally advanced tenosynovial giant cell tumour (TGCT): characterization of hepatic adverse reactions (ARs)","googleId":"qsIQCAhT4lwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603182","googleCitationCount":3,"googleAuthor":"H Gelderblom","doi":"10.1093/annonc/mdz283.029","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Phase II study of pembrolizumab with enzalutamide (Enz) in metastatic, castration-resistant prostate cancer (mCRPC): 30 patient expansion with examination …","googleId":"PknI-lUseN8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419590640","googleCitationCount":4,"googleAuthor":"JN Graff","doi":"10.1093/annonc/mdz248.005","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Treatment with pralsetinib (formerly BLU-667), a potent and selective RET inhibitor, provides rapid clearance of ctDNA in patients with RET-altered non-small …","googleId":"ofX1tZ97urAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419580383","googleCitationCount":3,"googleAuthor":"V Subbiah","doi":"10.1093/annonc/mdz431","elsevierAuthor":"Harada G.","publicationName":"Current Treatment Options in Oncology","elsevierCoverDate":"2020-05-01","elsevierCoverDisplayDate":"1 May 2020","elsevierCitationCount":"2","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"POD1UM-202: phase II study of retifanlimab in patients (pts) with squamous carcinoma of the anal canal (SCAC) who progressed following platinum-based …","googleId":"OpsBNuMSgF4J","googleLink":"https://portal.findresearcher.sdu.dk/en/publications/pod1um-202-phase-ii-study-of-retifanlimab-in-patients-pts-with-sq","googleCitationCount":2,"googleAuthor":"D Gilbert","doi":"10.1016/j.annonc.2020.08.2272","elsevierCitationCount":0,"altmetricAuthors":["S. Rao","J. Capdevila","D. Gilbert","S. Kim","L. Dahan","T. Kayyal","M. Fakih","A. Demols","L.H. Jensen","K-L.G. Spindler","D. Arnold","S. Tamberi","M.G. Guren","M. Cornfeld","M. Jones","C. Tian","M. Catlett","J-P. Spano"],"twitterCount":0,"altmetricId":98651286,"statusesArray":[]},{"title":"CHLOROBRAIN phase IB trial: The addition of chloroquine, an autophagy inhibitor, to concurrent radiation and temozolomide for newly diagnosed …","googleId":"KbMqFzUSgjQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586471","googleCitationCount":4,"googleAuthor":"I Compter","doi":"10.1093/annonc/mdz243.035","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Genomic characteristics and predicted ancestry of NTRK1/2/3 and ROS1 fusion-positive tumours from> 165,000 pan-solid tumours","googleId":"c1ST_xKjQ24J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586653","googleCitationCount":4,"googleAuthor":"","doi":"10.1093/annonc/mdz244.005","elsevierAuthor":"Russo A.","publicationName":"Current Oncology Reports","elsevierCoverDate":"2020-05-01","elsevierCoverDisplayDate":"1 May 2020","elsevierCitationCount":"6","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Clinical and molecular characteristics and treatment outcomes of advanced right-colon, left-colon and rectal cancers: data from 1180 patients in a phase III trial of …","googleId":"wa8O-X7nfCUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420397945","googleCitationCount":1,"googleAuthor":"","doi":"10.1016/j.annonc.2020.04.476","elsevierAuthor":"Seligmann J.F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-08-01","elsevierCoverDisplayDate":"August 2020","elsevierCitationCount":"1","altmetricAuthors":["J.F. Seligmann","F. Elliott","S. Richman","G. Hemmings","S. Brown","B. Jacobs","C. Williams","S. Tejpar","J.H. Barrett","P. Quirke","M. Seymour"],"twitterCount":8,"altmetricId":81784703,"statusesArray":["1327294939168993282","1327287761716580353","1295102575352709122","1260161946013351936","1259825977544388610","1259786094188482561","1259780037835993088","1259765456854028288"]},{"title":"Prognostic and predictive impact of high tumor mutation burden (TMB) in solid tumors: A systematic review and meta-analysis","googleId":"bvqTgtGDQVIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419583211","googleCitationCount":3,"googleAuthor":"","doi":"10.1093/annonc/mdz239","elsevierCitationCount":0,"altmetricAuthors":["M.G. McNamara","T. Jacobs","M. Frizziero","R. Pihlak","A. Lamarca","R. Hubner","J.W. Valle","E. Amir"],"twitterCount":2,"altmetricId":67616759,"statusesArray":["1179732079606669312","1179730078365868034"]},{"title":"Alpha-fetoprotein (AFP) response in patients with unresectable hepatocellular carcinoma (HCC) in the phase III RESORCE trial","googleId":"ksZUTftglUAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419589712","googleCitationCount":5,"googleAuthor":"","doi":"10.1093/annonc/mdz247.081","elsevierAuthor":"Zhang C.H.","publicationName":"Current Gene Therapy","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"1","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"On the right TRK: from oncogene discovery to cancer therapeutics","googleId":"KewhpccVYiYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)55115-8/abstract","googleCitationCount":3,"googleAuthor":"M Barbacid","statusesArray":[]},{"title":"Unintended on-target chromosomal instability following CRISPR/Cas9 single gene targeting","googleId":"9Q3W2gWG6YAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39799-4/fulltext","googleCitationCount":3,"googleAuthor":"J Przewrocka","statusesArray":[]},{"title":"Benefit of immunotherapy (IT) in advanced non-small cell lung cancer (NSCLC) in elderly patients (EP)","googleId":"moTCul8Dd6YJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30118-8/abstract","googleCitationCount":7,"googleAuthor":"","statusesArray":[]},{"title":"Results of the phase II TRAXAR study: A randomized phase II trial of axitinib and TRC105 (TRAX) versus axitinib (AX) alone in patients with advanced or …","googleId":"3EFTLs8XT2AJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591281","googleCitationCount":3,"googleAuthor":"TK Choueiri","doi":"10.1093/annonc/mdz249.011","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"A phase I clinical trial of malignant pleural mesothelioma treated with locally delivered autologous anti-FAP-targeted CAR T-cells","googleId":"YQuQ0fI90WUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594388","googleCitationCount":5,"googleAuthor":"","doi":"10.1093/annonc/mdz253.052","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Radiomics to predict response to immunotherapy, bridging the gap from proof of concept to clinical applicability?","googleId":"MZjlnOnzhZQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31212-8/abstract","googleCitationCount":4,"googleAuthor":"N Paragios","statusesArray":[]},{"title":"Monalizumab in combination with cetuximab in patients (pts) with recurrent or metastatic (R/M) head and neck cancer (SCCHN) previously treated or not with …","googleId":"E6Vk8Gjv91YJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419593462","googleCitationCount":4,"googleAuthor":"","doi":"10.1093/annonc/mdz252.026","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Prospective, multicenter registry trial to evaluate the clinical feasibility of targeted axillary dissection (TAD) in patients (pts) with breast cancer (BC) and core …","googleId":"-X1aZfiz550J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419584034","googleCitationCount":4,"googleAuthor":"M Reinisch","doi":"10.1093/annonc/mdz240.003","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus …","googleId":"1N9RO0A0CC4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311688","googleCitationCount":10,"googleAuthor":"","doi":"10.1093/annonc/mdz082","elsevierAuthor":"Santos C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-05-01","elsevierCoverDisplayDate":"May 2019","elsevierCitationCount":"6","altmetricAuthors":["C. Santos","D. Azuara","J.M. Viéitez","D. Páez","E. Falcó","E. Élez","C. López-López","M. Valladares","L. Robles-Díaz","P. García-Alfonso","C. Bugés","G. Durán","A. Salud","V. Navarro","G. Capellá","E. Aranda","R. Salazar"],"twitterCount":7,"altmetricId":56699914,"statusesArray":["1222797682302955520","1206665053828780037","1109754350652534784","1109728590428598272","1107757507764719616","1107251157821460480","1105485976158289920","1105484925095030784","1104403419937337351","1103939261508739073"]},{"title":"Antitumor activity of ipatasertib combined with chemotherapy: results from a phase Ib study in solid tumors","googleId":"AU74g6Q3CxIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420360543","googleCitationCount":2,"googleAuthor":"JC Soria","doi":"10.1016/j.annonc.2020.02.007","elsevierAuthor":"Isakoff S.J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-05-01","elsevierCoverDisplayDate":"May 2020","elsevierCitationCount":"1","altmetricAuthors":["S.J. Isakoff","J. Tabernero","L.R. Molife","J.-C. Soria","A. Cervantes","N.J. Vogelzang","M.R. Patel","M. Hussain","A. Baron","G. Argilés","P.R. Conkling","D. Sampath","D. Maslyar","P. Patel","W. Chan","S. Gendreau","L. Musib","N. Xu","H. Ma","K. Lin","J. Bendell"],"twitterCount":16,"altmetricId":76993442,"statusesArray":["1255479186917072896","1255389043124248577","1255110075942920192","1235185089593724928","1235146489472716800","1235105630144229381","1235097522214821888","1235082560260042753","1235062762121752577","1234923500814639114","1234887092318154754","1234877031759765504","1234877012369477632","1234872652461989889","1234866902167629824","1234866412667232256","1234853425810112513","1234853295568625665"]},{"title":"Preliminary results of a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer …","googleId":"fSY7723lzXIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419590652","googleCitationCount":5,"googleAuthor":"JR Osborne","doi":"10.1093/annonc/mdz248.006","elsevierAuthor":"Vlachostergios P.J.","publicationName":"Prostate","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"2021","elsevierCitationCount":"0","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Novel polyurea/polyurethane nanocapsules loaded with a tambjamine analog to improve cancer chemotherapy delivery and safety in lung cancer","googleId":"hW8cYuGDlp0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341960089X","googleCitationCount":3,"googleAuthor":"A Arias","doi":"10.1093/annonc/mdz268.088","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Safety of thoracic radiotherapy in patients with prior immune-related adverse events from immune checkpoint inhibitors","googleId":"NpLNUrSU99cJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420424664","googleCitationCount":1,"googleAuthor":"N Shaverdian","doi":"10.1016/j.annonc.2020.09.016","elsevierAuthor":"Shaverdian N.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-12-01","elsevierCoverDisplayDate":"December 2020","elsevierCitationCount":"1","altmetricAuthors":["N. Shaverdian","J. Beattie","M. Thor","M. Offin","A.F. Shepherd","D.Y. Gelblum","A.J. Wu","C.B. Simone","M.D. Hellmann","J.E. Chaft","A. Rimner","D.R. Gomez"],"twitterCount":9,"altmetricId":91734130,"statusesArray":["1316019662392451072","1315827819302313985","1315666046712504320","1315662086601670657","1314882104996638722","1314712671200194560","1313901632556539905","1313897908404658184","1312694984563290112"]},{"title":"Dissociated responses in patients with metastatic solid tumours treated with immunotherapy","googleId":"frcdHFz2Zz4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594935","googleCitationCount":4,"googleAuthor":"X Paoletti","doi":"10.1093/annonc/mdz253.107","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Efficacy of durvalumab in patients with stage III NSCLC who experience pneumonitis (PACIFIC)","googleId":"yJASw6h6rkIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419596673","googleCitationCount":4,"googleAuthor":"J Naidoo","doi":"10.1093/annonc/mdz259.002","elsevierAuthor":"Geng Y.","publicationName":"Cancer Medicine","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"2021","elsevierCitationCount":"0","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"TiNivo: tivozanib combined with nivolumab results in prolonged progression free survival in patients with metastatic renal cell carcinoma (mRCC): final results","googleId":"IN2ZAma8EnMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591608","googleCitationCount":4,"googleAuthor":"S Negrier","doi":"10.1093/annonc/mdz249.043","elsevierCitationCount":0,"altmetricAuthors":["P. Barthelemy","B. Escudier","S. Negrier","A. Ravaud","M.N. Needle","L. Albiges"],"twitterCount":0,"altmetricId":76294921,"statusesArray":[]},{"title":"Thrombosis as a treatment complication in Hodgkin lymphoma patients: a comprehensive analysis of three prospective randomized German Hodgkin Study …","googleId":"qggBJD9a4wwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312852","googleCitationCount":5,"googleAuthor":"","doi":"10.1093/annonc/mdz168","elsevierAuthor":"Borchmann S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-08-01","elsevierCoverDisplayDate":"1 August 2019","elsevierCitationCount":"6","altmetricAuthors":["S. Borchmann","H. Müller","I. Hude","M. Fuchs","P. Borchmann","A. Engert"],"twitterCount":19,"altmetricId":61173998,"statusesArray":["1187258342290444293","1133927972526862337","1133827839453728769","1133783234406490114","1133744973021679616","1133514736375599106","1133496208956305413","1133457165753159680","1133415877762736128","1133361835825143808","1133354904976670720","1133338910598152192","1133331652640432128","1133320272856199168","1133290072017711104","1133278635723354114","1133246443836313602","1133244931127037957","1133104663119769601"]},{"title":"High clinical benefit rates of pembrolizumab in very rare sarcoma histotypes: First results of the AcSé pembrolizumab study","googleId":"3e62PtuMWVoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594820","googleCitationCount":3,"googleAuthor":"JY Blay","doi":"10.1093/annonc/mdz253.096","elsevierCitationCount":0,"altmetricAuthors":["J.-Y. Blay","N. Penel","I.L. Ray-Coquard","R. Schott","E. Saada-Bouzid","F. Bertucci","C.M. Chevreau","E. Bompas","E. Coquan","S. Cousin","P. Soulié","A. Le Cesne","O. Mir","T. Ryckewaert","M. Brahmi","N. Hoog-Labouret","D. Couch","S. Chevret","J.-C. Soria","C. Massard"],"twitterCount":0,"altmetricId":92074547,"statusesArray":[]},{"title":"Incidence and clinical implications of late immune-related adverse events in long responders to PD-1/PD-L1 checkpoint inhibitors: a multicenter study","googleId":"4RgfXXB91GsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420344343","googleCitationCount":3,"googleAuthor":"A Cortellini","doi":"10.1093/annonc/mdz449.009","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Response to WC Taylor, and C. Fiala and EP Diamandis","googleId":"9_bm5usvF2sJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39895-1/abstract","googleCitationCount":2,"googleAuthor":"MC Liu","statusesArray":[]},{"title":"Phase I study of CC-90011 in patients with advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma (R/R NHL)","googleId":"wa-NvtqVoAgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30018-3/abstract","googleCitationCount":8,"googleAuthor":"A Hollebecque","statusesArray":[]},{"title":"Efficacy and safety of first-line durvalumab (D)±tremelimumab (T) vs platinum-based chemotherapy (CT) based on clinical characteristics in patients with metastatic (m …","googleId":"b8LcIsIcr9wJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30261-3/abstract","googleCitationCount":6,"googleAuthor":"","statusesArray":[]},{"title":"Therapeutic drug monitoring of oral anticancer drugs-preliminary results of a prospective study","googleId":"W5k8d2UdlDQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586641","googleCitationCount":3,"googleAuthor":"","doi":"10.1093/annonc/mdz244.004","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Identifying oncogenic drivers associated with increased risk of late distant recurrence in postmenopausal, estrogen receptor-positive, HER2-negative early breast …","googleId":"3bfWBaA1ZLQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420399348","googleCitationCount":1,"googleAuthor":"SJ Luen","doi":"10.1016/j.annonc.2020.06.024","elsevierAuthor":"Luen S.J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-10-01","elsevierCoverDisplayDate":"October 2020","elsevierCitationCount":"0","altmetricAuthors":["S.J. Luen","R. Asher","C.K. Lee","P. Savas","R. Kammler","P. Dell’Orto","O.M. Biasi","D. Demanse","W. Hackl","B. Thuerlimann","G. Viale","A. Di Leo","M. Colleoni","M.M. Regan","S. Loi"],"twitterCount":4,"altmetricId":85649524,"statusesArray":["1295687716659658754","1282893683608547333","1282825796982202369","1282219328872603649"]},{"title":"Patients and physicians' satisfaction with telemedicine (TM) in cancer care and factors that correlate with a positive patient's experience","googleId":"n5PdAVekb4sJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419599239","googleCitationCount":4,"googleAuthor":"T Abbas","doi":"10.1093/annonc/mdz265.037","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancer","googleId":"o40t9GGSxQ4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341936082X","googleCitationCount":5,"googleAuthor":"F Saad","doi":"10.1016/j.annonc.2019.10.025","elsevierAuthor":"Sternberg C.N.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-02-01","elsevierCoverDisplayDate":"February 2020","elsevierCitationCount":"3","altmetricAuthors":["C.N. Sternberg","F. Saad","J.N. Graff","A. Peer","U.N. Vaishampayan","E. Leung","E. Rosenbaum","H. Gurney","R.J. Epstein","I.D. Davis","B. Wu","L. Trandafir","V.J. Wagner","M. Hussain"],"twitterCount":13,"altmetricId":74058894,"statusesArray":["1238169739874140162","1238057148837318657","1226269564750659584","1220846190536937473","1218002915253682176","1217970393727848448","1217756362245099520","1217629529155436544","1217623548895907840","1217525338521010178","1217496299303587841","1217492982087266304","1217477225328586753","1217470732684447744"]},{"title":"ZEBRA: an ACCRU/IRCI multicenter phase 2 study of pembrolizumab in patients with advanced small bowel adenocarcinoma (SBA)","googleId":"AOWi8m4UCv8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30515-0/abstract","googleCitationCount":7,"googleAuthor":"","statusesArray":[]},{"title":"Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma …","googleId":"HLmNZ2rYVtwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341955116X","googleCitationCount":5,"googleAuthor":"","doi":"10.1093/annonc/mdz382","elsevierAuthor":"Bielack S.S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-11-01","elsevierCoverDisplayDate":"1 November 2019","elsevierCitationCount":"4","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"INOVATYON study: Randomized phase III international study comparing trabectedin/PLD followed by platinum at progression vs carboplatin/PLD in patients with …","googleId":"JRvuNa6PKCMJ","googleLink":"https://portal.findresearcher.sdu.dk/en/publications/inovatyon-study-randomized-phase-iii-international-study-comparin","googleCitationCount":3,"googleAuthor":"N Colombo","doi":"10.1016/j.annonc.2020.08.2260","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"1581O Estimation of European cancer burden for the year 2020","googleId":"QPFKKZvC4ZoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42388-9/abstract","googleCitationCount":1,"googleAuthor":"G Randi","statusesArray":[]},{"title":"Phase II study of lenvatinib plus pembrolizumab for disease progression after PD-1/PD-L1 immune checkpoint inhibitor in metastatic clear cell renal cell …","googleId":"uPWZfFwn83gJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419593991","googleCitationCount":4,"googleAuthor":"V Makker","doi":"10.1093/annonc/mdz253.013","elsevierCitationCount":0,"altmetricAuthors":["C.-H. Lee","A.Y. Shah","V. Makker","M.H. Taylor","D. Shaffer","J.J. Hsieh","A.L. Cohn","C. DiSimone","A Pinto Marin","D.W. Rasco","S.G. Ribe","D.A. Richards","D.E. Stepan","C.E. Dutcus","J. Wu","E.V. Schmidt","R.F. Perini","R.J. Motzer"],"twitterCount":0,"altmetricId":68179445,"statusesArray":[]},{"title":"IMMUNOSARC: A collaborative Spanish (GEIS) and Italian (ISG) sarcoma groups phase I/II trial of sunitinib plus nivolumab in advanced soft tissue and bone …","googleId":"xi2eNKKHCE8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419602917","googleCitationCount":3,"googleAuthor":"","doi":"10.1093/annonc/mdz283.002","elsevierAuthor":"Chen H.","publicationName":"Aging","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"January 2021","elsevierCitationCount":"0","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Analysis of tumour samples from SOLO1: frequency of BRCA specific loss of heterozygosity (LOH) and progression-free survival (PFS) according to …","googleId":"KkrDcw230UEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419592110","googleCitationCount":3,"googleAuthor":"C Gourley","doi":"10.1093/annonc/mdz250.006","elsevierAuthor":"Fabrizio D.A.","publicationName":"JAMA Oncology","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"0","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Quality of life of metastatic urothelial cancer (mUC) patients treated with enfortumab vedotin (EV) following platinum-containing chemotherapy and a …","googleId":"AMOF66wjPykJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591372","googleCitationCount":3,"googleAuthor":"","doi":"10.1093/annonc/mdz249.020","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Impact of germline mutations in homologous recombination (HR) genes on the response to Radium-223 for metastatic castration resistant prostate cancer …","googleId":"oWQibnv50MYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419590925","googleCitationCount":3,"googleAuthor":"E Castro","doi":"10.1093/annonc/mdz248.033","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Novel treatment options in the management of metastatic castration-naïve prostate cancer; which treatment modality to choose?","googleId":"tTPSvydvdLIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419609683","googleCitationCount":4,"googleAuthor":"","doi":"10.1093/annonc/mdz210","elsevierAuthor":"Belderbos B.P.S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-10-01","elsevierCoverDisplayDate":"1 October 2019","elsevierCitationCount":"3","altmetricAuthors":["B.P.S. Belderbos","R. de Wit","M.P.J. Lolkema","R.H.J. Mathijssen","R.J. van Soest"],"twitterCount":7,"altmetricId":64034534,"statusesArray":["1222933005603180545","1222922540609392641","1200783985829388288","1198856741380927490","1159285603554516999","1156120451455881217","1154444422592913408","1154411366079500289"]},{"title":"Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): integrated analysis of ALKA-372-001, STARTRK-1 and …","googleId":"MhlCcH1Dj0cJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30058-4/abstract","googleCitationCount":5,"googleAuthor":"A Drilon","statusesArray":[]},{"title":"Tepotinib plus gefitinib in patients with MET-amplified EGFR-mutant NSCLC: long-term outcomes of the INSIGHT study","googleId":"SHUxNIw4yZ4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419581236","googleCitationCount":3,"googleAuthor":"DW Kim","doi":"10.1093/annonc/mdz437.003","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Excellent CBR and prolonged PFS in non-squamous NSCLC with oral CA-170, an inhibitor of VISTA and PD-L1","googleId":"8H7rRIsg6pwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594212","googleCitationCount":5,"googleAuthor":"S Gupta","doi":"10.1093/annonc/mdz253.035","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"A phase III study comparing SB8, a proposed bevacizumab biosimilar, and reference bevacizumab in patients with metastatic or recurrent non-squamous …","googleId":"GHZFoxBDHvgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419597721","googleCitationCount":3,"googleAuthor":"I Bondarenko","doi":"10.1093/annonc/mdz260.087","elsevierCitationCount":0,"altmetricAuthors":["M. Reck","A. Luft","I. Bondarenko","S. Shevnia","D. Trukhin","N.V. Kovalenko","K. Vacharadze","F. Andrea","A. Hontsa","J. Choi","D. Shin"],"twitterCount":0,"altmetricId":68237440,"statusesArray":[]},{"title":"611O Abiraterone acetate plus prednisolone for hormone-naïve prostate cancer (PCa): Long-term results from metastatic (M1) patients in the STAMPEDE randomised …","googleId":"onqsdk_zovkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40867-1/abstract","googleCitationCount":2,"googleAuthor":"N James","statusesArray":[]},{"title":"Nimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV-negative oropharyngeal cancer","googleId":"a0838eudHKIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419593334","googleCitationCount":4,"googleAuthor":"V Noronha","doi":"10.1093/annonc/mdz252.013","elsevierAuthor":"Prabhash K.","publicationName":"Indian Journal of Cancer","elsevierCoverDate":"2020-02-01","elsevierCoverDisplayDate":"1 February 2020","elsevierCitationCount":"0","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Brigatinib in ALK TKI-pretreated ALK+ metastatic non-small cell lung cancer (mNSCLC): the use via expanded access to brigatinib (UVEA-Brig) study","googleId":"VVgT55uDczAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419597526","googleCitationCount":3,"googleAuthor":"","doi":"10.1093/annonc/mdz260.067","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"746P EV-201: Long-term results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and PD-1/PD …","googleId":"f1ZtrVyNfxEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40814-2/abstract","googleCitationCount":2,"googleAuthor":"","statusesArray":[]},{"title":"Second/third-line nivolumab vs nivo plus ipilimumab in malignant pleural mesothelioma: Long-term results of IFCT-1501 MAPS2 phase IIR trial with a focus on …","googleId":"_tkom3OgKyYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419599719","googleCitationCount":3,"googleAuthor":"G Zalcman","doi":"10.1093/annonc/mdz266","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"LBA18 Overall survival (os) results from SOLAR-1, a phase III study of alpelisib (ALP)+ fulvestrant (FUL) for hormone receptor-positive (HR+), human epidermal growth …","googleId":"yNQmpMwzDnQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42328-2/abstract","googleCitationCount":5,"googleAuthor":"F André","statusesArray":[]},{"title":"Personalized treatment according to geriatric assessment in first-line recurrent and/or metastatic (R/M) head and neck squamous cell cancer (HNSCC) …","googleId":"dYyiaYjvhP0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341959322X","googleCitationCount":3,"googleAuthor":"J Guigay","doi":"10.1093/annonc/mdz252.002","elsevierCitationCount":0,"altmetricAuthors":["J. Guigay","A. Auperin","C. Mertens","C. Even","L. Geoffrois","D. Cupissol","F. Rolland","C. Sire","J. Fayette","F. Peyrade","E. Blot","P. Debourdeau","L. Bozec","O. Capitain","Y. Pointreau","C. Brard","C. Michel","D. Schwob","C. Ortholan","H. Le Caer"],"twitterCount":0,"altmetricId":68179408,"statusesArray":[]},{"title":"1421MO Final results and subgroup analysis of the PETRARCA randomized phase II AIO trial: Perioperative trastuzumab and pertuzumab in combination with …","googleId":"ema9cK71UC4J","googleLink":"https://www.researchgate.net/profile/Manfred_Welslau2/publication/345365307_1421MO_Final_results_and_subgroup_analysis_of_the_PETRARCA_randomized_phase_II_AIO_trial_Perioperative_trastuzumab_and_pertuzumab_in_combination_with_FLOT_versus_FLOT_alone_for_HER2_positive_resectabl/links/5ff454db92851c13feebb30e/1421MO-Final-results-and-subgroup-analysis-of-the-PETRARCA-randomized-phase-II-AIO-trial-Perioperative-trastuzumab-and-pertuzumab-in-combination-with-FLOT-versus-FLOT-alone-for-HER2-positive-resectabl.pdf","googleCitationCount":2,"googleAuthor":"SE Al-Batran","statusesArray":[]},{"title":"Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase …","googleId":"jA5w4dxJwEUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310221","googleCitationCount":5,"googleAuthor":"D Schadendorf","doi":"10.1093/annonc/mdy500","elsevierAuthor":"Urbonas V.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-02-01","elsevierCoverDisplayDate":"1 February 2019","elsevierCitationCount":"3","altmetricAuthors":["V. Urbonas","D. Schadendorf","L. Zimmer","S. Danson","E. Marshall","P. Corrie","M. Wheater","E. Plummer","C. Mauch","C. Scudder","M. Goff","S.B. Love","S.B. Mohammed","M.R. Middleton"],"twitterCount":27,"altmetricId":51193087,"statusesArray":["1235526481553412099","1103911553655463936","1103911158048645121","1092655414993252352","1087702585950261248","1087613483871555584","1087585006569095168","1087497551245389824","1087410837634121728","1087364213301899264","1067429172916568064","1065669993977835520","1064806323391537152","1064806229447454720","1063829727281061888","1063371086191046656","1063150021019877377","1063114214158581761","1063061828815618049","1063035686566199298","1063005127865446400","1062918911241347072","1062909317588963329","1062907674910576640","1062842336533770240","1062820338344423426","1062820003555278848","1062818153565167625","1062808775067869185"]},{"title":"First report of efficacy and safety from a phase II trial of tislelizumab, an anti-PD-1 antibody, for the treatment of PD-L1+ locally advanced or metastatic …","googleId":"1pcTlI0Rld8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591360","googleCitationCount":7,"googleAuthor":"","doi":"10.1093/annonc/mdz249.019","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Disparities in access to oncology clinical trials in Europe in the period 2009-2019","googleId":"GfvWIbZZlTcJ","googleLink":"https://orbi.uliege.be/handle/2268/253768","googleCitationCount":2,"googleAuthor":"M Scheffler","statusesArray":[]},{"title":"Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in elderly patients: A subgroup analysis from TOSCA trial","googleId":"Rb9APBwvGqwJ","googleLink":"https://www.researchgate.net/profile/Gerardo_Rosati/publication/344414424_399O_Oxaliplatin_plus_fluoropyrimidines_as_adjuvant_therapy_for_colon_cancer_in_elderly_patients_A_subgroup_analysis_from_TOSCA_trial/links/5f730c5f92851c14bc9d0b0c/399O-Oxaliplatin-plus-fluoropyrimidines-as-adjuvant-therapy-for-colon-cancer-in-elderly-patients-A-subgroup-analysis-from-TOSCA-trial.pdf","googleCitationCount":2,"googleAuthor":"S Lonardi","statusesArray":[]},{"title":"Sex-based differences of the tumor mutational burden and T-cell inflammation of the tumor microenvironment","googleId":"lIDini_Z_jQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31120-2/abstract","googleCitationCount":6,"googleAuthor":"F Conforti","statusesArray":[]},{"title":"Divining responder populations from survival data","googleId":"DxPLrBUZ-2AJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311962","googleCitationCount":4,"googleAuthor":"S Ventz","doi":"10.1093/annonc/mdz087","elsevierAuthor":"Shervin T.","publicationName":"Neuro-Oncology","elsevierCoverDate":"2020-07-01","elsevierCoverDisplayDate":"1 July 2020","elsevierCitationCount":"0","altmetricAuthors":["R. Rahman","S. Ventz","G. Fell","A.M. Vanderbeek","L. Trippa","B.M. Alexander"],"twitterCount":6,"altmetricId":57089690,"statusesArray":["1115409088173813760","1115324070973845505","1113996387442724865","1108655471836217349","1107040044433461248","1106926128386764800","1106708827246915585"]},{"title":"Applicability of the Lung Immune Prognostic Index (LIPI) in patients with metastatic solid tumors when treated with Immune Checkpoint Inhibitors (ICI) in early clinical …","googleId":"PvfSsvT5LKYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30013-4/abstract","googleCitationCount":5,"googleAuthor":"","statusesArray":[]},{"title":"Vitamin B6 catabolism and lung cancer risk: results from the Lung Cancer Cohort Consortium (LC3)","googleId":"-sGV04b9ZXQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310828","googleCitationCount":3,"googleAuthor":"H Zuo","doi":"10.1093/annonc/mdz002","elsevierAuthor":"Zuo H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-03-01","elsevierCoverDisplayDate":"1 March 2019","elsevierCitationCount":"3","altmetricAuthors":["H. Zuo","P.M. Ueland","Ø Midttun","G.S. Tell","A. Fanidi","W. Zheng","X. Shu","Y. Xiang","J. Wu","R. Prentice","M. Pettinger","C.A. Thomson","G.G. Giles","A. Hodge","Q. Cai","W.J. Blot","M. Johansson","J. Hultdin","K. Grankvist","V.L. Stevens","M.L. McCullough","S.J. Weinstein","D. Albanes","R.G. Ziegler","N.D. Freedman","N.E. Caporaso","A. Langhammer","K. Hveem","M. Næss","J.E. Buring","I. Lee","J.M. Gaziano","G. Severi","X. Zhang","M.J. Stampfer","J. Han","A. Zeleniuch-Jacquotte","L.L. Marchand","J. Yuan","R. Wang","W. Koh","Y. Gao","U. Ericson","K. Visvanathan","M.R. Jones","C. Relton","P. Brennan","M. Johansson","A. Ulvik"],"twitterCount":2,"altmetricId":55104577,"statusesArray":["1093562684753219590","1093562537415602177"]},{"title":"Update on the phase II SUMMIT trial: Neratinib+ fulvestrant for HER2-mutant, HR-positive, metastatic breast cancer","googleId":"mFPiGnNqjqkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30302-3/abstract","googleCitationCount":7,"googleAuthor":"","statusesArray":[]},{"title":"PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous …","googleId":"C4yv7hcD0rYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419582126","googleCitationCount":3,"googleAuthor":"SK Sandhu","doi":"10.1093/annonc/mdz446.007","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Pharmacokinetics (PK), safety, and efficacy of trastuzumab deruxtecan with OATP1B/CYP3A inhibitors in subjects with HER2-expressing advanced …","googleId":"xuL_iwInvN8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419585520","googleCitationCount":3,"googleAuthor":"","doi":"10.1093/annonc/mdz242.025","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Comparison of real-world response rate (rwRR) to RECIST-based response rate in patients with advanced non-small cell lung cancer (aNSCLC)","googleId":"B_B8s3LvPd0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419597885","googleCitationCount":4,"googleAuthor":"AB Bourla","doi":"10.1093/annonc/mdz260.103","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"BGB-A333, an anti-PD-L1 monoclonal antibody, in combination with tislelizumab in patients with urothelial carcinoma","googleId":"OtEn42R-2PMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40645-3/abstract","googleCitationCount":2,"googleAuthor":"V Moreno","statusesArray":[]},{"title":"Efficacy and safety of isatuximab plus pomalidomide and dexamethasone in East Asian patients with relapsed/refractory multiple myeloma: A subgroup …","googleId":"UKhFf-qiTuUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419579431","googleCitationCount":3,"googleAuthor":"MC Wang","doi":"10.1093/annonc/mdz427.003","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Combination of intratumoural double-stranded RNA (dsRNA) BO-112 with systemic anti-PD-1 in patients with anti-PD-1 refractory cancer","googleId":"4h7XLnw8nw0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420344872","googleCitationCount":2,"googleAuthor":"I Marquez-Rodas","doi":"10.1093/annonc/mdz451.009","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Recent eUpdate to the ESMO Clinical Practice Guidelines on early and locally advanced non-small-cell lung cancer (NSCLC)","googleId":"dPfXRf0XN6IJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39865-3/pdf","googleCitationCount":1,"googleAuthor":"G Pentheroudakis","statusesArray":[]},{"title":"O-6 The novel regimen of tremelimumab in combination with durvalumab provides a favorable safety profile and clinical activity for patients with advanced …","googleId":"1JZSKItw8z0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39358-3/pdf","googleCitationCount":2,"googleAuthor":"","statusesArray":[]},{"title":"Efficacy and safety of nintedanib+ docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): Updated …","googleId":"3ydErE3j5G4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420344446","googleCitationCount":3,"googleAuthor":"","doi":"10.1093/annonc/mdz449.020","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"861P Limited implementation of the ESMO-ESGO (European Society of Gynaecological Oncology)-ESTRO (European Society for Radiotherapy and Oncology) …","googleId":"DQjMiB7syhcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40996-2/abstract","googleCitationCount":1,"googleAuthor":"N Colombo","statusesArray":[]},{"title":"Health-related quality of life after chemotherapy with or without rituximab in primary central nervous system lymphoma patients: results from a randomised phase III …","googleId":"Sy5NDsMVpmQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420393133","googleCitationCount":2,"googleAuthor":"M Van der Meulen","doi":"10.1016/j.annonc.2020.04.014","elsevierAuthor":"van der Meulen M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-08-01","elsevierCoverDisplayDate":"August 2020","elsevierCitationCount":"1","altmetricAuthors":["M. van der Meulen","K. Bakunina","M. Nijland","M.C. Minnema","G. Cull","W.B.C. Stevens","J.W. Baars","K.D. Mason","A. Beeker","M. Beijert","M.J.B. Taphoorn","M.J. van den Bent","S. Issa","J.K. Doorduijn","J.E.C. Bromberg","L. Dirven"],"twitterCount":1,"altmetricId":81562246,"statusesArray":["1258341138391609345"]},{"title":"FUSAFE individual patient data meta-analysis (MA) to assess the performance of dihydropyrimidine dehydrogenase (DPD) gene polymorphisms for predicting …","googleId":"T3_2w3N17WAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419587890","googleCitationCount":3,"googleAuthor":"","doi":"10.1093/annonc/mdz246.046","elsevierAuthor":"Seid H.","publicationName":"Swiss Medical Weekly","elsevierCoverDate":"2020-11-24","elsevierCoverDisplayDate":"24 November 2020","elsevierCitationCount":"0","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Anlotinib for advanced hepatocellular carcinoma: Interim results from the phase II ALTER0802 study","googleId":"R5-UvHVZPAQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419589670","googleCitationCount":3,"googleAuthor":"","doi":"10.1093/annonc/mdz247.077","elsevierAuthor":"Zhang C.H.","publicationName":"Current Gene Therapy","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"1","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"IMpower030: Phase III study evaluating neoadjuvant treatment of resectable stage II-IIIB non-small cell lung cancer (NSCLC) with atezolizumab (atezo)+ …","googleId":"dP8XbDbw4OwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30152-8/abstract","googleCitationCount":5,"googleAuthor":"S Peters","statusesArray":[]},{"title":"100,000 genomes project: Integrating whole genome sequencing (WGS) data into clinical practice","googleId":"pd3owMfB99AJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419619010","googleCitationCount":2,"googleAuthor":"J Mitchell","doi":"10.1093/annonc/mdz413.006","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"O-3 Efficacy and safety of entrectinib in NTRK fusion-positive gastrointestinal cancers: Updated integrated analysis of three clinical trials (STARTRK-2 …","googleId":"2o_TzVK1LlMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39355-8/pdf","googleCitationCount":2,"googleAuthor":"S Siena","statusesArray":[]},{"title":"Phase II trial of HER2-PET/CT using 68Ga-anti-HER2 VHH1 for characterization of HER2 presence in brain metastases of breast cancer patients","googleId":"D5iOGmfxCc4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30353-9/abstract","googleCitationCount":4,"googleAuthor":"M Keyaerts","statusesArray":[]},{"title":"The role of plasma microseminoprotein-beta in prostate cancer: an observational nested case–control and Mendelian randomization study in the European …","googleId":"dfJBOzJqmk4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312098","googleCitationCount":4,"googleAuthor":"KS Byrne","doi":"10.1093/annonc/mdz121","elsevierAuthor":"Smith Byrne K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-06-01","elsevierCoverDisplayDate":"1 June 2019","elsevierCitationCount":"3","altmetricAuthors":["K. Smith Byrne","P.N. Appleby","T.J. Key","M.V. Holmes","G.K. Fensom","A. Agudo","E. Ardanaz","H. Boeing","H.B. Bueno-de-Mesquita","M.D. Chirlaque","R. Kaaks","N. Larrañaga","D. Palli","A. Perez-Cornago","J.R. Quirós","F. Ricceri","M.J. Sánchez","G. Tagliabue","K.K. Tsilidis","R. Tumino","R.T. Fortner","P. Ferrari","E. Riboli","H. Lilja","R.C. Travis"],"twitterCount":20,"altmetricId":58826730,"statusesArray":["1146801262492442624","1146748326328643584","1146746987775217665","1146724379247726594","1146723832671043585","1139158896407326720","1139157491919441921","1134702422390116352","1134429772182892546","1134425313079898112","1134425137414115328","1129876205736484864","1129294660424409089","1128986137916268544","1128983743614586880","1128983066565734400","1128931414068670464","1120531144536207360","1120125607709483014","1116353850389291008","1115986038537592833"]},{"title":"Interim analysis of a phase Ib study of cobimetinib plus atezolizumab in patients with advanced BRAFV600 wild type melanoma progressing on prior anti-PD …","googleId":"I-4f5XrMMysJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419595679","googleCitationCount":2,"googleAuthor":"SK Sandhu","doi":"10.1093/annonc/mdz255.046","elsevierAuthor":"Morganti S.","publicationName":"ecancermedicalscience","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"0","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Durable anti-tumor activity of the multi-targeted inhibitor lenvatinib in patients with advanced or metastatic thymic carcinoma: Preliminary results from a …","googleId":"JsffEb0BREgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419599744","googleCitationCount":4,"googleAuthor":"","doi":"10.1093/annonc/mdz266.003","elsevierCitationCount":0,"altmetricAuthors":["S. Itoh","M. Satouchi","J. Sato","Y. Okuma","S. Niho","H. Mizugaki","H. Murakami","Y. Fujisaka","T. Kozuki","K. Nakamura","Y. Nagasaka","M. Kawasaki","T. Yamada","A. Kuchiba","N. Yamamoto"],"twitterCount":0,"altmetricId":68946554,"statusesArray":[]},{"title":"A novel bispecific BCMAxCD3 T cell-engaging antibody that treat multiple myeloma (MM) with minimal cytokine secretion","googleId":"qBPIrrCb_7AJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419601468","googleCitationCount":3,"googleAuthor":"","doi":"10.1093/annonc/mdz269.038","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO …","googleId":"E-bxMnWwjMQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420359299","googleCitationCount":4,"googleAuthor":"E Senkus-Konefka","doi":"10.1016/j.annonc.2020.01.008","elsevierAuthor":"Park Y.H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-04-01","elsevierCoverDisplayDate":"April 2020","elsevierCitationCount":"3","altmetricAuthors":["Y.H. Park","E. Senkus-Konefka","S.-A. Im","G. Pentheroudakis","S. Saji","S. Gupta","H. Iwata","M.Y. Mastura","R. Dent","Y.-S. Lu","Y. Yin","B.K. Smruti","T. Toyama","S. Malwinder","S.C. Lee","L.-M. Tseng","J.H. Kim","T.-Y. Kim","K.J. Suh","F. Cardoso","T. Yoshino","J.-Y. Douillard"],"twitterCount":2,"altmetricId":78574677,"statusesArray":["1244399552154628096","1244392522375446529"]},{"title":"LBA11 IMpassion031: Results from a phase III study of neoadjuvant (neoadj) atezolizumab+ chemotherapy in early triple-negative breast cancer (TNBC)","googleId":"LpSzIDhlyR4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42321-X/abstract","googleCitationCount":3,"googleAuthor":"CH Barrios","statusesArray":[]},{"title":"Multiple-cohort analysis investigating FGFR3 alteration as a predictor of non-response to neoadjuvant pembrolizumab (pembro) in muscle-invasive bladder …","googleId":"iYGyAXl2PrIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591219","googleCitationCount":5,"googleAuthor":"A Briganti","doi":"10.1093/annonc/mdz249.004","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Passion for immune checkpoint blockade in triple negative breast cancer: comment on the IMpassion130 study","googleId":"kBjNBT-v-bEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30988-3/abstract","googleCitationCount":6,"googleAuthor":"S Loi","statusesArray":[]},{"title":"Survival outcomes in stage IV small-cell lung cancer (IV-SCLC): Analysis from SEER database","googleId":"fr0HUE5jnSwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420344628","googleCitationCount":2,"googleAuthor":"MD Gomez","doi":"10.1093/annonc/mdz449.038","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Factors predicting relapse in early breast cancer patients with a pathological complete response after neoadjuvant therapy: Pooled analysis based on the GBG …","googleId":"DDv6qX5H1fMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30376-X/abstract","googleCitationCount":5,"googleAuthor":"","statusesArray":[]},{"title":"A phase I study of ATR inhibitor, AZD6738, as monotherapy in advanced solid tumours (PATRIOT part A, B)","googleId":"vbexyfXAgH4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586720","googleCitationCount":5,"googleAuthor":"M Dillon","doi":"10.1093/annonc/mdz244.012","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Durvalumab+ monalizumab, mFOLFOX6, and bevacizumab in patients (pts) with metastatic microsatellite-stable colorectal cancer (MSS-CRC)","googleId":"Bjk8T9XWrfQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594133","googleCitationCount":3,"googleAuthor":"M Cho","doi":"10.1093/annonc/mdz253.027","elsevierAuthor":"Zhou P.","publicationName":"Aging","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"January 2021","elsevierCitationCount":"0","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"METEOR-1: a phase I study of GSK3326595, a first-in-class protein arginine methyltransferase 5 (PRMT5) inhibitor, in advanced solid tumours","googleId":"MM784Tc0Lj8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586604","googleCitationCount":6,"googleAuthor":"LL Siu","doi":"10.1093/annonc/mdz244","elsevierAuthor":"Dadu R.","publicationName":"Endocrine-Related Cancer","elsevierCoverDate":"2020-08-01","elsevierCoverDisplayDate":"August 2020","elsevierCitationCount":"0","altmetricAuthors":["L.L. Siu","D.W. Rasco","S Postel Vinay","P Martin Romano","J. Menis","F.L. Opdam","K.M. Heinhuis","J.L. Egger","S.A. Gorman","R. Parasrampuria","K. Wang","B.E. Kremer","M.M. Gounder"],"twitterCount":0,"altmetricId":86749818,"statusesArray":[]},{"title":"PACIFIC-R: First real-world study of patients with unresectable, stage III NSCLC treated with durvalumab after chemoradiotherapy","googleId":"PrZYxMYAA_YJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30186-3/abstract","googleCitationCount":4,"googleAuthor":"","statusesArray":[]},{"title":"LBA65 The Canadian Cancer Trials Group PA. 7 trial: Results of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs GEM, nab-P …","googleId":"7sahSUxK7gUJ","googleLink":"https://www.researchgate.net/profile/Duan_Tu2/publication/345371394_LBA65_The_Canadian_Cancer_Trials_Group_PA7_trial_Results_of_a_randomized_phase_II_study_of_gemcitabine_GEM_and_nab-paclitaxel_Nab-P_vs_GEM_nab-P_durvalumab_D_and_tremelimumab_T_as_first_line_therapy_i/links/5ffbd5a5299bf14088886586/LBA65-The-Canadian-Cancer-Trials-Group-PA7-trial-Results-of-a-randomized-phase-II-study-of-gemcitabine-GEM-and-nab-paclitaxel-Nab-P-vs-GEM-nab-P-durvalumab-D-and-tremelimumab-T-as-first-line-therapy.pdf","googleCitationCount":2,"googleAuthor":"DJ Renouf","statusesArray":[]},{"title":"Comparison of immuno-oncology (IO) biomarkers in adenocarcinoma (ACB), urothelial carcinoma (UCB) and squamous cell carcinoma (SCCB) of the bladder …","googleId":"C-1XEyHC5q0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591463","googleCitationCount":3,"googleAuthor":"AB Schrock","doi":"10.1093/annonc/mdz249.029","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Alpelisib (ALP)+ fulvestrant (FUL) for patients with hormone receptor–positive (HR+), HER2− advanced breast cancer (ABC): Management and time course of …","googleId":"oQppqByNKqsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419585465","googleCitationCount":3,"googleAuthor":"F André","doi":"10.1093/annonc/mdz242.019","elsevierAuthor":"Donahue B.S.","publicationName":"Clinical Journal of Oncology Nursing","elsevierCoverDate":"2020-12-01","elsevierCoverDisplayDate":"December 2020","elsevierCitationCount":"0","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) in the real-world setting","googleId":"WulZALHnYxgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30992-5/abstract","googleCitationCount":5,"googleAuthor":"","statusesArray":[]},{"title":"Prospective testing of circulating tumour DNA in metastatic breast cancer facilitates clinical trial enrollment and precision oncology","googleId":"v_dRr6l4kF4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419583363","googleCitationCount":2,"googleAuthor":"","doi":"10.1093/annonc/mdz239.016","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"BRCA1/2 testing in HER2-advanced breast cancer (ABC): Results from the European component of a multi-country real-world study","googleId":"qbeJhOLnt5MJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419585143","googleCitationCount":3,"googleAuthor":"","doi":"10.1093/annonc/mdz241","elsevierAuthor":"Untch M.","publicationName":"Geburtshilfe und Frauenheilkunde","elsevierCoverDate":"2020-06-01","elsevierCoverDisplayDate":"1 June 2020","elsevierCitationCount":"0","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"NRG1-fusion positive gastrointestinal tumours: afatinib as a novel potential treatment option","googleId":"ZYYytu1qVxkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30807-5/abstract","googleCitationCount":3,"googleAuthor":"B Weinberg","statusesArray":[]},{"title":"Phase I/II study of combined BCL-XL and MEK inhibition with navitoclax (N) and trametinib (T) in KRAS or NRAS mutant advanced solid tumours","googleId":"DZin-WFLbh0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586690","googleCitationCount":3,"googleAuthor":"AR Parikh","doi":"10.1093/annonc/mdz244.009","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Phase I dose escalation study of a selective androgen receptor modulator RAD140 in estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer …","googleId":"XrBCZADY8pYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419585659","googleCitationCount":2,"googleAuthor":"","doi":"10.1093/annonc/mdz242.038","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"O-4 NTRK gene fusions in bilio-pancreatic cancers","googleId":"jpa8tI09ZSgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39356-X/pdf","googleCitationCount":2,"googleAuthor":"","statusesArray":[]},{"title":"A phase II basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumours","googleId":"y8iEV3ILn1oJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419590585","googleCitationCount":3,"googleAuthor":"A Drilon","doi":"10.1093/annonc/mdz247.169","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Immune checkpoint inhibitor-based combinations: is dose escalation mandatory for phase I trials?","googleId":"AQk2kGntoj0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325886","googleCitationCount":4,"googleAuthor":"","doi":"10.1093/annonc/mdz286","elsevierAuthor":"Simmet V.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-11-01","elsevierCoverDisplayDate":"November 2019","elsevierCitationCount":"1","altmetricAuthors":["V. Simmet","L. Eberst","A. Marabelle","P.A. Cassier"],"twitterCount":2,"altmetricId":65605825,"statusesArray":["1290591778157076481","1167029376011132928"]},{"title":"Outcome and mutational landscape of patients with PIK3CA-mutated metastatic breast cancer (mBC)","googleId":"gtkC0EYeKYIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30417-X/abstract","googleCitationCount":4,"googleAuthor":"A Lusque","statusesArray":[]},{"title":"New designs in early clinical drug development","googleId":"FfIjyVlSDqMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341945984X","googleCitationCount":2,"googleAuthor":"A Mansinho","doi":"10.1093/annonc/mdz191","elsevierAuthor":"Mansinho A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-09-01","elsevierCoverDisplayDate":"1 September 2019","elsevierCitationCount":"2","altmetricAuthors":["A. Mansinho","V. Boni","M. Miguel","E. Calvo"],"twitterCount":6,"altmetricId":67765046,"statusesArray":["1180986367062532096","1180958149290975233","1180941526341431297","1180876225624985601","1180870007783378944","1180869412812931073"]},{"title":"Prognostic value of tumour infiltrating lymphocytes (TILs) in patients with early-stage triple negative breast cancers (TNBC) in the absence of chemotherapy","googleId":"tuUrEWciQPIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419584010","googleCitationCount":3,"googleAuthor":"G Bataillon","doi":"10.1093/annonc/mdz240.001","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall …","googleId":"2ZDUJiGd-XEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420421556","googleCitationCount":6,"googleAuthor":"","doi":"10.1016/j.annonc.2020.08.2100","elsevierAuthor":"Papadimitrakopoulou V.A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-11-01","elsevierCoverDisplayDate":"November 2020","elsevierCitationCount":"2","altmetricAuthors":["V.A. Papadimitrakopoulou","T.S. Mok","J.-Y. Han","M.-J. Ahn","A. Delmonte","S.S. Ramalingam","S.W. Kim","F.A. Shepherd","J. Laskin","Y. He","H. Akamatsu","W.S.M.E. Theelen","W.-C. Su","T. John","M. Sebastian","H. Mann","M. Miranda","G. Laus","Y. Rukazenkov","Y.-L. Wu"],"twitterCount":2,"altmetricId":89498619,"statusesArray":["1302043508732235782","1302040332809449472"]},{"title":"Real life use of talimogene laherparepvec in melanoma in centers in Austria and Switzerland","googleId":"WZAmoDRAzPkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419595539","googleCitationCount":2,"googleAuthor":"C Hoeller","doi":"10.1093/annonc/mdz255.032","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Mixture-cure modeling for resected stage III/IV melanoma in the phase III CheckMate 238 trial","googleId":"SW9v8XEooG4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419595412","googleCitationCount":2,"googleAuthor":"M Kurt","doi":"10.1093/annonc/mdz255.020","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Phase I evaluation of AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced …","googleId":"77WKt7vB2NQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594182","googleCitationCount":2,"googleAuthor":"","doi":"10.1093/annonc/mdz253.032","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Exposure-response analyses of ALK-inhibitors crizotinib and alectinib in NSCLC patients","googleId":"KYiN-WlIBF4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419596946","googleCitationCount":2,"googleAuthor":"JM Janssen","doi":"10.1093/annonc/mdz260.008","elsevierAuthor":"Aghai F.","publicationName":"Analytical and Bioanalytical Chemistry","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"January 2021","elsevierCitationCount":"0","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Phase I study of the arginase inhibitor INCB001158 (1158) alone and in combination with pembrolizumab (PEM) in patients (Pts) with advanced/metastatic …","googleId":"3qpqT2NenAgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586628","googleCitationCount":6,"googleAuthor":"A Naing","doi":"10.1093/annonc/mdz244.002","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Pharmacokinetic (PK) assessment of BT1718: A phase I/II a study of BT1718, a first in class bicycle toxin conjugate (BTC), in patients (pts) with advanced solid …","googleId":"D8Qm5dbghikJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586860","googleCitationCount":2,"googleAuthor":"J Evans","doi":"10.1093/annonc/mdz244.026","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"A phase 3 study of durvalumab with or without bevacizumab as adjuvant therapy in patients with hepatocellular carcinoma (HCC) who are at high risk of recurrence …","googleId":"rPMFejUfIfkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30705-7/abstract","googleCitationCount":3,"googleAuthor":"J Knox","statusesArray":[]},{"title":"1688P Outcome of older cancer patients infected with COVID-19 at Gustave Roussy Cancer Center","googleId":"UDbt7KJmrIcJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506356/","googleCitationCount":1,"googleAuthor":"","doi":"10.1016/j.annonc.2020.08.1752","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Intracranial and extracranial efficacy of lorlatinib in the post second-generation ALK tyrosine kinase inhibitor (TKI) setting","googleId":"tGhrxE_2C8kJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419596958","googleCitationCount":2,"googleAuthor":"","doi":"10.1093/annonc/mdz260.009","elsevierAuthor":"Tabbò F.","publicationName":"Current Oncology Reports","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"January 2021","elsevierCitationCount":"0","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Predictive modeling in colorectal cancer: time to move beyond consensus molecular subtypes","googleId":"m7demNaXHzYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)32604-1/abstract","googleCitationCount":7,"googleAuthor":"","statusesArray":[]},{"title":"Post-hoc analyses of a subgroup of patients with advanced biliary tract cancer (BTC) who crossed over to treatment with etoposide toniribate (EDO-S7. 1) in a …","googleId":"afD_1o2WMEkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419589414","googleCitationCount":3,"googleAuthor":"S Kasper","doi":"10.1093/annonc/mdz247.051","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"WGS implementation in standard cancer diagnostics for every cancer patient (WIDE)","googleId":"02qI_6dBvKAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341959617X","googleCitationCount":2,"googleAuthor":"L Bosch","doi":"10.1093/annonc/mdz257.003","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"LBA50 ACTIVE: Apatinib plus gefitinib versus placebo plus gefitinib as first-line treatment for advanced epidermal growth factor receptor-mutant (EGFRm) non …","googleId":"aTmp9NJ8vX4J","googleLink":"https://www.researchgate.net/profile/Delvys_Rodriguez-Abreu/publication/345365073_LBA51_KEYNOTE-024_5-year_OS_update_First-line_1L_pembrolizumab_pembro_vs_platinum-based_chemotherapy_chemo_in_patients_pts_with_metastatic_NSCLC_and_PD-L1_tumour_proportion_score_TPS_50/links/5fe9ed4292851c13fecfa64a/LBA51-KEYNOTE-024-5-year-OS-update-First-line-1L-pembrolizumab-pembro-vs-platinum-based-chemotherapy-chemo-in-patients-pts-with-metastatic-NSCLC-and-PD-L1-tumour-proportion-score-TPS-50.pdf","googleCitationCount":2,"googleAuthor":"","statusesArray":[]},{"title":"Safety, antitumor activity, and pharmacokinetics (PK) of pamiparib (BGB-290), a PARP1/2 inhibitor, in patients (pts) with advanced solid tumours: Updated …","googleId":"hgOrPzbIFEIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586744","googleCitationCount":2,"googleAuthor":"M Voskoboynik","doi":"10.1093/annonc/mdz244.014","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Phase I Clinical Study for Validation of Fimaporfin-Based Photochemical Internalisation: A Novel Technology for Enhancing Cellular Immune Responses …","googleId":"qA9jNlWbkyYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420344963","googleCitationCount":2,"googleAuthor":"","doi":"10.1093/annonc/mdz451.018","elsevierCitationCount":0,"altmetricAuthors":["P.K. Selbo","S. Janetzki","M.J.P. Welters","M. Håkerud","A.G. Nedberg","V.T. Edwards","H. Olivecrona","S.H. van der Burg","T. Otterhaug","A. Hogset"],"twitterCount":4,"altmetricId":73554914,"statusesArray":["1216037752120102914","1213103861638090753","1213083633776562176","1213083346076684288"]},{"title":"Phase II multicenter open label study of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study)","googleId":"ffZwBxGmT6QJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341960428X","googleCitationCount":2,"googleAuthor":"H Jespersen","doi":"10.1093/annonc/mdz394.068","elsevierCitationCount":0,"altmetricAuthors":["H. Jespersen","R. Olofsson Bagge","G. Ullenhag","A. Carneiro","H. Helgadottir","I. Ljuslinder","M. Levin","C. All-Eriksson","B. Andersson","U. Stierner","L.M. Nilsson","J.A. Nilsson","L. Ny"],"twitterCount":1,"altmetricId":68305311,"statusesArray":["1183361898177290240"]},{"title":"LBA74 Disparities in cancer during the COVID-19 pandemic: COVID-19 and cancer outcomes study (CCOS)","googleId":"1nHwoT-ld-MJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506490/","googleCitationCount":1,"googleAuthor":"D Doroshow","doi":"10.1016/j.annonc.2020.08.2315","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Targeting NRG1-fusions in multiple tumour types: Afatinib as a novel potential treatment option","googleId":"Dx12fVzxsFoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419600967","googleCitationCount":3,"googleAuthor":"K Tolba","doi":"10.1093/annonc/mdz268.096","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"LBA72 Assessment of clinical and laboratory prognostic factors in patients with cancer and SARS-CoV-2 infection: The COVID-19 and Cancer Consortium …","googleId":"Jgu3FxhZB0gJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506465/","googleCitationCount":2,"googleAuthor":"J Warner","doi":"10.1016/j.annonc.2020.08.2313","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Phase I combination dose-finding/phase II expansion cohorts of lenvatinib+ etoposide+ ifosfamide in patients (pts) aged 2 to≤ 25 years with relapsed …","googleId":"dNKjQ3iilMQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341960298X","googleCitationCount":2,"googleAuthor":"R Venkatramani","doi":"10.1093/annonc/mdz283.009","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Assessing the clinical relevance of drug-drug interactions (DDI) with darolutamide (DARO)","googleId":"YI_MIgnKgNYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591062","googleCitationCount":2,"googleAuthor":"","doi":"10.1093/annonc/mdz248.047","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Comprehensive genomic profiling (CGP) of carcinoma of unknown primary origin (CUP): Retrospective molecular classification of potentially eligible patients …","googleId":"lcZoy9TOIo0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604540","googleCitationCount":4,"googleAuthor":"L Mileshkin","doi":"10.1093/annonc/mdz394.094","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Pre-specified pilot analysis of a randomised pilot/phase II/III trial comparing standard dose vs dose-escalated concurrent chemoradiotherapy (CRT) in anal …","googleId":"9D9lBdM51P4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419587567","googleCitationCount":4,"googleAuthor":"J Webster","doi":"10.1093/annonc/mdz246.013","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"The AST/ALT (De Ritis) ratio predicts clinical outcome in pancreatic cancer patients treated with first-line nab-paclitaxel and gemcitabine: post-hoc analysis of an …","googleId":"ElEXkI3qIx4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30802-6/abstract","googleCitationCount":4,"googleAuthor":"J Riedl","statusesArray":[]},{"title":"Meta-analysis on association of pathological complete response with long-term survival outcomes in triple-negative breast cancer","googleId":"SUE2pIt70EsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419584666","googleCitationCount":2,"googleAuthor":"","doi":"10.1093/annonc/mdz240.067","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Single cycle induction treatment with cisplatin/docetaxel plus durvalumab/tremelimumab in stage III-IVB head and neck squamous cell cancer (CheckRad …","googleId":"NErDi8rtr6cJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341959336X","googleCitationCount":2,"googleAuthor":"M Eckstein","doi":"10.1093/annonc/mdz252.016","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Safety and feasibility of extending flushing interval every 3 months for maintenance of TICVPS in CRC patients after completion of curative intended treatments","googleId":"D8yiNVBk3bsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)58092-9/abstract","googleCitationCount":3,"googleAuthor":"","statusesArray":[]},{"title":"Safety and efficacy of the oral CXCR4 inhibitor X4P-001+ axitinib in advanced renal cell carcinoma patients: an analysis of subgroup responses by prior …","googleId":"Y1Ehd4Qtk8oJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341959398X","googleCitationCount":2,"googleAuthor":"","doi":"10.1093/annonc/mdz253.012","elsevierCitationCount":0,"altmetricAuthors":["D.F. McDermott","U. Vaishampayan","M. Matrana","S.Y. Rha","A Zurita Saavedra","T. Ho","B. Keam","J.-L. Lee","R. Joseph","S. Ali","W. Stadler","N.B. Haas","S. Sundararajan","S.H. Park","R. Mowat","J. Picus","A.Z. Dudek","Y. Zakharia","L. Gan","M.B. Atkins"],"twitterCount":0,"altmetricId":68179444,"statusesArray":[]},{"title":"Gastric cancer in young Latin women: bad prognostic factors and outcomes","googleId":"B9eRc92XZUYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30664-7/abstract","googleCitationCount":4,"googleAuthor":"M Herrera","statusesArray":[]},{"title":"Osimertinib in epidermal growth factor receptor (EGFR) T790M advanced non-small cell lung cancer (NSCLC): Analysis of patients with central nervous …","googleId":"HRQjPB3zpxYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419597289","googleCitationCount":2,"googleAuthor":"G Metro","doi":"10.1093/annonc/mdz260.043","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Association between PIK3CA mutation status and development of brain metastases in HR+/HER2-metastatic breast cancer","googleId":"ex88wTlvvGMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419585404","googleCitationCount":2,"googleAuthor":"","doi":"10.1093/annonc/mdz242.013","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Inconsistencies in currently used definitions of sarcopenia in oncology","googleId":"9btYyxZDs9sJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)36077-6/abstract","googleCitationCount":2,"googleAuthor":"","statusesArray":[]},{"title":"Trybeca-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with …","googleId":"RoSwjtc3YZsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30626-X/abstract","googleCitationCount":5,"googleAuthor":"P Hammel","statusesArray":[]},{"title":"Phase II study of cetuximab rechallenge in patients with RAS wild-type metastatic colorectal cancer: E-Rechallenge trial","googleId":"FlutAU2M_2oJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)62207-6/abstract","googleCitationCount":3,"googleAuthor":"","statusesArray":[]},{"title":"Correlation of various clinical, imaging and laboratory parameters with outcome in patients with metastatic non-small cell lung cancer (NSCLC) treated with immune …","googleId":"24OcWWMgBTkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30115-2/abstract","googleCitationCount":5,"googleAuthor":"K Rounis","statusesArray":[]},{"title":"Interpreting the impact of apalutamide on overall survival among patients with non-metastatic castration-resistant prostate cancer","googleId":"Pu7Dv8snPvcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)43226-2/abstract","googleCitationCount":2,"googleAuthor":"ZR McCaw","statusesArray":[]},{"title":"An international randomized cross-over bio-equivalence study of oral paclitaxel+ HM30181 compared with weekly intravenous (IV) paclitaxel in patients with …","googleId":"tVq3UvRtUpwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586999","googleCitationCount":2,"googleAuthor":"C Jackson","doi":"10.1093/annonc/mdz244.039","elsevierCitationCount":0,"altmetricAuthors":["C G C A Jackson","S. Deva","K. Bayston","B. McLaren","P. Barlow","N.A. Hung","K. Clarke","E. Segelov","T.-Y. Chao","M.-S. Dai","H.-T. Yen","D. Cutler","D. Kramer","J. Zhi","W.-K. Chan","M -F R Kwan","C.-T. Hung"],"twitterCount":0,"altmetricId":67894406,"statusesArray":[]},{"title":"Revisiting surveillance schemes for cancer survivors","googleId":"mIWaWB4rZ44J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31201-3/abstract","googleCitationCount":3,"googleAuthor":"Ø Holme","statusesArray":[]},{"title":"Towards precision oncology for HER2 blockade in gastroesophageal adenocarcinoma","googleId":"uigtFEVq2q4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312748","googleCitationCount":4,"googleAuthor":"","doi":"10.1093/annonc/mdz143","elsevierAuthor":"Gambardella V.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-08-01","elsevierCoverDisplayDate":"1 August 2019","elsevierCitationCount":"2","altmetricAuthors":["V. Gambardella","T. Fleitas","N. Tarazona","J.M. Cejalvo","F. Gimeno-Valiente","C. Martinez-Ciarpaglini","M. Huerta","S. Roselló","J. Castillo","D. Roda","A. Cervantes"],"twitterCount":10,"altmetricId":59850131,"statusesArray":["1169682774262984704","1169288044932976640","1169127114383269888","1169114951040098304","1169108795596902405","1169100211492413440","1168983987014029312","1124618115869024256","1124333026174033920","1124193087142682624"]},{"title":"SELPAC: A 3 arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel (PT) in metastatic uveal melanoma (UM)","googleId":"D1-ZHc_ZHFgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604308","googleCitationCount":2,"googleAuthor":"S Danson","doi":"10.1093/annonc/mdz394.070","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"NY-ESO-1 and LAGE1A: An emerging target for cell therapies in solid tumours","googleId":"Jt8-Npq6L1gJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594418","googleCitationCount":2,"googleAuthor":"","doi":"10.1093/annonc/mdz253.055","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Initial results of a phase II study of nivolumab and ipilimumab in metastatic adrenal tumours","googleId":"RJhAO-HorzcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591992","googleCitationCount":2,"googleAuthor":"MA Habra","doi":"10.1093/annonc/mdz249.082","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Not only gene mutation matters: Development of flow cytometry panel to determine BRCA2 deficiency for personalised therapy by PARP inhibitors in …","googleId":"hEOyUqqtvVoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419619587","googleCitationCount":2,"googleAuthor":"","doi":"10.1093/annonc/mdz413.063","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"A phase II study of monalizumab in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN): Results of the I1 cohort …","googleId":"1obQciRoQDYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419593218","googleCitationCount":3,"googleAuthor":"","doi":"10.1093/annonc/mdz252.001","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Phase I clinical trial of PD-1 knockout anti-MUC1 CAR-T cells in the treatment of patients with non-small cell lung cancer","googleId":"gJE29fDVmmgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420344148","googleCitationCount":2,"googleAuthor":"E McGowan","doi":"10.1093/annonc/mdz448","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Pembrolizumab (pembro) plus mFOLFOX or FOLFIRI in patients with metastatic colorectal cancer (mCRC): KEYNOTE-651 cohorts B and D","googleId":"kEnW5m7b9aMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419588287","googleCitationCount":2,"googleAuthor":"M Fakih","doi":"10.1093/annonc/mdz246.085","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Harmonization study of tumour mutational burden determination in non-small cell lung cancer (NSCLC)","googleId":"LWzbjhWKsyQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603625","googleCitationCount":2,"googleAuthor":"","doi":"10.1093/annonc/mdz394.002","elsevierCitationCount":0,"altmetricAuthors":["E.M. Garrido-Martin","J. Ramos-Paradas","S. Hernandez Prieto","E. Sanchez","A. Rosado","T. Caniego-Casas","N. Carrizo","A.B. Enguita","M.T. Muñoz-Jiménez","B. Rodriguez","U. Perez-Gonzalez","D. Gomez Sanchez","I. Ferrer","S. Ponce Aix","A. Nuñez Buiza","P. Garrido","J. Palacios","F. Lopez-Rios","L. Paz-Ares"],"twitterCount":0,"altmetricId":67768407,"statusesArray":[]},{"title":"Are we assuming too much with our statistical assumptions? Lessons learned from the ALTTO trial","googleId":"67N87ZRmiaIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419459863","googleCitationCount":3,"googleAuthor":"EM Holmes","doi":"10.1093/annonc/mdz195","elsevierAuthor":"Holmes E.M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-09-01","elsevierCoverDisplayDate":"1 September 2019","elsevierCitationCount":"2","altmetricAuthors":["E.M. Holmes","I. Bradbury","L.S. Williams","L. Korde","E. de Azambuja","D. Fumagalli","A. Moreno-Aspitia","J. Baselga","M. Piccart-Gebhart","A.C. Dueck","R.D. Gelber"],"twitterCount":17,"altmetricId":62793928,"statusesArray":["1158434393297444864","1158372915148218369","1158330090369036295","1157985976687517696","1157983736371306498","1157954543344222208","1157953698552827905","1157939671579668482","1155118052750635009","1154892162351472641","1154303686631395328","1154285099556454400","1154118534261329921","1145267402084704256","1144549018384490502","1144544872403259393","1144530159204274176","1144522096854388736","1144487975465570305","1144476120936402945"]},{"title":"A Phase III study of TAS-118 plus oxaliplatin versus S-1 plus cisplatin as first-line chemotherapy in patients with advanced gastric cancer (SOLAR study)","googleId":"_qT-tXoBBbIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30957-3/abstract","googleCitationCount":4,"googleAuthor":"","statusesArray":[]},{"title":"EMERGE: Epigenetic modulation of the immune response in gastrointestinal cancers","googleId":"LfnoKY2R69kJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419588901","googleCitationCount":2,"googleAuthor":"","doi":"10.1093/annonc/mdz246.147","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"A Phase Ib study of oraxol in combination with ramucirumab in patients with gastric or esophageal cancers who failed previous chemotherapy","googleId":"e7SVTZpTMk0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419590160","googleCitationCount":2,"googleAuthor":"","doi":"10.1093/annonc/mdz247.126","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Association of lung immune prognostic index (LIPI) with survival of first line immune checkpoint inhibitors single agent or in combination with chemotherapy in …","googleId":"pyKjmBDf3xgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420343969","googleCitationCount":2,"googleAuthor":"","doi":"10.1093/annonc/mdz447.015","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"A case treated with Crizotinib after secondary MET amplification of a double rare L747S and G719S EGFR mutation pulmonary sarcomatoid carcinoma","googleId":"y3r_y9oSAGMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)35942-1/abstract","googleCitationCount":2,"googleAuthor":"","statusesArray":[]},{"title":"Identifying markers of immune response in ovarian cancer: does PD-L1 expression meet the mark?","googleId":"NB8Hi1GuwtUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31250-5/abstract","googleCitationCount":3,"googleAuthor":"","statusesArray":[]},{"title":"Longitudinal circulating tumour DNA (ctDNA) monitoring for early detection of disease progression and resistance in advanced NSCLC in FLAURA","googleId":"ad5a_MrcssIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419582217","googleCitationCount":3,"googleAuthor":"","doi":"10.1093/annonc/mdz446.016","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Androgen deprivation therapy may constitute a more effective COVID-19 prophylactic than therapeutic strategy","googleId":"LA6rI0swtecJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42103-9/abstract","googleCitationCount":2,"googleAuthor":"IM Bennani-Baiti","statusesArray":[]},{"title":"Phase i/ii study with cxcl12 inhibitor nox-a12 and pembrolizumab in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer","googleId":"f1NLCQtfecsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419588330","googleCitationCount":2,"googleAuthor":"","doi":"10.1093/annonc/mdz246.090","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"1916P Larotrectinib treatment of advanced TRK fusion thyroid cancer","googleId":"JD7DrLjBn8MJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41400-0/abstract","googleCitationCount":3,"googleAuthor":"A Drilon","statusesArray":[]},{"title":"Olaparib as maintenance treatment following first-line platinum-based chemotherapy in patients with a germline BRCA mutation and metastatic pancreatic cancer …","googleId":"NtLBNKXgZ6UJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30955-X/abstract","googleCitationCount":3,"googleAuthor":"P Hammel","statusesArray":[]},{"title":"Phase I study evaluating safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-428, first-in-class mesothelin (MSLN)-CD40 …","googleId":"2kUiw_nlLiYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594327","googleCitationCount":2,"googleAuthor":"JJ Luke","doi":"10.1093/annonc/mdz253.046","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Immune activation with a novel immune switch anti-macrophage antibody (anti-Clever-1 mAb; FP-1305) in phase I/II first-in-human MATINS trial in patients …","googleId":"jYGxuKR16nsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603789","googleCitationCount":2,"googleAuthor":"P Bono","doi":"10.1093/annonc/mdz394.018","elsevierAuthor":"Chen Y.","publicationName":"Journal of Cellular Physiology","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"0","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Randomised efficacy and safety results for atezolizumab (Atezo)+ bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular …","googleId":"4xLbTARyipwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419582114","googleCitationCount":2,"googleAuthor":"","doi":"10.1093/annonc/mdz446.006","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Impact of digital patient monitoring (DPM) on quality of clinical care of cancer immunotherapy (CIT)-treated patients (pts) with advanced/metastatic non-small …","googleId":"Lo2Empmm3LIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375342034463X","googleCitationCount":2,"googleAuthor":"C Jacob","doi":"10.1093/annonc/mdz449.039","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Analysis of efficacy outcomes based on programmed death ligand 1 (PD-L1) scoring techniques in patients with head and neck squamous cell carcinoma …","googleId":"jt_ciYIBIWcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419593279","googleCitationCount":2,"googleAuthor":"E Cohen","doi":"10.1093/annonc/mdz252.007","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Cancer immunotherapy with STING agonist and PD-1 immune checkpoint inhibitor effectively suppresses peritoneal carcinomatosis of colon cancer","googleId":"e4WPTloFnGUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30650-7/abstract","googleCitationCount":4,"googleAuthor":"C Kim","statusesArray":[]},{"title":"A single-arm, open-label, multicenter, phase IIIb clinical trial with nivolumab in subjects with recurrent or metastatic platinum-refractory squamous cell …","googleId":"7DB2nfYUFLcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419593528","googleCitationCount":2,"googleAuthor":"MC Merlano","doi":"10.1093/annonc/mdz252.032","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"1294P RELAY, erlotinib plus ramucirumab or placebo in untreated EGFR-mutated metastatic NSCLC: Outcomes by EGFR mutation type","googleId":"mIsXPR15CTYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41604-7/abstract","googleCitationCount":2,"googleAuthor":"E Nadal","statusesArray":[]},{"title":"Tucatinib vs placebo added to trastuzumab and capecitabine in previously treated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB)","googleId":"H7qFJpIuA94J","googleLink":"https://portal.findresearcher.sdu.dk/en/publications/tucatinib-vs-placebo-added-to-trastuzumab-and-capecitabine-in-pre","googleCitationCount":1,"googleAuthor":"S Loi","doi":"10.1016/j.annonc.2020.03.238","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Homozygous HSD3B1 (1245C) inheritance and poor outcomes in metastatic castration-resistant prostate cancer with abiraterone or enzalutamide: what does it mean …","googleId":"nA72TrqVfTIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39896-3/abstract","googleCitationCount":2,"googleAuthor":"N Sharifi","statusesArray":[]},{"title":"First-in-human phase I study of TAS-117, an allosteric AKT inhibitor, in patients with advanced solid tumours","googleId":"NBUe0qPYAdoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586781","googleCitationCount":2,"googleAuthor":"","doi":"10.1093/annonc/mdz244.018","elsevierCitationCount":0,"altmetricAuthors":["M. Yunokawa","S. Takahashi","D. Aoki","K. Yonemori","H. Hara","K. Hasegawa","K. Takehara","K. Harano","H. Nomura","E. Noguchi","K. Horie","A. Ogasawara","S. Okame","T. Doi"],"twitterCount":0,"altmetricId":100658799,"statusesArray":[]},{"title":"Phase II study of DHP107 oral paclitaxel in first-line, HER2 negative recurrent/metastatic breast cancer (OPTIMAL study, NCT03315364)","googleId":"v3vmDg4a2jQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419585684","googleCitationCount":2,"googleAuthor":"","doi":"10.1093/annonc/mdz242.041","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"PACIFIC-5: Phase III study of durvalumab after either concurrent or sequential chemoradiotherapy (CRT) in patients with stage III NSCLC","googleId":"QY7AZBRV7b8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419582035","googleCitationCount":2,"googleAuthor":"","doi":"10.1093/annonc/mdz438.021","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Nab-paclitaxel (Nab) plus gemcitabine (G) is more effective than G alone in locally advanced, unresectable pancreatic cancer (LAUPC): The GAP trial, a …","googleId":"4siBliACusoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419588925","googleCitationCount":2,"googleAuthor":"S Cascinu","doi":"10.1093/annonc/mdz247.001","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Relationship between tumor infiltrating lymphocytes (TILs) and response to pembrolizumab (pembro)+ chemotherapy (CT) as neoadjuvant treatment (NAT) for triple …","googleId":"D2YnAkBP9dEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30276-5/abstract","googleCitationCount":4,"googleAuthor":"S Loi","statusesArray":[]},{"title":"1676MO Prevalence and clinical impact of asymptomatic or mildly symptomatic SARSCoV-2 infection among actively treated cancer patients during COVID-19 …","googleId":"AI38wiGVXOsJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/pmc7506461/","googleCitationCount":1,"googleAuthor":"","doi":"10.1016/j.annonc.2020.08.1741","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Phase II monotherapy efficacy of cancer metabolism targeting SM-88 in heavily pre-treated PDAC patients","googleId":"gm6dYt9myO4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419589360","googleCitationCount":3,"googleAuthor":"","doi":"10.1093/annonc/mdz247.046","elsevierCitationCount":0,"altmetricAuthors":["A. Ocean","M. Noel","A. Wang-Gillam","S. Chawla","V. Chung","S. Pant","R. Korn","G.l. De Priore","V. Picozzi"],"twitterCount":0,"altmetricId":97829025,"statusesArray":[]},{"title":"Efficiency of controlled cryotherapy in prevention of chemotherapy induced peripheral neuropathy (CIPN)","googleId":"wTtQBxEakAgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419599343","googleCitationCount":2,"googleAuthor":"","doi":"10.1093/annonc/mdz265.048","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Tepotinib in NSCLC patients with METex14 mutations: interim results from the phase II VISION study","googleId":"tXHXunOKD9AJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419621745","googleCitationCount":3,"googleAuthor":"J Mazieres","doi":"10.1093/annonc/mdz338.079","elsevierCitationCount":0,"altmetricAuthors":["Hiroshi Sakai","Remi Veillon","Alexis B. Cortot","Enriqueta Felip","Julien Mazieres","Masahiro Morise","Tomohiro Sakamoto","Takaaki Tokito","Shinji Atagi","Terufumi Kato","Toru Kumagai","Hiroshi Tanaka","Rolf Bruns","Josef Straub","Juergen Scheele","Xiuning Le","Paul K. Paik"],"twitterCount":0,"altmetricId":68314296,"statusesArray":[]},{"title":"Real-world (RW) treatment patterns and outcomes for second-line (2L) therapy and beyond in patients (pts) with epidermal growth factor receptor-mutated …","googleId":"uAuosOTlk2cJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419597290","googleCitationCount":2,"googleAuthor":"SP Nagar","doi":"10.1093/annonc/mdz260.044","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Final results of phase II trial (MIRACULUM) of the novel PD-1 inhibitor prolgolimab in patients with advanced melanoma","googleId":"CY6u8HvTEhMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420345051","googleCitationCount":3,"googleAuthor":"","doi":"10.1093/annonc/mdz451.027","elsevierCitationCount":0,"altmetricAuthors":["S. Tjulandin","M. Fedyanin","L. Demidov","V. Moiseyenko","S. Protsenko","S. Odintsova","T.Y. Semiglazova","R. Zukov","S. Lazarev","A. Andreev","M. Nechaeva","J. Makarova","N. Fadeeva","A. Tarasova","O. Kozlova","M. Shustova","A. Garipov","R. Ivanov"],"twitterCount":0,"altmetricId":80707639,"statusesArray":[]},{"title":"Encorafenib plus cetuximab with or without binimetinib for BRAF V600E–mutant metastatic colorectal cancer: Expanded results from a randomized, 3-arm …","googleId":"fCa6o1I8_hYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603819","googleCitationCount":4,"googleAuthor":"A Grothey","doi":"10.1093/annonc/mdz394.021","elsevierCitationCount":0,"altmetricAuthors":["J. Tabernero","A. Grothey","E. Van Cutsem","R. Yaeger","H. Wasan","T. Yoshino","J. Desai","F. Ciardiello","F. Loupakis","Y Sang Hong","N. Steeghs","T.K. Guren","H.-T. Arkenau","P. García-Alfonso","A. Gollerkeri","M. Pickard","K. Maharry","J.L. Christy-Bittel","L. Anderson","S. Kopetz"],"twitterCount":1,"altmetricId":69049442,"statusesArray":["1222769243000918016"]},{"title":"1410P Safety and efficacy of vibostolimab, an anti-TIGIT antibody, plus pembrolizumab in patients with anti-PD-1/PD-L1-naive NSCLC","googleId":"jGq6KQxpLx8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41720-X/abstract","googleCitationCount":2,"googleAuthor":"A Nagrial","statusesArray":[]},{"title":"The ImmunoTOX multidisciplinary board: A descriptive study of collaborative management of immune-related adverse events","googleId":"hOgZijI-dfgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419598891","googleCitationCount":2,"googleAuthor":"JM Michot","doi":"10.1093/annonc/mdz265.003","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"RASA1 loss in a BRAF-mutated Langerhans cell sarcoma: a mechanism of resistance to BRAF inhibitor","googleId":"HoJIEUcsR9YJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31233-5/abstract","googleCitationCount":3,"googleAuthor":"F Jouenne","statusesArray":[]},{"title":"Androgen deprivation and SARS-CoV-2 in men with prostate cancer","googleId":"fWeuxuYYrWYJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7323668/","googleCitationCount":2,"googleAuthor":"M Koskinen","doi":"10.1016/j.annonc.2020.06.015","elsevierAuthor":"Koskinen M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-10-01","elsevierCoverDisplayDate":"October 2020","elsevierCitationCount":"0","altmetricAuthors":["M. Koskinen","O. Carpen","V. Honkanen","M.R.J. Seppänen","P.J. Miettinen","J.A. Tuominen","T. Raivio"],"twitterCount":2,"altmetricId":85165519,"statusesArray":["1281114603854929920","1278993047884165121"]},{"title":"Development and validation of a risk model integrating plasma Epstein-Barr virus DNA (EBV DNA) level and TNM stage for stratification of nasopharyngeal …","googleId":"cYq55jv6cTsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419579601","googleCitationCount":2,"googleAuthor":"BBY Ma","doi":"10.1093/annonc/mdz428.001","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Response of nivolumab monotherapy in 124 Japanese patients with advanced melanoma: interim analysis of prospective observational study (CREATIVE …","googleId":"louUt74M-ysJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341957990X","googleCitationCount":2,"googleAuthor":"","doi":"10.1093/annonc/mdz429.001","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"A phase II study of trastuzumab deruxtecan (DS-8201a) in HER2-overexpressing or-mutated advanced non-small cell lung cancer","googleId":"5yPVK7GH5egJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30132-2/abstract","googleCitationCount":5,"googleAuthor":"","statusesArray":[]},{"title":"A Food and Drug Administration analysis of survival outcomes comparing the Adjuvant Paclitaxel and Trastuzumab trial with an external control from historical clinical …","googleId":"0DGABh4XKK4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420421714","googleCitationCount":2,"googleAuthor":"","doi":"10.1016/j.annonc.2020.08.2106","elsevierAuthor":"Amiri-Kordestani L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-12-01","elsevierCoverDisplayDate":"December 2020","elsevierCitationCount":"1","altmetricAuthors":["L. Amiri-Kordestani","D. Xie","S.M. Tolaney","E. Bloomquist","S. Tang","A. Ibrahim","K.B. Goldberg","M.R. Theoret","R. Pazdur","R. Sridhara","E.P. Winer","J.A. Beaver"],"twitterCount":25,"altmetricId":89259831,"statusesArray":["1306386793407811585","1306341525912276995","1306233060229292033","1306231619561365506","1306212796472860675","1306077735870226436","1306075330512257024","1306067809022009345","1306064503998541824","1306057767472463873","1306029390464258050","1306027813246504960","1305985758357065729","1305965361146331139","1305958379265970177","1305923924581126145","1305919036929331206","1305893830277947392","1305887550058364929","1305885178590621697","1305876036324855808","1305854383771602944","1305854287667437569","1302605951523008513","1302597688651919361","1302555678570156033","1300736441371095040"]},{"title":"An international, randomized, open-label, phase III trial of adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for surgically resected pancreatic …","googleId":"rhCYcC3cfbIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30509-5/abstract","googleCitationCount":4,"googleAuthor":"M Reni","statusesArray":[]},{"title":"Buparlisib (BKM120) in refractory head and neck squamous cell carcinoma harbouring or not a PI3KCA mutation: A phase II multicenter trial","googleId":"zLpEFL-CsTEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419593322","googleCitationCount":4,"googleAuthor":"","doi":"10.1093/annonc/mdz252.012","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"A meta-analysis of efficacy and safety of cetuximab with biweekly vs. weekly dosing","googleId":"QaM3tlOhPAAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40562-9/abstract","googleCitationCount":1,"googleAuthor":"A Parikh","statusesArray":[]},{"title":"Predictive and prognostic value of B-cell gene-expression signatures and B-cell receptor (BCR) repertoire in HER2+ breast cancer: A correlative analysis of …","googleId":"PDHCFlrKjn0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419584009","googleCitationCount":3,"googleAuthor":"JS Parker","doi":"10.1093/annonc/mdz240","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Evaluation of pathological complete response as a trial-level surrogate for long-term survival outcomes among triple-negative breast cancer patients receiving …","googleId":"xFvnvNHIew4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30378-3/abstract","googleCitationCount":4,"googleAuthor":"","statusesArray":[]},{"title":"PARP inhibition increases immune infiltration in homologous recombination repair (HRR)-deficient tumors","googleId":"KdtwSYSXS5YJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419600025","googleCitationCount":2,"googleAuthor":"B Pellegrino","doi":"10.1093/annonc/mdz268","elsevierAuthor":"Scripcariu V.","publicationName":"Romanian Journal of Morphology and Embryology","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"0","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Multicenter phase I/II study of nivolumab combined with paclitaxel plus ramucirumab as the second-line treatment in patients with advanced gastric cancer","googleId":"EL75b4wb0gwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30945-7/abstract","googleCitationCount":3,"googleAuthor":"","statusesArray":[]},{"title":"Efficacy and safety of darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) in the ARAMIS trial","googleId":"aS4oO7lBsqIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419578796","googleCitationCount":2,"googleAuthor":"","doi":"10.1093/annonc/mdz424.001","elsevierCitationCount":0,"altmetricAuthors":["J.S.-T. Pang","N. Shore","M.R. Smith","T.L. Tammela","A. Ulys","E. Vjaters","S. Polyakov","M. Jievaltas","M. Luz","B. Alekseev","I. Kuss","M.-A. Le Berre","A. Snapir","T. Sarapohja","K. Fizazi"],"twitterCount":0,"altmetricId":74737030,"statusesArray":[]},{"title":"685P A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer …","googleId":"c2htdNIdOQgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42076-9/abstract","googleCitationCount":2,"googleAuthor":"","statusesArray":[]},{"title":"Immunogenicity and optimal timing of 13-valent pneumococcal conjugate vaccination during adjuvant chemotherapy in gastric and colorectal cancer: a …","googleId":"J2ABQE-6r_UJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419599562","googleCitationCount":3,"googleAuthor":"W Choi","doi":"10.1093/annonc/mdz265.071","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"TATTON expansion cohorts: A phase Ib study of osimertinib plus savolitinib in patients (pts) with EGFR-mutant, MET-positive NSCLC following disease …","googleId":"3VJRYijmLokJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419582060","googleCitationCount":2,"googleAuthor":"H Yu","doi":"10.1093/annonc/mdz446.001","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"LBA41 LEAP-005: Phase II study of lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with previously treated advanced solid tumours","googleId":"AfUTAaXE7fAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42353-1/abstract","googleCitationCount":2,"googleAuthor":"Z Lwin","statusesArray":[]},{"title":"Important considerations prior to elimination of breast cancer surgery after neoadjuvant systemic therapy: Listening to what our patients want","googleId":"jd_s87TWJ-0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39307-8/abstract","googleCitationCount":2,"googleAuthor":"","statusesArray":[]},{"title":"1400P Vibostolimab, an anti-TIGIT antibody, as monotherapy and in combination with pembrolizumab in anti-PD-1/PD-L1-refractory NSCLC","googleId":"b939U1-GnKgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41710-7/abstract","googleCitationCount":2,"googleAuthor":"DW Kim","statusesArray":[]},{"title":"Impact of adjuvant trastuzumab emtansine (T-DM1) on incidence of metastatic breast cancer (mBC): An epidemiological model of patients with HER2-positive …","googleId":"YruXwnOts50J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419584198","googleCitationCount":2,"googleAuthor":"","doi":"10.1093/annonc/mdz240.019","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Making adjuvant therapy decisions with uncertain data","googleId":"Iu7s_aK0S5IJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31093-2/abstract","googleCitationCount":4,"googleAuthor":"B Gyawali","statusesArray":[]},{"title":"Prognostic and predictive value of baseline alpha-fetoprotein (AFP) in patients with advanced hepatocellular carcinoma (HCC) treated with ramucirumab from …","googleId":"rK2GK2fBgYQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419589694","googleCitationCount":2,"googleAuthor":"PR Galle","doi":"10.1093/annonc/mdz247.079","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Efficacy of weekly paclitaxel-bevacizumab combination in advanced non squamous non-small cell lung cancer (NSCLC): a retrospective multicentric study","googleId":"kPve2_AhyTMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419597745","googleCitationCount":3,"googleAuthor":"","doi":"10.1093/annonc/mdz260.089","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Liposomal irinotecan (nal-IRI) plus 5-fluorouracil/levoleucovorin (5 FU/LV) vs 5-FU/LV in Japanese patients (pts) with gemcitabine-refractory metastatic …","googleId":"yl34LOkGaDwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419578097","googleCitationCount":2,"googleAuthor":"S Nakamori","doi":"10.1093/annonc/mdz422.010","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"External validation and longitudinal extension of the LIPI (Lung Immune Prognostic Index) for immunotherapy outcomes in advanced non-small cell lung …","googleId":"nCESRACd8y0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594741","googleCitationCount":2,"googleAuthor":"JM Riedl","doi":"10.1093/annonc/mdz253.088","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Efficacy and safety of ceritinib in ALK-positive non-small cell lung cancer (NSCLC) patients with leptomeningeal metastases (LM): results from the phase II …","googleId":"XPTk6jg5xqIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586124","googleCitationCount":2,"googleAuthor":"DW Kim","doi":"10.1093/annonc/mdz243","elsevierAuthor":"Petrelli F.","publicationName":"JAMA Oncology","elsevierCoverDate":"2020-07-01","elsevierCoverDisplayDate":"July 2020","elsevierCitationCount":"6","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"A phase I study of XZP-3287, a novel oral CDK4/6 Inhibitor, administered on a continuous dosing schedule, in patients with advanced solid tumours","googleId":"R6XvKv7w69sJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419585660","googleCitationCount":2,"googleAuthor":"","doi":"10.1093/annonc/mdz242.039","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"A phase Ia/b first-in-human, open-label, dose-escalation, safety, PK and PD study of TP-0903 in solid tumours","googleId":"d6q3u8tfYYwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586823","googleCitationCount":2,"googleAuthor":"","doi":"10.1093/annonc/mdz244.022","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 …","googleId":"dBARTukM_5wJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419579066","googleCitationCount":3,"googleAuthor":"","doi":"10.1093/annonc/mdz426.006","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"CANOPY phase III program: Three studies evaluating canakinumab in patients with non-small cell lung cancer (NSCLC)","googleId":"o7qdLJTA-PYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419597940","googleCitationCount":2,"googleAuthor":"","doi":"10.1093/annonc/mdz260.109","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Efficacy and safety of first-line durvalumab (D)±tremelimumab (T) vs chemotherapy (CT) in Asian patients with metastatic NSCLC: Results from MYSTIC","googleId":"dw4y7ELbNuIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419581820","googleCitationCount":2,"googleAuthor":"KH Lee","doi":"10.1093/annonc/mdz437","elsevierAuthor":"Johne A.","publicationName":"Investigational New Drugs","elsevierCoverDate":"2020-10-01","elsevierCoverDisplayDate":"1 October 2020","elsevierCitationCount":"2","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Peripheral neuropathy (PN), thrombocytopenia (TCP) and central nervous system (CNS) recurrence: An update of the phase III KATHERINE trial of post …","googleId":"5vHVrvAxEYMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603650","googleCitationCount":6,"googleAuthor":"C Huang","doi":"10.1093/annonc/mdz394.005","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Safety, anti-tumour activity, and biomarker results of the HER2-targeted bispecific antibody ZW25 in HER2-expressing solid tumours","googleId":"yBMiiQjgbm4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586756","googleCitationCount":4,"googleAuthor":"F Meric-Bernstam","doi":"10.1093/annonc/mdz244.015","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"1675MO Screening of COVID-19 disease based on chest CT and PCR for cancer patients undergoing radiotherapy in a French coronavirus hotspot","googleId":"bCf50oQfxm4J","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506406/","googleCitationCount":1,"googleAuthor":"R Sun","doi":"10.1016/j.annonc.2020.08.1740","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Afatinib in EGFR TKI-naïve patients (pts) with locally advanced/metastatic NSCLC harbouring EGFR mutations: an interim analysis of a phase IIIB trial","googleId":"todCCo1_l5IJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30064-X/abstract","googleCitationCount":3,"googleAuthor":"","statusesArray":[]},{"title":"Personalized cancer supportive care in COVID-19 era","googleId":"xCatCs0USeYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39817-3/pdf","googleCitationCount":2,"googleAuthor":"GH Lyman","statusesArray":[]},{"title":"Machine learning-based predictors for immune checkpoint inhibitor therapy of non-small-cell lung cancer","googleId":"ISCb3cBe54YJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31129-9/abstract","googleCitationCount":4,"googleAuthor":"H Reis","statusesArray":[]},{"title":"Association between immune-related adverse events and efficacy of immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma","googleId":"PNkhgBKrIdAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341958190X","googleCitationCount":2,"googleAuthor":"SH Tan","doi":"10.1093/annonc/mdz438.008","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"P-342 Margetuximab combined with anti-PD-1 (MGA012) or anti-PD-1/LAG-3 (MGD013)+/-chemotherapy in first-line therapy of advanced/metastatic HER2+ …","googleId":"iIoVroCLPRQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39723-4/pdf","googleCitationCount":1,"googleAuthor":"D Catenacci","statusesArray":[]},{"title":"Osimertinib for patients (pts) with leptomeningeal metastases (LM) associated with EGFRm advanced NSCLC: the AURA LM study","googleId":"FU8-tSIevcQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30054-7/abstract","googleCitationCount":3,"googleAuthor":"","statusesArray":[]},{"title":"FOLFIRI plus panitumumab as second-line treatment in mutated RAS metastatic colorectal cancer patients who converted to wild type RAS after receiving first-line …","googleId":"GOGOFPbOMe4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30617-9/abstract","googleCitationCount":3,"googleAuthor":"NM Lago","statusesArray":[]},{"title":"Successful pregnancy in a cancer patient previously cured of a gestational trophoblastic tumor by immunotherapy","googleId":"jL-uesfRr6YJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)36076-2/pdf","googleCitationCount":2,"googleAuthor":"PA Bolze","statusesArray":[]},{"title":"3-year follow-up of a phase III trial comparing the efficacy and safety of neoadjuvant and adjuvant trastuzumab and its biosimilar CT-P6 in HER2 positive early …","googleId":"oVlrd_Ab0HQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419584162","googleCitationCount":2,"googleAuthor":"J Stebbing","doi":"10.1093/annonc/mdz240.016","elsevierCitationCount":0,"altmetricAuthors":["J. Stebbing","Y. Baranau","V. Baryash","A. Manikhas","V. Moiseyenko","G. Dzagnidze","E. Zhavrid","D. Boliukh","D. Stroyakovskiy","J. Pikiel","A. Eniu","D. Komov","S.J. Lee","M.J. Kim","S. Kim","S. Park","J.H. Bae","F.J. Esteva"],"twitterCount":0,"altmetricId":68237421,"statusesArray":[]},{"title":"EPI-7386 is a novel N-terminal domain androgen receptor inhibitor for the treatment of prostate cancer","googleId":"VHtqWSAlVF0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419587257","googleCitationCount":2,"googleAuthor":"","doi":"10.1093/annonc/mdz244.065","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"1736P Elevated AXL expression following SARS-CoV-2 infection in non-small cell lung cancer","googleId":"rmAOvs9ZKqYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41796-X/abstract","googleCitationCount":1,"googleAuthor":"","statusesArray":[]},{"title":"Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study","googleId":"Tsu3sX5eSsYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420398665","googleCitationCount":3,"googleAuthor":"","doi":"10.1016/j.annonc.2020.05.024","elsevierAuthor":"Van Cutsem E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-09-01","elsevierCoverDisplayDate":"September 2020","elsevierCitationCount":"2","altmetricAuthors":["E. Van Cutsem","I. Danielewicz","M.P. Saunders","P. Pfeiffer","G. Argilés","C. Borg","R. Glynne-Jones","C.J.A. Punt","A.J. Van de Wouw","M. Fedyanin","D. Stroyakovskiy","H. Kroening","P. Garcia-Alfonso","H. Wasan","A. Falcone","A. Kanehisa","A. Egorov","P. Aubel","N. Amellal","V. Moiseenko"],"twitterCount":13,"altmetricId":83301942,"statusesArray":["1268856718013992961","1268846179720105986","1268501258295533568","1268172768786464768","1268019239669112832","1267993043077967873","1267949800646901760","1267944566231105537","1267922103266934784","1267917594843058178","1267895651280584705","1267880218863243264","1267866998287073280"]},{"title":"Intracranial efficacy of entrectinib in patients with NTRK fusion-positive solid tumours and baseline CNS metastases","googleId":"KgiU8DlZtzIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40469-7/abstract","googleCitationCount":1,"googleAuthor":"M Fakih","statusesArray":[]},{"title":"1731P Molecular diagnostics for cancer patients and high-risk individuals during the SARS-CoV-2 pandemic at the Institute for Oncology and Radiology of Serbia","googleId":"rCzAkN1XBz8J","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506399/","googleCitationCount":1,"googleAuthor":"","doi":"10.1016/j.annonc.2020.08.1795","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"LBA47 Primary analysis of phase II results for cemiplimab in patients (pts) with locally advanced basal cell carcinoma (laBCC) who progress on or are intolerant to …","googleId":"5aUqOdWE4MsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42359-2/abstract","googleCitationCount":1,"googleAuthor":"AJ Stratigos","statusesArray":[]},{"title":"Facilitating access to new therapeutic options through clinical trials: the vision of a regulator to reconcile innovation and safety","googleId":"Gwz6taFR2CEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)32597-7/abstract","googleCitationCount":3,"googleAuthor":"","statusesArray":[]},{"title":"Clinical activity of vofatamab (V), an FGFR3 selective antibody in combination with pembrolizumab (P) in metastatic urothelial carcinoma (mUC), updated …","googleId":"NS34qDYlvgAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591335","googleCitationCount":2,"googleAuthor":"","doi":"10.1093/annonc/mdz249.016","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Ramucirumab in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): An exposure-response analysis","googleId":"naVJ4qFrV54J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419589748","googleCitationCount":2,"googleAuthor":"J Llovet","doi":"10.1093/annonc/mdz247.084","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Safety and efficacy of atezolizumab (atezo) in patients (pts) with autoimmune disease (AID): subgroup analysis of the SAUL study in locally advanced …","googleId":"PRxBhRqxQckJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591384","googleCitationCount":2,"googleAuthor":"Y Loriot","doi":"10.1093/annonc/mdz249.021","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Early-phase clinical drug development of novel agents: a changing paradigm","googleId":"ONY8k1TXc-wJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31249-9/abstract","googleCitationCount":2,"googleAuthor":"E Calvo","statusesArray":[]},{"title":"Integrated safety analysis of the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with ovarian cancer in the treatment and …","googleId":"CMbRgxvaWm4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419592158","googleCitationCount":2,"googleAuthor":"C Aghajanian","doi":"10.1093/annonc/mdz250.010","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group","googleId":"XscrBF8ltDgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341953229X","googleCitationCount":7,"googleAuthor":"T André","doi":"10.1016/j.annonc.2019.12.006","elsevierAuthor":"André T.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-02-01","elsevierCoverDisplayDate":"February 2020","elsevierCitationCount":"2","altmetricAuthors":["T. André","D. Vernerey","S.A. Im","G. Bodoky","R. Buzzoni","S. Reingold","F. Rivera","J. McKendrick","W. Scheithauer","G. Ravit","G. Fountzilas","W.P. Yong","R. Isaacs","P. Österlund","J.T. Liang","G.J. Creemers","M. Rakez","E. Van Cutsem","D. Cunningham","J. Tabernero","A. de Gramont"],"twitterCount":1,"altmetricId":74361623,"statusesArray":["1220017044600606721"]},{"title":"LBA77 Anti-SARS-CoV-2 antibody response in patients with cancer and oncology healthcare workers: A multicenter, prospective study","googleId":"K8jhajoEZD8J","googleLink":"https://www.researchgate.net/profile/Antonio_Marra2/publication/345371398_LBA77_Anti-SARS-CoV-2_antibody_response_in_patients_with_cancer_and_oncology_healthcare_workers_A_multicenter_prospective_study/links/5faa9f42299bf15bae0638e6/LBA77-Anti-SARS-CoV-2-antibody-response-in-patients-with-cancer-and-oncology-healthcare-workers-A-multicenter-prospective-study.pdf","googleCitationCount":1,"googleAuthor":"A Marra","statusesArray":[]},{"title":"Prevalence and prognostic effect of high tumor mutation burden (TMB-H) across multiple less common solid cancers using a real-world dataset","googleId":"5IbZrRpOqzIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419600062","googleCitationCount":3,"googleAuthor":"","doi":"10.1093/annonc/mdz268.004","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Phase II study of neoadjuvant cemiplimab prior to surgery in patients with stage III/IV (M0) cutaneous squamous cell carcinoma of the head and neck (CSCC …","googleId":"HhvvRV3UX04J","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341960431X","googleCitationCount":3,"googleAuthor":"P Nagarajan","doi":"10.1093/annonc/mdz394.071","elsevierAuthor":"Varra V.","publicationName":"Current Treatment Options in Oncology","elsevierCoverDate":"2020-05-01","elsevierCoverDisplayDate":"1 May 2020","elsevierCitationCount":"0","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Efficacy results of selective AXL inhibitor bemcentinib with pembrolizumab following chemo in patients with NSCLC","googleId":"YGj1j2ZWDW8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419597836","googleCitationCount":2,"googleAuthor":"","doi":"10.1093/annonc/mdz260.098","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"1261MO Updated results from a phase I/II study of mobocertinib (TAK-788) in NSCLC with EGFR exon 20 insertions (exon20ins)","googleId":"SIrJm2zEaAoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41571-6/abstract","googleCitationCount":1,"googleAuthor":"GJ Riely","statusesArray":[]},{"title":"89Zr-labeled anti-PD-L1 CX-072 PET imaging in human xenograft and syngeneic tumors","googleId":"LCytYZI8LlYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30019-5/abstract","googleCitationCount":4,"googleAuthor":"MN Lub-De Hooge","statusesArray":[]},{"title":"Immunotherapy for early breast cancer: too soon, too superficial, or just right?","googleId":"sYebn7048YoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420431989","googleCitationCount":0,"googleAuthor":"MA Franzoi","doi":"10.1016/j.annonc.2020.11.022","elsevierAuthor":"Franzoi M.A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2021-03-01","elsevierCoverDisplayDate":"March 2021","elsevierCitationCount":"0","altmetricAuthors":["M.A. Franzoi","E. Romano","M. Piccart"],"twitterCount":3,"altmetricId":95817630,"statusesArray":["1338778013337530371","1338224685205450752","1337350925095198721"]},{"title":"Impact of tucatinib on progression free survival in patients with HER2+ metastatic breast cancer and stable or active brain metastases","googleId":"WOqWRwvqpl8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40391-6/abstract","googleCitationCount":1,"googleAuthor":"NU Lin","statusesArray":[]},{"title":"ANCHOR CRC: A phase 2, open-label, single arm, multicenter study of encorafenib (ENCO), binimetinib (BINI), plus cetuximab (CETUX) in patients with previously …","googleId":"o1HzbkB3jaMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30911-1/abstract","googleCitationCount":7,"googleAuthor":"A Grothey","statusesArray":[]},{"title":"Efficacy and safety of first China-manufactured trastuzumab biosimilar HLX02 for metastatic breast cancer: A phase III trial","googleId":"EcdVH7h5gNEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419585313","googleCitationCount":2,"googleAuthor":"","doi":"10.1093/annonc/mdz242.004","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Basal NK activity and early Treg function inhibition predicts Nivolumab responsiveness in metastatic renal cancer patients (REVOLUTION) trial","googleId":"iujQYs4F7JoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419600359","googleCitationCount":2,"googleAuthor":"","doi":"10.1093/annonc/mdz268.033","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"CN14 The utility of a brief clinical frailty scale (CFS) in predicting prognosis and discharge destination in oncology inpatients","googleId":"2HGbUOJMhjsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42184-2/abstract","googleCitationCount":1,"googleAuthor":"","statusesArray":[]},{"title":"Atezolizumab in combination with bevacizumab for patients with unresectable/metastatic anal cancer","googleId":"stf_1Rbb89sJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40510-1/abstract","googleCitationCount":1,"googleAuthor":"","statusesArray":[]},{"title":"Health-related quality of life (HRQoL) and updated follow-up from KEYNOTE-057: Phase II study of pembrolizumab (pembro) for patients (pts) with high-risk …","googleId":"anvSGoPYA_AJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591323","googleCitationCount":2,"googleAuthor":"JL Boormans","doi":"10.1093/annonc/mdz249.015","elsevierCitationCount":0,"altmetricAuthors":["R. de Wit","G.S. Kulkarni","E. Uchio","J.L. Boormans","M. Roumiguié","L.E.M. Krieger","E.A. Singer","D.F. Bajorin","A.M. Kamat","P. Grivas","H.K. Seo","H. Nishiyama","B.R. Konety","T. Saretsky","H. Li","K. Nam","E. Sbar","A.V. Balar"],"twitterCount":0,"altmetricId":68179456,"statusesArray":[]},{"title":"Integrative analysis of metabolic subtypes in triple-negative breast cancer reveals new therapeutic strategies","googleId":"K2m7GyTjNQYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)57684-0/abstract","googleCitationCount":2,"googleAuthor":"","statusesArray":[]},{"title":"PD-1 Systematic review and meta-analysis of the efficacy of chemotherapeutic regimens in advanced gallbladder cancer: Assessing current practice and …","googleId":"FUMHmJ5sa2EJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39756-8/pdf","googleCitationCount":1,"googleAuthor":"","statusesArray":[]},{"title":"First-line versus second-line immunotherapy in recurrent/metastatic squamous cell carcinoma of the head and neck","googleId":"hfJoBMQsxnEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419593504","googleCitationCount":2,"googleAuthor":"T Ibrahim","doi":"10.1093/annonc/mdz252.030","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck …","googleId":"KypbCAHcyn0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325965","googleCitationCount":6,"googleAuthor":"","doi":"10.1093/annonc/mdz388","elsevierAuthor":"Guo Y.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-11-01","elsevierCoverDisplayDate":"November 2019","elsevierCitationCount":"3","altmetricAuthors":["Y. Guo","M.-J. Ahn","A. Chan","C.-H. Wang","J.-H. Kang","S.-B. Kim","M. Bello","R.S. Arora","Q. Zhang","X. He","P. Li","A. Dechaphunkul","V. Kumar","K. Kamble","W. Li","A. Kandil","E.E.W. Cohen","Y. Geng","E. Zografos","P.Z. Tang"],"twitterCount":5,"altmetricId":66380052,"statusesArray":["1176170654439133184","1172436264580075526","1172405609100017665","1171407399309066240","1171407233722146816"]},{"title":"560P Safety and efficacy of Debio 1143, an antagonist of inhibitor of apoptosis proteins (IAPs), in combination with nivolumab in a phase Ib/II trial in patients (pts) …","googleId":"o5v912RcMqUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40670-2/abstract","googleCitationCount":1,"googleAuthor":"V Moreno","statusesArray":[]},{"title":"ADAPTeR: A phase II study of anti-PD1 (nivolumab) therapy as pre-and post-operative therapy in metastatic renal cell carcinoma","googleId":"jR8UP_IqdjgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591232","googleCitationCount":2,"googleAuthor":"K Litchfield","doi":"10.1093/annonc/mdz249.006","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Baseline characteristics from CLARINET FORTE: Evaluating lanreotide autogel (LAN) 120 mg every 14 days in patients with progressive pancreatic or midgut …","googleId":"VRxsloAi5NcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419595977","googleCitationCount":2,"googleAuthor":"P Ruszniewski","doi":"10.1093/annonc/mdz256.008","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"833P Mirvetuximab soravtansine (MIRV), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin (CARBO) and …","googleId":"O2tHeIifR0IJ","googleLink":"https://www.clearityfoundation.org/wp-content/uploads/2020/10/Mirv-and-CarboPt-and-Bev-ESMO-2020-abstract.pdf","googleCitationCount":1,"googleAuthor":"IB Vergote","statusesArray":[]},{"title":"633P Tolerability and treatment response to darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) in the phase III …","googleId":"uG0jYDN-dI8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40888-9/abstract","googleCitationCount":1,"googleAuthor":"","statusesArray":[]},{"title":"Patient-reported outcomes associated with switching to rivaroxaban for the treatment of venous thromboembolism (VTE) in patients with active cancer","googleId":"1X0gEWAsBXgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419599069","googleCitationCount":2,"googleAuthor":"AT Cohen","doi":"10.1093/annonc/mdz265.020","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"CRYODESMO-O1: A French nationwide phase II study on cryoablation in progressing desmoid tumour (DT) patients (pts)","googleId":"qPPV5tYr15IJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419602905","googleCitationCount":2,"googleAuthor":"X Buy","doi":"10.1093/annonc/mdz283.001","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Mutation tracking in circulating tumour DNA (ctDNA) detects minimal residual disease (MRD) in patients with localized colorectal cancer (CRC) and identifies …","googleId":"B_LK2dxCXp4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419587439","googleCitationCount":2,"googleAuthor":"","doi":"10.1093/annonc/mdz246","elsevierAuthor":"Al Baghdadi T.","publicationName":"Targeted Oncology","elsevierCoverDate":"2020-12-01","elsevierCoverDisplayDate":"December 2020","elsevierCitationCount":"0","altmetricAuthors":["N Tarazona Llavero","F. Gimeno-Valiente","V. Gambardella","M. Huerta","S Rosello Keranen","G. Bruixola","E. Fontana","C Martinez Ciarpaglini","S. Zuñiga","P. Rentero","T. Fleitas","F. Papaccio","D. Moro","V. Pla","G. Nyamundanda","J. Castillo","A. Sadanadam","A. Espí","D. Roda","A. Cervantes"],"twitterCount":0,"altmetricId":68177196,"statusesArray":[]},{"title":"375O Final efficacy results from IMpower132: First-line atezolizumab+ chemotherapy in patients with stage IV non-squamous NSCLC","googleId":"ARmSy5Aheq4J","googleLink":"https://digitalcommons.psjhealth.org/publications/4179/","googleCitationCount":1,"googleAuthor":"","statusesArray":[]},{"title":"Microsatellite instability status in metastatic colorectal cancer and effect of immune checkpoint inhibitors on survival in MSI-high metastatic colorectal cancer","googleId":"DGUwXDRfcWEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419588342","googleCitationCount":2,"googleAuthor":"Y Nakamura","doi":"10.1093/annonc/mdz246.091","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Pharmacokinetic (PK) analysis of weight-based and fixed dose cemiplimab in patients (pts) with advanced malignancies","googleId":"PQUTwvhfc9UJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341959490X","googleCitationCount":2,"googleAuthor":"","doi":"10.1093/annonc/mdz253.104","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"1922P Exploratory patient-reported outcomes among patients with RET-mutant medullary thyroid cancer in LIBRETTO-001: A phase I/II trial of selpercatinib (LOXO …","googleId":"IewcorYOaKoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41406-1/abstract","googleCitationCount":1,"googleAuthor":"DSW Tan","statusesArray":[]},{"title":"1255TiP CheckMate 73L: A phase III study comparing nivolumab (NIVO) plus concurrent chemoradiotherapy (CCRT) followed by NIVO±ipilimumab (IPI) versus CCRT …","googleId":"HzqNwfiVwEoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40124-3/abstract","googleCitationCount":1,"googleAuthor":"D De Ruysscher","statusesArray":[]},{"title":"735P Metastatic renal medullary and collecting duct carcinoma in the era of antiangiogenic and immune checkpoint inhibitors: A multicentric retrospective study","googleId":"LF5K4uty_74J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40803-8/abstract","googleCitationCount":1,"googleAuthor":"","statusesArray":[]},{"title":"Relationships between approved combination therapies and clinical data packages in anti-cancer drugs in Japan","googleId":"agtxvr933WwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)62115-0/abstract","googleCitationCount":2,"googleAuthor":"S Shibata","statusesArray":[]},{"title":"1620O Phase I study of TK216, a novel anti-ETS agent for Ewing sarcoma","googleId":"QL1UTYzSdDMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41842-3/abstract","googleCitationCount":1,"googleAuthor":"","statusesArray":[]},{"title":"Multicenter phase II trial of axitinib monotherapy for advanced biliary tract cancer refractory to gemcitabine-based chemotherapy","googleId":"4EkgiJdfoA8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419589542","googleCitationCount":2,"googleAuthor":"","doi":"10.1093/annonc/mdz247.064","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Differential expression of immunoregulatory molecules and highly-associated cancer genes may provide novel insights into strategic trial design for …","googleId":"eGUdGonHd8EJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594479","googleCitationCount":2,"googleAuthor":"JJ Adashek","doi":"10.1093/annonc/mdz253.061","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"1256TiP Phase III study of pembrolizumab (Pembro) with concurrent chemoradiation therapy (CCRT) followed by pembro with or without olaparib (Ola) vs CCRT …","googleId":"_keJheLVu6QJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40147-4/abstract","googleCitationCount":2,"googleAuthor":"T Kato","statusesArray":[]},{"title":"1914MO Randomized phase II study of radiation therapy and paclitaxel with pazopanib or placebo: NRG-RTOG 0912","googleId":"akhEJ0vvpTcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41398-5/abstract","googleCitationCount":1,"googleAuthor":"","statusesArray":[]},{"title":"LBA48 Clinical efficacy and immunity of combination therapy with nivolumab and IDO/PD-L1 peptide vaccine in patients with metastatic melanoma: A phase I/II trial","googleId":"qgqqPxUMuT8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42360-9/abstract","googleCitationCount":1,"googleAuthor":"","statusesArray":[]},{"title":"810MO Patient-reported outcomes (PROs) in patients (pts) receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial","googleId":"PDS1Ci9Si98J","googleLink":"https://www.researchgate.net/profile/Lydia_Gaba2/publication/345369214_810MO_Patient-reported_outcomes_PROs_in_patients_pts_receiving_niraparib_in_the_PRIMAENGOT-OV26GOG-3012_trial/links/5fac2cfe45851507810c6247/810MO-Patient-reported-outcomes-PROs-in-patients-pts-receiving-niraparib-in-the-PRIMA-ENGOT-OV26-GOG-3012-trial.pdf","googleCitationCount":1,"googleAuthor":"F Heitz","statusesArray":[]},{"title":"Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab (BEV), carboplatin (C) and paclitaxel (P) for advanced cervical …","googleId":"5yMGZYzEQGkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419592663","googleCitationCount":2,"googleAuthor":"N Colombo","doi":"10.1093/annonc/mdz250.061","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"LBA1 Osimertinib adjuvant therapy in patients (pts) with resected EGFR mutated (EGFRm) NSCLC (ADAURA): Central nervous system (CNS) disease recurrence","googleId":"1gtQRydSW8EJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42361-0/abstract","googleCitationCount":1,"googleAuthor":"","statusesArray":[]},{"title":"973TiP LEAP-010: Phase III study of first-line pembrolizumab with or without lenvatinib in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell …","googleId":"UtiKVD5wyxkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41084-1/abstract","googleCitationCount":1,"googleAuthor":"LL Siu","statusesArray":[]},{"title":"LBA1 Interim results of a phase I/Ib study of LSZ102, an oral selective estrogen receptor degrader (SERD), in combination with ribociclib (RIB) or alpelisib (ALP) in …","googleId":"JwdSWsqQNjMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39305-4/abstract","googleCitationCount":4,"googleAuthor":"","statusesArray":[]},{"title":"915MO Long-term outcomes from KEYNOTE-048: Pembrolizumab (pembro) alone or with chemotherapy (pembro+ C) vs EXTREME (E) as first-line (1L) therapy for …","googleId":"2qUEWpUGcj4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41026-9/abstract","googleCitationCount":1,"googleAuthor":"R Greil","statusesArray":[]},{"title":"A phase III trial of capivasertib and fulvestrant versus placebo and fulvestrant in patients with HR+/HER2− breast cancer (CAPItello-291)","googleId":"qWpq2Vlgh7wJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40448-X/abstract","googleCitationCount":1,"googleAuthor":"H Gomez","statusesArray":[]},{"title":"nextMONARCH: Final overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with HR+, HER2-metastatic breast cancer","googleId":"6gZitA8fgOcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40371-0/abstract","googleCitationCount":2,"googleAuthor":"","statusesArray":[]},{"title":"1293P IMpower150: Updated efficacy analysis in patients with EGFR mutations","googleId":"bhmE0KVSISwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41603-5/abstract","googleCitationCount":2,"googleAuthor":"","statusesArray":[]},{"title":"Safety profile of tepotinib in patients with advanced solid tumors: Pooled analysis of phase I and II data","googleId":"2oDQPhGScwAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419587014","googleCitationCount":2,"googleAuthor":"","doi":"10.1093/annonc/mdz244.041","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Application of a sequential multiple assignment randomized trial (SMART) design in older patients with chronic lymphocytic leukemia","googleId":"y1RZxKuk894J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311329","googleCitationCount":3,"googleAuthor":"J Yin","doi":"10.1093/annonc/mdz053","elsevierAuthor":"Ruppert A.S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-04-01","elsevierCoverDisplayDate":"April 2019","elsevierCitationCount":"0","altmetricAuthors":["A.S. Ruppert","J. Yin","M. Davidian","A.A. Tsiatis","J.C. Byrd","J.A. Woyach","S.J. Mandrekar"],"twitterCount":3,"altmetricId":56641801,"statusesArray":["1222477010137518081","1140332552542138369","1103620346681454593"]},{"title":"SO-3 Maintenance olaparib in patients aged≥ 65 years with a germline BRCA mutation and metastatic pancreatic cancer: phase III POLO trial","googleId":"8Yv2sJvT6dsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39317-0/pdf","googleCitationCount":1,"googleAuthor":"P Hammel","statusesArray":[]},{"title":"Palbociclib-fulvestrant (PALBO-FUL) and everolimus-exemestane (EVE-EXE) for second line hormonal treatment (HT) of metastatic breast cancer (MBC) with …","googleId":"xD5spR4tj_oJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419585611","googleCitationCount":2,"googleAuthor":"A Orlandi","doi":"10.1093/annonc/mdz242.034","elsevierAuthor":"Orlandi A.","publicationName":"Breast Journal","elsevierCoverDate":"2020-07-01","elsevierCoverDisplayDate":"1 July 2020","elsevierCitationCount":"1","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"A phase Ib/II study of APG-115 in combination with pembrolizumab in patients with unresectable or metastatic melanomas or advanced solid tumors","googleId":"gXfXABWXVs0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30012-2/abstract","googleCitationCount":3,"googleAuthor":"","statusesArray":[]},{"title":"Debio 1347 in patients with gastrointestinal cancers harboring an FGFR gene fusion: preliminary results","googleId":"6ByIHVIf1kYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30947-0/abstract","googleCitationCount":2,"googleAuthor":"","statusesArray":[]},{"title":"O-12 KEYNOTE-061: Response to subsequent therapy following second-line pembrolizumab or paclitaxel in patients with advanced gastric or …","googleId":"nVo1n8hbzWQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39364-9/pdf","googleCitationCount":1,"googleAuthor":"M Özgüroğlu","statusesArray":[]},{"title":"Sarcoidosis-like reaction mimics progression in patients treated with immune checkpoint inhibitors","googleId":"PcMKTU9myeMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419595138","googleCitationCount":1,"googleAuthor":"L Dercle","doi":"10.1093/annonc/mdz253.127","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Side-effect management of chimeric antigen receptor (CAR) T-cell therapy.","googleId":"67zBGPfQwbgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420429801","googleCitationCount":0,"googleAuthor":"M Schmitt","doi":"10.1016/j.annonc.2020.10.478","elsevierAuthor":"Schubert M.L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"January 2021","elsevierCitationCount":"0","altmetricAuthors":["M.-L. Schubert","M. Schmitt","L. Wang","C.A. Ramos","K. Jordan","C. Müller-Tidow","P. Dreger"],"twitterCount":14,"altmetricId":93771700,"statusesArray":["1324655640166436865","1324625153607815168","1324598528547659781","1324592978141339648","1324578417891835905","1324547043071807489","1324480940693807106","1324460554434482177","1324443497512857600","1324431191982829568","1324410921100431360","1324409725757345793","1324409403521589250","1324405477879533569"]},{"title":"The art of innovation: clinical development of trastuzumab deruxtecan and redefining how antibody-drug conjugates target HER2-positive cancers","googleId":"StuV43LM6-0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)43225-0/abstract","googleCitationCount":1,"googleAuthor":"JC Soria","statusesArray":[]},{"title":"Drinking alcohol, smoking, multiple dysplastic lesions and the risk of field cancerization of squamous cell carcinoma in the esophagus and head and neck …","googleId":"8vgKZGg1stkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419589815","googleCitationCount":2,"googleAuthor":"","doi":"10.1093/annonc/mdz247.091","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"T-cell bispecific antibodies to bypass MHC class I loss in breast cancer","googleId":"lUXD5Q8uKuoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31207-4/abstract","googleCitationCount":2,"googleAuthor":"A Marra","statusesArray":[]},{"title":"Risk and impact of renal impairment of locally advanced head and neck squamous cell carcinoma patients who received chemoradiotherapy with cisplatin","googleId":"671672nGWlgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419593449","googleCitationCount":2,"googleAuthor":"","doi":"10.1093/annonc/mdz252.024","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"cfDNA analysis from phase I/II study of lerociclib (G1T38), a continuously dosed oral CDK4/6 inhibitor, with fulvestrant in HR+/HER2-advanced breast cancer patients","googleId":"oy-99SWGxfYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40376-X/abstract","googleCitationCount":1,"googleAuthor":"","statusesArray":[]},{"title":"Trifluridine/tipiracil in metastatic colorectal cancer: An updated multicentre real-world analysis on efficacy, safety and predictive factors","googleId":"9feVajlwTO0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419588202","googleCitationCount":1,"googleAuthor":"C Stavraka","doi":"10.1093/annonc/mdz246.077","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"LBA-7 Encorafenib plus cetuximab with or without binimetinib for BRAFV600E metastatic colorectal cancer (mCRC): Relationship between carcinoembryonic …","googleId":"wKjH-Apta5MJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39901-4/pdf","googleCitationCount":1,"googleAuthor":"A Grothey","statusesArray":[]},{"title":"1986P MDM2 amplification and hyperprogression following treatment with immune checkpoint inhibitors in advanced non-small cell lung cancer","googleId":"65ykF2K6ZpgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41288-8/abstract","googleCitationCount":2,"googleAuthor":"","statusesArray":[]},{"title":"Expression of PD-L1 in plasma exosomes of NSCLC patients and its associations with PD-L1 expression of corresponding tumour tissues","googleId":"I5ScCeYtBR4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)58369-7/abstract","googleCitationCount":2,"googleAuthor":"","statusesArray":[]},{"title":"Calcium and vitamin D intake and colorectal cancer morbidity rates in Poland","googleId":"gINSqbrPimcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30702-1/abstract","googleCitationCount":2,"googleAuthor":"","statusesArray":[]},{"title":"A comprehensive model of genetic-features predicts outcome of personalized adjuvant treatment in resected EGFR-mutant stage II-IIIA NSCLC: Results from a …","googleId":"5hFkV9SdP4YJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419596508","googleCitationCount":2,"googleAuthor":"","doi":"10.1093/annonc/mdz258.002","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Inactivation of RB1 and histological transformation in EGFR-mutant lung adenocarcinoma","googleId":"xer-T65hrJkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)53227-6/abstract","googleCitationCount":1,"googleAuthor":"M Jamal-Hanjani","statusesArray":[]},{"title":"Personal antigen selection calculator (PASCal) for the design of personal cancer vaccines","googleId":"94ZhRiFcsI4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419593930","googleCitationCount":2,"googleAuthor":"","doi":"10.1093/annonc/mdz253.007","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Comprehensive genomic and transcriptomic profiling in advanced-stage cancers and rare malignancies: Clinical results from the MASTER trial of the German …","googleId":"VBqsrTnuLJ4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419619794","googleCitationCount":1,"googleAuthor":"","doi":"10.1093/annonc/mdz413.085","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Patients should be the tipping point of individualizing breast cancer surgery: Commentary on 'Eliminating the breast cancer surgery paradigm after neoadjuvant …","googleId":"ULCB3jPL9iUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39844-6/fulltext","googleCitationCount":1,"googleAuthor":"","statusesArray":[]},{"title":"Trilaciclib improves overall survival when given with gemcitabine/carboplatin (GC) in patients with metastatic triple negative breast cancer (mTNBC) in a …","googleId":"sFkFRBwmHaoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603716","googleCitationCount":1,"googleAuthor":"","doi":"10.1093/annonc/mdz394.011","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Phase 3 multicenter, open-label, randomized study of infigratinib versus gemcitabine plus cisplatin in the first-line treatment of patients with advanced …","googleId":"O_JR-p5pnmsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30743-4/abstract","googleCitationCount":2,"googleAuthor":"I Borbath","statusesArray":[]},{"title":"Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic …","googleId":"gcnNZ0WMpM4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419578036","googleCitationCount":1,"googleAuthor":"P Hammel","doi":"10.1093/annonc/mdz422.004","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"SO-5 Efficacy of second-line chemotherapy in patients with advanced or metastatic cholangiocarcinoma and FGFR2 fusions: A retrospective analysis","googleId":"Z_pafHY7GMAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39319-4/pdf","googleCitationCount":1,"googleAuthor":"S Roychowdhury","statusesArray":[]},{"title":"Sequential treatment with afatinib followed by 3rd generation EGFR-TKI–subgroup analysis of the GIDEON trial: A prospective non-interventional study (NIS) …","googleId":"3RFqdhqFUsIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419597344","googleCitationCount":1,"googleAuthor":"","doi":"10.1093/annonc/mdz260.049","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Clinical benefit and prices of cancer drugs in the US and Europe","googleId":"BFvgEUdXwJ0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604461","googleCitationCount":1,"googleAuthor":"TJ Rosemann","doi":"10.1093/annonc/mdz394.086","elsevierAuthor":"Demartino P.C.","publicationName":"JAMA Internal Medicine","elsevierCoverDate":"2021-02-01","elsevierCoverDisplayDate":"February 2021","elsevierCitationCount":"0","altmetricAuthors":["K.N. Vokinger","T. Hwang","A. Tibau","T.J. Rosemann","A.S. Kesselheim"],"twitterCount":5,"altmetricId":67560303,"statusesArray":["1179613073742716928","1179398403618476035","1179264095498969089","1179263958903119874","1179261481428369408"]},{"title":"EGFR mutation subtype impacts efficacy of immune checkpoint inhibitors in non-small-cell lung cancer","googleId":"sVclRPc67_4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31295-5/abstract","googleCitationCount":3,"googleAuthor":"S Peters","statusesArray":[]},{"title":"THOR-707, a novel not-alpha IL-2, promotes all key immune system anti-tumoral actions of IL-2 without eliciting vascular leak syndrome (VLS)","googleId":"TgobxYTR3YIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594376","googleCitationCount":1,"googleAuthor":"","doi":"10.1093/annonc/mdz253.051","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Treatment compliance in early-stage anal cancer","googleId":"NqMJpWbtFlgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39941-5/abstract","googleCitationCount":1,"googleAuthor":"","statusesArray":[]},{"title":"ESMO-MCBS and health technology assessment (HTA): Does value for physicians correspond to value for payers?","googleId":"spiEMXlmivYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419598325","googleCitationCount":2,"googleAuthor":"","doi":"10.1093/annonc/mdz263","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"3O Mutation analysis of circulating tumour DNA from baseline and study discontinuation samples in SANDPIPER, a phase III study of taselisib or placebo with …","googleId":"OUd4oL6qsqwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)36218-9/abstract","googleCitationCount":1,"googleAuthor":"","statusesArray":[]},{"title":"Phase Ib/II study of antibody-drug conjugate, sacituzumab govitecan, in combination with the PARP inhibitor, talazoparib, in metastatic triple-negative breast cancer","googleId":"gKnxvFJ3ChQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40456-9/abstract","googleCitationCount":1,"googleAuthor":"","statusesArray":[]},{"title":"Efficacy and safety of early administration of pegfilgrastim in patients with esophageal cancer treated by docetaxel, cisplatin, and 5-fluorouracil (DCF): a phase 2 …","googleId":"Mt2DvbCYFfcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30576-9/abstract","googleCitationCount":2,"googleAuthor":"","statusesArray":[]},{"title":"Does adjuvant therapy reduce postmetastatic survival?","googleId":"-IWTwYUh7uAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31279-7/abstract","googleCitationCount":4,"googleAuthor":"","statusesArray":[]},{"title":"KEYNOTE-495/KeyImPaCT: A randomized, biomarker-directed, phase II trial of pembrolizumab-based therapy for non–small cell lung cancer (NSCLC)","googleId":"vPES9qw9-ewJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419597964","googleCitationCount":1,"googleAuthor":"M Gutierrez","doi":"10.1093/annonc/mdz260.111","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Safety and antitumor activity of sitravatinib in combination with tislelizumab in patients with advanced solid tumors: Ovarian cancer cohort data","googleId":"VyWm6T5VmXIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420344811","googleCitationCount":1,"googleAuthor":"J Goh","doi":"10.1093/annonc/mdz451.003","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"1686P The impact of the COVID-19 crisis on perceived changes in care and wellbeing of cancer patients and norm participants: Results of the PROFILES registry","googleId":"We0CRr7hCNMJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506350/","googleCitationCount":1,"googleAuthor":"LV Van de Poll-Franse","doi":"10.1016/j.annonc.2020.08.1750","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"CAM-H2 effectively targets and treats HER2 positive brain lesions: A comparative preclinical study with trastuzumab","googleId":"lqrcfCD8X58J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30452-1/abstract","googleCitationCount":2,"googleAuthor":"M D'Huyvetter","statusesArray":[]},{"title":"1761P Universal screening of SARS-CoV-2 of oncology healthcare workers—a Brazilian experience","googleId":"Pqbx6qaEleoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41821-6/abstract","googleCitationCount":1,"googleAuthor":"","statusesArray":[]},{"title":"Natural dendritic cell vaccinations generate immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate …","googleId":"MqsjJTjPqzgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419593917","googleCitationCount":1,"googleAuthor":"","doi":"10.1093/annonc/mdz253.005","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"SYNERGY: Phase I and randomized phase II trial to investigate the addition of the anti-CD73 antibody oleclumab to durvalumab, paclitaxel and carboplatin for …","googleId":"RcE-NvuOiXAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30463-6/abstract","googleCitationCount":2,"googleAuthor":"D Eiger","statusesArray":[]},{"title":"CN5 Video consultations with older patients in the oncology nursing outpatient clinic","googleId":"-_HRuKob9zEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42173-8/abstract","googleCitationCount":1,"googleAuthor":"KB Dieperink","statusesArray":[]},{"title":"Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine","googleId":"E6PI733lPH4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420431680","googleCitationCount":0,"googleAuthor":"G Malleo","doi":"10.1016/j.annonc.2020.11.013","elsevierAuthor":"Casolino R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2021-02-01","elsevierCoverDisplayDate":"February 2021","elsevierCitationCount":"0","altmetricAuthors":["R. Casolino","C. Braconi","G. Malleo","S. Paiella","C. Bassi","M. Milella","S.B. Dreyer","F.E.M. Froeling","D.K. Chang","A.V. Biankin","T. Golan"],"twitterCount":3,"altmetricId":95129617,"statusesArray":["1333739390024245249","1333573330398564357","1333004810333765632"]},{"title":"Fresh blood Immune cell monitoring in patients treated with nivolumab in the GETUG-AFU26 NIVOREN study: Association with toxicity and treatment outcome","googleId":"9jN25C6C5q4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591852","googleCitationCount":1,"googleAuthor":"A Desnoyer","doi":"10.1093/annonc/mdz249.068","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Efficacy and safety of pegvorhyaluronidase alfa (PEGPH20; PVHA) and pembrolizumab (pembro) combination therapy in patients (Pts) with stage III/IV non …","googleId":"BM80VvjOZvMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419581522","googleCitationCount":1,"googleAuthor":"","doi":"10.1093/annonc/mdz437.032","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Adverse event (AE) kinetics in patients (pts) treated with dabrafenib+ trametinib (D+ T) in the metastatic and adjuvant setting","googleId":"RD4eizhxe4QJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419595436","googleCitationCount":1,"googleAuthor":"VG Atkinson","doi":"10.1093/annonc/mdz255.022","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Lerociclib (G1T38), an oral CDK4/6 inhibitor, dosed continuously in combination with osimertinib for EGFRmut non-small cell lung cancer: Initial phase Ib …","googleId":"J3gfDnPW7BAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419597447","googleCitationCount":1,"googleAuthor":"","doi":"10.1093/annonc/mdz260.059","elsevierCitationCount":0,"altmetricAuthors":["D. Berz","A. Spira","S.M. Gadgeel","I.C. Anderson","J.W. Goldman","J. Thompson","T. Foster","Y.L. Pritchett","C.G. Cisneros","C. Li","J.A. Sorrentino","R. Malik","A.P. Beelen"],"twitterCount":0,"altmetricId":97380090,"statusesArray":[]},{"title":"First China-manufactured trastuzumab biosimilar HLX02 global phase III trial met primary endpoint in breast cancer","googleId":"P2gG6v2AKr8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419582102","googleCitationCount":1,"googleAuthor":"","doi":"10.1093/annonc/mdz446.005","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Pioglitazone and clarithromycin combined with metronomic low-dose chemotherapy versus nivolumab in patients with advanced non-small cell lung cancer …","googleId":"jLzf3Z5Def8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419597770","googleCitationCount":1,"googleAuthor":"","doi":"10.1093/annonc/mdz260.092","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Induction gefitinib followed by standard chemoradiotherapy in locally advanced (LA) non-small cell lung cancer (NSCLC) with epidermal growth factor …","googleId":"6MqQ3ixX2c4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419581200","googleCitationCount":1,"googleAuthor":"","doi":"10.1093/annonc/mdz436","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"ACTL6A is a novel oncogene and prognostic biomarker for prostate cancer","googleId":"7iOypAmsw7kJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)62164-2/abstract","googleCitationCount":2,"googleAuthor":"","statusesArray":[]},{"title":"Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors","googleId":"E_MOggVKGL0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420344483","googleCitationCount":1,"googleAuthor":"","doi":"10.1093/annonc/mdz449.024","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"CCTG IND 232: A phase II study of durvalumab with or without tremelimumab in patients with metastatic castration resistant prostate cancer (mCRPC)","googleId":"0RzqGui7u6oJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604047","googleCitationCount":1,"googleAuthor":"","doi":"10.1093/annonc/mdz394.044","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"ADRIATIC: A phase III trial of durvalumab±tremelimumab after concurrent chemoradiation for patients with limited stage small cell lung cancer","googleId":"ftbI-B4GBZQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30216-9/abstract","googleCitationCount":4,"googleAuthor":"","statusesArray":[]},{"title":"KEYLYNK-010: Phase III study of pembrolizumab (pembro) plus olaparib (OLA) vs enzalutamide (ENZA) or abiraterone (ABI) in ENZA-or ABI-pretreated …","googleId":"hT32St6t38oJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591098","googleCitationCount":1,"googleAuthor":"E Yu","doi":"10.1093/annonc/mdz248.050","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"O-16 Relative impact of T4 and N2 on the efficacy of 3 versus 6 months of adjuvant CAPOX for high-risk stage II and stage III colon cancer: ACHIEVE and …","googleId":"OdXen-7HWm0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39368-6/pdf","googleCitationCount":1,"googleAuthor":"","statusesArray":[]},{"title":"FGFR2 fusions and its effect of patient (pt) outcomes in intrahepatic cholangiocarcinoma (iCCA)","googleId":"k2CcsSvkTxsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419589438","googleCitationCount":2,"googleAuthor":"","doi":"10.1093/annonc/mdz247.053","elsevierCitationCount":0,"altmetricAuthors":["D.R. Almquist","M. Javle","K.K. Ciombor","M. Roth","R. Abdel-Wahab","F.-S. Ou","E. Wolfe","K. Mody","A. Mahipal","M.J. Borad","T. Bekaii-Saab","D. Ahn"],"twitterCount":1,"altmetricId":89528360,"statusesArray":["1302269529754660865"]},{"title":"FOLFOXIRI versus FOLFOX or FOLFIRI with targeted therapy in patients with mutant BRAF metastatic colorectal cancer: A systematic review and meta-analysis","googleId":"lHaRMqGuDzYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40573-3/abstract","googleCitationCount":3,"googleAuthor":"","statusesArray":[]},{"title":"Relation between objective tumour shrinkage and progression-free survival (PFS) in the NETTER-1 population","googleId":"xP4E40xlVZoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419595916","googleCitationCount":1,"googleAuthor":"P Broberg","doi":"10.1093/annonc/mdz256.002","elsevierAuthor":"Papantoniou D.","publicationName":"Endocrine","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"0","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Phase 1 studies assessing the safety and clinical activity of autologous and allogeneic NKG2D-based CAR-T therapy in metastatic colorectal cancer","googleId":"Td_fJZvc2JIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30953-6/abstract","googleCitationCount":3,"googleAuthor":"J Machiels","statusesArray":[]},{"title":"Understanding mechanisms of primary resistance to checkpoint inhibitors will lead to precision immunotherapy of advanced gastric cancer","googleId":"gKFnfrSlMbwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31088-9/abstract","googleCitationCount":2,"googleAuthor":"A Cervantes","statusesArray":[]},{"title":"Next-generation sequencing (NGS) in metastatic colorectal cancer (mCRC): Novel mutated genes and their effect on response to therapy (Alliance)","googleId":"AkWYnOyFirgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419587452","googleCitationCount":1,"googleAuthor":"F Innocenti","doi":"10.1093/annonc/mdz246.002","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Impact of neurological symptom burden on the survival prognosis in a real-life cohort of patients with non-small cell lung cancer brain metastases","googleId":"RTVHl4jhvUAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586240","googleCitationCount":1,"googleAuthor":"","doi":"10.1093/annonc/mdz243.012","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Combined detection of CD137 and type 1 functions improves identification and characterization of the activated T lymphocyte repertoire","googleId":"oF5sYcgRVlIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420344689","googleCitationCount":1,"googleAuthor":"A Draghi","doi":"10.1093/annonc/mdz450.001","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Addition of an oral docetaxel treatment (ModraDoc006/r) to androgen deprivation therapy (ADT) and intensity-modulated radiation therapy (IMRT) in patients …","googleId":"fERiGY0xi8cJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591153","googleCitationCount":1,"googleAuthor":"JM Janssen","doi":"10.1093/annonc/mdz248.056","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"PIPAC paclitaxel: A systematic and peritoneal tissue pharmacokinetic study in swine","googleId":"9RGf8S4QxvwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30787-2/abstract","googleCitationCount":2,"googleAuthor":"G Kim","statusesArray":[]},{"title":"Immune cell biomarkers on neo-adjuvant chemo-immunotherapy treatment for resectable stage IIIA NSCLC patients","googleId":"LDeNl8LgkvcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594534","googleCitationCount":2,"googleAuthor":"R Laza-Briviesca","doi":"10.1093/annonc/mdz253.067","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Efficacy of weekly paclitaxel-bevacizumab combination in advanced non squamous non-small cell lung cancer (NSCLC) progressing after immune checkpoint …","googleId":"43nEeF8SvQUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420344598","googleCitationCount":2,"googleAuthor":"","doi":"10.1093/annonc/mdz449.035","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"St Gallen International Consensus Guidelines in early breast cancer: experts to prevent patients' overtreatment and breaking the bank?","googleId":"fkRqMy5pLNsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)60985-3/abstract","googleCitationCount":1,"googleAuthor":"","statusesArray":[]},{"title":"Chemotherapy-free treatments: are we ready for prime time?","googleId":"j5UHrrShDjkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31135-4/abstract","googleCitationCount":2,"googleAuthor":"","statusesArray":[]},{"title":"Interim results from trial of SL-801, a novel XPO-1 inhibitor, in patients with advanced solid tumours","googleId":"jkuMuSTAGRkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586884","googleCitationCount":1,"googleAuthor":"","doi":"10.1093/annonc/mdz244.028","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Future of checkpoint blockade in triple-negative breast cancer: combination strategies to lead the way","googleId":"MvqWZxdZgv8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31094-4/abstract","googleCitationCount":2,"googleAuthor":"","statusesArray":[]},{"title":"Extracellular matrix and tissue derived metabolites in a liquid biopsy identifies endotypes of metastatic melanoma patients with differential response to …","googleId":"oLMHQTDc_GoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594613","googleCitationCount":1,"googleAuthor":"N Willumsen","doi":"10.1093/annonc/mdz253.075","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Health-related quality of life (HRQoL) impact of pembrolizumab (pembro) versus best supportive care (BSC) in previously systemically treated patients (pts) …","googleId":"jXFA4DdbIloJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419588950","googleCitationCount":1,"googleAuthor":"","doi":"10.1093/annonc/mdz247.004","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"A phase Ib study of the safety and efficacy of atezolizumab (atezo)+ bevacizumab (bev)+ cobimetinib (cobi) in patients (pts) with metastatic colorectal cancer …","googleId":"TD278wIMCsYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419588238","googleCitationCount":1,"googleAuthor":"C Lieu","doi":"10.1093/annonc/mdz246.080","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Predictive value of neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) In hepatocellular carcinoma (HCC) patients treated with nivolumab …","googleId":"I07qd83MzwcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341958961X","googleCitationCount":4,"googleAuthor":"S Dharmapuri","doi":"10.1093/annonc/mdz247.071","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Combination of triptorelin with nivolumab in ICI resistant advanced melanoma","googleId":"vbogscWIyFAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420345063","googleCitationCount":1,"googleAuthor":"","doi":"10.1093/annonc/mdz451.028","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"SO-20 Consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer (mCRC): Prognostic and predictive impact in the …","googleId":"gvMOfy8USTMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39334-0/pdf","googleCitationCount":1,"googleAuthor":"E Fontana","statusesArray":[]},{"title":"From astrology to prostate cancer: what is the role of subgroup analyses?","googleId":"kZfkia4YjDEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)40700-X/abstract","googleCitationCount":1,"googleAuthor":"C Cattrini","statusesArray":[]},{"title":"1061P TCR and HLA analysis of patients in a phase I/IIa trial of a therapeutic CMV vaccine against recurrent glioblastoma (GBM)","googleId":"t-v6NdueLaIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41177-9/abstract","googleCitationCount":1,"googleAuthor":"DE Anderson","statusesArray":[]},{"title":"Real-world implementation of sequential targeted therapies for EGFR-mutated NSCLC","googleId":"X6PzddP8yL8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419597459","googleCitationCount":1,"googleAuthor":"AL Volckmar","doi":"10.1093/annonc/mdz260.060","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Patient-reported outcomes (PROs) from TITAN: A phase III, randomized, double-blind study of apalutamide (APA) versus placebo (PBO) added to androgen …","googleId":"wdypMvur_2EJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419590676","googleCitationCount":1,"googleAuthor":"N Agarwal","doi":"10.1093/annonc/mdz248.008","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Splenic metabolic activity as biomarker in cervical cancer","googleId":"RsgPRl1WWwAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419583818","googleCitationCount":1,"googleAuthor":"EA De Jaeghere","doi":"10.1093/annonc/mdz239.062","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Expression analysis of NHEJ and HR genes in Ewing sarcomas: Indications of DSB repair dysfunction","googleId":"GNJMS0UWq2MJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603480","googleCitationCount":1,"googleAuthor":"M Liontos","doi":"10.1093/annonc/mdz283.060","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Clinical outcomes by sex with atezolizumab (atezo) monotherapy in patients (pts) with locally advanced/metastatic urothelial carcinoma (mUC)","googleId":"BybQbBQefOwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591438","googleCitationCount":1,"googleAuthor":"","doi":"10.1093/annonc/mdz249.026","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"ADP-A2M4 (MAGE-A4) in patients with synovial sarcoma","googleId":"ifUK-TOgwHoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419602929","googleCitationCount":4,"googleAuthor":"BA Van Tine","doi":"10.1093/annonc/mdz283.003","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Diagnostic value of serum HER-2 level in compression with tissue HER-2 in breast cancer: A systematic review and meta-analysis","googleId":"Vhb10xmGYcUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419577006","googleCitationCount":1,"googleAuthor":"A Shamshirian","doi":"10.1093/annonc/mdz416.019","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"First in human phase I/IIa study of PEN-866, a heat shock protein 90 (HSP90) ligand–SN38 conjugate for patients with advanced solid tumours: Phase I …","googleId":"6yOJo9dSgCEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586835","googleCitationCount":1,"googleAuthor":"","doi":"10.1093/annonc/mdz244.023","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"1880P Two thousand consecutive parallel evaluations of Karnofsky and ECOG performance status: looking for a correct comparison","googleId":"QLEyvLxmvE8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41523-6/abstract","googleCitationCount":1,"googleAuthor":"","statusesArray":[]},{"title":"The extended/phase II study of safety and tolerability of proxalutamide (GT0918) in subjects with metastatic castrate resistant prostate cancer (mCRPC) who …","googleId":"xjRTrUh-71QJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591141","googleCitationCount":1,"googleAuthor":"","doi":"10.1093/annonc/mdz248.055","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Radiosurgery followed by tumour treating fields (TTFields) for brain metastases (1-10) from NSCLC in the phase III METIS trial","googleId":"7Y5XXzKdM14J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419598015","googleCitationCount":1,"googleAuthor":"","doi":"10.1093/annonc/mdz260.116","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Ribociclib (RIB)+ letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) …","googleId":"yze9x7dnfdQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419585556","googleCitationCount":1,"googleAuthor":"","doi":"10.1093/annonc/mdz242.028","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"The extended/phase II study of safety and tolerability of proxalutamide (GT0918) in subjects with metastatic castrate resistant prostate cancer (mCRPC) who …","googleId":"xjRTrUh-71QJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591141","googleCitationCount":1,"googleAuthor":"","doi":"10.1093/annonc/mdz248.055","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Radiosurgery followed by tumour treating fields (TTFields) for brain metastases (1-10) from NSCLC in the phase III METIS trial","googleId":"7Y5XXzKdM14J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419598015","googleCitationCount":1,"googleAuthor":"","doi":"10.1093/annonc/mdz260.116","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Ribociclib (RIB)+ letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) …","googleId":"yze9x7dnfdQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419585556","googleCitationCount":1,"googleAuthor":"PH Cottu","doi":"10.1093/annonc/mdz242.028","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Real-world outcomes of patients with locally advanced or metastatic epithelioid sarcoma","googleId":"cpej2ItxAR4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603091","googleCitationCount":1,"googleAuthor":"","doi":"10.1093/annonc/mdz283.020","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"A Phase I Study of an Anti-IDO1 Inhibitor (LY3381916) as Monotherapy and in Combination with an Anti-PD-L1 Antibody (LY3300054) in Patients with …","googleId":"wBU_3ms3b4EJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420344999","googleCitationCount":1,"googleAuthor":"B O'Neil","doi":"10.1093/annonc/mdz451.021","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"ACCURACY a phase (P) II trial of AL101, a pan-Notch inhibitor, in recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) patients (pts) with Notch …","googleId":"HHkW1RRqr7UJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419593607","googleCitationCount":2,"googleAuthor":"","doi":"10.1093/annonc/mdz252.040","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"SO-007Regorafenib plus nivolumab in patients with advanced colorectal or gastric cancer: an open-label, dose-finding, and dose-expansion phase 1b trial …","googleId":"qpidwajojO4J","googleLink":"https://lirias.kuleuven.be/retrieve/569297","googleCitationCount":3,"googleAuthor":"","statusesArray":[]},{"title":"Sentinel node biopsy in patients with melanoma improves the accuracy of staging when added to clinicopathological features of the primary tumor","googleId":"9QCOzUf91I0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420431709","googleCitationCount":3,"googleAuthor":"","doi":"10.1016/j.annonc.2020.11.015","elsevierAuthor":"El Sharouni M.A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"1","altmetricAuthors":["M.-A. El Sharouni","M.D. Stodell","T. Ahmed","K.P.M. Suijkerbuijk","A.E. Cust","A.J. Witkamp","V. Sigurdsson","P.J. van Diest","R.A. Scolyer","J.F. Thompson","C.H. van Gils","S.N. Lo"],"twitterCount":6,"altmetricId":95256758,"statusesArray":["1335620998469718018","1335581532904427521","1335513580792377345","1335509907588583424","1335509233492664321","1333729846824878083"]},{"title":"126TiP a Phase I Study of NBTXR3 Activated by Radiotherapy for Patients with Advanced Cancers Treated with an Anti-PD-1 Therapy","googleId":"vg0QQo3BGZAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420345129","googleCitationCount":1,"googleAuthor":"","doi":"10.1093/annonc/mdz451.034","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"A randomized, double-blinded, controlled study of tucatinib (ONT-380) vs placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated …","googleId":"G-mO4Q6gxDQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30466-1/abstract","googleCitationCount":2,"googleAuthor":"E Paplomata","statusesArray":[]},{"title":"1422MO Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-low, advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Results of the …","googleId":"72zpEF70Ye8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41924-6/abstract","googleCitationCount":1,"googleAuthor":"","statusesArray":[]},{"title":"Effect of selumetinib plus AZD8186 treatment on cabazitaxel sensitivity in docetaxel-acquired resistant metastatic prostate cancer cell lines","googleId":"vGPUlqLq_gMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419600785","googleCitationCount":1,"googleAuthor":"","doi":"10.1093/annonc/mdz268.077","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Aberrant glycolysis associates with inflammatory tumour microenvironment and promotes metastasis in triple negative breast cancer","googleId":"e6Gfl-QLeVsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)58253-9/abstract","googleCitationCount":2,"googleAuthor":"","statusesArray":[]},{"title":"A randomized trial of sodium alginate prevention of radiation-induced esophagitis in patients with locally advanced NSCLC receiving concurrent …","googleId":"qeo4Sm3QL9UJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419599380","googleCitationCount":1,"googleAuthor":"I Oze","doi":"10.1093/annonc/mdz265.052","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"The impact of late-line treatment on overall survival (OS) from the initiation of first-line chemotherapy (CT) for patients (pts) with metastatic colorectal cancer …","googleId":"Go4zileQcCYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341958807X","googleCitationCount":1,"googleAuthor":"","doi":"10.1093/annonc/mdz246.064","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Prognostic and predictive impact on FMS-like tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancer","googleId":"9j71E1XhOI4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419588561","googleCitationCount":1,"googleAuthor":"","doi":"10.1093/annonc/mdz246.113","elsevierAuthor":"Al Baghdadi T.","publicationName":"Targeted Oncology","elsevierCoverDate":"2020-12-01","elsevierCoverDisplayDate":"December 2020","elsevierCitationCount":"0","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Pertuzumab (P)+ trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression in patients with HER2-positive metastatic breast cancer …","googleId":"Io66kfPm7iMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30418-1/abstract","googleCitationCount":2,"googleAuthor":"","statusesArray":[]},{"title":"Application of multi-modal approach to palliation in end of life head and neck cancer pain","googleId":"yau8u-8CYDUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341958005X","googleCitationCount":1,"googleAuthor":"","doi":"10.1093/annonc/mdz430.006","elsevierAuthor":"Mahl C.","publicationName":"Brazilian Oral Research","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"0","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Applicability of the LIPI score to metastatic microsatellite instability high cancer patients treated with immune checkpoint inhibitors","googleId":"_eq8q8qZ_QcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420344331","googleCitationCount":1,"googleAuthor":"","doi":"10.1093/annonc/mdz449.008","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Platelet Lymphocyte Ratio (PLR) Related with Clinicopathological Characteristics of Balinese Women Breast Cancer Patient","googleId":"cmSZPWL1sAkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419623732","googleCitationCount":4,"googleAuthor":"","doi":"10.1093/annonc/mdz343.124","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]}]